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ABSTRACT 
Oligopeptide transport in rat small intestine has been studied in intact tissue, 
using the luminally and vascularly perfused isolated jejunum in situ technique, and a 
hydrolysis-resistant dipeptide (D-Phe-L-Gln). The data in this thesis can be divided 
into two main sections: (l) identification of the transporter proteins, and (2) 
short-term regulation of transport. 
The basolateral peptide transporter protein has not, to date, been identified. A 
candidate protein was identified from membrane vesicles by a photo affinity labelling 
technique using a dipeptide derivative ([4-azido-3,5-3H-D-Phe]-L-Ala), previously 
shown to be an efficient substrate for the basolateral transporter. The labelled 
candidate protein was successfully isolated by 2-DE, which revealed an apparent Mr 
of 112 ± 2 kDa and a pI of approximately 6.5. Initial sequence analysis, tryptic 
digestion followed by MALDI-TOF analysis and Q-TOF fragmentation of a tryptic 
peptide, produced a peptide fingerprint and a sequence tag of 9 amino acids, 
respectively, which, together, did not completely and conclusively match to any 
known protein sequence contained within databases, therefore suggesting that the 
112 kDa protein may be novel. 
Short-term regulation of peptide transport was also investigated using the 
vascular perfusion method. An amino acid-sensing pathway was discovered, using 
L-Leucine as the regulator, involving protein kinase cacades leading to p70S6k 
activation and subsequent stimulation ofbasolateral membrane peptide transport. 
A major conclusion arising from the data was the distinction between PepTl 
and the basolateral transporter, i.e. the sequence data obtained from the candidate 
protein did not match to the PepTl sequence; in addition there appeared to be distinct 
mechanisms of regulatory control at the two membranes. 
Efficient delivery of peptidomimetic drugs when adminsitered by the oral 
route requires knowledge of short-term regulation of intestinal peptide transport, in 
addition to the sequence and structure of the basolateral transporter. This thesis 
provides essential information, which may eventually contribute to the unequivocal 
identification and sequencing of the intestinal basolateral peptide transporter, 
ultimately leading to the future development of compounds with. high bioavailability. 
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CHAPTER 1: INTRODUCTION 
1.1 ANATOMY OF THE SMALL INTESTINE 
1.1.1 Basic structure and functions 
The small intestinal epithelium, as with many other epithelia, has the 
immense task of separating the general internal milieu of the organism from a harsh 
external environment. The main duties of the epithelium are to act as a major barrier 
to potentially threatening luminal agents, for example ingested bacteria or antigens in 
food, in addition to participating in the digestion and selective absorption of major 
nutrients whilst actively absorbing and/or secreting electrolytes and water. Due to 
the vast extent of its roles, the epithelium is structurally complex and its precise 
architectural design enhances its functional capabilities. 
The small intestine is part of the alimentary canal, beginning at the pyloric 
valve of the stomach and terminating at the caecum. Three consecutive sections; the 
duodenum, jejunum and ileum, constitute its total length (approximately 6 m in 
humans). 
The duodenum is the most proximal region and also the smallest of the 
three, forming only one twelfth of its total length. It originates at the pyloric valve of 
the stomach and descends to the ligament of Treitz. It is secured to the rear wall of 
the abdominal cavity by attachment to the mesentery (membranous tissue), in 
contrast to the remainder of the small intestine, which is able to move freely (Moog, 
1981). 
The jejunum commences at the ligament of Treitz, and is anatomically 
located in the upper left side of the abdominal cavity. The jejunum comprises one 
third of the total length of the small intestine and is the predominant site for the 
absorption of luminal nutrients. 
The small intestine terminates after the ileum, the most distal region. The 
ileum is the longest section and extends to the large intestine via the ileocaecal valve. 
It occupies the lower abdomen and is not primarily involved in the absorption of 
nutrients. Both the ileum and jejunum are tightly coiled so as to enable their 
containment within the peritoneal cavity. 
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1.1.2 Anatomy of the intestinal wall 
All three longitudinal sections of the small intestine possess an identical .. 
structural organisation. The walls are composed of four concentric layers; the serosa, 
muscularis, submucosa (the three outer strata) and the mucosa itself (figure l.la) 
(Moog, 1981). The serosa is the layer most distant from the lumen and is formed by 
visceral peritoneum combining with connective tissue. It is in direct contact with the 
vascular system of capillaries. The muscularis lies close to its inner surface. This 
layer consists of two discrete types of muscle, longitudinal and circular; the two types 
collectively function to maintain the overall shape of the small intestinal wall. 
Adjacent to the muscle layer is the submu,cosa, containing the blood and lymph 
vessels. The submucosa is a deep, connective tIssue layer that physically supports 
the mucosa. 
The mucosa is the most physiologically significant tissue region in terms of 
nutrient absorption. It is an aggregate of three separate layers; the muscularis 
mucosa, lamina propria and the epithelial layer, each having distinct roles due to their 
highly specific structures. The muscularis mucosa is the outermost sheath of this 
tissue and forms a muscle sheet, three to ten cells deep. Contraction of these muscle 
cells causes movement of the villi and secretion of mucous from goblet cells. The 
lamina propria is adjacent to the muscularis and underlies the epithelium. It consists 
of glycosaminoglycan chains, entangled and cross-linked to produce a gel-like 
structure, forming a continuous connective tissue that acts as a mechanical support 
for the epithelium. It contains many different cells which confer its immunological 
importance, e.g. plasma cells, lymphocytes and macrophages. An additional role is 
that it permits the transfer of nutrients away from the intestine via its blood vessels. 
Small nerve fibres are sparsely scattered throughout the lamina propria and by 
releasing substances, such as biologically active peptides or neurotransmitters, these 
nerves may potentially regulate epithelial function. The epithelial layer is the only 
tissue of the small intestine in direct contact with the luminal contents. It cellular 
constituents are described in section 1.1.4. 
The surface area of the intestine is greatly enhanced by three specialised 
structural features that extend into the lumen (in commonly used laboratory animals 
only the latter two are found) (Moog, 1981).. These structures, in order of 
diminishing size and increasing physiological importance, are designated the circular 
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Figure 1.1 
Structure of the lining of the small intestine, in particular; the organisation of the 
intestinal wall (a), and the circular folds (plicae circulares) (b) and villi (c,d) which 
function to increase the absorptive area of the luminal surface. Source: Moog 
(1981). 
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folds, villi and microvilli. The circular folds (plicae circulares) are ridges of 
approximately 8-10 nun that are orientated circumferentially around the lumen 
(figure 1.1 b). They are periodically found in one-half to two-thirds of the lumen, 
more numerous in the jejunum than the ileum, and cause the surface area of the 
lumen to triple in size. The remaining sets of projections (villi and microvilli) 
physically protrude into the luminal space. Collectively, the three structures result in 
a vast enhancement of the surface area of the intestine; the small intestine of the 
human has a surface of approx. 300 m2, which is effectively contained in the small 
cavity of the peritoneum. 
1.1.3 Villi 
Villi are small (1.5-5.0 nun) vascularised projections found on the circular 
folds and the remaining luminal surface of the small intestine (figure l.Ic,d). They 
are present at a very high density (10-40 mm-2) which gives the appearance of velvet 
to the naked eye and dramatically increases the surface area of the epithelium by 
ten-fold. They range from finger-shaped to leaf-shaped; the contour varies with the 
region of the intestine, the animal species and its diet (Moog, 1981). 
A central arteriole penetrates each villus core and, at the tip of the villus, 
splays to form several capillaries that cascade down the peripheral margins of the 
villus in close proximity to the basal surface of enterocytes. Also present in each of 
the villi is a centrally located lymphatic lacteal with a highly permeable endothelial 
lining to allow drainage of escaped plasma proteins and uptake of particulate 
absorption products, e.g. chylomicrons. 
The structure and functions of microvilli will be discussed in section 1.1.6.1. 
1.1.4 Compartmentalisation of the epithelia 
The small intestinal epithelium can be segregated into three individual 
compartments; crypts, villi and Peyer's patches, each possessing a distinct cellular 
composition. 
The chief cellular component in the crypts of Lieberkuhn are 
undifferentiated cells, but also present are enteroendocrine cells,. Paneth cells, goblet 
cells and occasional cuplike cells. The undifferentiated crypt cell acts as a progenitor 
from which all types of cell originate. The cells migrate towards the villus surface, 
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with the exception of Paneth cells, and many of the undifferentiated cells begin to 
acquire structural and functional characteristics of absorptive cells. 
The villus base contains nascent absorptive cells originated from the crypt. 
They migrate up the villus axis (the transient layer of cells on the surface of the villus 
is only one cell thick), where they reside for a few days at the tip, before being 
sloughed off from an exclusion zone. The whole process only takes 3-4 days, so a 
near complete turnover of the epithelium occurs on a weekly basis; approx. 17 billion 
cells are discarded along the length of human small intestine per day. This cycle of 
cellular proliferation and migration occurs in roughly the same time period in all 
mammals. During the migratory period, the cells mature by distinct processes, for 
example, enterocytes express enzymes involved in digestion while differentiating 
into their final structure. 
Peyer's patches are clusters of follicular domes scattered throughout the 
intestine at irregular sites, which overlay dense accumulations of lymphoid cells. 
Larger patches are visible by eye as pale oval plaques on the surface of the 
epithelium. Although cells present in other compartments are also found in Peyer's 
patches, a minor population of a functionally important class of cells is also present; 
M cells provide an effective immune response within the small intestine when 
required. 
In summary, the specific functions of the individual compartments are as 
follows: the crypts are the sites for electrolyte and water secretion, villi are the loci 
for electrolyte and nutrient absorption and Peyer's patches are the major sites of 
antigen sampling from the lumen. 
1.1.5 The intestinal vascular system 
The aorta supplies the small intestine with blood via two branches of the 
mesenteric circulation; the superior and inferior mesenteric arteries. Blood exiting 
the small intestine drains into a tributary of the hepatic portal vein. 
Aside from this systemic circulation, there is an additional extensive 
microcirculation within the small intestinal tissue. The muscularis extema and the 
mucosa itself have distinct microvasculatures, which are connected in parallel at the 
level of the submucosa (figure 1.2). The microvasculature of the muscularis extema 
initially originates from a small artery in the mesentery, which extends into a large 
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Figure 1.2 
Schematic diagram of the vascular system of the small intestine (adapted from 
Cooke, 1987). 
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arteriole leading eventually to the microvasculature. The large arteriole penetrates 
both the longitudinal and circular muscle layers and runs to the outer surface of the 
submucosa. It then gives rise to smaller second and third order arterioles, which 
eventually branch to form a complex series of vessels. These vessels lie 
perpendicular to the muscle fibres and supply the longitudinal and circular muscle 
capillaries which, in turn, run parallel to the muscle fibres in each layer. These 
capillaries then join a network of vessels, which return the blood from the muscle, 
and connect with the small veins in the mesentery. 
The vasculature of the mucosa is composed of distinct independent units; 
each villus has a miniature vascular bed with separate arterial and venous 
vasculatures. As mentioned previously in section 1.1.3, a single main arteriole 
supplies the villus; this is usually a terminal extension of a third order arteriole 
descending from the mus~ularis mucosa. Blood is drained from the villi by 
capillaries within the mucosa joining venules, which then lead to collecting venules 
in the muscularis mucosa. All blood leaving the small intestine does so via the 
hepatic portal vein. 
1.1.6 Absorptive cells 
Absorptive cells (enterocytes) are tall columnar cells with a highly polar 
nature that allows the vectorial transport of ions and nutrients from the lumen of the 
small intestine eventually to the systemic circulation. The structural polarity of 
enterocytes can be easily examined using a light microscope, where two distinct 
plasma membranes at opposing ends of the cell can be observed (figure 1.3a). The 
two membranes differ both morphologically and biochemically, and meet at the 
intercellular junctional complex. The cellular location of cytoplasmic organelles also 
forms the basis for cellular polarity. The nucleus is situated in the basal portion of 
the cell with the Golgi apparatus directly above. Other organelles are scattered 
throughout the cytoplasm (including the rough endoplasmic reticulum) whereas the 
smooth endoplasmic reticulum is most abundant in the apical half of the cell, beneath 
the terminal web. 
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Introduction 
GLYCOCALYX 
Structural polarity of an absorptive cell of the small intestine (a) and an enhanced 
view of the microvilli at the apical membrane (b), showing the underlying terminal 
web and surrounding glycocalyx. Source: Moog (1981). 
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1.1.6.1 The apical membrane 
Under the light microscope it can be seen that the apical membrane, facing 
directly into the lumen of the intestine, has a striated border composed of microvilli, 
at a density of approx. 2 x 105 rnm-2• Microvilli have a relatively uniform height 
(1 !J.Ill); their presence expands the surface area of the epithelium by a factor of 20, 
thereby significantly increasing the efficiency of the small intestine for nutrient 
absorption. The apical (or brush-border) membrane has an unusually high protein to 
lipid ratio (1.7:1) and this, in conjunction with a high cholesterol/glycolipid to 
phospholipid ratio, confers a relatively low fluidity of the membrane. The 
brush-border membrane (BBM) is also 20% thicker than plasma membranes in most 
other mammalian cells (approx. 10 nm), which is also due to the enhanced protein to 
lipid ratio. 
Directly below the microvilli is the terminal web (figure 1.3b). This area is 
free from organelles but contains proteins such as a-actinin and filamin. It is also 
integrated with a cytoskeleton consisting of approx. 20-30 microfilaments lying in 
parallel, which consist of a protein similar to actin. The terminal web, in conjunction 
with the cytoskeleton, functions to stabilise the microvilli by extending upwards into 
each individual microvillus to form an internal network. This network provides 
rigidity and, as the cytoskeleton contracts, it causes brush-border motility which, in 
tum, causes circulation of the gut contents and maintains continuous contact of the 
microvilli with nutrients. 
Projecting from the surface of the microvilli is a 'fuzzy coat' or glycocalyx 
(figure 1.3b). This network is composed of thin branching filaments, rich in 
polysaccharide that extend approx. 0.5-2.0!J.Ill. Aside from forming a separate 
compartment through which substrates must cross to gain access to the cell, the exact 
function of the glycocalyx is not clear. Various roles have been speculated, including 
a barrier to molecular diffusion (Hamilton & McMicheal, 1968), a site for absorption 
of extracellular enzymes (Pritchard, 1969) and as a protective barrier. It is known to 
have a considerable influence on the transport properties of the intestine because it 
interacts with the unstirred water layer (Thompson & Dietschy, 1977). 
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1.1.6.2 The unstirred water layer 
Adjacent to the surface of the apical membrane is an aqueous boundary 
layer; a proportion of this is trapped within the interstices of the glycocalyx filaments 
and the remainder forms a distinct region. The presence of the unstirred water layer 
increases the diffusion path for the movement of solutes which, in turn, influences 
the kinetics of membrane transport (Thompson & Dietschy, 1977). During 
investigations using intestinal perfusion techniques it is common to initiate stirring of 
the bulk medium adjacent to the unstirred water layer to reduce its effects on solute 
transport (Gardner, 1978). 
1.1.6.3 The basolateral membrane 
The basolateral (or basal) membrane IS structurally, chemically and 
physically distinct to the apical membrane, i.e. it is of similar composition as the 
majority of mammalian plasma membranes. In contrast to the presence of microvilli 
on the BBM, the surface of the BLM forms smooth contours with broad folds that 
may interdigitate with similar folds of adjacent cells (figure l.3a). Also in contrast to 
the brush-border membrane, it has a relatively high fluidity, due to a lower 
abundance of cholesterol. Its basal surface is closely associated with the basal lamina 
and an intercellular junctional complex separates it from the apical membrane. 
1.1.6.4 Junctional complexes 
Junctional complexes, or intercellular attachment zones, form the basis by 
which adjacent epithelial cells associate. The complex consists of three components 
that have distinct structural and functional characteristics. 
The component situated closest to the lumen is the tight junction (or zona 
occludens) which binds neighbouring cells just below the microvilli surface. These 
junctions are known to play an important role in regulating epithelial permeability by 
influencing the paracellular flow of fluid and ions. The structure of tight junctions 
appears to correlate inversely with permeability, i.e. as the number of interlocking 
ridges forming the junction increases, permeability is reduced. In addition to this 
major permeability role, the tight junction also serves as a barrier to the movement of 
integral membrane proteins and thereby preserves membrane polarity within the 
enterocyte. 
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Directly below the tight junction is the intennediate junction (or zonulae 
adherens) fonning a zone approx. 15-20 run wide. It is made of a fibrous material 
that fonns a mesh of microfilaments, which radiate into the tenninal web. As with 
the tight junctions, the intennediate junctions bind adjacent enterocytes together to 
fonn a continuous sheet as the cells traverse the villi. 
The third and final component of the junctional complex is the spot 
desmosome (or macula adherens). Unlike the tight and intennediate junctions, the 
spot desmosomes fonn a discontinuous belt around the cell. The lateral membranes 
of adjacent cells run parallel and, in the region of the spot desmosomes, the 
cytoplasm of the cells contains numerous tonofilaments embedded into a disc-like 
plaque (Kelly, 1966). These tonofilaments loop through the tenninal web and attach 
onto other spot desmosomes. Finer filaments spread from the plaque and anchor 
onto the tonofilaments and the lateral membrane. The spot desmosomes 
predominantly function to complete the structure of the junctional complex, to act as 
attachment sites for stabilising the cytoskeleton and to serve as spot welds between 
adjacent epithelial cells. 
1.2 PEPTIDE TRANSPORT 
1.2.1 History of protein absorption 
The early theories on protein absorption are covered in great depth by 
Matthews (1991); a brief description of the key ideas from the last two hundred years 
concerning the mechanism by which ingested protein is absorbed across the intestinal 
wall is given here and is summarised in table 1.1. 
It was long assumed that digestion predominantly occurred in the lumen of 
the small intestine and the intestinal lining served only as a passive membrane for the 
movement of the digestion products into the bloodstream (Moog, 1981). However, 
investigations into intestinal tissue demonstrated this was not the case. By the early 
20th century it was established that proteins comprised of chains of individual amino 
acids linked by peptide bonds. It had also been realised that the action of trypsin and 
'erepsin' (peptidases) resulted in the breakdown of proteins to peptones (small 
peptides) and amino acids, respectively. Absorption of intact proteins was no longer 
thought probable; digestion of proteins to peptones occurred, and the peptones were 
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Haller (mid 18th century) A substance that was an essential constituent of animal 
and plant tissue was discovered; this substance 
resembled modern protein. 
Halle (1792) Theory of animalisation of vegetable matter; 
nitrogen was incorporated into plant material in the 
lumen of the gut by highly nitrogenous intestinal 
secretions. Other theories suggested incorporation of 
nitrogen from the air. 
Dumas (1843) Solution theory; protein was dissolved within the gut 
lumen into a form that could be absorbed. 
Prout (1843) The level of protein 'lowered' during digestion and 
formed Albuminose, which was later renamed as 
'peptones' by Lehman in the 1950's. 
Funk (1850's) Proteins were absorbed as peptones by a 
combination of passive processes i.e. filtration, simple 
diffusion and osmosis. This theory was not widely 
accepted for a number of years because peptones could 
not be detected in the blood. 
Cohnheim (1901) Erepsin was discovered and shown to digest peptones 
to their constituent free amino acids. 
1920-1950 'Classical Theory of protein absorption': proteins 
are digested completely to amino acids before passive 
absorption into the tissue. 
Van Syke & Meyer (1921) a-amino nitrogen detected in blood 
Cathcart (1921) Demonstration that the intestinal tissue could 
actumulate intact peptides. This theory was also 
overlooked at the time. 
Wiseman (1951) Active transport of amino acids was demonstrated; 
additional experiments confirming this theory soon 
followed. 
Matthews (1968) Formation of the 'Dual Hypothesis' due to the 
transmural transport of intact peptides. This was the 
beginning of the end for the 'Classical Theory of 
protein absorption'. 
Table 1.1 
A summary of historically important ideas regarding the mechanism of intestinal 
protein absorption (Matthews, 1991). 
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readily, but passively, absorbed from the lumen by the gut tissue. However, 
scepticism with regard to this process flourished due to the fact that peptones could 
not be detected in the tissues or in blood (in retrospect this was due to the 
insensitivity of the assay methods used) and this theory, which is similar to the 
modem view, was completely overlooked for many years. 
The 'Classical Hypothesis of Protein Absorption' was widely accepted by 
the 1920's; ingested protein was thoroughly digested to free amino acids within the 
gut lumen and the amino acids were absorbed across the intestine into the 
bloodstream via passive mechanisms. Confirmation of this theory came with the 
detection of a-amino nitrogen in the bloodstream. Despite the controversial 
recognition by Cathcart (1921; see Matthews, 1991) that small peptides could be 
absorbed intact by tissues, this 'Classical Theory' dominated the world of protein 
absorption for more than 30 years. 
In the 1950's, Wiseman (1951; see Matthews, 1991) demonstrated that the 
transport of amino acids was an active process and, due to this revelation, the cellular 
mechanism of amino acid transport and protein absorption in general, received much 
attention. A great number of advances were made; transport was shown to be 
saturable, sodium-coupled and to obey Michaelis-Menten kinetics, mutual inhibition 
between some amino acids was observed and the idea was formed that different 
systems existed for the transport of distinct amino acids. 
Some years later, between 1956 and 1964, Newey and Smyth demonstrated 
that small peptides could be absorbed intact into the intestinal wall and then 
underwent cytosolic degradation to their constituent amino acids, the form in which 
they were released into the serosa (Newey & Smyth, 1960). The 'Dual Hypothesis' 
was instigated by the demonstration of transmural peptide transport by Matthews 
(1968; see Matthews, 1991), who stated that protein could be absorbed across the 
intestine in two ways; peptide transport followed by intracellular hydrolysis or 
luminal hydrolysis followed by amino acid absorption. These revelations, coupled 
with ever-increasing evidence that the 'Classical Hypothesis' could not adequately 
explain many experimental observations (table 1.2), opened the way for studies into 
the importance and mechanism of peptide transport in protein absorption. Therefore, 
some 20 years after the controversial revelations by Cathcart, the process of intact 
peptide absorption was finally accepted. 
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Predominant reasons for the fall of the 'Classical Hypothesis of protein 
absorption' 
(l) Complete intraluminal peptide hydrolysis to amino acids was never 
unequivocally demonstrated 
(2) Long standing notion that intestinal peptidases did not function in the lumen 
(3) Absorption of protein and free amino acids were equally as rapid 
(4) During protein absorption, ammo acid plasma levels peaked pnor to 
intracellular levels of the enterocytes 
(5) Inferiority of amino acid mixtures in simulating protein composition 
(6) Emergence of numerous reports claiming large scale entry of pep tides into the 
blood 
(7) Absence of protein malnutrition in patients with ammo acid absorption 
diseases e.g. Hartnup disease and cystinuria 
(8) Initial experiments examining peptide transport showed that dipeptide 
hydrolysis occurred at an intracellular location and not in the lumen. 
Table 1.2 
A summary of the experimental observations that could not be fully explained by the 
'Classical Theory' of protein absorption (Matthews, 1991). 
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1.2.2 Peptide transport 
The transmembrane transport of peptides is a phenomenon widely 
distributed throughout nature; it is found in animals (including man), in bacteria, in 
yeast, in mould and also in germinating seeds of higher plants (Matthews, 1991). 
Peptide transport is not only conserved as a process throughout evolution, its 
operational mechanism has also been stringently preserved. In biological systems, 
the transport of organic solutes is an active step coupled primarily to transmembrane 
ion gradients. The principal inorganic coupling ion in microbes is H+, and it is the 
proton-motive force that provides the primary energy source for solute transport. In 
contrast the principal coupling ion in the animal kingdom is Na +, though peptide 
transport is an exception. The energetics of ion-coupled peptide transport are unique; 
the evolutionary shift in the coupling ion, i.e. from W to Na+, that occurred in the 
case of amino acids and sugars, did not occur in the case of peptides, and this alone 
distinguishes it from most other mammalian solute transport processes. 
1.2.2.1 Advancement in the study of peptide transport 
The cellular mechanism of peptide transport has only been seriously 
investigated for about the last 20 years and so our understanding of the precise nature 
of transmural peptide transfer across the membrane has fallen considerably behind 
that for amino acid and sugar transport. A major obstacle in the progression of our 
comprehension of peptide transport has been due to the reluctance of many different 
groups, who were interested in absorption, to accept its important nutritional role. 
Furthermore, a lack of suitable hydrolysis-resistant substrates with which to 
investigate the characteristics of transport only augmented this mainstream 
resistance. A couple of major advances rapidly paved the way for a great number of 
studies into peptide transport; the first was the development of the method for 
efficiently isolating membrane vesicles (Sigrist-Nelson, 1975) and the second was 
the realisation that Gly-containing di- and tripeptides were relatively resistant to 
hydrolysis. 
1.2.2.2 Sites of oligopeptide transport 
The small intestine is obviously an important site of protein absorption from 
a nutritional point of view and therefore much attention has focused on the 
15 
Chapter 1 Introduction 
mechanisms of oligopeptide (di- and tripeptide) transport in this tissue. In addition to 
an intestinal location, other important sites of transmural peptide transfer have now 
been recognised in various epithelial tissues; these include the apical membrane of 
the kidney proximal tubule, the lung (Meredith & Boyd, 1995) and the placenta 
(Meredith & Laynes, 1996). Peptide transport in the kidney proximal tubule serves 
to reabsorb peptides from the tubule lumen, including those from the glomerular 
filtrate, and also oligopeptides formed from the action of brush-border membrane 
peptidases on large filtered endogenous peptides. 
1.2.2.3 Importance of peptide transporters 
The function of peptide transporters has three distinct implications; 
nutritional, pharmacological and clinical. 
1.2.2.3.1 Nutritional implications 
Peptide transporters in both the intestine and the kidney are involved in the 
nutritional status of the organism, in a direct and indirect manner, respectively. The 
absorption of protein digestion products occurs primarily as peptides, not amino 
acids; intact uptake of peptides provides an efficient and economic route for cells to 
absorb amino acids which are needed for growth and development. Early 
experiments have shown that 3 h after a protein meal, the intestinal lumen contains a 
higher proportion of peptides than amino acids (Adibi & Mercer, 1973; see 
Matthews, 1991); approx. 80% of jejunal contents were in the form of small peptides 
(2-4 amino acids) and the remainder in the form of free amino acids. It is also well 
known that peptides are absorbed more rapidly than free amino acids (Matthews, 
1991). In addition, more than 50% of the plasma amino acid pool is in the form of 
peptides, one quarter to a half of this percentage are di- or tripeptides (Leibach & 
Ganapathy, 1996). 
Peptide transporters m the kidney play a role in conservmg the 
peptide-bound amino nitrogen, which would otherwise be lost in the urine; the 
excretion of peptide-bound amino acids in the urine is extremely low demonstrating 
the efficiency of the system. 
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1.2.2.3.2 Clinical implications 
In current clinical practice, small peptides are seriously considered as viable 
substitutes for free amino acids to provide a nitrogen source in enteral and parenteral 
solutions. These peptide solutions may provide an absorptive advantage to patients 
that have a severely reduced intestinal absorptive area and also to patients who are 
acutely catabolic (trauma, sepsis or burns) (Leibach & Ganapathy, 1996). The use of 
peptides, rather than free amino acids, has several advantages, for example it is well 
known that all amino acids are absorbed more efficiently as part of a peptide than 
alone, with the exception of arginine (Adibi, 1997). In addition, the absorption of 
free amino acids is highly selective whereas the absorption of peptides is less so, 
possibly due to the carrier having a greater capacity for transport and a very broad 
substrate specificity. Certain free amino acids cannot be included in enteral solutions 
for various reasons, e.g. glutamine is very unstable and tyrosine is insoluble, and so 
current elemental diets are lacking in them. The use of peptides can be used to 
overcome this major problem. Elemental diets are also very hypertonic; this high 
pressure can be reduced with the replacement of amino acids for peptides. A reduced 
osmolarity is an advantage especially for patients with severe fluid restriction 
(Leibach & Ganapathy, 1996). 
1.2.2.3.3 Pharmacological implications 
A number of orally active peptide antibiotics possess structural features 
similar to physiologic substrates of the peptide transporters. They are accepted as 
substrates by the peptide carriers; the transporters in the lumen of the intestine act as 
vehicles for their efficient absorption when administered by the oral route. The 
relative efficacy of the peptidomimetic drugs is determined by their relative affinity 
for the peptide transporters; their pharmacological potency is not only determined by 
their rate of absorption from the small intestine, but also by their half-life in 
circulation. Peptide transporters in the kidney are responsible for the reabsorption of 
these drugs from the glomerular filtrate and function to prolong their time spent in 
the bloodstream (Le. increase their bioavailability) in order to aid in their 
pharmacological action. Peptidomimetic drugs can be used to treat infection 
(~-lactam antibiotics), hypertension (angiotensin-converting enzyme (ACE) 
inhibitors and renin inhibitors) and cancer (bestatin). Intravenous administration of 
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drugs is often associated with a wide range of potential problems, which can be 
avoided with an oral delivery. 
It has also been suggested that peptide transporters, in conjunction with the 
action of cytosolic peptidases, can be exploited for the systemic delivery of certain 
drugs in the form of peptide pro-drugs. For example, a-methyldopa is a 
poorly-absorbed antihypertensive agent and amino acid analogue. Dipeptide 
analogues of a-methyldopa, for example, L-a-methyldopa-Phe (Tsuji et al., 1990) 
and L-a-methyldopa-Pro (Hu et al., 1989), are found to be absorbed from the 
intestinal lumen significantly better than a-methyldopa because they can utilise the 
peptide transporters. Once inside the enterocyte the peptide analogues are hydrolysed 
by cytosolic peptidases to release L-a-methyldopa. 
There are also possibilities of utilising oligopeptide transporters in the 
chemotherapeutic treatment of cancer. A dipeptide transport system, which is 
similar, but not identical to PepTI and PepT2, has been discovered in 
fibroblast-derived tumour cells but which is not present in normal fibroblast cells 
(Nakanishi et al., 1997). This novel finding could form the basis for a strategy in the 
delivery of peptidomimetic anticancer drugs specifically into the tumour cells. 
However, further work is required in order to elucidate whether there is selective 
expression of this transport system in various tumour cells, but not in normal cells. 
1.2.3 Mechanism of peptide transport 
1.2.3.1 Driving force for active transport 
Peptide transport was demonstrated to be an active process by early studies 
using everted sacs of hamster jejunum (Addison et al., 1972); Gly-Sar was shown to 
accumulate inside the jejunal sacs. However, unlike amino acid transport, peptide 
transport was not driven by a sodium gradient, demonstrated by sodium replacement 
experiments (Cheeseman & Parsons, 1974). Boyd & Ward (1982) revealed that 
peptide transport was electrogenic (Le. influenced by changes in membrane potential) 
by investigations in which the application of neutral peptides (Leu-Leu, Val-Val) to 
the apical membrane of the mud puppy Necturus maculosus small intestine, even in 
the absence of sodium, caused depolarisation of the membrane. The use of peptides 
with no net charge signified that the membrane depolarisation was not due to the flux 
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of the peptide itself, but that the flow of another ionic species was associated with 
entry of the peptide into the epithelium. 
The stimulation of peptide transport by an inwardly directed proton gradient 
(suggesting H+ -coupled transport) was initially detected using intestinal epithelial 
brush-border membrane vesicles (BBMV) by Ganapathy & Leibach (1983). They 
found that peptide uptake was optimal at an extravesicular pH of 5.5-6.0. It was 
thought that this optimisation in transport was not a result of a change in the 
abundance of transportable zwitterionic species of the peptides used (Gly~Pro, 
carnosine), because they have widely different pI values (5.8 and 8.7, respectively). 
Neither was it due to a change in external pH per se, but a result of generating an 
inwardly directed H+ gradient, due to the acidity or'the external medium relative to 
intracellular medium. An equivalent stimulation of peptide transport in renal BBMV 
was demonstrated virtually simultaneously by subsequent experiments performed by 
Ganapathy et al. (1984) and Takuwa et al. (1985). In particular, Takuwa and 
colleagues revealed that the uptake of Gly-Gly into BBMV exhibited the classical 
'overshoot' phenomenon (figure 1.4), providing the first evidence for the transient 
uphill transport of the peptide against its concentration gradient. 
Ganapathy & Leibach (1983) agreed with previous investigations by Boyd & 
Ward (1982) that the H+ gradient-dependent transport of peptides was electrogenic. 
An inside-negative membrane potential (generated by valinomycin) enhanced the 
proton-dependent transport of Gly-Pro two-fold, whereas an inside-positive 
membrane potential (generated by FCCP) significantly reduced transport. This 
indicated that peptide transport across the brush-border membrane was associated 
with the net transfer of a positive charge. This proton-dependent and membrane 
potential-stimulated transport of zwitterionic peptides also occurred in the absence of 
Na+, suggesting that peptides were cotransported with a cation other than Na+. 
Further work by Ganapathy & Leibach (1985) demonstrated the specific inhibition of 
H+ gradient-stimulated transport by the presence of a proton ionophore; this was the 
first real indication that H+ may be cotransported with peptides and, therefore, that an 
electrochemical H+ gradient might be the driving force for peptide transport. 
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The time CQurse for the uptake of the neutral dipeptide (Gly-Gly) into renal brush-
border membrane vesicles in the absence (open symbol) and presence (filled symbol) 
of an inwardly directed proton gradient and an inside negative membrane potential. 
The transport of Gly-Gly exhibits the classical 'overshoot' phenomenon in the 
presence of an electrochemical W gradient, demonstrating that the transport of the 
peptide is an active step and is performed against its concentration gradient. Source: 
Takuwa et 01. (1985). 
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1.2.3.2 Role of the acidic microclimate 
The presence of an acidic microclimate, an area of low pH immediately 
adjacent to the brush-border membrane, has been well documented. The first 
evidence of its existence in vitro was achieved using everted sacs of rat proximal 
jejunum by Lucas et al. (1975), using microelectrodes. It was then demonstrated in 
vivo (McEwan et al., 1988). A region of low pH (PH - 5.5) was found at the luminal 
surface of the apical membrane, although the pH of the bathing solution was pH 7.2. 
Additional studies using biopsy samples have demonstrated its presence in man 
(Lucas et al., 1976; Lucas et al., 1978, see Ganapathy & Leibach, 1985). 
The precise mechanisms involved in the generation and maintenance of the 
acidic microclimate are not well understood, but the Na + /H+ exchanger located in the 
apical membrane (NHE-3) is at least partially responsible for the secretion of protons 
into the lumen in vivo. The action of this membrane protein indirectly provides the 
driving force for peptide transport and as such is described as a secondary transport 
system (figure 1.5). The luminal concentration of Na+, in vivo,. is greater than its 
intracellular concentration (originating from the diet and gastric, pancreatic and 
intestinal secretions). These high levels would drive the exchanger in the direction of 
proton secretion, thus generating an inwardly-directed proton gradient across the 
brush-border membrane. The co-transfer of protons with peptides into the cell causes 
the intracellular pH to drop and this increase in cytosolic H+ concentration would 
stimulate the Na+/H+ exchanger to transport H+ out, and Na+ into the cell. The action 
of the exchanger means that both the intracellular pH and the transmembrane 
electrical potential would be restored to basal levels. Intracellular Na+ concentration 
is maintained low by the action of a primary transport system, the Na + /K+ -ATPase 
located in the basolateral membrane. This protein functions to re-establish the high 
extracellular Na + gradient, at the cost of ATP hydrolysis. Due to the actions of these 
two ion transporters in providing the driving force for peptide transport, the peptide 
transporter in the apical membrane is classified as a tertiary transport system. 
In addition to the role of the apical Na+~ exchanger in restoring 
intracellular pH following peptide-induced acid load in the enterocytes, Thwaites et 
al. (1993) demonstrated that pHi recovery also occurred in the absence of external 
Na+. They suggested that an alternative transporter (H+/K+-ATPase) may also 
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Schematic diagram showing the transport systems involved in intestinal peptide 
absorption, either directly or indirectly. The primary transport system is the 
Na+/K+-ATPase located in the basolateral membrane, which forms the sodium 
gradient across the apical membrane. The secondary system is the Na+/H+ exchanger 
in the apical membrane, which, in turn, creates the transmembrae H+ gradient (the 
acidic microclimate) to drive peptide uptake into the cell by PepTl (the tertiary 
system). The peptide transporter in the basolateral membrane has not yet been 
identified. 
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function in this capacity, albeit to a lower extent. The relative roles of the two 
transporters would depend on the nutritional status of the intestinal contents. 
The acidic microclimate is present in the lumen of both the intestine and the 
kidney. In the intestine the H+ concentration of the microclimate is at least ten times 
that found inside the enterocytes and in the kidney the concentration is thought to be 
approx. 4-fold higher (Ganapathy et al., 1987). Therefore, in both intestinal and 
renal tissue, where peptide transport is known to be significant, an inwardly-directed 
proton gradient is thought to be due to the existence of an acidic microclimate. 
Although its presence at the apical membrane had been elucidated, its physiological 
significance had not been postulated, although it now seems clear that it has a major 
role in the maintenance of protein nutrition in man and other animals. 
The physiological importance of the acidic microclimate is indicated by 
vanous intestinal disorders wherein it becomes relatively alkaline, for example 
coeliac sprue, tropical sprue and Crohn's disease. These disorders are associated 
with the malabsorption of peptides, demonstrating a cause-and-effect relationship 
(Ganapathy et al., 1991). It is also advantageous to the organism in a nutritional 
aspect to utilise a proton gradient for the active absorption of peptides and a sodium 
gradient to energise amino acid absorption because it eliminates competition between 
peptides and amino acids for the same driving force. The distinct processes allow 
both systems to operate simultaneously and in parallel to increase the efficiency of 
the absorption of amino nitrogen by the small intestine. 
1.2.3.3 pH-dependence of transport 
As previously mentioned, it is thought that any effect of extracellular pH on 
peptide transport is indirect and is due specifically to changes in the 
inwardly-directed proton gradient. However, a protein has been identified from the 
Caco-2 cell line by Saito et al. (1997) which they suggest is a novel pH-sensing 
regulatory factor that modulates transport activity of the human peptide transporter 
(hPepTl). The 23 kDa protein, consisting of 208 amino acids, was identified from a 
human duodenum eDNA library during the course of homology screening using a 
partial cDNA fragment coding for hPepTI in an attempt to obtain related proteins. 
The novel eDNA clone has been termed hPepTI-RF. Hydropathy analysis of its 
primary amino acid sequence indicates five transmembrane (TM) a-helices, but no 
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potential sites for eith~r protein kinases C or A, or N-linked glycosylation sites have 
been speculated. Interestingly, the 18-195 amino acid sequence of hPepTI-RF is 
identical to the corresponding sequence (8-185) in hPepTl, whereas the N-tenninal 
residues (1-17) and C-tenninal residues (196-208) were unique and showed no 
homology with the corresponding regions ofhPepTI. 
hPepTI-RF does not have transport activity but co-injection of its cRNA 
into Xenopus laevis oocytes with hPepTl cRNA causes a shift in the pH optimum for 
Gly-Sar transport from pH 5.4 to a more neutral pH 6.0, when compared to hPepTl 
expression alone. However, hPepTI-RF did not appear to have any regulatory 
activity at pH 6.0-7.4, suggesting that it does not function by affecting membrane 
insertion/targeting or synthesis of hPepTl. A structural interaction has been 
hypothesised due to extensive homology between the two proteins, especially the 
entire amino acid identity around their predicted TM domains. However, further 
work is required to elucidate the role of this protein in peptide transport. 
1.2.3.4 Mechanism ofW/peptide cotransport 
In contrast to the work by Saito. et al. (1997) above, Nussberger and 
co-workers (1997) proposed that PepTl is able to sense the pH of both the external 
and intracellular medium and it is this ability which regulates peptide transport, not 
an additional associated protein. They state that PepTI has a single H+-binding site 
which is accessible from both faces of the apical membrane, and that binding of a 
proton at either surface results in a confonnational change of the protein. If the 
proton binds at the extracellular surface, the protein adopts an outwardly occluded 
confonnation, and vice versa. However, the protonated states of the protein are not 
able to cycle between the two faces of the membrane without associated binding of a 
peptide. It is thought that it is the ratio of H+ concentration on either side of the 
membrane which detennines the direction of transport, i.e. if plIo < pHi then W will 
bind predominantly at the extracellular surface to induce transport of peptides into 
the cell, and vice versa. H+ binding has been shown to be voltage dependent (Uiuger 
& Jauch, 1986), however, the charge movements of transport are due to reorientation 
of the empty, charged carrier within the membrane field, in addition to H+ 
binding/dissociation from the carrier (MacKenzie et al., 1996). 
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The exact mechanism they propose is as follows; H+ bind to PepTI prior to 
substrate, in an orderly manner (MacKenzie et al., 1996). At low pHo the number of 
PepTI protein molecules that exist in the outwardly-occluded state, due to bound H+, 
increases and in this state the carrier has an increased affinity for substrates 
(MacKenzie et al., 1996; Nussberger et al., 1997). Binding of the substrate 
completes this process and translocation of both if and substrate occurs 
simultaneously in the same reaction step (MacKenzie et al., 1996). The process 
makes physiological sense, i.e. the acidic microclimate would promote the existence· 
of the proton bound/outwardly-occluded conformation and therefore stimulate 
efficient peptide absorption. 
1.2.4 Membrane preparations used to study peptide transport 
A number of different preparations have been used to study peptide 
transport, including brush-border and basolateral membrane vesicles (Temple et al., 
1995; Dyer et al., 1990, respectively), isolated cells (Cheeseman & Devlin, 1985), 
cell lines, e.g. Caco-2 (Thwaites et al., 1993b), MDCK cells (Brandsch et al., 1995), 
and intact epithelial tissue (Lister et al., 1995). Each of these has distinct advantages 
and disadvantages with respect to the other preparations. 
Intact tissue preparations provide information on transmural substrate 
transport. However, transmural transport involves a solute traversing two distinct 
membranes, apical and basolateral, and these can be difficult to distinguish in intact 
tissue (except when using the vascular perfusion, in situ, technique - for details see 
the relevant results chapters (3 & 6». Vesicles produced from either apical or 
basolateral membranes can be used to separate the transport mechanisms at the 
distinct membranes. Isolated cells are useful for electrophysiological studies and for 
fluorescence studies, i.e. in the measurement of intracellular pH, but the polarity of 
epithelial cells begins to dissipate within a few hours of isolation. Cell lines 
(e.g. Caco-2) have the same polarity as intestinal epithelial cells and retain it for 
longer. Due to the advancement in recent years, many solute transporters have now 
been cloned (see section.1.3) and these proteins can be over-expressed in cells which 
have little or no endogenous transport activity for the protein under investigation to 
allow the study of a single protein in isolation. For example, Xenopus laevis oocytes 
are used to over-express PepTI and study apical peptide transport. This is an 
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advantage if there are a number of different members of a transporter family present 
in a native membrane and only one is of interest, but if a number of different proteins 
interact with each other for substrate transport this will not be feasible. 
However, what is observed in vitro might not actually be the same as what 
occurs in vivo, and so a range of different preparations should be used for the study of 
a transport process. 
1.3 MOLECULAR PHYSIOLOGY OF THE PEPTIDE 
TRANSPORTERS 
1.3.1 Cloning of the intestinal peptide transporter, PepTl 
Although considerable progress has been made in the elucidation of 
transporter function and mechanism over the last decade, the precise structure and 
molecular properties of the proteins had not been determined until recent years. 
An initial step towards cloning and characterisation of the mammalian 
peptide transporters was performed in 1991 by Miyamoto and co-workers. 
Microinjection of rabbit intestinal poly(At mRNA into Xenopus laevis oocytes led 
to the first functional expression of a peptide transport system with characteristics 
similar to those of the transporter in its native tissue. Transport inhibition studies 
using dipeptides and free amino acids demonstrated that the transporter retained its 
H+ -dependence and substrate specificity. 
The year of 1994 saw the beginning of a new era of peptide transport 
studies, which progressed from this preliminary study. The rabbit intestinal peptide 
transport system was the first mammalian transporter to be cloned and sequenced 
(Fei et al., 1994). Briefly, poly(At mRNA Was isolated from rabbit small intestine 
and injected into Xenopus laevis oocytes. Transport activity of mRNA-injected 
oocytes was assessed against water-injected cells using radioactively labelled 
peptides as substrates. This was followed by size-fractionation of the mRNA, and an 
RNA-pool containing the required message was used to construct a cDNA library in 
a bacterial vector. Individual cDNA clones from the library were transcribed into the 
corresponding cRNAs, which were then individually injected into oocytes. The 
oocytes containing distinct cRNAs were assayed for the induced peptide transporter 
activity. This screening procedure was performed to isolate a single clone encoding 
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the transport activity of interest. The cDNA of the specific clone was analysed to 
determine the primary amino acid sequence of the transport protein. Hydropathy 
analysis of the protein's amino acid sequence permitted initial predictions of the 
topological arrangement of the transporter protein within the plane of the cell 
membrane. 
Using this approach Fei et al. (1994), followed closely by Boll et al. (1994), 
identified a 2.7 bp and 2.9 bp· cDNA, respectively, that, after injection of the 
corresponding cRNAs into oocytes, induced a transport activity resembling all 
aspects of peptide transporter characteristics observed in intestinal vesicles. The 
cDNAs were obtained from rabbit mucosa and, following in vitro transcription and 
expression in oocytes, the uptake of 14C-Gly-Sar was more than 63-fold above 
control oocytes (Fei et al., 1994) and 3H-cefadroxil uptake was 50-fold higher (Boll 
et al., 1994). To investigate the characteristics and rheogenicity of transport, the 
two-electrode voltage clamp technique was applied. Large inward currents, causing 
depolarlsation of the membrane, were found when substrates such as dipeptides, 
tripeptides and [3-lactam antibiotics were applied, but single amino acids or 
tetrapeptides did not evoke a similar current (Fei et al., 1994; Boll et al., 1994). H+ 
cotransport was demonstrated by monitoring the intracellular pH of the oocytes by 
using a pH-sensitive microelectrode (Fei et al., 1994) or a pH-sensitive fluorescent 
dye (carboxy-SNARF1) (Boll et ai., 1994). In these studies, application of Gly-Sar 
or cefadroxil, respectively, to the oocytes caused pHi to decrease significantly, 
whereas single amino acids did not evoke the same effect. 
The functionally expressed protein isolated by both groups was found to be 
the same; the intestinal peptide transporter, PepTl. The cDNA coding for the 
expressed protein revealed 707 amino acid residues (71 kDa) and hydropathy 
analysis of its primary sequence designated 12 transmembrane (TM) domains and an 
unusually large hydrophilic loop located between TM 9 and 10. A detailed 
description and diagram depicting the membrane model of the protein is given in a 
later section (section 1.4.1). 
Although the protein isolated by the two groups was thought to be identical, 
differences in transport function became apparent, for example, pH-dependence and 
effect of membrane potential. Boll et al. (1994) detected a pH optimum of 6.5 for 
cephadroxil uptake, whereas Fei et al. (1994) found the optimum uptake for Gly-Sar 
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was pH 5.5. Fei et al. (1994) also discovered that transporter activity was 
independent of membrane potential, in opposition to the situation that Boll et al. 
(1994) reported. It is clear that the observed discrepancies of pH-dependence are 
potentially due to the different substrate employed, but the distinct views on 
membrane potential were not explained. 
Subsequent to the cloning and expression of rabbit PepTl, other groups 
followed suit and the following few years saw the cloning of many other mammalian 
peptide transporters. Human PepTl was the next transporter to be cloned and 
sequenced (Liang et al., 1995). A human intestinal cDNA library was screened with 
a probe derived from the rabbit peptide transporter previously cloned by this group 
(Fei et al., 1994). A cDNA was identified which when expressed in oocytes or HeLa 
cells induced a H+-dependent peptide transport activity. 
At the same time, Saito et al. (1995) reported the cloning and sequencing of 
the peptide transporter from rat small intestine. 
A detailed discussion of the structure, plus sequence comparisons, of the 
aforementioned PepTl protein(s) cloned from the different species is given in section 
1.4.1. 
1.3.2 Cloning of the renal peptide transporter, PepT2 
Although it was known that peptide transport occurred in the kidney, 
characterisation of the protein responsible was not conducted until after the intestinal 
isoform had been cloned in many species. Cloning and characterisation of PepT2 
will be discussed only briefly, with a more detailed account of its structure given in 
section 1.4.1. 
The first renal isoform cloned was from human tissue (Liu et al., 1995). Its 
cDNA was predicted to encode a protein of 729 amino acids, expected to have a 
molecular weight of 81,940 Da and a pI of 8.26. The following year both rat (Saito 
et al., 1996) and rabbit (Boll et al., 1996) PepT2 were cloned and sequenced. 
PepT2 mRNA is predominantly expressed in the kidney (especially in the 
medulla compared to the cortex) but cannot be detected in the small intestine. It has 
also been shown to be present in brain, lung and spleen where it is thought that it may 
participate in unrecognised physiological function(s) related to active transport of 
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oligopeptides into these tissues (Saito et al., 1996). Rabbit PepT2 is also expressed 
in these tissues, but has an additional location in the heart (Boll et al., 1996). 
1.3.3 Sequence similarity of mammalian peptide transporters with 
other known proteins 
. PepTI and PepT2 belong to the POT (proton-dependent oligopeptide 
transport) family recently identified by Paulsen & Skurray (1994). Following cloning 
and expression of rabbit PepTI by Fei and co-workers (1994), they reported that two 
other proteins share limited sequence similarity; ChLl (a proton-dependent nitrate 
transporter identified from Arabidopsis thaliana) and Ptr2 (a peptide transporter 
identified from Saccharomyces cerevisiae). Paulsen & Skurray used the rabbit 
sequence to scan the SwissProt database in an attempt to identify similar proteins. 
Several proteins were found including DtpT (an oligopeptide transporter from 
Lactococcus lactis), partially sequenced open reading frames from rice, yhiP (a 
hypothetical protein) and a region downstream of the cadA and cadB genes on the 
Esherichia coli chromosome. All of the proteins identified have 12 TM domains and 
share two highly conserved regions; sequence 1 (located between TM 2 & 3), 
sequence 2 (located within TM 5) (table 1.3). All of the proteins show 
H+ -dependence in the transport of their substrates. 
Subsequent to this study, additional protein sequences have been deposited 
into this database (table 1.3); these transporter proteins are isoforms of those already 
published by Paulsen & Skurray. 
A few years later, Graul & Sadee (1997) performed their own investigations 
m which they compared the primary sequences of all PTR family members 
(equivalent to the POT family described by Paulsen & Skurray, 1994) to determined 
whether the order of the TM domains, including adjoining loops, had changed during 
evolution. In addition, conserved domains and/or residues were identified in an 
attempt to relate them to POT transporter function. The results revealed the presence 
of highly conserved regions/residues interspersed with less well conserved 
sequences. The two consensus motifs found by Paulsen & Skurray were identified in 
this study, in addition to other regions and residues, including; 
• a glycine-rich domain (GLALIALGTGGI) in TM 4, 8, 10, 11 - may 
represent a region of functional significance 
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Name Source and function Accession no. Sequence 1 Sequence 2 
PepTl# rabbit intestine P36836 LGALIADAWLGKFKTIVWLSIVYTIG FSIFYLAINAGSLLS 
PepTl human intestine P46059 LGALIAD+WLGKFKTIV LSIVYTIG FSIFYLAINAGSLLS 
PepTl rat intestine P51574 LGALIAD+WLGKFKTIV LSIVYTIG FSIFYLAINAGSLLS 
PepT2 rabbit kidney P46029 LGA IAD+WLGKFKTI++LS+V +G FS FYLAINAGSLLS 
PepT2 Hhuman kidney *S78203 LGA IAD+WLGKFKTI++LS+VY +G FS+FYL+INAGSL+S 
PepT2 rat kidney *063149 LGA IADAWLGKFKTI++LS+V +G FS+FYLAINAGSL+S 
PTR2# yeast peptide transporter P32901 G +AD + GK+ TI + +Y G F FY IN GSL 
PTR2 yeast peptide transporter P46030 +G + D LG +TIV ++V IG F++FY++IN GSL++ 
PTR2A yeast peptide transporter P46031 ALIAD +LG++ TIV +++Y IG + IFY IN GSL 
PTR2B yeast peptide transporter P46032 +GA++ADA+ G++ TI S +Y IG F+ FY +IN G+L+S 
DTPT# diltri peptide transporter P36574 +G +AD LG +TI I+ TIG F+IF + IN GSL++ 
TAT2 yeast tryptophan transporter P38967 A+ W ++W++I Y + 
CHLl# nitrate/chlorate transporter Q05085 LG lAD +LG++ TI + + G F+ F IN GSLL+ 
NIRC potential nitrate transporter P25926 A++ WLG V+++++Y+ G 
NIRC potential nitrate transporter Pll097 A++ WLG V+++++Y+ G 
QAY quinate transporter P1l636 L A +LG+ K+++ S+V+ IG 
ATKB . KlCu transporting ATPase P05425 +G FK WLS++ IG 
YHIP# Hhypothetical protein P36837 +G + D LG +TIV ++V IG F++FY++IN GSL++ 
Table 1.3 
Membrane proteins which have identity/similarity (+) to two sequences in rabbit PepTl (taken from Paulsen & Skurray, 1994, #), which are both 
.conserved in members of the POT family of transporter proteins; sequence 1 (located between TM 2 & 3), sequence 2 (located within TM 5). 
NB only members of the POT family have sequence identity/similarity to sequence 2. Accession no. is for the Swiss Protein database (*Genbank). 
Source: C. Temple thesis (1996). 
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• several conserved proline residues in TM 1, 2, 7, 8 - structurally 
important because of their ability to induce bends in a.-helices 
• a glutamine residue in TM 10 - the only charged residue fully 
conserved, therefore may have a possible role in W translocation 
• glycine residues in several TM's - suggest a common structure for 
portions of the transporters. 
They concluded that the PTR transporters have a modular structure, each module 
consisting of one or more TM domains that were rearranged by a number of 
evolutionary mechanisms to affect their order in the primary structure of the protein. 
1.3.4 Cloning of other Ir/peptide co-transporters 
A 92 kDa protein (HPT-I) has been cloned from Caco-2 cells which, when 
expressed in Chinese Hamster ovary (CHO) cells, enhances the transport of 
dipeptides and other PepT substrates (bestatin, cephalexin) in a pH-dependent 
manner (Dantzig et al., 1994). However, it has only one putative TM domain, in 
contrast to the previously described peptide transporters, and is therefore thought 
unlikely to function as a transporter, although it may self-aggregate or associate with 
another (unidentified) protein to form a multimeric protein that exhibits transport 
activity. HPT-l does not show any sequence homology with the POT family of 
transporters but database searches revealed a certain similarity (20-30% identity) to 
members of the cadherin superfamily of calcium-dependent, cell-cell adhesion 
proteins. In the single. TM domain there are no residues which implicate it is a 
functional transporter, i.e. there are no charged groups for substrate interaction. 
Therefore, it may possibly act as a modulator of peptide transport in Caco-2 cells 
(Hediger et al., 1995) through another carrier, e.g. PepTl (HPT-l is only expressed 
in the intestine). 
Other putative mammalian peptide transporters that have been identified 
include a peptide/histidine transporter (PHT1) from a rat brain cDNA library 
(Yamashita et al., 1997). This is the first neurospecific PepT member to be reported, 
however, it not only transports small peptides, but histidine is also a substrate. The 
amino acid sequence of PHTI has 17% identity (32% similarity) to known PepTl 
proteins, and 12% identity (27% similarity) to known PepT2 proteins. 
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Potential peptide transporters have also been found in non-mammalian 
specles. Fei et al. (1998a) revealed the existence of two carrier proteins in 
Caenorhabditis elegans by performing database searches. The proteins, designated 
OPT! and OPT2, are homologous to mammalian counterparts, PepT! and PepT2. A 
moderate sequence identity is observed between the two distinct groups, i.e. 36-47% 
amino acid identity, in addition to some similarity with PHT1 (approx. 25%). 
Transport characteristics are comparable to the mammalian proteins; transport 
exhibited electrogenicity plus dependence on membrane potential and substrate 
concentration (transport is saturable). 
A later study by Fei and co-workers (2000) identified a third putative 
peptide transporter (OPT3) from C. elegans, which was expressed only in neurons. 
The primary sequence of OPT3 has 49% identity (38% similarity) with OPT1, and 
48% identity (39% similarity) with OPT2. However, this protein was also found to 
function as a It channel, suggesting an important role in It homeostasis, in addition 
to its likely role in the clearance of peptides formed from the metabolism of 
neuropeptides. 
1.3.5 Tissue distribution of peptide transporters 
It is widely known that PepT1 is predominantly expressed in the small 
intestine, whereas PepT2 is localised to the kidney. The functional characteristics of 
peptide transporters have been only investigated thoroughly in these tissues, but, in 
addition to these two predominant sites of expression, the transporters are also found 
in other tissues, although the localised function may not be known. Northern blot 
analysis of cloned PepT1 and PepT2 reveal distinct species differences in tissue 
distribution. Although PepT! mRNA is found ubiquitously in the small intestine of 
rabbit, rat and human, and at lower levels in the kidney, it can also be detected in the 
liver (rabbit and human), in addition to the brain (rabbit) and pancreas (human) (Fei 
et al., !994; Liang et al., 1995; Saito et al., 1995). Ogihara and co-workers (1996) 
used immunoblotting and immunofluorescence techniques to demonstrate that PepT1 
was localised to the apical membrane of intestinal enterocytes, with the jejunum 
showing the strongest signal (Miyamoto et al., 1996a). The intensity of PepT1 
staining in the villi increased from the villus base to the villus tip, indicating that 
during the maturational process the absorptive cells acquire and express PepT! 
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mRNA (Ogihara et al., 1996), also demonstrated by Freeman et al. (1995) in which 
the maximum level of PepTI mRNA was detected at approx. 100-200 J..lm from the 
crypt-villus junction and then reached a plateau towards the tip. 
In contrast, PepT2 mRNA is detected in great abundance in the kidney of 
rat, rabbit and human and to a lower extent in rat and rabbit lung (Lui et al., 1995; 
Saito et al., 1996; Boll et al., 1996). It can also be found in rat brain and spleen, and 
in the heart tissue of rabbit, but it is not detected in the small intestine. 
The findings that PepTl and PepT2 mRNA are both expressed in kidney are 
consistent with results of vesicle studies indicating that at least two transporters exist 
in this tissue (Miyamoto et al.~ 1988; Daniel et al., 1991; Takahashi et al., 1998); 
they may be differentially expressed along the length of the nephron (Leibach & 
Ganapathy, 1996). It is likely that PepT2 is expressed predominantly in the proximal 
region of the nephron and PepTI located in more distal parts, corresponding to a 
potential increase in peptide concentration through the length of the nephron due to 
the action of highly active BBM peptidases. Differential expression might provide 
an absorptive advantage under physiological conditions. 
A comparison of rabbit PepTI and PepT2 has indicated certain similarities 
between the two isoforms, but also distinctly different features (Boll et ai., 1994; 
1996), some of which are also found in other species. For example, distinct pH 
dependencies are detected under identical experimental conditions. In addition, 
PepT2 has been shown to have a substrate affinity that is 40-fold higher than PepT1, 
plus different substrate specificities (see section 1.4.5). As such, PepTl is generally 
classified as a low affinity/high capacity transporter, whereas PepT2 is a high 
affinity/low capacity transporter. This is related directly to their individual roles in 
peptide absorption within the body. 
Various functions of the peptide transporter(s) in other tissues have been 
proposed; these include a role in the liver, whereby PepTl at the surface of 
hepatocytes may be involved in removal of degradation products of peptide 
hormones and peptide-derived drugs from circulation. In the brain tissue it may 
serve to clear degraded neuropeptides from the bloodstream (Fei et al., 1994). In 
other tissues, the transporters participate in as yet undetermined physiological 
functions. 
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1.3.6 One or two intestinal peptide transporters? 
In previous years it wasn't clear whether PepTI was the only peptide 
transporter mediating the absorption of small peptides and peptide-like drugs from 
the intestinal lumen; for example Inui et al. (1988) suggested the existence of two 
different transporters. They named these distinct transport systems Type I (a neutral 
pH-preferring system) and Type II (an acidic pH-preferring system). Zwitterionic 
substrates were shown to be transported by both systems, whereas a 
double-negatively charged cephalosporin was only accepted by Type II. Kramer et 
al. (1993) also implied, from vesicle studies, that differently charged J3-lactam 
antibiotics used different transporters. However, mutual inhibitions in transport 
between zwitterionic and dianionic cephalosporins were observed (Inui et al., 1988). 
Therefore, the difference in transport of the various compounds may have been due 
to distinct pH-dependencies, i.e. convincing evidence for kinetic heterogeneity in the 
intestine was lacking. 
Recent evidence provided by Hediger's group (Fei et al., 1994) during 
cloning and expression of rabbit PepT1 implied that there was only one intestinal 
peptide transporter, located on the brush-border membrane, that was involved in the 
transport of Gly-Sar. Hybrid depletion of rabbit small intestinal poly(At RNA, to 
block PepT1 expression before injection into oocytes, resulted in a loss of induced 
peptide transport activity, i.e. levels were comparable to water-injected oocytes. 
Although a clear conclusion was reached with G1y-Sar as a substrate, the existence of 
additional peptide transporters for other substrates cannot be completely disregarded. 
They further suggested that peptide transporter activity in the basolateral 
membrane is also due to expression of PepT1. However, it is possible that the 
anti-sense to PepT1 mRNA might bind to the mRNA for the basolateral transporter, 
therefore simultaneously blocking its expression with PepTI. In addition, work by a 
number of groups have provided convincing evidence of a distinct transporter protein 
at this membrane (see section 1.5). 
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1.4 STRUCTURE AND FUNCTION OF THE PEPTIDE 
TRANSPORTERS 
1.4.1 Membrane model of the peptide transporters 
Cloning and expression of peptide transporters from both intestine and 
kidney, from a number of different species, has allowed the protein(s)' structure and 
its arrangement and orientation in the plasma membrane to be elucidated. The 
structure of rabbit PepTl was proposed by Fei et al. (1994) following cloning and 
expression of the protein. However, all of the cloned mammalian peptide 
transporters have the same predominant structural features, which are retained 
throughout distinct species. 
The peptide transporters possess 12 hydrophobic sequences, each of a 
sufficient length to span the bilayer as an a-helix; these are designated 
transmembrane domains (TM) (figure 1.6). This structure is typical of a number of 
other solute transporters e.g. SGLTI (Hediger et al., 1987). These 12 TM domains 
were predicted from hydropathy analysis of the primary amino acid sequences of the 
protein, but it couldn't be unequivocally proven. Confirmation of the number and 
orientation of the TM's and adjoining loops was only made in 1998 by Covitz et al. 
This group inserted a small epitope tag into various points throughout the protein 
structure. A combination of monoclonal antibodies and immunofluorescence 
confocal microscopy was used to detennine whether the connecting loops and/or 
amino/carboxyl termini were located on the extracellular or intracellular surface of 
the bilayer. The predicted orientation originally proposed by Fei et al. (1994) was 
ascertained to be correct. 
The TM domains are connected by loops of varying length, in particular 
there is a large hydrophilic loop present between TM 9 and 10. This extracellular 
loop was subsequently found in other peptide transporters that were cloned in the 
following years and its presence makes this protein distinct from those of previously 
reported organic solute transporters. Although the main structural features of the 
peptide transporters are found in both isoforms in all species, specific differences are 
apparent, such as the number and location of putative glycosylation sites, PKA and 
PKC sites, etc. 
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Schematic diagram showing the membrane model of the peptide transporter located 
in the apical membrane of rabbit small intestine (PepTl). Boxes represent the 12 
transmembrane (TM) domains interconnected by intra- and extra-cellular loops of 
varying length. H; histidine residue, PKA and PKC show the regions postulated as 
the sites for phosphorylation by protein kinases, charged residues in the TM domains 
are shown, and branches represent putative N-glycosylation sites. Adapted from 
Meredith & Boyd (1995). 
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1.4.1.1 Species differences in PepTl structure 
The primary sequence of rabbit PepTI contains four putative N-linked 
glycosylation sites (N-x-S/T) (Asnso, ASI1439, ASI1498 , AsnS13), a potential protein 
kinase C regulatory site (Ser357) and a PKA site (Thr362) (see figure 1.6). The authors 
proposed, on the position of these specific sites, that the amino and carboxyl 
terminals would be intracellular (Fei et al., 1994). The large extracellular loop in 
rabbit PepTI consists of 202 amino acids and contains thr~e of the four potential 
glycosylation sites. Another notable loop (intracellular) connects TM 6 and 7 and 
contains a high density of cationic amino acids (>25%) suggesting a possible 
interaction with another protein within the cytosol. The apparent molecular weight 
of the rabbit PepTI protein is 71 kDa; it is thought that at least 11 kDa is due to core 
glycosylation of the protein, indicated by endoglycosidase H treatment. 
Human PepTl, cloned by Liang et al. (1995), was predicted to consist of 
708 amino acids and have a molecular weight of -79 kDa, with an isoelectric point of 
8.6. In comparison to rabbit PepTl it has seven putative N-linked glycosylation sites 
and two PKC sites (Ser3S7 and Ser704), but no PKA site. 
The cDNA isolated and cloned from rat small intestine (Saito et aZ., 1995) encoded a 
protein of 710 amino acids with a molecular weight of -75 kDa. The primary 
sequence of the protein possesses 5 potential N-linked glycosylation sites (ASI141S, 
ASI1439, AsnSlO, AsnS32, AsnS39), a PKC site (Ser3S7) and a PKA site (Thr362)' A 
comparison of key points and similarities between cloned rat, rabbit and human 
PepTI structure and sequence are described in table 1.4. 
1.4.1.2 Species differences in PepT2 structure 
In contrast to human PepTl, hPepT2 only has 3 putative N-linked 
glycosylation sites, but five PKC regulatory regions and no PKA site (Uu et al., 
1995). It was demonstrated to have a 50% identity and 70% similarity to hPepTl, 
although it was 21 amino acids longer. The similarity between the two proteins was 
much higher in the TM domains, than in the large extracellular loop or either termini. 
A summarisation of key structural and functional features of rat PepT2 are 
described in table 1.5, in a direct comparison with rat PepT1. Sequence analysis 
(Saito et al., 1996) shows that rat PepT2 (81 kDa) has an 83% amino acid identity to 
hPepT2. In addition it is interesting to note that two PKA sites (Thr12 & Thr727) and 
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RAT RABBIT HUMAN 
cDNA 2,921 bp 2,746 bp 2,127 bp 
Molecular weight 
-75 kDa 71kDa -79 kDa 
Amino acid residues 710 707 708 
N-linked 
glycosylation sites 5 4 7 
PKAmotifs Thr362 Thr362 -
PKC motifs Ser357 Ser357 Ser357, Ser704 
Amino acid sequence 
identity 
Total 77% to rabbit 81% to human 83% to rat 
Hydrophilic loop 58% to rabbit 69% to rat 
Pattern of expression Small intestine> Small intestine> Small intestine> 
kidney cortex kidney cortex, kidney cortex> 
liver> brain liver, placenta & 
pancreas 
Reference Saito et al. (1995) Fei et al. (1994) Liang et al. (1995) 
Table 1.4 
A comparison of the structural features of the cloned H+/peptide transporter PepTl 
isolated from rat, rabbit and human small intestine. Amino acid residues shown in 
bold type are conserved residues between species forming PKAlPKC motifs. 
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PepTl PepT2 
CDNA 2,921 bp 3,938 bp 
Structure 
Molecular weight 
-75 kDa 81 kDa 
Amino acid residues 710 729 
N-linked glycosylation ASll4IS, AS1l439, Asnslo, AS1l43S, ASI448, AsnS28, 
sites AsnS32, AsnS39 AsnS87 
PKA motifs Thr362 Thr12, Ser33, Thr727 
PKC motifs Ser357 Ser376, Ser640, Thr708 
Homology 48% 
Essential residues Hiss7 & His l21 Hiss7 & Hisl42 
Pattern of expression Small intestine> Kidney medulla> 
kidney cortex kidney cortex> brain, 
lung & spleen 
Function 
Driving force H+ gradient, H+ gradient, 
membrane potential membrane potential 
Substrate Di-/tri-peptides, Di-/tri-peptides, 
~-lactam antibiotics, p-Iactam antibiotics, 
bestatin, ACE inhibitors bestatin 
Substrate afrmity 
Km for Gly-Sar (mM) 1.1 0.11 
Table 1.S 
A comparison of the structural and functional features of the cloned W /peptide 
co-transporters, PepTl and PepT2, isolated from rat small intestine and kidney, 
respectively. Data taken from Saito et al. (1995 & 1996), Terada et al. (1996 & 
1997a,b). 
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two PKC sites (Ser376 & Ser640) are conserved in the transporter between the two 
species. 
Rabbit PepT2 has a molecular weight of approx. 107 kDa (with core 
glycosylation) and it possesses five potential N-linked glycosylation sites and four 
PKC motifs (Boll et al., 1996). It shows a 47% identity to rabbit PepTl; again, the 
majority of the sequence identity is found in the TM domains, the extracellular loop 
only showing a 21 % match. 
1.4.1.3 Additional structural features 
It is well known that membrane potential has a considerable effect on 
peptide transport, as a consequence Meredith & Boyd (1995) predicted that the 
portion of the protein that lies inside the plane of the bilayer would carry a net 
negative charge. Fei et al. (1994) also predicted a negative charge of the membrane 
field region of the protein, after consideration of all the charged amino acids in the 
proposed TM. A charge of -2 to -4 was stated, depending on the degree of 
protonation of the amino acid residues. 
Within the transmembrane regions of the transporter, amino acids such as 
proline and glycine are prevalent. These are generally classed as 'helix-breaking' 
amino acids and may act as hinges to allow the flexibility required for the transport of 
the unusually diverse range and size of substrates (Meredith & Boyd, 1995). These 
'hinges' are present in all TMs except TM 12, at an average number of two per TM. 
1.4.2 Essential amino acid residues of the peptide transporter(s) 
Specific amino acid residues within the transporter protein(s) have essential 
roles, for example in substrate recognition (binding and/or transport), proton 
interaction/translocation. The precise residues can be identified by chemical 
modification followed by uptake/transport studies to determine their role in the 
transport process. Such modifying agents include those which specifically react with , 
histidine or tyrosine residues, and those which interact with thiol-containing amino 
acid residues, e.g. cysteine and methionine. 
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1.4.2.1 Histidine residues 
Histidyl residues are predominantly focused upon when studying transport 
systems because the imidazole group of its side chain has a pK value of 6.5, which is 
very close to physiological pH. This particular characteristic of histidine confers its 
ability of accepting and releasing H+ very easily under physiological conditions. 
Therefore, it is likely that these residues are involved in binding and translocation of 
H+ in PepTI and PepT2. 
In many ion coupled transport processes, the systems are activated by the 
ability of the coupling ion to increase the affinity of the transporter for their 
respective substrates, for example, Na+/proline cotransporter, H+/leucine 
cotransporter (Brandsch et al., 1997). However, this is not the case with the 
intestinal Wlpeptide transporter. MacKenzie et al. (1996) proposed an ordered 
transport model in which protons bind first, followed by substrate binding and 
translocation. In this system the cotransported H+ was found to activate peptide 
transport by increasing the maximal velocity (V max), but it had no significant effect 
on substrate affinity (Ganapathy et al., 1984). This suggestion was confirmed by 
investigations conducted by Miyamoto and co-workers (1986), on the renal isoform, 
whereby treatment of BBMV with DEPC caused a reduction in V max of Gly-Sar 
transport without affecting Km. The results indicated that DEPC inhibits peptide 
transport in a non-competitive manner by covalently modifying histidine residues and 
this, in turn, results in a reduction in the number or availability of active transport 
proteins in the membrane. 
However, the following years brought conflicting results concerning the 
influence of H+ and/or DEPC on the kinetic parameters of PepTl, from many 
different groups. In 1989, Kato et al. published data that agreed with Miyamoto's 
group, demonstrating that modification of histidine residues resulted in a decrease in 
V max, but no change in substrate affinity. This was later confirmed by Thwaites et al. 
(l993b) on experiments with Caco-2 cells. However, Kramer and co-workers (1988) 
disputed these conclusions, reporting that DEPC treatment lead to an increase in 
affinity for cephalexin transport without influencing the maximal velocity of 
transport. 
The prevIous studies also revealed that pre-incubation with substrates 
prevented the DEPC-induced inhibition (Miyamoto et al., 1986; Kato et al., 1989; 
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Kramer et al., 1988; Terada et al., 1998). However, substrate protection only 
prevailed when the substrate in question had a free a-amino group, suggesting a 
direct interaction of histidyl residues with this group (Kramer et al., 1988; Terada et 
al., 1998), possibly in the role of a proton donor/acceptor capacity. 
Site-directed mutagenesis studies identified individual histidine residues 
required for efficient peptide transport. Terada et al. (1996) demonstrated that Hiss7 
and Hisl2l, located in TM 2 and 4 respectively of rat PepTl, are absolutely essential 
for transport. Interestingly, the corresponding residues are conserved in human (Liu 
et al., 1995), rabbit (Boll et al., 1996) and rat (Saito et al., 1996) kidney transporters. 
Similar experiments performed by Leibach's group (Fei et aI., 1997) on cloned 
human transporters confirmed the requirement of Hiss7 in PepTl, plus Hiss7 in 
PepT2, as being obligatory for transport. But, in contrast to Terada et al. (1996) 
postulated that His l2l in PepTl, and the equivalent in PepT2 (His147) were not 
absolutely critical. 
The studies so far indicate that the essential histidine residues are localised 
in the substrate binding site of the transporter(s) and may be involved in intrinsic 
transport activity, although their precise roles have not yet been elucidated. 
1.4.2.2 Thiol residues 
Amino acid residues containing thiol (sulphydryl) groups are also thought to 
be located at or near the substrate binding site of the H+ -coupled peptide transporter 
and therefore may be involved in substrate interaction/translocation. Thiol groups 
have the potential to undergo oxidation-reduction reactions in response to a proton 
gradient across the membrane (Miyamoto et al., 1986) and these reactions may 
induce changes in substrate affinity, specifically due to regulation by a dithiol and a 
disulphide situated in the binding site. A number of thiol-oxidising agents inhibited 
Gly-Sar transport in rabbit renal BBMV s, for example, NBD-CI 
(7-chloro-4-nitrobenz-2-oxa-l,3-diazole), NEM (N-ethylmaleimide) and PCMBS 
(p-chloromercuri-benzenesulfonic acid). Preincubation with substrates protected 
these groups from modification and preserved the transport ability of the protein 
(Miyamoto et al., 1986). 
In contrast, the role ofthiol groups in PepTI transport is unclear. Kato et al. 
(1989) and Kramer et al. (1990a) demonstrate a lack of effect of PCMBS and NEM, 
42 
Chapter I Introduction 
respectively, on substrate transport by rabbit PepTI. However, treatment of Caco-2 
cells expressing hPepTI with PCMBS resulted in a reduction in transport (Inui et al., 
1992). This latter study implicated sulphydryl groups located at the external surface 
of the intestinal peptide transporter as being directly involved in translocation, in an 
undefined way. 
1.4.2.3 Tyrosine residues 
A role for tyrosine residues in transport activity has only been implicated in 
PepTI. Studies on rabbit PepTI and PepT2 demonstrated that acetylation of tyrosine 
by N-acetylimidazole lead to a concentration-dependent inhibition of PepTI 
transport, but had no effect on PepT2 activity (Kramer et al., 1990a). Furthermore, a 
recent study by Yeung and co-workers (1998) constructed a computer model to create 
half of a putative channel formed by a number of TMs in PepTI to illustrate key 
charged and aromatic residues that were oriented into the channel and may be 
involved in peptide transport. They specifically identified Tyr167 and subsequent site 
directed mutagenesis of this residue confirmed its absolute requirement for efficient 
transport. They hypothesised that its phenolic side chain might be a ligand to the 
a-amino group of the substrates. Graul and Sadee (1997) performed multiple 
sequence alignment and demonstrated Tyr167 to be conserved in peptide transporters 
from bacteria, fungi, yeast, plant, rabbit and human. 
In conclusion, specific residues have been directly implicated as having an 
essential role in peptide transport. However, further work is required to clarify 
exactly which residues are important and to determine if tissue and/or species 
differences occur. 
1.4.3 Substrate transport 
The intestinal and renal oligopeptide carriers transport the same solutes; 
small peptides and peptidomimetic drugs, but their affinities and specificities for the 
substrates are slightly different. Expression of the transporter proteins in various 
heterologous systems, in addition to whole tissue and membrane vesicles studies, has 
provided an insight into the similarities and differences of their substrate 
requirements. These will be discussed in the following sections. 
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1.4.3.1 Maximum size of oligopeptides 
In contrast to other solute transporters, e.g. for amino acids or sugars, the 
substrate-specificity of the peptide transport system is extremely broad. 
Oligopeptides consisting of either two or three amino acids are accepted as 
substrates; there are potentially 400 dipeptides and 8000 tripeptides (excluding 
D-isomers), which can be composed of either acidic, neutral or basic amino acids, all 
of which are transported efficiently. The molecular weight of the peptide substrates 
range from 102 Da (Gly-Gly) to 576 Da (Trp-Trp-Trp) (Meredith & Boyd, 1995). 
The broad substrate specificity of PepTl was initially implied due to studies by Das 
& Radhakrishran (1975) who showed that over 30 dipeptides and three tripeptides 
were able to inhibit the uptake of Gly-Leu into monkey or human jejunal strips. This 
inhibition was also shown to be competitive, indicating they shared the same 
transport system. 
Tetrapeptides were shown not to be efficient substrates of the transporters. 
Boyd & Ward (1982) first conducted investigations showing the ability of peptides to 
induce a depolarisation of the brush-border membrane of Necturus small intestine. 
Di- and tri-Gly caused large membrane depolarisations, whereas tetra-Gly or free 
glycine induced no response (figure 1.7). Both PepT! and PepT2 have been 
subsequently shown to have this same basic substrate requirement, i.e. peptides 
composed of only two or three amino acids will be transported efficiently (Boll et al., 
1996). 
Molecular volume is not the determining factor in whether a peptide 
substrate is to be transported, acceptance as a substrate is entirely dependent on chain 
length (Matthews, 1991). The fact that certain antibiotics with a molecular weight of 
many hundred are transported efficiently shows the unimportance of large molecular 
volume, providing the substrate is suitable for transport (Matthews, 1991). 
1.4.3.2 Stereospecificity of substrates 
Early studies by Burston et al. (1972) provided initial evidence that peptides 
containing L- and D-amino acids were substrates for the peptide transporter, although 
L-containing peptides were transported to a relatively greater extent. Experiments by 
Boyd & Ward (1982) also demonstrated that L-amino acid-containing peptides were 
better substrates; in comparison to L-Leu-L-Leu, when D-Leu-D-Leu was exposed to 
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Figure 1.7 
Effect of glycine (0) and glycine oligopeptides (20, 30, 40) on the potential of the 
brush-border membrane of Necurus small intestine (upper trace); the lower trace 
indicates the presence of a substrate. Source: Boyd & Ward (1982). 
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the apical membrane of Necturus small intestine no change in membrane potential 
was observed. In addition, the side chains of f3-lactam antibiotics also contain an 
asymmetric carbon atom, and the L-isomers of these drugs are better substrates than 
D-isomers (Leibach & Ganapathy, 1996). A more recent investigation by Lister et al. 
(1995) has shown that peptides containing mixed L- and D-amino acid isomers are 
actively transported. In this systematic study, the transport of all the possible (eight) 
dipeptides that can be formed from both L- and D-isomers of phenylalanine and 
alanine was investigated in isolated loops of rat small intestine (table 1.6). The study 
had many advantages over previous investigations; including (1) net transmural 
peptide transport was measured for each of the distinct substrates; (2) HPLC was 
used to detect the intact peptide and the individual amino acids, which allowed the 
extent of hydrolysis to be monitored, in addition to the transport rate; and (3) because 
the peptides were composed of the same amino acid residues direct comparisons 
between the individual isomers could be made. The results are summarised in 
table 1.6. Briefly, dipeptides composed of only L-amino acids were transported with 
the highest efficiency, but were also subject to rapid intracellular hydrolysis. In 
contrast, dipeptides containing only D-amino acids were extremely 
hydrolysis-resistant, but were also very poorly transported. This latter finding 
highlights the very low paracellular transport rate for dipeptides in the native 
epithelium, because peptide transport was studied in the presence of a high 
concentration of luminal glucose (28 mM). Pappenheimer & Reiss (1987) suggested 
that the passive flow of non-hydrolysed peptides by solvent drag through paracellular 
channels, induced by the active co-transport of glucose and Na +, is quantitatively 
important in peptide absorption. The data from Lister et al. (1995) indicates this not 
to be the case and demonstrates that the absorption of peptides from the lumen is an 
active process. Mixed stereoisomers, where the D-amino acid was located at the 
N-terminus (D-Phe-L-Ala, D-Ala-L-Phe), were actively transported by the intestine, 
in particular D-Phe-L-Ala was largely transported intact showing considerable 
resistance to intracellular hydrolysis. However, if the D-amino acid was located at 
the C-terminus the dipeptide was not transported to any appreciable extent. 
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Peptide Absorption Hydrolysis Serosal 
appearance 
L-Ala-L-Phe ++++ ++++ 0 
L-Ala-D-Phe ++++ ++++ 0 
D-Ala-L-Phe +++ +++ + 
D-Ala-D-Phe minimal minimal minimal 
L-Phe-L-Ala ++++ ++++ 0 
L-Phe-D-Ala ++ ++ 0 
D-Phe-L-Ala + minimal + 
D-Phe-D-Ala 0 minimal minimal 
Table 1.6 
Stereospecificity study examining the fate of eight dipeptides of Phe and Ala when 
perfused through the lumen of rat small intestine (reproduced from Lister et al., 
1995); + represent relative transport rates. 
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1.4.3.3 Charged substrates 
Although peptides containing basic, neutral and acidic amino acids are 
accepted as substrates by the peptide transporters, the charge of the structure affects 
the efficiency by which it is transported. Moreover, it is the nature and position of 
the charge within the peptide structure that influences its transport ability (Meredith 
& Boyd, 1995). Hidalgo and co-workers (1995) reported that there was no difference 
in interaction of linear dipeptides with the peptide transporter, regardless of the net 
charge but, despite this view, other groups corroborate the charge dependence of 
transport. 
1.4.3.3.1 Distinct pH-dependence in the transport of charged peptides 
It appears that differently charged peptides vary in their dependence on 
medium pH for transport. A general conclusion is that anionic/zwitterionic 
substrates are transported with a relatively higher efficiency at a more acidic pH 
(-5.5), whereas cationic substrates are more rapidly transported at a slightly higher 
pH (-6.5) (Temple et al., 1995; Wenzel et al., 1996; Amasheh et al., 1997; Steel et 
al., 1997). Collectively, the investigations indicate distinct pH optima for differently 
charged substrates, whether peptides or ~-lactam antibiotics. For example, the 
presence of an inwardly-directed proton gradient has a distinct effect on the transport 
of differently charged peptides when compared to transport in the absence of the 
gradient; transport of D-Phe-L-Ala (a neutral peptide) is stimulated, but not as much 
as transport of D-Phe-L-Glu (an anionic peptide). In contrast, however, transport of 
D-Phe-L-Lys (a cationic peptide) is not altered. In the absence of a pH gradient, the 
initial rate of substrate entry into vesicles is entirely dependent on charge; relative 
transport rates are as follows: cationic > neutral > anionic. In conclusion, the 
W -dependence of transport is not identical for all substrates. The differences in 
transport due to medium pH and charge are thought to be due to differences in 
affinity for the binding site, rather than in intrinsic activity of the transporter (Steel et 
al., 1997). 
In addition to the direct effect of proton gradient on transport, the external 
pH has also been shown to affect the membrane potential-dependence of transport in 
a substrate specific way (Wenzel et al., 1996). For example, zwitterionic antibiotics 
were demonstrated to lose their membrane potential dependence when pHo was 
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reduced from 6.5 to 5.5, whereas the transport of anionic substrates was independent 
of membrane potential. The reason for this is not clear, further studies are needed to 
clarify the exact mechanisms involved. 
1.4.3.3.2 Distinct iT flux coupling ratios of charged substrates 
Wenzel and co-workers (1996) proposed that the most plausible explanation 
for the differences in the pH-dependence of transport of differently charged 
substrates is that a discrete flux coupling ratio for H+ -mediated transport occurs, 
which is entirely due to the net charge of the substrate. The results from previous 
studies (Temple et al., 1995; Steel et al., 1997) corroborated this hypothesis, 
although Amasheh et al. (1997) stated that extracellular H+ affects the affinities of 
charged substrates for the transporter and that W binding itself.is affected by charged 
substrates. It was stated (Wenzel et ai, 1996; Temple et ai., 1995; Steel et ai., 1997) 
that anionic peptides are transported in conjunction with two protons, whereas 
neutral peptides are coupled with one proton and cationic peptides also with one 
proton, if any at all. This means that the H+ -dependence of transport is not 
universally fixed for all substrates, but depends specifically on the charge of the 
transported substrate. In this way, the total charge translocated into the cell remains 
constant despite the varying anionic, neutral or cationic nature of the substrate itself. 
The extra proton transported with anionic substrates would primarily function to 
compensate for the substrates negative charge and the remaining proton, common to 
all substrates, would drive transport across the membrane in the normal way. 
As mentioned in section 1.4.2.1, PepTl has two histidine residues located in 
TM domains 2 and 4 (Hiss7 and His12l in rabbit) which are conserved in the two 
isoforms in many species. Temple et ai. (1995) proposed that protonation of both of 
these residues is essential for the transporter to bind anionic peptides and this does 
not occur unless the external pH is less than pH 6.5. However, neutral peptides only 
require one residue to be protonated and a cationic peptide can bind in the absence of 
an associated proton. Temple and co-workers (1996) devised a model for peptide 
transport and suggested that the carrier was negatively charged (C"). They suggested 
that the charged nature of the carrier protein depended entirely on the pH of the 
external (luminal) medium, i.e. when plIo is neutral (7.4) the empty carrier is 
returned to the external (luminal) surface of the apical membrane possessing a 
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negative charge (C), but ifpHo is more acidic (5.5), the carrier will return in a neutral 
state (CH+). It is evident that cationic substrates would be able to bind at a higher 
efficiency to the carrier at a more neutral pH than neutral/anionic substrates. The 
study also states that H+ binding is rate limiting for transport, not the return of the 
empty carrier to the luminal surface. 
Elucidation of the precise nature of the transport of differently charged 
substrates will aid in the design of drugs that will be efficiently absorbed across the 
apical membrane of the intestine at the pH of the acidic microclimate located 
adjacent to the brush-border in vivo. 
1.4.4 Substrate binding site 
1.4.4.1 Localisation of the substrate binding site 
It is thought that the differences observed between PepTI and PepT2 in their 
relative substrate specificities and/or affinities were very likely due to variations in 
the structure of the substrate binding domain of the two proteins. Chimeras can be 
generated between closely related family members in order to identify the structural 
features responsible for these functional properties of the transporters. 
DOring et al. (1996) constructed a chimeric cDNA from rabbit (CHIPep) 
consisting of the N-terminal region of PepT2 (amino acid residues 1-401) and the 
C-terminal region of PepTI (residues 402-707), including the large extracellular loop 
between TM 9 and 10. The cDNA was expressed in Xenopus oocytes and its 
transport characteristics were compared to the parent isoforms. The studies showed 
that all of the important phenotypic functions of PepT2 were located in its amino 
terminal region, including its pH-dependence, substrate specificity and its high 
affinity component. The extracellular loop and carboxy terminal regions were not 
implicated in these features. However, it was thought that they might be involved in 
trafficking of the protein or in regulation of transport, due to the fact that PepT2 
possesses two additional PKC sites in its C-terminal tail that are not present in 
PepTl. 
In contrast to this study, Fei and co-workers (1998b) reported that the 
substrate binding domain was located within TM domains 7, 8 and 9 (the C-terminal 
half of the transporter), as a result of experiments with a number of human PepTlIrat 
PepT2 chimeras. They also postulated that Hiss? in TM2 might lie in close proximity 
so 
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to this suggested binding site within the 3-D topology of the transporter and so was 
also implicated in substrate interaction. 
Investigations with rat PepTl/PepT2 chimeras (Terada et ai., 2000) also 
indicated that the H+ binding site and substrate recognition site were located in the 
N-terminal halves of the transporters, i.e. in TM 1-6, in agreement with DOring et al. 
(1996). Their results correlated with previous investigations, which showed that 
histidine residues (57 & 121 in PepTl) were the binding site of the a-amino group of 
substrates (Terada et al., 1998), and with studies by Yeung et al. (1998) which 
implicated a tyrosine residue in TM 5 of hPepTl having an essential role. In 
addition, Terada et al. (2000) expressed the possibility that both the N- and 
C-terminal halves of PepT2 may be involved in determination of substrate affinity, 
. 
although the C-terminal region of PepTl does not appear to play the same role. As 
such, the region influencing substrate affinity is not necessarily the substrate-binding 
site. The variances observed between theirs and Doring's work compared with the 
study by Fei et al. Were attributed to species differences (Fei's group used chimeras 
constructed from human and rat transporters). As a result of this major difference in 
the results, Terada et al. (2000) postulated that TM 7-9 of rat PepT2 are the critical 
regions for substrate affinity, rather than the actual binding site. 
1.4.4.2 Template for the substrate binding site 
Bailey et al. (2000) generated a template for the substrate binding site of 
PepTl by examining the binding and translocation data of virtually all substrates 
published so far. They proposed that the simple model would provide an indication 
of whether potential substrates would be transported by PepTI with high, medium or 
low efficiency, and may eventually aid in the design of efficiently absorbable drugs. 
The model has the following features in 3-D topology, described from the N- to the 
C-terminus, but only 4 are depicted in figure 1.8a (indicated by #): 
(I) a strong attachment site for the amino terminal NH3 + group 
(#1) 
(2) a planar backbone from N- to C-terrnini (optimum 6 A) 
(3) a hydrogen bond to the carbonyl group of the first peptide 
bond (#2) 
(4) alkylation ofN2 is accepted 
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The substrate binding template proposed by Bailey et al. (2000) shows the layout of 
the 4 main binding features (see section 1.4.4.2) (a) and their orientation (b), viewed 
as indicated in (a). A refined model is shown in (c), designating certain features for 
specific roles within the 3-D structure (Meredith et al., 2000). 
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(5) specific orientation of three groups at the second residue 
(usually L isomer) 
(6) a hydrophobic pocket (#4) 
(7) a carboxylic acid binding site (#3) 
(8) potential space for the side chain of the third residue (if a 
tripeptide) 
(9) a second carboxylic acid binding site (#3) 
Binding to the active site is maximised by a combination of all of the above factors, 
i.e. it is an aggregate of all features that determines whether a substrate binds with 
high or low affinity. Substrates with a high affinity for the binding site are abl~ to 
adopt the correct conformation to fit into the 3-D pocket without paying a high 
energetic price. 
The same group (Meredith et ai., 2000) refined this model by designating 
certain features for specific roles within the 3-D structure. The revised model is 
shown in figure I.Sb. Overall, it is thought that the N terminus is the primary 
binding site for the substrate and that interaction of a tripeptide, in comparison to a 
dipeptide, occurs through accommodation of the additional C terminus within an 
extended model (#3 on the initial template). In this way the amino terminus has a 
fixed location in the binding site, whereas binding of the carboxyl terminus is 
relatively flexible within the defined space. Specifically, it is thought that Glu595 
anchors the N terminus and histidine residues are involved in binding of the 
C-terminus (His57 for dipeptides, Hisl21 for tripeptides). 
1.4.5 Exploitation of PepTI for efficient drug delivery 
The specific requirements for potential substrates of the peptide transporters 
are not fully understood, although all of the substrates studies so far bear steric 
resemblance to the backbone of physiologically occurring di- and tripeptides. PepTl 
has the potential to be exploited for the efficient absorption of orally active 
peptidomimetic drugs and could be used to aid rational drug design by the 
modification of compounds with good pharmacological activity, but poor 
bioavailability, to allow uptake via PepTl from the intestine following oral 
administration. However, in order for this to become a reality, a comprehensive 
. understanding of the pharmacophoric pattern required for interaction of substrates 
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with the active site of PepTl is needed. This pharmacophoric pattern of atoms, or 
groups of atoms, mutually oriented in space can be defined by studies using a set of 
structurally similar compounds showing affinity for the transporter. The compounds 
used to study peptide transporters are not peptides, but generally cephalosporins 
(figure 1.9). This is due to a relatively low conformational flexibility, which means 
that they are expected to have a few energy minima through which they can interact 
with the active site, although they resemble the planar backbone of tripeptides. 
Peptides possess freely rotatable bonds and therefore lack the rigid structure required 
for this investigation. 
The requirement of a free N-terminal <x-amino group of substrates has been 
most extensively studied and all groups unanimously agree that it is not required for 
transport by PepTI (Bai et al., 1991,1992b; Oh et al., 1993; Yuasa et al., 1993; Li et 
al., 1996; Raessi et al., 1999). In contrast, substrates without a C-terminal carboxyl 
group are not transported (Bai et al., 1992b; Hidalgo et al., 1995). ~-amino acids at 
either side of the peptide bond are compatible with the transporter, whereas y-amino 
acids are not (Bai et al., 1992b). Interestingly, it has been demonstrated that a 
peptide bond is not an absolute requirement for a substrate; Temple et al. (1998) first 
reported the translocation of a compound lacking a peptide bond 
(4-amino-phenylacetic acid). Other examples of such transported compounds are 
ro-amino fatty acids (DOring et al., 1998), L-valine ester compounds (Sawada et al., 
1999) and Ac-Phe (Meredith et al., 2000). However, though PepTI can tolerate 
many diverse substrates, it appears as though it can differentiate between the two 
possible configurations of a solute; thus Brandsch and co-workers (1998) revealed 
that only the trans isomer of Ala-Pro was accepted as a substrate. 
As mentioned in section 1.4.3.1, it is thought that the chain length of a 
substrate is the determining factor in whether it will be transported, not molecular 
volume. Li et al. (1996) showed that although PepTl can accommodate a range of 
distances between the N and C termini of 5.5 and 9 A, the optimum is 5.S A; any 
increase reduces affinity of the substrate for the transporter. This group extended 
their study to explain the differences between transport of L and D isomers of 
peptides (Li et al., 1998). In this latter paper they suggested that inclusion of a 
D-amino acid at the C-terminus of a dipeptide (L-V al-D-Val) decreased the distance 
between the amino and carboxyl termini more dramatically than a D-amino acid at 
the N terminus (D-Val-L-Val). This may account for the low affinity of these mixed 
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Figure 1.9 
The structure of cephalosporins used to determine the substrate requirements of the 
peptide transporters. Source: Raessi et al. (1999). 
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stereoisomers (N terminal L-amino acid, C terminal D-amino acid) for the 
transporters (as described in section 1.4.3.2). The postulated minimum distance of 
5 A also partially explains a general low affinity of free amino acids. Doring et al. 
(1998) suggested a minimum distance between the two head groups for efficient 
transport, but stated that at least four methylene groups are required between the 
N-and C-termini, which corresponds to a distance of 500-630 pm. They also 
contrasted their results with another group (Brandsch et al., 1998) to explain the 
cis/trans discrimination by PepTl. DOring et al. (1998) postulated that it may not be 
the absolute conformation of the structure that determines transport, but the 
associated changes in spacial location and/or separation of the head groups, i.e. cis 
bond substrates are excluded because the N to C distance is too short to interact with 
important groups in the binding domain. Li et al. (1998) reported that the distance 
between the amino terminus and the second peptide bond (in a tripeptide) is also 
important. 
There are contrasting results concerning the transport of linear and cyclic 
peptides; Mizuma et al. (1998) reported the translocation of cyclic peptides, whereas 
Hidalgo et al. (1995) suggested that cyclisation of peptides reduces transport. 
Certain groups have published data which demonstrate a differential 
recognition and transport of substrates by the intestinal and renal peptide transporters 
(Ganapathy M. E. et al., 1995; Terada et al., 1997a, b). These data suggest that 
PepT2 has a higher affinity for ~-lactam antibiotics with an (X-amino group than 
PepTl does, whereas PepTl appears to prefer ~-lactam antibiotics without an 
(X-ammo group. 
Overall, certain substrate requirements of the peptide transporters have been 
defined, but further studies are needed to obtain a complete understanding of what 
exactly is required for maximum bioavailability of potential pharmacologically active 
compounds, i.e. for efficient interaction with both the intestinal and renal 
transporters. 
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1.5 PEPTIDE TRANSPORT AT THE BASOLATERAL 
MEMBRANE 
Although extensive functional and molecular information on peptide 
transport at the apical membrane of many tissues in a number of different organisms 
is now available, the importance of the basolateral membrane peptide transporter has 
been overlooked thus far. Previously is was thought that peptides were not 
transported intact into the circulation, but hydrolysed to their constituent amino acids 
prior to entry into the portal blood (Matthews, 1975). It is now accepted that 
peptides are transported intact into the bloodstream; recent studies have demonstrated 
that approx. 50% of plasma amino acids are in the form of peptides, the majority as 
di- and tri-peptides. In addition, orally active f3-lactam antibiotics are also efficiently 
absorbed through the intestinal wall, in spite of their low lipophilicity and resistance 
to hydrolytic breakdown. Despite this revelation, leading workers still doubted the 
existence of a basolateral transporter, as a distinct protein to the apical transporter. 
For example, Fei et al. (1994) suggested, as a result of hybrid depletion studies, that 
PepTl was responsible for all Gly-Sar uptake activity in Xenopus laevis oocytes 
injected with rabbit small intestinal mRNA. 
However, in recent years its existence has been postulated and subsequent 
studies have provided proof of this, in addition to revealing certain features regarding 
its mechanism and function. Walker et al. (1998) performed experiments which 
proved that there was a separate transporter, which was not PepTI, at the basolateral 
membrane. Using hPepTl-specific antibodies, they immunolocalised hPepTI 
expression exclusively to the apical membranes of human enterocytes in vivo and in 
vitro (Caco-2 cells). Ogihara and co-workers (1996) demonstrated the same in rat 
small intestine. 
However, very little is actually known about this area of peptide transport, 
despite the huge amount of pharmaceutical interest in the exploitation of peptide 
transporters as a whole to achieve intact and efficient drug delivery after oral 
administration. This section will review the (finite) knowledge about this 
physiologically and therapeutically important peptide carrier. 
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1.5.1 Mechanism of peptide transport 
It must first be stated that although we do have a basic understanding of the 
function of the basolateral peptide transporter, the membrane protein has not been 
identified to date. 
The results concerning the mechanism of this transporter are conflicting; 
some groups have reported that transport is stimulated by the presence of a H+ 
gradient, much in the same way that PepTl functions, whereas other have postulated 
it is a facilitative transporter. W -stimulated transport has been demonstrated in 
BLMV isolated from rabbit intestine (Dyer et al., 1990) and in Caco-2 cells 
(Thwaites et al., 1993a, b). These studies have shown that although the basolateral 
transporter does not appear to have an optimum pH for transport, in the same way 
that PepTl does, transport is stimulated by a more acidic pH. In addition, Dyer and 
co-workers (1990) revealed an inhibitory effect of proton ionophores (CCCP and 
TTFB) on W-stimulated uptake in BLMV. Thwaites et al. (1993a) demonstrated 
that Gly-Sar only induced intracellular acidification across the BLM in the presence 
of a proton gradient. 
Other groups (Saito et al., 1993; Terada et al., 1999; Matsumoto et al., 
1994) reported that because the effect of external pH at the basolateral membrane 
was less pronounced than that observed at the apical membrane, transport was due to 
a facilitative component. Matsumoto et al. (1994) indicated a major difference in 
transport between PepTl and the basolateral transporter associated with a pH 
gradient; FCCP had a dramatic effect on apical transport but did not affect basolateral 
transport to any appreciable extent, implying it is unlikely that a W gradient is 
coupled to this transporter. 
It is evident that further work is required to elucidate the precise driving 
force and mechanism of the basolateral peptide transporter. 
1.5.2 Transport kinetics 
Despite the conflicting views about the mechanism of transport, all of the 
investigations performed so far collectively agree that basolateral transport is due to a 
single carrier mediated system (for example, Dyer et al., 1990; Terada et al., 1999). 
For the majority of the substrates studied, transport has been shown to be saturable 
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and conform to Michaelis-Menten kinetics. The single exception to this was 
ceftibuten (Matsumoto et al., 1994) in which transport was linear, even up to 20 mM. 
Kinetic studies have revealed an important distinction between apical and 
basolateral transport; a lower Km value coupled with a higher Vmax value ofPepTI 
for substrates demonstrates that the apical carrier has a relatively higher affinity for 
substrates and a considerably higher capacity for transport than the basolateral 
transporter. The kinetics are summarised in table 1.7. This difference in transport 
kinetics has physiological relevance, i.e. PepTI mediates the active transport of 
substrates against a concentration gradient, which results in accumulation of the 
substrate within the cell. If the basolateral transporter had a similar high affinity for 
substrates, it would constantly be saturated by the elevated levels in the cytosol. A 
corresponding situation is found with glucose transporters; SGL Tl at the apical 
membrane has a Km for glucose of 0.8 mM, whereas GLUT2 in the basolateral 
membrane has a Km of 15-20 mM (Hediger & Rhoads, 1994). 
The substrate specificity of the basolateral peptide transporter is generally 
thought to be very similar to PepTI (Saito et al., 1993; Matsumoto et al., 1994). 
However, during transport inhibition studies by Terada and co-workers (1999) and 
Thwaites et al. (1995) it was shown that there might be a variation in specificity by 
the two transporters. For example, out of a number of substrates studied, ceftibuten 
had the highest affinity for PepTl, whereas it had the lowest affinity for the 
basolateral transporter (Terada et al., 1999). 
It has been unequivocally demonstrated that uptake across the apical 
membrane into the cell (Caco-2) is considerably greater than uptake across the 
basolateral membrane; the extent ranging from 3 to 10-fold (Inui et al., 1992; Saito et 
al., 1993; Thwaites et al., 1993b; Terada et al., 1999), depending on the substrate 
used. A number of groups have shown that efflux across the basolateral membrane 
occurs at a significantly faster rate than exit at the apical membrane (Inui et al., 1992; 
Matsumoto et al., 1994), although Thwaites et al. 1993b indicated that basolateral 
efflux is slower than apical eftlux. The direction of transport is also important; 
transport from the apical to basolateral membrane is more rapid than the reverse 
(basolateral-to-apical) (Inui et al., 1992; Saito et al., 1993; Thwaites et al., 1993b). 
This preferred undirectionality of transport corresponds to the absorptive process in 
vivo, and so makes physiological sense. However, it cannot be ruled out that the 
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SUBSTRATE TRANSPORTER 
Cepbradinel PepT! 
BLT 
Bestatin2 PepT! 
BLT 
Gly-S~ PepT! 
BLT 
Table 1.7 
5.9 
9.2 
0.34 
0.71 
0.65 
2.1 
Vmax 
1.9 
0.7 
0.62 
0.24 
l3 
9.5 
Introduction 
Kinetic parameters collated from distinct studies which compared substrate transport 
by PepTl and the basolateral peptide transporter (BLT) in Caco-2 cells. Km is 
expressed as mM, Vmaxis expressed as nmol'min-l-[mg protein]"l. lMatsumoto et al. 
(1994), 2Saito et al. (1993), 3Terada et al. (1999). Results suggest that the basolateral 
transporter has a lower affinity and lower capacity for transport, relative to PepTl, 
for all substrates investigated. 
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basolateral transporter participates in additional transport functions; for example, it 
may act to clear dipeptides which have been released due to hydrolysis of bioactive 
peptides directed at the basolateral surface of intestinal cells in vivo (Thwaites et al., 
1993b). 
1.5.3 Essential residues of the transporter 
As stated previously, the basolateral membrane peptide transporter of 
intestinal enterocytes has not yet been identified. Therefore, no structural 
information is available on the membrane protein. However, the studies performed 
so far have revealed that sulfhydryl groups located on the external surface of the 
transporter are essential for function; PCMBS abolishes transport (lnui et al., 1992; 
Saito et al., 1993). 
PepTl has been shown to possess essential histidine residues thought to be 
involved in H+ binding or interaction with the a-amino group of substrates. DEPC 
also inhibits activity of the basolateral transporter, albeit to a lesser extent than with 
PepTl (Terada et al., 1999) and preincubation of the membrane with substrates 
prevents this DEPC-induced inhibition. Therefore, if the basolateral transporter is 
eventually proven to be independent of a proton gradient, the histidine residues might 
be later demonstrated by site-directed mutagenesis to be involved in substrate 
recognition. 
1.5.4 Is basolateral transport the rate-limiting step in peptide 
absorption? 
In the past it was generally believed that transport at the basolateral 
membrane is the rate-limiting step in absorption (Thwaites et al., 1993a,b; 
Matsumoto et al., 1994), due to the relative rates of transport at the apical and 
basolateral membranes. Data regarding the relative affinities and transport capacities 
of the transporters have also corroborated this view (see table 1.7), i.e. the basolateral 
transporter has a lower -affinity for substrates and lower capacity for transport than 
PepTl (Saito et al., 1993; Matsumoto et al., 1994; Terada et al., 1999). However, 
the data is disputable because most of the studies on basolateral transport have 
examined uptake into the cell, not the efflux process which occurs in vivo during 
absorption. Hori et al. (1988) demonstrated a good correlation between the apparent 
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absorption rates of a number of cephalosporins, which were estimated by their 
disappearance from the lumen of an isolated intestinal loop, and their initial uptake 
rates by intestinal BBMV. They proposed that it is apical transport that is the 
rate-limiting step in the intestinal absorption of the antibiotics. 
It is clear that a considerable amount of work is required to elucidate the 
structural and functional features of the basolateral peptide transporter. Only when 
this knowledge equals that of PepTl, or progresses even further with both proteins, 
can orally active drugs be designed, which will be transported efficiently across the 
intestine as a whole, to exert their pharmacologic action. 
1.6 REGULATION OF INTESTINAL PEPTIDE TRANSPORT 
Regulation of peptide transport in the small intestine has received far less 
attention than regulation of sugar and amino acid transport. Early investigations (see 
Ferraris et al., 1988) produced inconsistent results, probably due to methodological 
problems; for example, the effects of the unstirred water layer and the use of 
hydrolysis-susceptible peptides made transport difficult to measure. 
In principle, peptide absorption can be regulated at either the apical or 
basolateral membrane of the enterocytes. Regulation can occur both in the long-term 
(days to weeks); adaptation to dietary changes or alterations in the endocrine status of 
the animal, or in the short-term (minutes to hours); during assimilation of a meal. 
Long-term regulation usually involves the biosynthesis of new (additional) 
transporters, and is associated with epithelial turnover. In contrast, short-term 
phenomena incorporates either the recruitment of transporters from a pre-formed 
intracellular pool, followed by their membrane insertion, or modulation of the 
intrinsic activity of the transporters already present in the membrane. The (limited) 
investigations concerning the regulation of intestinal peptide transport performed 
thus far have concentrated exclusively on the apical membrane, and dealt largely with 
long-term adaptation to dietary changes. In contrast, short-term regulation has barely 
been studied, despite the fact that this information is crucial if we are to understand 
the fundamental physiological processes that control the absorption of nutrients after 
a meal. Even such basic information as to how peptides themselves, and other 
dietary constituents (amino acids in particular), regulate the absorption of peptides 
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from the lumen of the intestine is unknown. In addition, a comprehensive knowledge 
of the roles that hormones, and associated intracellular signalling pathways, play in 
peptide transport is crucial. Not only is this information required to understand the 
mechanisms behind nutrient absorption following food intake, but also for the 
efficient transfer of bio-active drugs into the bloodstream when administered by the 
oral route. In order for the entire transmural transfer processes to be elucidated, 
knowledge of regulation, not only at the apical membrane, but also at the basolateral 
membrane, is required. 
This section will report the present knowledge of long-term dietary control 
of peptide transport, and the finite information available for short-term regulation of 
transport, at the brush-border membrane. 
1.6.1 Long-term regulation of peptide transport 
At present, the majority of investigations into long-term regulation of 
peptide transport have been directed at the role of dietary constituents, or lack thereof 
( fasting/starvation). 
1.6.1.1 Adaptation to changes in luminal nutrient levels 
One of the initial studies which examined the effect that high- and 
low-protein diets had on peptide absorption was performed by Ferraris et al. (1988), 
on the uptake of L-carnosine. They discovered that carnosine transport was 
considerably higher in rats fed a higher protein ration for two weeks and postulated 
that the mechanism of stimulation might be due to the induction of more transporters 
at the apical membrane. A study by Erickson et al. (1995) found that, coupled with 
the stimulation in transport activity, there was an increase in PepTI mRNA levels in 
the middle and distal sections of the small intestine. 
Subsequent investigations by Thamotharan et al. (1998), Walker et al. 
(1998) and Shiraga et al. (1999) have extended the knowledge of substrate 
up-regulation of its own transport. It was found that not only does a high protein diet 
influence the transport activity of PepT!, but certain individual dipeptides also 
produce the same effect. The increase in transport activity (figure 1.10) is due to a 
rise in V max of the transporter, without a corresponding change in Km. There is a 
concomitant elevation in PepTI protein expression at the apical membrane (ranging 
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from 1.72 to 2.2 fold) (figure 1.10), plus an enhancement ofmRNA levels (ranging 
similarly from 1.98 to 3.0 fold) (figure 1. lla,b). Coupled with this, an increase in 
mRNA half life, from 8.9 to 12.5 h, due to both enhanced stability and transcription 
(figure 1.llc) was observed. However, these effects were not universal with all 
substrates; whereas Gly-Sar (Thamotharan et a/., 1998; Walker et a/., 1998; Adibi, 
1997) and Gly-Phe (Shiraga et a/., 1999) induced the stimulation in activity, Gly-Gln 
did not (Shiraga et a/., 1999). Therefore, it appears that the effect might be peptide 
specific. 
In addition to the long-term stimulatory effect of dipeptides on peptide 
transport, there also appears to be an effect of amino acids (Ferraris et a/., 1988). 
Shiraga and co-workers (1999) demonstrated that free phenylalanine (Phe) enhanced 
transport in a comparable way to Gly-Phe, in contrast glycine (Gly) and glutamine 
(GIn) did not. As such, the induced stimulation also seems to be amino acid-specific. 
It was proposed that certain small peptides and amino acids produced from hydrolytic 
breakdown of large peptides or proteins in the lumen enter the enterocytes, by their 
individual carriers, to directly stimulate transcriptional activation of the PepTI gene. 
However, it is not known whether the effects of peptides and amino acids are by the 
same, or completely different, mechanisms. 
Walker et at. (1998) explained the stimulation in transport as the control of 
mRNA accumulation, rather than translation or post-translational modification of the 
protein. However, Thamotharan et at. (1998) performed experiments with brefeldin, 
which disrupts the trans-Golgi network (TGN) required for processing of membrane 
proteins, and showed that substrate stimulation was abolished despite an increase in 
gene expression. As such they suggested that stimulation in transport was probably 
due to membrane recruitment of the transporter protein from a newly synthesised 
pool. 
Substrate upregulation of nutrient transporters is known to be an efficient 
mechanism for ensuring cellular economy in balancing the costs of synthesis and 
maintenance. It can be concluded that there is a direct effect of nutrient supply on the 
function of epithelial cells to induce peptide transport, which doesn't involve neural 
and/or hormonal factor(s). These findings have therapeutic value, i.e. if the 
bioavailability of a particular drug is low, absorption may be enhanced by 
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Dipeptide stimulation of peptide transport in Caco-2 cells. Pre-treatment of cells 
with 10 mM Gly-Sar for 24 h induced an increase in transport rate of Gly-Gln (a), 
and a higher abundance of PepT! protein mass in apical membranes, demonstrated 
by SDS-PAGE (b,c). Source: Thamotharan et al. (1998). 
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Effect of dipeptide pre-treatment of Caco-2 cells on the abundance and half-life of 
PepTl mRNA. Pre-treatment of cells with 10 mM Gly-Sar for 24 h induced an 
increase in PepTl mRNA abundance (a), demonstrated by densitometric analysis of 
the Northern blot (b) (Thamotharan et ai., 1998). In addition, pre-treatment of cells 
with 4 mM Gly-Gln for 72 h causes an increase in PepTl mRNA half-life (c) 
(Walker et ai., 1998). 
66 
Chapter 1 Introduction 
co-administration with a high protein diet, containing specific dipeptides and amino 
acids. 
1.6.1.2 Adaptation to fasting and/or starvation 
An early experiment by Cheeseman (1986) showed that peptide transport 
activity per unit of intestinal surface area was initially elevated following 
administration of a low protein diet. In contrast, amino acid transport activity was 
suppressed under the same conditions. Recent investigations (Thamotharan et al., 
1999a; Ihara et al., 2000; Ogihara et al., 1999) have also demonstrated this to be the 
case following a brief fast (1 day food deprivation) and starvation (more than four 
days without food). It was generally found that the stimulation in transport was due 
to an increase in V max of PepTl, with no apparent effect on Km. This was associated 
with increased levels of PepTI protein at the apical membrane and a comparable 
increase in mRNA levels (approx. 3-fold). As such, starvatiQn appears to enhance 
peptide transport at a pre-translational level. . However, an examination of other 
membrane transporters (e.g. SGL Tl) during this situation showed no such change in 
activity (Ihara et al., 2000). 
Although the effects of starvation appear to mirror the peptide-induced 
stimulation in activity, it is thought that the two are distinct regulatory mechanisms. 
Re-feeding, following starvation, causes a significant decrease in PepTI mRNA 
levels (Ihara et al., 2000). In addition, whereas the site for substrate-induced activity 
has been demonstrated to be localised in the middle and distal sections of the small 
intestine, starvation causes changes in the proximal region (Ihara et al., 2000). 
It is generally assumed that these responses to fasting and starvation 
function to minimise nitrogen loss from the body. From the initiation of fasting,. as 
early as 1 day, mucosal cells are sloughed from the villi into the lumen of the small 
intestine at a considerable rate. This is indicated by a reduction in the weight of the 
intestinal mucosa (McManus & Isselbacher, 1970). If these cells were lost, it would 
contribute to a major loss of nitrogen from the body. However, the remaining cells 
appear to have an increased efficiency of absorption of small peptides, produced from 
the hydrolytic degradation· of the protein content of the sloughed cells, to maintain 
the nitrogen levels required. In contrast, glucose and amino acid transport activity 
are reduced, therefore the effects on peptide transport appear to be paradoxical to 
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effects on these other nutrient transporters (Thamotharan et al., 1 999a). Matthews & 
Adibi (1976) stated some time ago that the response of the intestinal peptide 
transporter to nutritional and pathological situations was distinct from the effect on 
amino acid transport proteins. In this way, one method of absorbing amino nitrogen 
is better preserved than the other in adversity. 
The different responses of nutrient transporters are not unique in dietary 
situations. Tanaka et al. (1998) discovered that injury to cells by 5-fluorouracil had 
no effect on the amount of PepTl protein, but seriously affected the levels of sucrase 
and glucose transporters. In fact, PepTl mRNA levels were elevated, whereas the 
mRNA levels of amino acid, glucose and phosphate transporters were depressed. 
The biological significance of this starvation-induced enhancement in 
peptide absorption is not for storage of fuel, because body fat and glycogen are 
available for calorific use. It probably functions as a precautionary mechanism in the 
reabsorption of protein during re-feeding. Protein malnutrition is a serious problem 
because, although protein forms structural and functional tissue, it cannot be stored 
for future use. Ihara and co-workers (2000) speculated that the stimulation in 
transport during starvation would act to promote the maximum absorptive ability 
immediately after a meal is consumed. Therefore, even though upregulation of 
peptide transport by substrates is moderately slow (i.e. in a time scale of days), the 
essential nutrients won't be lost by non-absorptive transit through the intestine. 
From a clinical viewpoint, the results indicate that if the body were in a 
malnourished state, peptide feeding in enteral nutrition would have an absorptive 
advantage over amino acids. From a therapeutic viewpoint, peptidomimetic drugs 
may be more efficiently absorbed during fasting and/or starvation. 
1.6.2 Short-term regulation of peptide transport 
As previously mentioned, investigations into short-term regulation of 
peptide transport are scarce. The studies that have been performed demonstrate an 
effect of a number of mediators, but no mechanism has been advanced. This area of 
regulation can be segregated into two distinct groups, regarding the mediator(s) 
involved; nutrients and hormones, acting through protein kinase cascades. 
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1.6.2.1 Amino acid regulation 
It has been described that certain amino acids in the diet have the ability to 
up-regulate peptide transport over a period of days (Ferraris et aZ., 1988; Shiraga et 
aI., 1999). A series of experiments by Boyd et aZ. (1996) demonstrated a stimulation 
of dipeptide transport by specific amino acids in the short-term. In this study the 
amino acids were infused in the vasculature of the small intestine, rather than being 
presented in the lumen. The amino acids (GIn and Leu) caused an increase in the 
transmural transport of D-Phe-L-Gln, but the effect was more pronounced at the 
basolateral membrane, indicated by reduced intracellular concentrations of substrate. 
Therefore, a similar mechanism of regulation by amino acids appears to be in force at 
the basolateral membrane, although it isn't clear from this data at which membrane 
regulation is predominant, or ifboth are equal, but due to different processes. 
1.6.2.2 Hormonal regulation 
Very little is actually known about the regulation of peptide transport by 
hormones, but a recent study by Thamotharan et aZ. (1999b) implicated insulin as a 
possible mediator. A physiological concentration (5 nM) of insulin caused a 2-fold 
increase in Gly-Gln transport, due to an increase in maximal velocity of the 
transporter with no effect on substrate affinity. This was associated with an increase 
in the amount of PepTI protein at the apical membrane, but was not due to changes 
in mRNA levels. They concluded that insulin acted to increase the membrane 
population of PepTI by stimulating its translocation from a pre-formed cytoplasmic 
pool. Insulin acts through its receptors; an intrinsic protein with tyrosine kinase 
activity. The exact process by which peptide transport is stimulated by insulin is, as 
yet, unknown. However, although receptors for insulin are located on both apical 
and basolateral membranes on enterocytes, they are more concentrated at the 
basolateral pole. Therefore, insulin might also act to regulate peptide transport at the 
basolateral membrane. 
Another hormone has also been implicated as having a role in the regulation 
of peptide transport, under specific circumstances; progesterone. Fujita et al. (1999) 
demonstrated that peptide transport is enhanced by treatment of Caco-2 cells with 
(+)pentazocine, a selective al receptor ligand. al receptors are a subclass of 
s receptors thought to be involved in the pathogenesis of psychiatric disorders in the 
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central nervous system. However, they are also expressed in peripheral tissues 
including the gastrointestinal tract, but little is known regarding their physiological 
function. (+ )pentazocine stimulated peptide transport by increasing V max, coupled 
with an increase in steady state levels of PepTI mRNA, although the exact 
mechanisms are not clear. One physiological implication of this type of regulation 
might involve progesterone. Progesterone is an endogenous ligand for the 
0'1 receptor, and its plasma concentration varies dramatically in women depending on 
their physiological condition, for example during the menstrual cycle. In particular it 
is known that levels increase considerably in late pregnancy; in this state women 
require a large amount of nutrition to nurture their foetus. Fujita et 01. (1999) 
speculated that these high levels of progesterone might upregulate the intestinal 
absorption of peptides by interacting with the 0' 1 receptor, in order to meet these high 
nutritional demands. At this point it isn't known whether the effect is specific for 
peptide transport, or if other nutrient transporters are controlled in a similar way. 
1.6.2.3 Additional regulatory mechanisms 
In addition to the potential role of protein kinase activity modulated by 
insulin, a role of other kinases has been postulated. PKC regulation of peptide 
transport was demonstrated by Brandsch and co-workers (1994) using a series of 
activators and inhibitors. Treatment of Caco-2 cells with PKC activators resulted in 
a significant inhibition of PepTI activity due to a decrease in V max, but no change in 
Km; inhibitors blocked the inhibitory effect ofPKC. In contrast leucine transport was 
not affected. This regulation could potentially be due to a number of different 
mechanisms, however, it was demonstrated that a block in de novo synthesis or 
alterations in the transmembrane pH gradient were not involved. It was postulated 
that regulation of this kind may involve post-translational modifications due to 
phosphorylation/dephosphorylation of the protein. This could be either a direct effect 
by PKC itself, or indirect via the action of additional protein kinases or phosphatases. 
Further work is required to elucidate the precise mechanism. 
Muller et 01. (1996) reported a potential role of PKA, in addition to PKC, in 
a cAMP-dependent manner. Although an increase in cAMP levels are known to 
activate PKA, the mechanism by which PKC is activated by cAMP is not clear. 
Studies in other cell types (Trautwein et 01., 1990; Church et 01., 1994, see Muller et 
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al., 1996) have indicated that cAMP might act to increase intracellular Ca2+ levels 
due to activation of Ca2+ channels; this might form the basis by which PKC regulates 
transport in this instance. 
In summary, it is clear that although initial investigations have demonstrated 
a variety of ways in which peptide transport appears to be regulated (for instance, 
dietary and hormonal), both in the long-term and short-term, further work is required 
In order to determine the precise molecular mechanisms and the 
physiological/clinical implications. 
1.7 AIMS OF THIS THESIS 
The wider general aim of this thesis was to investigate oligopeptide 
transport in rat small intestine. Specifically, attempts to identify the carrier proteins 
in both the apical and basolateral membranes of jejunal mucosa were made. Protein 
identification was performed using the technique of photoaffinity labelling, and so 
the initial aim was to identify a compound, which would specifically interact with the 
transporters, and could be developed as a potential label. Secondly, direct interaction 
of the label with the transporter protein( s) had to be demonstrated in order to prove 
the reliability of the approach. Once the viability of the potential photoaffinity label 
had been determined, investigations were performed for the specific identification of 
the carrier proteins. 
PepTI from rat small intestine has previously been cloned and sequenced 
(see section 1.3.1); therefore the purpose of its identification was not a new concept, 
but a necessary process to allow investigations in its structural requirements to be 
performed. The equivalent protein in the basolateral membrane has not been 
previously identified from any species, or tissue; therefore its identification would be 
a novel and exciting discovery. Once the protein had been isolated, the primary aim 
was to obtain structural information with the hope that it could lead to cloning and 
sequencing of the protein in the near future. Pharmacologically, this protein is 
equally as important as the apical transporter protein for the efficient absorption of 
biologically-active peptidomimetic drugs, and clearly its transport properties and 
substrate requirements need clarification. However, this can only be undertaken if its 
potential importance is realised and the protein itself has been identified. 
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A distinct aim of this thesis was to investigate the short-term regulation of 
transmural peptide transport, i.e. the physiological processes that occur during 
assimilation of a meal. Limited knowledge regarding the precise mechanisms of 
transporter regulation has been obtained (see section 1.6); some of these have 
implicated a potential role of protein kinases and/or phosphatases: Therefore, studies 
were performed in order to determine the activators/inhibitors, cellular proteins 
and/or protein kinase pathways involved in peptide transport regulation. 
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CHAPTER 2: MATERIALS AND METHODS 
Animals used in all studies were male Wistar rats bred and supplied by the 
Animal House of the Biology Department, University of York. They were kept under 
controlled light conditions of a 12 hour day/night cycle at a constant temperature and 
ventilation and were fed ad libitum on Bantin & Kingman standard rat and mouse 
diet (Bantin & Kingman Ltd., Humberside, UK.) with free access to water. 
All procedures involving animals were performed in accordance with Home 
Office Regulations under the Animals (Scientific Procedures) Act 1986. 
2.1 PROCEDURE FOR THE STUDY OF PEPTIDE 
TRANSPORT IN' THE ISOLATED LUMINALLY AND 
V ASCULARL Y PERFUSED RAT JEJUNUM IN SITU 
The vascular perfusion apparatus and technique used were modified slightly 
from that originally described by Hanson & Parsons (1976), incorporating certain 
features described by Bronk & Ingham (1979) and Nicholls et al. (1983). 
2.1.1 Animals 
Rats of 260-280 g bodyweight were used in perfusion studies. At the 
desired weight, access to food was denied overnight prior to the perfusion, and 
drinking water was supplemented with 0.5% D-glucose. 
2.1.2 Chemicals and materials 
Dipeptides (D-Phe-L-Gln, D-Phe-L-Ala) and the photoaffinity label 
([4-azido-D-Phe]-L-Ala) were custom-synthesised by Prof. P. D. Bailey and Dr. I. 
Collier in the Chemistry Department, Heriot Watt University, Edinburgh, U.K. 
Amino acids (D-Phe, L-Gln, L-Leu) and bovine serum albumin (BSA) 
fraction V powder were supplied by Sigma Chemical Co. Ltd., Poole, U.K. 
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Enzyme inhibitors; rapamYClD and wortmannin, were obtained from 
Calbiochem ®. 
NaCI, KCI, MgS04, NaHC03, CaCh, D-glucose, methanol, PCA and 
KOH were supplied by BOH Laboratory Supplies, Poole, U.K. and were of AnalaR® 
grade. 
KH2P04, NaH2P04 and Na2HP04 were supplied by Fisons Scientific 
Equipment, Loughborough, U.K. and were of Analytical Reagent grade. 
Sagatal® (60mg mrl Pentobarbitone sodium B.P.) general anaesthetic was 
supplied by Rhone Merieux Ltd., Harlow, UK. 
Gas cylinders (95% 02/5% C02) were supplied by BOC Medical Gases, 
BOC Ltd., Guildford, UK. 
Mersilk® 2/0 braided silk suture was supplied by Ethicon Ltd., Edinburgh, 
UK. 
Nalgene tubing (Ld. 114", o.d. 5/16") was supplied by Nalge Co., Rochester, 
New York, USA. 
Plastic tubing (Ld. 2.0 nun, o.d. 3.0 nun), silicone tubing (Ld. 3.0 nun, 
o.d. 5.0 nun) and nylon tubing cannula for vasculature (Ld. 0.75 nun, o.d. 0.94 mm) 
were supplied by Portex Ltd., Hythe, UK. 
Standard PVC manifold pump tubing for peristaltic pumps was supplied by 
Altec, Alton, UK. 
All glassware used to construct the perfusion apparatus and the portal vein 
cannula were either supplied. by the university glassblower or York Glassware 
Services Ltd., York, UK. 
Glucose GOO-Perid® spectrophotometric analysis kits were supplied by 
Boehringer Mannheim U.K., Lewes, UK. 
Variable speed laboratory motor (model S63C) homogeniser was obtained 
from Tri-R Instruments, Inc. 
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2.1.3 Solutions 
All solutions were made up in diH20 unless otherwise stated. 
Modified Krebs-Ringer bicarbonate saline medium, pH 6.8 
A fresh working medium was produced from concentrated stock solutions, 
which were stored at 4°C, on the day of perfusion. The solution was gassed with 
95% 0 2/5% CO2 for 45 min before the subsequent addition of CaCho 
Component Final concentration (mM) 
NaCI 140.0 
KCI 4.5 
MgS04 1.0 
Na2HP04 1.8 
NaH2P04 0.2 
NaHC03 5.0 
CaCh 1.25 
BSA stock solution 
AIL 10% (w/v) BSA solution containing 0.01% (w/v) streptomycin 
sulphate was made with modified Krebs-Ringer medium, pH 6.8. The solution was 
vacuum-filtered through a coarse filter (Whatman 541, 11.0 cm diameter) using a 
Buchner funnel, bottled in 75 ml aliquots and stored at -20°C. 
Luminal and vascular perfusate solutions 
Both the vascular and luminal perfusates were based on the modified 
Krebs-Ringer medium. The vascular perfusate contained 5 mM D-glucose, 5% (w/v) 
BSA (using the 10% stock solution), 0.005% (w/v) streptomycin sulphate and 
0.0035% (w/v) heparin. The luminal perfusate consisted solely of Krebs-Ringer. 
Substrates were added to the perfusates as required. 
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Rapamycin stock solution 
A 100 JlM stock solution was made by dissolving 100 Jlg into 1.094 ml 
DMSO. A 4,000-fold dilution into the required perfusate produced a final 
concentration of 25 nM. 
Wortmannin stock solution 
A 2 mM stock solution was made by dissolving 1 mg into 1.17 ml diH20. A 
1O,000-fold dilution into the required perfusate produced a final concentration of 
200nM. 
Solutions for sample treatment and analysis 
0.6MKOH 
6% (w/v) PCA 
HPLC buffer 
21 mMKH2P04 
2.1.4 Perfusion apparatus 
3.37 g/100 ml 
17.5 mll250 ml 
14.29 g/5 L 
The set-up of the perfusion apparatus is shown in a schematic diagram 
(figure 2.1). 
Perfusions were performed at a physiological temperature of 37°C. A 
constant temperature was maintained inside a closed cabinet by a thermostatically 
controlled heater and fan. Doors at the front of the cabinet permitted interior access. 
Within the cabinet the perfusate reservoirs and oxygenator were maintained at 37°C, 
as was the dissection plate upon which the rat was placed, by circulating heated water 
through the jackets of the apparatus from an external water bath. 
The individual parts of the perfusion apparatus were connected using a 
combination of nalgene, plastic and silicone tubing. Vascular and luminal perfusates 
were circulated through the tubing by a 4-channel peristaltic pump. 
The luminal perfusate constituted a segmented flow at the rate of 
2.0 ml·minot based on single pass through the isolated region of small intestine. The 
segmented flow was created by introducing bubbles of gas (95% 02/5% C02) into the 
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Schematic diagram of the apparatus used for luminal and vascular perfusions, in situ, 
of isolated rat jejunum. 
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luminal circuit using a bubble trap located after the pump. Gas segmentation causes 
an increase in stirring of the luminal contents (Fisher & Gardner, 1974) and therefore 
minimises the effects of the stationary, unstirred water layer adjacent to the tissue on 
the transport of substrates, in addition to an ensuing an improvement in oxygenation 
of the epithelial cell layer. 
The vascular perfusate system consisted of both a single pass and a 
re-circulated flow (both non-segmented), however the re-circulated flow functions 
solely for oxygenation of the perfusate, not to perfuse the jejunal mesentery. The 
dual system was accomplished by pumping perfusate from the reservoir into two 
separate channels; the first channel recirculated the solution at a rate of 7 ml·minot 
through a multi-bulb oxygenator to feed back into the reservoir, whereas the second 
channel formed a single pass flow to perfuse the superior mesenteric artery of the 
animal at a rate of 1.5 ml·minot • This arrangement ensured that the vascular perfusate 
entering the mesenteric cannula was continuously oxygenated via passage through 
the glass multi-bulb. 
An additional external pump permitted compounds to be infused into the 
luminal and/or vascular perfusates at specific time points during the experiment 
without interruption to the perfusate flow. 
Perfusion of the vascular bed was performed using a nylon tubing cannula 
via a sharpened distal end. The vascular effiuent was collected using a glass 
'Z'-shaped portal vein cannula connected to a short length of plastic tubing 
(Ld. 1.0 mm, o.d. 1.2 mm). In order to attain a negative hydrostatic pressure, the 
tubing attached to the portal vein cannula was adjusted to lie approximately 3-5 cm 
below the portal vein, as a result of the unique shape of the cannula. This pressure 
was sufficient to overcome the frictional resistance associated with flow through a 
narrow tube. 
2.1.5 Operative procedure 
A schematic diagram of the dissection is shown in figure 2.2. Bracketed 
numbers and letters in the text correspond to the placement of ligatures and cannulae, 
respectively, during the operation. 
Prior to surgery the rats were anaesthetised with an intraperitoneal injection 
ofSagata1® (10 mg·[100g body weightr1). 
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Schematic diagram of the operative procedure followed for luminal and vascular 
perfusions of isolated rat jejunum, in situ. Numbers and letters depict the placement 
of ligatures and cannulae, respectively, and correspond to the text in section 2.1.5. 
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An incision was made on the midline of the abdomen, followed by a lateral 
incision at midpoint to open up the abdominal cavity. The spleen (1) was ligated 
along with the rectum (2), followed by the right colic artery and vein (3 & 4). The rat 
was rotated 90° clockwise and the vein running parallel to the oesophagus from the 
stomach was secured (5). The rat was returned to its original position and, using a 
'flipping and twisting' action, the intestine was re-positioned to display the jejunum 
and adjacent mesentery. The ligament of Treitz was freed from its surrounding 
connective tissue and the mesenteries supplying the duodenum (prior to the ligament 
of Treitz) exposed. These mesenteries from the ligament of Treitz back up to the 
stomach were ligated (6); several ties were used to prevent constriction of the portal 
vein. The final tie included ligature of the bile duct. 
Approximately 25 cm of intestine was measured from the ligament of Treitz 
down the length of jejunum. Ties were placed around the mesenteric branch (7) and 
the main artery (8) at the 25 cm point. The intestine was cut two-thirds across its 
diameter at positions A and B of the measured section. The isolated segment of 
jejunum was then flushed through from the oral end with 15 ml warm gassed 
Krebs-Ringer followed by 15 ml air to remove debris. The intestine was cannulated 
at points A and B and the jejunum left in situ. The blood supply to the jejunum was 
isolated by ligating vessels leading to the ileum, caecum and proximal colon (9). 
The rat was again rotated 90° clockwise and displacement of the intestine 
exposed the systemic arches of the aorta and the coeliac-mesenteric artery, following 
separation from surrounding connective tissue. A loose tie was placed around the 
aorta (10) to the far side of the coeliac artery and another was placed around the 
superior mesenteric artery (II). Cannulation of the mesenteric artery was performed 
with minimum disruption of the blood flow. The peristaltic pump was started and 
the aorta tied offby tightening of the ligature (10). A small incision was made in the 
left systemic arch (at the junction of the aorta and superior mesenteric artery) (C) and 
the cannula inserted immediately. This ligature (11) was gently tightened around the 
cannula to avoid constriction of the vascular flow. Upon completion of the vascular 
perfusate circuit, the rat was killed by an overdose of Sagatal into the heart (1 ml). 
Rapid cannulation of the mesenteric artery is necessary (within 20 s). and 
success at the first attempt is crucial, because vascular back pressure and tissue 
anoxia begin to develop as soon as the animals blood supply is constricted . 
.. 
80 
Chapter 2 Materials and methods 
Cannulation should also avoid damage to other major blood vessels in the vicinity of 
the mesenteric artery. Successful cannulation of the artery was indicated by a colour 
change of the isolated section of jejunum, from pink to white, which demonstrated 
that it was being supplied by the external reservoir and no longer by the blood supply 
of the animal. 
When the arterial cannula was secured the animal was rotated 180° 
clockwise to display the hepatic portal vein. Two loose ties were made around the 
vein (12 & 13) approximately 1.0 cm apart. The upper ligature (12) was tied tightly 
and a small incision (D) made into the wall of the vein. The portal vein cannula was 
inserted and the second ligature (13) secured it in place. 
Once the flow through the vascular bed was established the luminal circuit 
was completed by connecting cannulae A and B to the corresponding perfusate 
tubing. The exposed intestine was kept moistened with a swab soaked in 
Krebs-Ringer at 37°C to prevent drying of the tissue. 
Timed sampling began with completion of both the vascular and luminal 
circuits. Vascular effluent samples were taken at 1 min intervals every 2 min by 
collecting fluid in a pre-weighed autoanalyser cup. The flow rate (ml.min- l ) was 
monitored by the weight of the sample and venous recovery was calculated. Luminal 
effluent samples were collected at 1 min intervals every 5 min. All samples were 
treated as described in section 2.1.6 prior to analysis. 
At the end of the experiment, the perfused segment of intestine was removed 
from the rat and its linear dimensions measured at resting length. The tissue was 
treated as described in section 2.1.7 prior to analysis. 
Following every perfusion, the apparatus and tubing were rinsed with 
copious amounts of diH20 to remove any traces of perfusate and/or substrates. 
2.1.6 Sample treatment 
Treatment of the luminal and vascular samples was identical; 
de-proteinisation by a 2-fold dilution in 6% PCA followed by centrifugation at 
1800 g for 2 min. The supernatant was neutralised by a 1.8-fold dilution in 0.6 M 
KOH and the fmal sample was rapidly frozen in liquid nitrogen before being stored at 
-20°C. 
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2.1. 7 Tissue sample treatment 
Mucosal epithelial tissue and its underlying muscle were analysed 
post-perfusion to calculate the extent of substrate accumulation during the transfer 
process across the intestinal wall. 
At the end of the perfusion the section of intestine was opened along its 
antimesenteric surface and blotted well. A 4 cm section was taken and the mucosal 
layer removed by scraping gently with a microscope slide. The mucosa was plunged 
into liquid nitrogen and frozen rapidly before its weight was recorded. The frozen 
pellet was then homogenised in 1 ml 0.6% PCA with a smooth Teflon® pestle using a 
variable speed laboratory motor (model S63C) homogeniser on setting 4.5. The 
remaining muscle layer was also frozen, weighed and homogenised in the same way. 
The resulting homogenates were centrifuged at 1800 g for 2 min, the supernatant 
neutralised with a 2-fold dilution in 0.6 M KOH and the samples frozen in liquid 
nitrogen before being stored at -20°C. 
Additional sections of the intestine were taken to calculate wet and dry 
weights of the mucosal and muscle tissue. These tissue scrapes, in conjunction with 
a whole tissue sample, were heated to dryness for 24 h in a constant temperature oven 
in a pre-weighed glass vial. This information allowed transport rates to be expressed 
as ~ol·min-l.[g dry weightr1• 
2.1.8 Sample analysis 
2.1.8.1 Glucose analysis 
(a) Solutions 
10 mM D-glucose 
(b) Test Principle 
0.18 gllOO ml 
Glucose utilisation by the isolated jejunum was an indication of the viability 
of the perfusion (see section 3.3); represented by the glucose concentration remaining 
in the vascular effluent following passage through the jejunal vasculature. Vascular 
samples were analysed on a Cobas-MlRA robotic analyser (Roche Products Ltd., 
Welwyn Garden City, UK.) using automated enzymatic analysis. Glucose 
concentration was measured using a commercially available kit, GOD-Perid® 
(Boehringer Mannheim) which uses the following test principle: 
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POD 
GOD = glucose oxidase 
POD = peroxidase 
Materials and methods 
GOD 
ABTS® = di-ammonium 2,2'azino-bis[3-ethyl-benzothiazoline-6-
sulphonate] 
The green reaction product has a strong absorbency at 578 run and the intensity of the 
coloured complex is directly related to the amount of glucose in the sample. Glucose 
concentration was calculated using a standard curve of 0-10 mM. 
2.1.8.2 HPLC analysis 
Vascular and luminal samples, in addition to mucosal and muscle tissue 
samples, were analysed by HPLC using an automated computer-controlled system 
(Kontron model 4100) from Kontron Instruments. A 25.0 cm * 4.6 mm column 
(Jones Chromatography) was used in conjunction with a methanol:H20 mobile 
phase. The ratio of methanol to H20 varied with the dipeptide under analysis, i.e 
with D-Phe-L-Gln the ratio was 1 :9, whereas with the photo affinity label 
([4-azido-D-Phe]-L-Ala) it was 1.5:8.5; both solutions were buffered with 21 mM 
KH2P04. The mobile phase had a flow rate of 1 ml·min'l. Before sample injection, 
the column was equilibrated with the mobile phase for approx. 15 min using an 
automatic pump (Kontron 420). Samples contained in 2 ml vials, situated in the 
sample tray of the autosampler (Kontron 460), were automatically injected onto the 
column. Dipeptide and amino acid elution were detected at 210 run using a detector 
(Kontron 430) for a specified time period depending on the dipeptide under analysis, 
e.g. D-Phe-L-Gln; 12 min, [4-azido-D-Phe]-L-Ala; 20 min. 
Typical elution profiles of D-Phe with D-Phe-L-Gln or 
[4-azido-D-Phe ]-L-Ala are shown in Appendix I. The amount present in each sample 
was calculated by a comparison of the actual peak area to peaks of known standard 
concentrations. 
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2.1.9 Expression of results 
Results from these experiments are expressed as the mean ± standard error 
of the mean (s.e.m.) for n number ofperfusions. 
2.1.9.1 Viability of perfusions determined by glucose utilisation, by the 
isolated jejunum, from the vascular perfusate 
Glucose analysis using the Cobas-MlRA gives the concentration of glucose 
remaining in the vascular effluent after passage through the jejunal mesenteries. 
From these values (in mM) the rate of vascular uptake of glucose was determined. 
The basic calculation is as follows: 
At any given time the uptake of glucose is represented as: 
~C.F 
where: ~C is the initial concentration of glucose in the reservoir minus 
the concentration measured in the effluent sample 
F is the flow rate of the perfusate per minute. 
However, the most accurate representation of uptake analysis is to express it 
as the gradient of cumulative uptake under steady state conditions over time. 
Cumulative uptake (in J.1II1ol·[g dry wt] -1) is expressed by equation 2.1: 
Equation 2.1 
where t is the time interval between successive samples 
W is the total dry weight of the isolated intestine. 
This is represented as a graph showing glucose uptake against perfusion time and is 
expressed as an uptake rate of J.1mol.min:l[g dry wt] -I. 
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2.1.9.2 Intestinal transport of a dipeptide as determined by its 
appearance in the vascular effluent 
Graphical representations of the perfusions show the cumulative vascular 
appearance of dipeptide substrates (y-axis) against time (x-axis). 
The rates of dipeptide transport were calculated as /-Lmol.min:l.[g dry wtrl. 
HPLC analysis of vascular samples detected the amount of substrate present and 
expressed it as a peak area. The concentration of substrate in each sample was 
calculated by a comparison of the actual peak area to peaks of known standard 
concentrations. Standards (D-Phe and the dipeptide under study) were analysed at a 
concentration of 0.01 MM. The equation used to calculate the concentration of 
peptide (mM) in the samples is as follows: 
Equation 2.2: 
(D/S)*C 
where: D is the dipeptide peak area 
S is the standard peak area 
C is the correlation factor; .by which sample treatment and 
dilution of standards are taken into account. 
This value (in mM) is then taken through equation 2.1 described in section 
2.1.9.1 to calculate the cumulative transport rate of dipeptide and express it as 
i!lll01.min-1'[g dry wtrl. 
2.1.9.3 Tissue accumulation of peptide and corresponding exit ratio 
Additional graphs show accumulations of dipeptide substrates (mM) in 
mucosal and muscle tissues following the perfusions, plus their corresponding exit 
ratios. The tissue concentrations of substrate are calculated by equation 2.1. Exit 
ratios represent the proportion of the substrate that is accumulated in the tissue with 
respect to its individual transport rate. It is expressed in equation 2.3 as follows: 
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Equation 2.3: 
tissue concentration / final vascular sample concentration 
where: the tissue concentration is the concentration of dipeptide 
(mM) in either the mucosal or muscle tissue 
the final vascular sample is the concentration (mM) in the 
sample taken at 50 min during the perfusion. 
2.1.9.4 Statistical analysis 
Differences in rates of peptide transport between various conditions were 
calculated using analysis of variance performed in Excel. The time period analysed 
was from 20 to 50 min because a steady state of transport was not achieved until 
approx. 15-20 of perfusion. Differences in tissue concentrations were analysed using 
unpaired 2-tailed t tests in Excel, assuming equal variances. 
2.2 DUAL PREPARATION OF BRUSH-BORDER AND 
BASOLATERAL MEMBRANE VESICLES FROM RAT 
JEJUNAL MUCOSA 
Brush-border membrane vesicles (BBMV) and basolateral membrane 
vesicles (BLMV) were prepared from rat jejunal mucosa as previously described by 
Maenz & Cheeseman (1981) and Corpe et al. (1996), with some modifications. The 
alteration in the method of primary importance was to anaesthetise the rat prior to 
removal of the intestine. It has been shown that if the rat is killed before dissection, 
instead of being maintained under anaesthesia, the rate of release/leakage of peptide 
hydrolase activities increases 4-8 fold (Plumb et al. 1987). In addition, if the small 
intestine is deprived of oxygen, even for as little as 4 min, severe destruction of the 
villi is observed, including detachment of cells from the mucosal layer, oedema, etc. 
All changes are characteristic of damage caused by ischaemia (Plumb et al. 1987). 
2.2.1 Animals 
Fed rats of 260-300 g bodyweight were used in vesicle preparation. 
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2.2.2 Chemicals and materials 
Mannitol, imidazole, MgCh, Tris, EDT A, TCA and ethanol were supplied 
by BDH Laboratory Supplies, Poole, U.K. and were of AnalaR® grade. 
PM SF, Percoll, ATP and ouabain were obtained from Sigma Chemical Co. 
Ltd., Poole, UK. 
The BCA protein assay kit was supplied by Pierce, Warrington, UK. 
The alkaline phosphatase assay kit was supplied by Roche Diagnostic 
Systems. 
A polytron GS25 homogenising tube and Kinematica large head 
homogeniser were obtained from The Northern Media Supply Ltd., North Cave, 
North Humberside, UK. 
A superspeed Sorval centrifuge and SS34 rotor were obtained from Du Pont 
Instruments, Du Pont (UK) Ltd. Herts. UK. 
The L 71L8 ultracentrifuge and SW28 (96E 6426) rotor and the IL I 00 
centrifuge and SN 2291 rotor were obtained from Beckman, PK Services. 
Remaining chemicals and materials have been described in previous 
methods sections. 
2.2.3 Solutions 
All solutions were made up in diH20, unless otherwise stated. 
Buffered mannitol, pH 7.5 
250 mM mannitol 
20 mM imidazole 
50mMPMSF 
100' mM MgCl2 
2.2.4 Membrane vesicle preparation 
45.542 gil 
1.362 gIL 
8.8 mg/ml ethanol 
2.03 g/100 ml 
All preparative steps were carried out on ice or at 4°e. 
12 rats were anaesthetised with an intraperitoneal injection of Sagatal® 
(10 mg·[IOOg body weightr1). An incision was made on the midline of the abdomen, 
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followed by a lateral incision at midpoint to open up the abdominal cavity. 
Approximately 40 em of small intestine distal to the ligament if Treitz was removed 
and flushed through with 25 ml ice cold buffered mannitol containing 0.1 mM 
PMSF. The segments were placed in fresh mannitollPMSF on ice. Following 
removal of the jejunum, the rats were killed by the method of exsanguination. The 
jejunal segment was placed on a chilled glass plate, opened along its antimesenteric 
surface and the mucosa was isolated by gentle scraping using a microscope slide. 
This was performed with a total of 4 rats. The mucosal scrapes were combined, its 
weight noted and placed in buffered mannitol (l0 ml/g of scrape) in the pre-chilled 
Polytron GS25 homogeniser tube. PMSF was added to a final concentration of 
0.1 mM. The mucosa was homogenised using a Kinematica homogeniser (large 
h~ad) on setting 7 for 4 * 30 s pulses, with 20 s rest on ice between each pulse. This 
dissection and homogenisation procedure was repeated until the jejunal mucosa from 
all 12 rats had been treated. A homogenate sample for enzyme assays was taken; this 
was a combined sample from all rats used. 
The final homogenate was centrifuged at 2500 g for 15 min using the 
pre-chilled SS34 rotor in the Sorval centrifuge. After centrifugation, the fatty 
material was removed and the pellet discarded.. The supernatant was centrifuged at 
21000 g for 20 min. A double layer pellet was formed of which the fluffy, white 
upper layer was rich in basolateral membranes and the hard, dark lower layer was 
brush-border rich. The vesicle preparation then diverged into two separate protocols 
performed simultaneously to purify the respective membranes. 
2.2.4.1 Basolateral membrane purification 
The upper fraction was isolated by gently swirling the pellet in buffered 
mannitol, to dislodge only these membranes, and the suspension was transferred to a 
fresh tube. PMSF was added to a concentration of 0.1 mM. The membranes were 
resuspended in buffer by 6 strokes in a hand-held glassffeflon homogeniser. The 
solution was made up to 38 ml, containing 12% (v/v) Percoll, and the solution gently 
mixed by inversion. The suspension was centrifuged at 48,000 g for 60 min in a 
Beckman ultraclear (344058) tube using SW28 (96E 6426) rotor in the Beckman 
L71L8 centrifuge. This resulted in a self-forming Percoll density gradient in which 
the basolateral membranes were concentrated in a tight band towards the top of the 
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centrifuge tube. BLMV were recovered and resuspendedlrevesiculated in buffered 
mannitol containing 0.1 mM PMSF using a 21 G hypodermic needle and syringe. 
The Percoll was washed out of the sample by centrifuging the suspension at 48,000 g 
for 30 min in the Sorval. Membranes were recovered and concentrated by 
centrifugation at 166,000 g for 15 min using the TLI00 centrifuge and pre-chilled 
rotor (SN 2291). The final membrane sample was revesiculated as before. 
2.2.4.2 Brush-border membrane purification 
The inner pellet was resuspendedlrevesiculated in buffered mannitol plus 
0.1 mM PMSF using a 21G needle. MgCh was added to a final concentration of 
10 mM and solution inverted six times and incubated on ice for 20 min, with gentle 
agitation at 10 min. Differential centrifugation of the suspension followed at 3,000 g 
for 10 min using the SS34 rotor to pellet unwanted precipitated membranes. Fatty 
material and the gelatinous pellet were discarded. The supernatant containing pure 
brush-border membranes was then centrifuged at 27,000 g for 30 min. The 
supernatant was discarded and the pellet resuspendedlrevesiculated in buffered 
mannitol plus 0.1 mM PMSF. The vesicle suspension was centrifuged at 27,000 g 
for 30 min. The final pellet was resuspendedlrevesiculated to a required final 
concentration in buffered mannitol. 
2.2.5 Assays to establish vesicle purity 
Final membrane samples and original tissue homogenate (taken after the 
initial crude intestinal scrape homogenisation) were routinely assayed for protein 
purification and to ensure that the purified membranes were enriched over the 
homogenate sample. The enzyme assays chosen were specific marker enzymes for 
either the brush-border or basolateral membrane; 
Sucrase 
Alkaline phosphatase 
Ouabain-sensitive 
Na + /K+ -ATPase 
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An assay to determine protein concentrations of the membrane samples and 
homogenate were also performed. 
All assays (except the ouabain-sensitive Na+/K+-ATPase) were performed 
on a Cobas-MIRA robotic analyser (Roche Products Ltd., Welwyn Garden City, UK.) 
which performs automated enzymatic analysis based on user-specific criteria outlined 
in designated programs. 
2.2.5.1 Protein assay 
Protein was assayed using a commercially available kit; BCA Protein Assay 
Kit from Pierce. This kit uses BCA (bicinchoninic acid) for the quantitation of total 
protein content within a sample using a colorimetric detection method. It involves 
the biuret reaction in which protein causes the reduction of Cu2+ to Cu + in an alkaline 
medium. BCA is highly sensitive to Cu+; it binds in a 2:1 ratio to form a 
purple-coloured reaction product. This coloured complex exhibits a high absorbancy 
at 562 nm that is linear with increasing protein concentrations. The reaction scheme 
is summarised as follows: 
Protein (peptide bonds) + Cu2+ :::::::- tetradentate-Cu+ complex 
Cu+ + 2BCA :::::::- BCA- Cu+ complex (purple coloured) 
The protein concentration in the samples were calculated based on a standard curve 
of 0.02-2.0 mg·mr l BSA. 
2.2.5.2 Alkaline phosphatase assay 
Alkaline phosphatase (ALP) hydrolyses monophosphate esters to form a 
phenol and a phosphate ion; 
ALP 
4-nitrophenyl-phosphate + H20 c:::::====:::::::- 4-nitrophenol + phosphate 
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Under alkaline conditions 4-nitrophenol is yellow with a strong absorbency at 
405 nm. Its rate of formation is directly proportional to ALP activity within the range 
studied. 
ALP activity is expressed as U·[mg protein]"i. 
2.2.5.3 Sucrase assay 
(a) Solutions 
Assay buffer (J 00 ml) 
100 mM imidazole, pH 7.0 
100mMNaCI 
0.681 g 
0.584 g 
2.054 g 60 mM sucrose 
J 0 mM D-glucose 0.18 gil 00 ml 
0.6MKOH 3.37 glI00 ml 
6% (w/v)PCA 17.5 m1l250 ml 
(b) Assay 
Sample preparation was as follows; an aliquot of membrane/homogenate 
sample was incubated with 1 ml assay buffer for 15 min at 37°C in an Eppendorf 
heating block. The reaction was quenched by a 2-fold dilution in 6% PCA followed 
by centrifugation at 1800 g for 2 min. The supernatant was neutralised by a 1.6-fold 
dilution into 0.6 M KOB. Sucrase activity (mM) was measured by the amount of 
glucose generated in 15 min at 37°C by membrane samples minus a blank sample 
(buffered mannitol replacing membranes to eliminate buffer activity). 
The reaction scheme and testing protocol are described in section 2.1.8.1. 
Sucrase specific activity was calculated using the following equation: 
[G*(l.O+V»)/[V*lS*P) 
J.Ull0l.min·1.(mg protein)"l 
G = glucose (mM) 
V = volume of sample 
P = protein concentration (mg·mr1) 
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2.2.5.4 Ouabain-sensitive Na+/K+-ATPase assay 
The ouabain-sensitive Na+fK+-ATPase enzyme is located predominantly in 
the basolateral membrane, with very little or no activity detected in the brush-border 
(Fujita et al., 1971; Harms et al., 1980). As such, it can be used as a reliable marker 
to demonstrate the purity of a BLMV preparation. 
This assay consisted of two distinct steps. In the initial sample assay, ATP 
is cleaved in the presence of Na+, K+ and Mg2+, with ouabain present or absent as 
required, to generate inorganic phosphate (Pi). The second detection step measures 
the amount of Pi produced during the first step using the method of Fiske & 
Subbarrow (1925); Pi reacts with molybdate to produce phosphomolybdic acid. 
Phosphomolybdic acid is, in tum, is reduced to a blue coloured reaction product 
possessing a high absorbency at 680 nm. 
(a) Solutions 
(A) Assay buffer (100 ml) 
(B) 
(C) 
(D) 
(E) 
(F) 
200 mM Tris, pH 7.6 
10mMMgCh 
4mMEDTA 
1 MNaCI 
0.5MKCI 
30mMATP 
5.714 mM Ouabain 
30% (w/v) TCA 
Phosphate standard stock solution 
0.5 mM K2HP04 
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0.1169 g 
5.844 g 100 ml 
3.728 g 100 ml 
18.4 mg/ml 
20.8 mg/ml 
30 g/100 ml 
8.7 mg/l00 ml 
3.6 ml of98% pure S. G. 1.84 
acid /100 ml 
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2.5% (w/v) ammonium molybdate 
0.25% (w/v) F &S reducer 0.25 gil 00 ml 
(b) Sample assay 
100 III of diluted samples (10-fold dilutions of BBMV and homogenate (H), 
100-fold dilution of BLMV) were incubated under the following conditions; without 
ouabain ('total') or with ouabain (,ouabain-inhibited'), in conjunction with a blank 
(in which buffered mannitol replaced the membranes). The constituents of each 
assay is shown in table 2.1. 
SOLUTION TOTAL OUABAIN BLANK 
A 250 250 250 
B 100 
-
100 
C 20 
-
20 
D 
-
350 -
E 430 200 430 
Table 2.1 Constituents of each of the different conditions in the 
ouabain-sensitive Na+/K+-ATPase assay. Volumes are 
in Ill. 
Solutions were incubated for 15 min at 37°C; during this time solution D was 
equilibrated to temperature. 100 /-11 of pre-warmed solution D was added to each 
sample which was mixed and incubated for a further 20 min. The reaction was 
quenched by the addition of 200 /-11 solution F and the sample centrifuged at 1800 g 
for 2 min. 
(c) Pi detection 
A standard curve of 0-0.5 mM phosphate was constructed. Standards and 
sample were analysed in the same way; the solution was as follows: 
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• 750 JlI diH20 
• 175 JlI 2.5% (w/v) ammonium molybdate 
• 75 JlI 0.25% (w/v) F &S reducer 
• 100 JlI of assayed sample 
The solution was mixed and incubated at room temperature for 15 min. Samples 
were then read at A68o. 
Absorbance of the blank assay was subtracted from the membrane samples 
and Pi concentration in the sample was calculated using the phosphate standard 
curve. The specific activity of ATPase within the sample was calculated using the 
following equation; 
[[(x* 1.2*(60/20»/0.1] *D]/P 
x = Pi concentration (mM) 
D = dilution factor 
J.lInol. .h-1·(mg protein)"l 
P = protein concentration (mg·mr1) 
The difference in UV absorbancy, and therefore the difference in specific activity, 
between samples incubated ± ouabain represent the ouabain-sensitive 
Na+/K+-ATPase located at the basolateral membrane. 
2.2.5.5 Enrichment factors of marker enzymes 
Enrichment factors for all marker enzymes were calculated in both 
basolateral and brush-border membranes to demonstrate purity of the vesicle 
preparation and is represented by the ratio of activity in pure membranes to activity 
present in the crude homogenate. 
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2.3 IDENTIFICATION OF PEPTIDE TRANSPORTERS BY 
PHOTOAFFINITY LABELLING OF INTESTINAL MEMBRANE 
PROTEINS USING [4-AZIDO-3,5-3H-D-PHE]-L-ALA 
Membrane vesicles were labelled with the photo labile dipeptide derivative 
[4-azido-3,5)H-D-Phe]-L-Ala. Labelling was performed within two possible 
environments; in the absence of substrates (unprotected) and in the presence of a high 
concentration of a particular substrate (protected). The substrates used for protection 
studies were either a dipeptide (D-Phe-L-Gln) or its constituent amino acids (D-Phe 
and L-Gln). Potential differences in label incorporation by membrane proteins would 
demonstrate substrate-specific labelling and indicate the preferred nature of the 
substrate with which the protein interacts. 
2.3.1 Photoaffinity labelling of membrane vesicles 
2.3 .1.1 Chemicals and materials 
The photoaffinity label (custom-synthesised by Prof. P. D. Bailey and Dr. I. 
Collier in the Chemistry Department, Heriot Watt University, Edinburgh, U.K.) was 
tritiated to form ([4-azido-3,5-3H-D-Phe]-L-Ala) by Zeneca. 
Amino acids (D-Phe, L-Gln, L-Leu), MES and bestatin were supplied by 
Sigma Chemical Co. Ltd., Poole, U.K. 
Xenon arc lamp (Wotan 250 W) positioned 22 cm from the sample cuvette. 
Remaining chemicals and materials have been described in previous 
methods sections. 
2.3 .1.2 Solutions 
All solutions were made up in diH20 unless otherwise stated. 
[4-azido-3,5-3H-D-Phe]-L-Ala in 35% aqueous ethanol was supplied as a 42 JJM 
stock solution (37 MBq/ml; 888 GBqlmmol.) 
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Labelling buffer 
50 mM MES, pH 5.5 0.976 glI00 ml 
16.7 mM D-Phe-L-Gln 4.912 mglml MES 
16. 7 mM D-Phe 2.77 mglml MES 
16.7 mM L-Gln 2.43 mglml MES 
20 pM bestatin 6.89 mglml MES 
2.3 .1.3 Labelling protocol 
Transport by PepTl has been shown by a number of groups to be optimum 
at pH 5.5-6.0 (reviewed in Meredith & Boyd, 1995). In addition, the limited studies 
conducted on the basolateral peptide transporter have shown that although transport 
does not have an optimum pH, it is maximal at a slightly acidic pH (Saito et al. 1993; 
Thwaites et al. 1993a; Matsumoto et al. 1994; Terada et al. 1999). As such, prior to 
photoaffinity labelling, vesicles were equilibrated at pH 5.5 by repeated wash and 
centrifugation steps. 200 Jlg membrane vesicles were re-suspended in 1 ml MES, 
pH 5.5 in a Beckman 1.5 ml centrifuge tube and centrifuged at 106,000 g in the 
TL 100 ultracentrifuge for 10 min at 4°C. This process was repeated 3 times. It 
ensured that potential substrates would have a higher affinity for the transporters, and 
therefore maximised potential interactions. 
The pellet from the final wash and centrifugation step was resuspended in 
the appropriate experimental solution; 
'unprotected': MES, pH 5.5 
'protected': either 16.7 mM D-Phe-L-Gln 
or 16.7 mM D-Phe & 16.7 mM L-Gln 
at a concentration of 1 mg.mr1 and incubated at room temperature for 15 min with 
gentle agitation. Subsequent steps were all performed in the absence of light. 
[4-azido-3,5}H-D-Phe]-L-Ala (740 KBq) was added to the vesicle 
suspension at a final concentration of 4.2 J.1M. The solution was vortexed and 
incubated at room temperature for a further 10 min. The sample was then transferred 
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to a quartz cuvette and this was placed in a cuvette stand positioned 22 cm from the 
Xenon arc lamp. The sample was irradiated with intense UV light for 20 s to 
stimulate covalent binding of the azide moiety to proteins. The sample was then 
transferred to another pre-chilled 1.5 ml Beckman tube. The quartz cell was washed 
with two additional 300 J.t! aliquots of MES, which were combined with the original 
sample. The initial wash and centrifugation steps were performed again on the 
labelled sample to eliminate any unbound/loosely bound label remaining in solution. 
The final pellet was subjected to either SDS-PAGE (section 2.3.2) or IEF (section 
2.3.3) in rod gels to resolve the membrane proteins based on either their molecular 
mass or isoelectric point, respectively. 
For photoaffinity labelling studies in the presence of bestatin, vesicles were 
incubated with 20 J.1M bestatin for 30 min prior to the labelling procedure in the same 
way as the substrate protection studies~ 
2.3.2 SDS-polyacrylamide gel electrophoresis of photoaffinity 
labelled membrane vesicles 
SDS-P AGE was used to resolve the vesicle membrane proteins as a function 
of their relative molecular weights. SDS is an anionic detergent that binds to proteins 
in a ratio of 1.4: 1. This not only causes complete disruption of the proteins 
secondary and tertiary structures, but SDS also masks the charge of the proteins due 
to the formation of anionic complexes, all of which possess an equal negative charge 
per unit mass. In the presence of a reducing agent, e.g. ~-mercaptoethanol, the 
polypeptides form flexible rod shapes and so the relative mobility of a protein within 
an SDS-P AGE gel is directly proportional to its molecular weight. 
2.3 .2.1 Chemicals and materials 
SDS, glycerol and glycine were obtained from BDH Laboratory Supplies, 
Poole, U.K. and were of AnalaR® grade. 
~-mercaptoethanol, TEMED, APS, bromophenol blue and pre-stained 
molecular weight markers were supplied by Sigma Chemical Co. Ltd., Poole, UK. 
Packard. 
AcrylamidelBisacrylamide solution (37.5: 1) was obtained from Protogel. 
Optiphase Scintillation Cocktail (Ultima-Gold™ XR) was obtained from 
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A gel slicer with razor blades positioned exactly 3 nun apart was 
custom-made in the Biology Dept., University of York 
Remaining chemicals and materials have been described In previous 
methods sections. 
2.3.2.2 Solutions 
All solutions were made up in diH20 unless otherwise stated. 
Gel buffers (100 ml) 
1.5 M Tris 
8mMEDTA 
18.165 g 
0.297 g 
Stacking gel was titrated to pH 6.8 with HCI 
Resolving gel was titrated to pH 8.9 with HCI 
30 mM Tris-HCI, pH 7.8 
10% (w/v) SDS 
Sample buffer (10 ml in 30 mM Tris-HCI, pH 7.8) 
9% (w/v) SDS 
6% (v/v) J3-mercaptoethanol 
Tracker dye (10 ml in 30 mM Tris-HCI, pH 7.8) 
15% (v/v) Glycerol 
0.05% (w/v) bromophenol blue 
Tank buffer (2.4 L) 
40 mM Tris 
0.38 M glycine 
0.1% (w/v) SDS 
1% (w/v)APS 
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0.363 glI00 ml 
10 gil 00 ml 
0.9 g 
0.6ml 
1.5 ml 
0.005 g 
9.0 g 
43.2 g 
3.0 g 
0.1 gllO ml 
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Extraction buffer (1 L) 
0.1 % (w/v) SDS 
50 mM Tris-Hel, pH 7.5 
2.3.2.3 Casting of the gels 
1.0 g 
6.057 g 
Materials and methods 
Gels were cast in glass tubes (i.d. 5 mm) based on a discontinuous system; 
the 10% resolving gel formed 10 cm of the total length and the 5% stacking gel was 
1.5 cm in length. The bottoms of the tubes were covered with numerous layers of 
Parafilm to; a) prevent leakage of the gel solution during polymerisation, and b) to 
prevent entry of air through the slightly porous film which may affect polymerisation. 
The resolving and stacking gel monomer solutions were prepared as shown in 
table 2.2. Values shown are per 12 gels cast. 
5% STACKING 100/0 RESOLVING 
TrislEDTA 12.6 ml 12.6 ml 
AcrylamidelBis 8.4ml 16.6 ml 
10% SDS 0.5ml 0.5 ml 
diH20 23.8 ml 15.4 ml 
TEMED 50 fll 50 fll 
1%(w/v)APS 5.0ml 5.0ml 
Table 2.2 Constituents of gel monomer solutions used to cast 
SDS-PAGE rod gels 
The resolving gel solution (without TEMED and APS) was degassed using a vacuum 
pump and Buchner funnel for 15 min. Polymerisation was initiated by the addition 
of 50 fll TEMED and 5.0 mll% (w/v) APS. The solution was gently mixed to avoid 
the introduction of air and then pipetted directly into the top of the glass tube towards 
the wall to prevent the formation of air bubbles during polymerisation. Once the 
solution reached the 10 cm mark, the gel was overlaid with isopropanol to ensure an 
even interface between the two gel solutions. The resolving gel was allowed to 
polymerise for approx. 30 min at room temperature. Upon completion of 
polymerisation, the isopropanol was poured off and the surface of the gel was washed 
with copious amounts of ddH20, before blotting any excess water. The degassed 
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stacking gel solution was pipetted on top of the resolving gel and again overlaid with 
isopropanol. The gels were left to polymerise and their surfaces washed in the same 
way as before, prior to being positioned in the electrophoresis tank. The upper and 
lower reservoirs were filled with tank buffer, ensuring leakage from the upper 
chamber did not occur. The gels could be stored in the tank at 4°C for approx. one 
week or until required. 
2.3.2.4 Sample preparation and electrophoresis 
The pellet from the final spin of the PAL procedure was resuspended in 
70 Jll freshly made sample buffer and the proteins denatured by incubation at 70°C in 
an Eppendorf heating block for 2 min. The sample was left to cool to room 
temperature prior to the addition of 35 JlI tracker dye. Samples were loaded 
individually onto rod gels in conjunction with a sample of pre-stained molecular 
weight markers. Gels were electrophoresed overnight (approx 16 h) at a constant 
voltage of90 V at 4°C. 
2.3.2.5 Detection ofa labelled protein 
Following electrophoresis, the gels were extruded from the glass tubes by 
injection of diH20 between the two surfaces using a hypodermic needle and syringe. 
The stacking gel was removed and the resolving gel sectioned into 3 mm pieces using 
the razor blade slicer. The slices were stored individually in labelled 1.5 ml 
Eppendorf tubes and mashed dry using a custom-made Teflon® pestle. 1 ml 
extraction buffer was added to each crushed slice, the solution was vortexed and 
samples were incubated overnight at 18°C with gentle rotation to allow passive 
extraction of the proteins from the gel. 
The following day, samples were microfuged at 1800 g for 5 min and 100 JlI 
supernatant was removed and added to 3 ml Optiphase scintillation fluid in 6 ml 
capacity PonyTM vials. The samples were vortexed and subjected to scintillation 
counting using a Tri-Carb® liquid scintillation analyser, model 1900CA. 
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2.3.2.6 Expression of results 
Efficiency of scintillation counting of [4-azido-3, 5_3 H-D-PheJ-L-Ala 
Each individual scintillation counter is different in its efficiency for counting 
and this efficiency is also compound-dependant. To obtain the results from PAL 
experiments in 100% form, the counting efficiency of the label was calculated using 
equation 2.4: 
Equation 2.4 
Efficiency = (cpm/dpm)*100 
This value was used to correct raw data to obtain a 100% efficiency of results. 
Normalisation of data 
As described in the protocol section, 20 J.1l of radioactive label was added to 
each vesicle suspension and this is equivalent to 740 kBq of radioactivity. However, 
minor inherent errors in the pipette may result in slightly more or less actually being 
used. Whereas this wouldn't have a dramatic impact on labelling results per se, a 
direct comparison between the different conditions couldn't reliably be done. And 
so, the degree of inhibition by certain substrates could not be calculated accurately. 
So, the exact amount of label added to the vesicles was measured by taking a sample 
of supernatant following the first centrifugation step after labelling and counting it. 
The total amount in the whole sample could then be calculated. An average of total 
counts between experiments performed simultaneously was used to normalise the 
data to one final initial radioactivity content added to the vesicles, using the 
following equation (2.5): 
Equation 2.5 
Normalised data = (peak dpm * mean total dpm) I actual total dpm 
The data, following manipulation by these two equations, are shown in graphical 
form of radioactive label incorporation expressed as dpm (y axis) versus gel slice 
number (x axis). Therefore, peaks of radioactivity represent specific label 
incorporation by a protein. 
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Conversion of dpm to Becquerels 
The results obtained from scintillation counting (in dpm) were converted to 
actual radioactivity for additional calculations. The following information was 
required for this: 
• ImCi = 2.2 x 1012 dpm 
• ImCi = 37 MBq 
therefore, 
• 37 MBq = 2.2 x 1012 dpm 
• 1 dpm = 0.0168 Bq 
Calculation of the amount of label specifically bound to a membrane protein 
The amount of label covalently attached to specific membrane proteins are 
expressed both as the percentage of the initial amount applied and the actual amount 
in picomoles. The percentage of label incorporation was calculated in the following 
way (equation 2.6): 
Equation 2.6 
Bq contained in the peak I total Bq added to vesicles 
The volume of label added to the vesicles was 20 JlI; this is equivalent to a total of 
42 JlM. However, a 10-fold dilution of the label into the vesicle suspension gave a 
final concentration of 4.2 JlM. This information was used to calculate the amount of 
dipeptide label covalently attached to a protein. The amount of label added to the 
vesicles is expressed as; 
2 X 10.5 * 4.2 X 10.5 = 8.4 X 10.10 
A total of 840 pmoles of label added to the membrane vesicles. Using the percentage 
incorporation calculated in equation 2.6 it is possible to calculate the amount of label 
(in femtomoles) bound to a particular protein. 
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2.3.3 Isoelectric focusing (IEF) of photoaffinity labelled membrane 
proteins 
Isoelectric focusing separates proteins solely on the basis of their isoelectric 
point (PI). Proteins isolated from the first dimension (SDS-PAGE) required 
re-solubilisation in a high concentration of urea and non-ionic detergent to displace 
the SDS and disrupt the anionic complexes so that the proteins were able to regain 
their native charge. A pH gradient was formed using commercially available 
ampholytes and within this gradient proteins have either a positive, negative or zero 
net charge based on the pH of their surroundings. Under the influence of an electric 
field proteins migrate to a point where their net charge is zero, i.e. at their pI. IEF 
concentrates proteins at their pI and separates on the basis of very small charge 
differences «0.01 pH unit). 
2.3.3.1 Chemicals and materials 
Triton X-IOO, urea, NaOH and H3P04 were supplied by Sigma Chemical 
Co. Ltd., Poole, U.K. 
Ampholytes (Bio-Lyte® 517, Bio-Lyte® 3/10) were supplied by Bio-Rad. 
Remaining chemicals and materials have been described in previous 
methods sections. 
2.3.3.2 Solutions 
All solutions were made up in diH20 unless otherwise indicated. 
10% (w/v) Triton X-I 00 
IEF sample buffor 
9.5 M urea 
2% (v/v) Triton X-I 00 
5% (v/v) J3-mercaptoethanol 
1.6% (v/v) 5-7 ampholytes 
0.4% (v/v) 3-10 ampholytes 
10 gil 00 ml 
5.7 g 
2.0 ml (of 10% stock) 
0.5 ml 
0.16 ml 
0.04 ml 
Solution was warmed in a water bath to dissolve the urea, made up 
to a total of 10 ml and stored at -80°C. 
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IEF sample overlay buffer 
9.0 M urea 
0.8% (v/v) 5-7 ampholytes 
0.2% (v/v) 3-10 ampholytes 
bromophenol blue 
5.41g 
80 J..lI 
20 J..lI 
trace 
Materials and methods 
Solution is warmed in a water bath to dissolve the urea, made up 
to a total of 10 ml and stored at -80°C. 
Upper electrolyte buffer (PH 2. 2) 
20mMNaOH 
Lower electrolyte buffer (PH 12.2) 
100 mM H3P04 
10% (w/v) APS 
2.3.3.3 Casting of the IEF gels 
0.8 gIL 
0.68 milL 
1.0 g/IO ml 
Gels were cast in the same glass tubes as the SDS-PAGE gels (Ld. 5.0 mm) 
and were 10 cm total in length (IEF gels are a continuous system). The bottoms of 
the tubes were wrapped in Parafilm as before (section 2.3.2.3) and the monomer 
solution was mixed as shown in table 2.3. This produced enough solution to cast five 
gels. 
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FINAL CONCENTRATION AMOUNT 
9.2 m urea 13.75 g 
4% (v/v) T (acrylamide) 3.325 ml of37.5:1 stock 
0.1% (v/v) Triton X-IOO 3.0 ml of 10% stock 
2.5% (v/v) 5-7 ampholytes· 625 J.11 
2.5% (v/v) 3-10 ampholytes· 625 J.11 
diH20 4.925 ml 
TEMED 25 J.11 
10% (w/v) APS 25 J.11 
Table 2.3 Constituents of the gel monomer solution used to 
cast IEF rod gels 
• A total volume of 5% ampholytes were used, but the proportions 
of the samples could be altered to create the gradient required. The 
proportions indicated here produced a non-linear gradient pH 3-10. 
The solution (without inclusion of the catalysts) was heated gently in a water bath to 
dissolve the urea. Polymerisation was initiated by adding 25 J.11 10% (w/v) APS and 
25 J.11 TEMED. The solution was pipetted into the glass tubes to the 10 cm mark and 
overlaid with isopropanol. Gels were allowed to polymerise at 37°C for approx. 2 h. 
Upon completion of polymerisation, the gel surfaces were washed with diH20 and the 
tubes positioned in the tank. Gels were equilibrated by adding 30 J.11 of IEF sample 
buffer to their surface for 15 min at room temperature. 
Electrolytes were degassed in Buchner funnels using vaccum pumpS for 
30 min before pouring into their respective chambers. All air bubbles surrounding 
the gels were removed using a Pasteur pipette. 
2.3.3.4 Sample preparation and electrophoresis 
Samples (either from the first dimension; SDS-P AGE, or original samples 
from PAL) were incubated in IEF sample buffer at room temperature for 15 min. 
Samples from the SDS-P AGE gels were diluted so that the concentration of SDS was 
less than 0.25% and its ratio to Triton X-100 was at least 1:8. SDS interferes with 
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IEF because the negatively charged complex it forms with the proteins disrupts their 
focusing process. The urea and Triton X-I00 ensured the proteins remained in 
solution and this solubility was enhanced by the presence of ampholytes in the buffer. 
Ampholytes help to minimise protein aggregation caused by charge-charge 
interactions. Under no circumstances should the sample in the urea buffer be heated 
because this could introduce considerable charge heterogeneity of the proteins due to 
carbamoylation of the proteins by isocyanate formed from the decomposition of urea. 
Before the samples were loaded onto the gels, a pre-electrophoresis stage 
created the pH gradient of the ampholytes within the gels. The step-wise procedure 
was as follows: 
• 200 V for 10 min 
• 300 V for 15 min 
• 400 V for 15 min 
Once this step was complete, samples were loaded onto the gel surface. 
Gel loading was a little more difficult than with SDS-PAGE gels because 
the buffer doesn't contain glycerol to give the sample a lower density than the 
electrolyte; the sample was overlaid with another buffer with an intermediate density 
to prevent its diffusion from the surface of the gel. This had to be done immediately 
after sample loading to ensure the sample was in direct contact with the gel surface. 
Electrophoresis began with another stepwise process that primarily 
functioned to prevent overheating of the gels due to the high voltages employed in 
this technique. The procedure was as follows: 
• 500 V for 10 min 
• 750 V for 15 min 
• 1000 V for 8 h 
The gels were electrophoresed at a constant voltage for 8 h at room temperature. An 
indication that IEF was complete was shown by a very low final current, typically 
less than 1 mAo This demonstrated that the proteins had reached their pI and that 
there was very little ionic movement within the system. 
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2.3.3.5 Detection of a labelled protein 
Once the voltage had been switched off, slicing of the IEF gels was 
performed quickly because a loss of current resulted in the highly focused proteins 
starting to diffuse away from their pI. 
Sectioning of the IEF gels was a little more difficult than with SDS-PAGE 
gels due to a lower acrylamide content, as such the custom-made slicer could not be 
used satisfactorily. Gels were sliced using a scalpel blade into 2 mm sections. The 
pH of each individual slice was measured using a flat bulb electrode and pH meter; 
the flat bulb ensured direct contact of the electrode with the surface of the gel. The 
gel slices were crushed and the protein extracted in the same way as described in 
section 2.3.2.5. Scintillation counting to detect labelled proteins was also performed 
in the same way. 
2.3.3.6.Expression of results 
Results from IEF of photoaffinity labelled proteins are graphically 
represented as radioactive incorporation (y-axis) against the pH gradient throughout 
the length of the gel (x-axis). This permitted the pI of a labelled protein to be 
measured. 
2.3.4 Papain digestion of membrane vesicles 'prior to photoamnity 
labelling 
Digestion of BBMV using papain was employed to solubilise all known 
hydro lases located in that membrane. BBMV have a right side out orientation, 
i.e their outer surface is the outer surface of the enterocyte which faces the intestinal 
lumen. Brush-border hydrolases have an asymmetric orientation within the 
membrane, i.e. the bulk of the molecule is exposed at the luminal surface (Kenny & 
Maroux, 1982). As such, papain treatment can hydrolyse these proteins from the 
membrane whilst conserving the integrity of the lipid bilayer structure. Papain 
digestion was conducted prior to labelling of BBMV in order to prevent 
incorporation of the label by the hydro lases during PAL. 
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2.3 .4.1 Chemicals and materials 
Papain was commercially available as a 23 mg.mr1 suspension in sodium 
acetate from Sigma Chemical Co. Ltd., Poole, U.K. Cysteine, HEPES and 
dithiothreitol were also supplied by Sigma. 
Remaining chemicals and materials have been described in previous 
methods sections. 
2.3.4.2 Solutions 
All solutions were made up in diH20 unless otherwise stated. 
Potassium phosphate buffer, pH 6.2 
Consisted of 2 stock solutions; 
(A) 50 mM KH2P04 
(B) 50 mM K2HP04 
0.68 gllOO ml 
0.871 gl100 m1 
A working buffer of pH 6.2 contains 40.75 ml solution A and 9.25 
ml solution B. 
Hepes/mannito/ buffer, pH 7.5 (100 ml) 
1 mMHEPES 
100 mM mannitol 
50 mM cysteine 
3 mMDIT 
2.3.4.3.Papain digestion protocol 
0.026 g 
1.822 g 
79 mgll 0 ml phosphate buffer 
46 mgll00 ml phosphate buffer 
All steps were performed at 4°C unless otherwise stated. 
200 J,1g BBMV were centrifuged in the TL100 at 106,000 g for 10 min to 
pellet the membranes. The vesicles were equilibrated at pH 6.2 by repeated wash and 
centrifugation steps as described in section 2.3.1.3 but using the potassium phosphate 
buffer. The pellet from the final spin was resuspended in potassium phosphate buffer 
at a concentration of 5 mg.mr1• 
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Papain was required at a concentration of 39 mg.mr1 in potassium 
phosphate buffer, so 39 mg of the commercial suspension (169.6 J.Ll) was pelleted by 
centrifugation at 240,000 g in the TLI00. Papain was activated by resuspension of 
the pellet in 100 J.LI potassium phosphate buffer containing (final concentration) 
5 mM cysteine and 0.03 mM DTT and incubated for 15 min on ice. Activated papain 
was then added to the vesicle suspension at the concentration required, e.g. 
• 0.5 mg·mr1 = 0.51 J.LI papain 
• 0.25 mg·mr1 = 0.26 J.LI papain 
The sample was vortexed and incubated at 37°C for the required time period of 
digestion. 
Following digestion, the reaction was quenched in one of two different 
ways; 
(i) chilled to 4°C (Ganapathy et al., 1981) 
(ii) 5-fold dilution with ice-cold HEPES/mannitol buffer, 
pH 7.5 (Berteloot et al. 1980). 
The suspension was centrifuged at 106,000 g for 45 min. The membrane pellet was 
then equilibrated to pH 5.5 with 50 mM MES as described in section 2.3.1.3 and the 
photoaffinity labelling procedure was performed exactly as before. 
2.4 ISOLATION AND PURIFICATION OF AN INDIVIDUAL 
MEMBRANE PROTEIN 
Proteins can be isolated using two-dimensional electrophoresis (2-DE) with 
immobilised pH gradients (IPGs). However, during each of the distinct steps a 
certain amount of the initial protein is lost. These sequential losses are summarised 
as follows: 
• IEF 30-35% loss 
• Equilibration 40-45% loss 
• SDS-P AGE 43-48% loss 
(taken from Celis & Bravo, 1984) 
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At the end of the procedure as much as half of the initial protein applied to 
the IEF strip may b~ lost. If the protein of interest is a minor component of the 
sample, there won't be a sufficient amount remaining at the end to be used for 
sequence analysis. As such, in order to ensure a satisfactory yield of a specific 
membrane protein, it was necessary to employ a scaled-up protein isolation procedure 
using the rod gels prior to the 2-D purification step. 
2.4.1 Identification of a protein by photoaffinity labelling 
Samples (200 J.1g) of membrane vesicles were photoaffinity labelled 
following the protocol previously described (section 2.3.1) and the radioactive 
membranes were subjected to SDS-PAGE in rod gels as previously described 
(section 2.3.2.). A total of 10 samples could be run due to the structure of the 
electrophoresis system. 
Following resolution, the gels were sliced, crushed and the proteins 
extracted as before. The labelled samples were subjected to scintillation counting to 
determine which slice number contained the radioactively labelled protein. 
2.4.2 Isolation of a specific protein using SDS-P AGE slab gels 
The slice(s) containing the labelled protein from all gels were run on 10% 
slab gels in a Mini-Protean® II dual slab gel kit (Bio-Rad) to determine precisely 
which samples contained the protein of interest only, without contamination from 
other proteins of similar molecular weight. 
A discontinuous system was employed in the slab gels following standard 
Bio-Rad protocols. Gel solutions and buffers were as described in section 2.3.2, 
however, gels were cast between two glass plates (inner plate 7.3* 10.2 cm, outer 
plate 8.3 * 10.2 cm) to form a gel of dimensions 7.0 cm in length by 8.0 cm in width. 
PVC (polyvinyl chloride) spacers determined the thickness of the gel (0.75 mm). 
Teflon® combs formed the sample loading wells within the stacking gel. 
From each of the required samples, 15 , . .1.1 of supernatant was added to 2 J.11 
f3-mercaptoethanol and 7 J.11 tracker dye, and vortexed. 20 J.11 of the final samples 
were loaded onto the gel, in conjunction with a sample of pre-stained molecular 
weight markers. Gels were electrophoresed at a constant voltage (100 V) for approx. 
2-3 h until the required resolution was attained. 
110 
Chapter 2 Materials and methods 
2.4.3 Silver staining 
Protein bands were visualised by silver staining of the gels following the 
standard Bio-Rad protocol, based upon a photochemical process outlined by Merril 
(1981), described below. 
2.4.3.1 Solutions 
All solutions were made up in diH20 unless otherwise stated. 
Fixative (100 ml per gel) 
Oxidiser 
40 % (v/v) methanol 
10 % (v/v) acetic acid 
40ml 
10 ml 
This was supplied as a lOx concentrated solution and had to be diluted prior 
to use. 
Silver reagent 
This was supplied as a lOx concentrated solution and had to be diluted prior 
to use. 
Stop solution (lOO ml per gel) 
5% (v/v) acetic acid 
Developer 
5ml 
This was supplied as a dry chemical blend (115 g). 
One bottle was dissolved in 3.6 L. 
2.4.3.2 Staining protocol 
All steps were performed on an orbital shaker table to ensu.re contact of the 
gel with solutions at all times. 
Immediately following the electrophoretic run, the gel was separated from 
the glass plates, the stacking gel removed and the resolving gel placed in fixative 
solution for 30 min. The gel was then transferred to oxidiser for a further 5 min 
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followed by repeated washing in several changes of diH20 for 15 min. The gel was 
then immersed in silver reagent for 20 min before another rapid wash «30 s) in 
diH20. The gel was submerged in developer to visualise the protein bands; the 
appearance of a brown precipitate indicated the need for fresh developer. The bands 
were imaged as dark lines on a pale background. When the required intensity was 
achieved, image development was quenched by immersing the gel in stop solution. 
2.4.4 Protein isolation and concentration 
Silver staining of the gels allowed the final step of isolation of the desired 
protein from an initial complex mixture. A preliminary step was to calculate the 
approximate molecular weight of the radioactively labelled protein using the 
pre-stained molecular markers to construct a standard curve based on their relative 
distances travelled through the gel. The gel was analysed using an imaging system 
(AlphaEase™ version 3.3, Alpha Innotech Corporation) in which the positions of the 
standards in the gel were manually indicated along with their known molecular 
weights. The AlphaEase ™ Stand Alone Software constructed a calibration curve 
which it then used to calculate the molecular weight of the labelled protein who's 
position in the gel was also indicated. Once the apparent molecular weight of the 
labelled protein had been calculated, all samples containing this protein were 
isolated. 
The isolated protein samples were then concentrated from an approx. 800 III 
initial individual volume (per sample) to a combined final volume of 50 Ill. This was 
performed using a NANOSEpTM Microconcentrator (Pall Filtron Corporation). 
Samples were pipetted into the device which was spun at 1800 g in a bench top 
angled centrifuge at 4°C. The final sample was stored at -80°C. 
2.4.5 Determination of protein content in the pure sample 
Prior to analysis, the amount of protein contained in the final sample 
required elucidation. This was achieved using BSA as an indicator of protein content 
within a band fonned by SDS-PAGE in slab gels when silver stained. A calibration 
curve (50-400 ng) was constructed within the gel. 
The spot densitometry program on the AlphaEase™ was used to measure the 
pixels associated with the IDV (integrated density value) of the stained BSA bands. 
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The IDV of an individual protein is proportional to the amount stained, up to a 
saturation point. Although BSA would stain slightly differently to the isolated 
protein, it was still a reliable marker for calculating the amount of protein present in a 
band. To ensure an accurate estimate was achieved, only values lying within the 
linear range were used. Determination of the protein content within a known volwne 
permitted the total amount, plus the protein concentration, to be calculated. This 
information was useful at a later date when performing analysis of the protein. 
2.5 TWO-DIMENSIONAL ELECTROPHORESIS OF 
MEMBRANE PROTEINS USING AN IMMOBILISED pH 
GRADIENT 
Two-dimensional electrophoresis (2-DE) is a powerful method for the 
analysis of protein mixtures from biological samples. The two distinct steps have 
been briefly described in sections 2.3.2 and 2.3.3.; this technique using carrier 
ampholytes was first introduced by O'Farrell in 1975, however due to various 
problems, such as low reproducibility, the technique wasn't widely used. Its 
application has only become significant in the past few years as the result of a 
number of developments. The major improvement in technique was to replace the 
carrier ampholyte gels with immobilised pH gradient (IPG) gels; IPGs have permitted 
extremely high resolution with very small initial quantities of protein. As such, this 
2-DE procedure was used to isolate an individual labelled protein with which to 
perform sequence analysis to aid in its identification. 
2.5.1 Chemicals and materials 
Urea (Electran), Resolytes 4-8 and glycerol ( .... 87%) were supplied by BOH 
Laboratory Supplies, Poole, U.K. and were of AnalaR® grade. 
Thiourea, DTE (BioChemika), SDS and sodium thiosulphate were supplied 
by Fluka. 
CHAPS, iodoacetamide, and brilliant blue G-colloidal stain were supplied 
by Sigma Chemical Co. Ltd., Poole, UK. 
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Agarose and the Protein II xi cell for the second dimension were supplied by 
Bio-Rad. 
Immobiline dry strips non-linear pH 3.5-10.0 (18 cm), IPG strip holders 
(18 cm), IPG rehydration tray, IPG cover fluid and the IPGphorTM isoelectric 
focusing system were obtained from Amersham Pharmacia Biotech. 
Remaining chemicals and materials have been described In previous 
methods sections. 
2.5.2 Solutions· 
All solutions were made up in diH20 unless otherwise stated. 
Sample/rehydration buffer (100 ml) 
7 M urea 
2 M thiourea 
4% (w/v) CHAPS 
65mMDTE 
0.8% (v/v) Resolytes 4-8 
bromophenol blue 
42.04 g 
15.22 g 
4.0 g 
5.0 g 
0.8ml 
trace 
Solution was aliquoted and stored at -20°C. 
Equilibration stock solution (100 ml) 
50 mM Tris-HCI, pH 6.8 
6 Murea 
30% (v/v) glycerol 
2% (w/v) SDS 
Solution was stored at 4°C. 
Equilibration solution 1 (per 10 ml stock solution) 
0.61 g 
36.03 g 
30.0 ml 
2.0 g 
1 % (w/v) DTE 10.0 mg 
Equilibration solution 2 (per 10 ml stock solution) 
4% (w/v) iodoacetamide 40.0 mg 
bromophenol blue trace 
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SDS-PAGE gel monomer solution (10% gel) 
1.5 M Tris-Hel, pH 8.8 
Acrylamidelbisacrylamide (37.5: 1) 
Sodium thiosulphate 
diH20 
TEMED 
10% (w/v) APS 
Second dimension electrolyte buffer (2 L) 
25 mMTris 
198 mM glycine 
0.1 % (w/v) SDS 
13.25 ml 
17.7 ml 
0.042 g 
21.5 ml 
26.5 f.ll 
0.53 ml 
6.06g 
29.72 g 
2.0 g 
Materials and methods 
0.5% (w/v) agarose 0.05 gllO ml electrolyte buffer 
2.5.3 First dimension: Isoelectric focusing 
2.5.3.1 Sample loading 
The IPG ceramic holders were used for both gel rehydration/sample loading 
and IEF. 
At this stage in the protein isolation procedure, the required protein in the 
concentrated sample was not completely pure, i.e other proteins with similar 
molecular weights may have been extracted from the rod gels simultaneously. So, in 
order to be able to specifically identify the protein of interest in the final 2-DE gel, a 
sample of radioactively labelled protein was subjected to 2-dimensional 
electrophoresis. 
Immediately before re-swelling of the gel strip, an aliquot of rehydration 
buffer was thawed out to room temperature. The 50 f.ll labelled protein sample 
(obtained from the concentration step in section 2.4.4) was combined with this; a 
total rehydration solution volume of 350 f.ll was used for an 18 em IPG strip. This 
7-fold dilution factor ensured that the SDS contained in the primary sample was 
reduced to less than 0.25% and was present in a ratio of 8:1 
non-ionic detergent: SDS. 
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The 350 fll rehydration sample was pipetted into the ceramic holder by 
'spotting' the solution along its length and air bubbles were removed. The IPO strips 
were stored at -20°C until required; at room temperature the protective cover from 
the gel was removed and the strip was placed gel-side down into the ceramic holder, 
over the rehydration solution, with the pointed (anodic) end at the pointed end of the 
holder. Positioning the strip was achieved by lowering the anodic end into the slot 
first and gently sliding the gel over the buffer, ensuring good contact between the 
ends of the gel strip and electrodes. Once in position, the strip was overlaid with 
approx. 3 ml of IPO cover fluid by pipetting it drop-wise at one end of the holder 
until half of the strip was covered, and then repeating this at the other end until the 
whole strip was overlaid. The cover was placed onto the ceramic boat; pressure 
blocks on the underside of the lid maintained continuous contact between the strip 
and the electrodes in the holder as the gel re-swelled. 
2.5.3.2 Rehydration and isoelectric focusing 
Rehydration and IEF of the strip were performed on the IPOphor at 20°C. 
The ceramic boat holding the gel strip was placed onto the plate of the IPGphor 
ensuring its correct orientation by using the guidemarks. The safety lid of the 
IPGphor was closed; at least two of the three pressure pads on the underside of the lid 
was required to touch the cover of the ceramic boat in order to gain efficient contact 
between the holder electrodes and the electrode areas of the IPOphor plate. 
The rehydration step was incorporated into a standard user-defined program 
on the IPOphor. A summary of the rehydrationlIEF program for an 18 cm strip is as 
follows; 
• Rehydration 22h 
• IEF: 'step 'n' hold' gradient 300-3,500 V 3h 
• 3,500 V 3h 
• 5,000 V -15 h 
The low initial voltage, combined with 'step 'n' hold' gradients, functioned to 
minimise overheating of the gel strip and prevent sample aggregation. Subsequent to 
the build up of voltage, the system was maintained at 5,000 V for a necessary time 
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period to give a volt-hour product of 100,000; this was generally about 15 h. Each 
step defined in the protocol was controlled by the IPGphor, therefore the system 
could be left unattended until the IEF was complete. 
After strip rehydration, tracking of the bromophenol blue in the re-swelled 
gel indicated that IEF had been initiated and that a current was flowing. But, clearing 
of the dye front from the gel wasn't a sign that IEF was complete because it leaves 
the gel well ahead of protein focusing. Focusing was achieved when the specified 
number of volt hours was reached. 
2.5.4 Equilibration of the focused IPG strip 
Equilibration was performed in the rehydration tray. Equilibration solutions 
I and 2 were made using the stock solution immediately before use. 
After completion of IEF, the strip was removed from the ceramic boat and 
rinsed thoroughly with diH20 before placing it into a groove in the rehydration tray 
gel-side upwards. Approx. 3 ml of equilibration solution I was pipetted over the 
strip and incubated for 12 min. This solution was removed by pipetting it out of the 
groove and 3 ml equilibration solution 2 was added for a 5 min incubation period. 
Immediately after equilibration was finished the gel strips were loaded onto 
the second dimension (SDS-PAGE) slab gels. 
2.5.5 Second dimension: SDS-PAGE 
The second dimension slab gels were cast prior to strip equilibration. The 
gels used were of a large format (18 cm * 16 cm '" 1 mm) to be run in the 
Protein II xi cell (Bio-Rad). The procedure used for casting of the gels was as 
described in section 2.3.2 but with the solutions specified in section 2.5.2, except that 
this slab gel was a continuous system (no stacking gel) and the gel solution was 
overlaid with water-saturated butanol instead of isopropanol during polymerisation. 
The other difference was that the gels were polymerised in the dark for 2 h. Once the 
gels were cast, the butanol was removed and replaced with electrolyte buffer and 
stored at 4°C until required. 
Prior to strip loading, the electrolyte was removed. The 0.5% (w/v) agarose 
solution was mixed, heated in a microwave oven and poured on top of the slab gel. 
The strip was loaded onto the surface of the gel through the hot agarose solution, 
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using a spatula to push it between the glass plates and attain complete contact with its 
surface. The orientation of the strip was noted; the acidic end (pointed) was placed at 
the left side of the slab gel when facing it during loading. The agarose solution 
cooled and solidified to hold the strip in full contact with the slab gel. 
The slab gels were placed in the tank and electrophoresed at 40 rnA per gel 
until the required resolution was achieved. The gels were maintained at 4°C by 
recirculating chilled water around the tank by an external bath. 
After the second dimension, the gels were removed and the protein spots 
visualised by an appropriate stain. Care was taken to note the correct orientation of 
the gel by notching the upper acidic comer. 
2.5.6 Staining of the 2 .. D gel with brilliant blue G-colloidal 
2.5.6.1 Solutions 
All solutions were made up in diH20 unless otherwise stated. 
Fixative (500 ml per gel) 
7% (v/v) glacial acetic acid 
40% (v/v) methanol 
35 ml 
200ml 
Brilliant blue G-colloidal stain (J x working solution) 
Add 800 ml to contents of the bottle and mix thoroughly 
Colloidal stain (500 ml per gel) 
20% (v/v) methanol in Ix working 
solution 
Destaining solution 1 (500 ml per gel) 
10% (v/v) glacial acetic acid 
25% (v/v) methanol 
Destaining solution 2 (500 ml per gel) 
25% (v/v) methanol 
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2.5.6.2 Staining protocol 
After the electrophoretic run was complete, the gels were stained using a 
brilliant blue G-colloidal stain. Initially they were fixed for 1 h in fixative solution 
on an orbital shaker table. The staining solution was made immediately before use 
and added to the gels after the fixing stage. The gels remained in stain overnight 
with gentle agitation. They were then immersed in destaining solution 1 for 10-30 s 
before being transferred to solution 2 to rinse excess stain from their surface. This 
solution was replaced after 30 s and was used to store the gels in until it was 
photographed and/or used for further analysis. 
2.6 IN GEL TRYPTIC DIGEST OF AN INDIVIDUAL 
MEMBRANE PROTEIN ISOLATED BY 2-DIMENSIONAL 
ELECTROPHORESIS 
Once an individual protein had been isolated by the 2-DE procedure, an initial 
step in its identification was to establish whether it had previously been documented, 
or whether it was novel. The most rapid method of protein identification that could 
be performed with relative ease was to do an enzymatic digest of the protein using 
trypsin and then use the resulting peptide fingerprint in database searches. Trypsin is 
a highly specific serine protease that exclusively cleaves the peptide backbone at the 
carboxylic side of lysine and arginine residues to produce a series of peptide 
fragments. These fragments constitute a unique fingerprint of a particular protein and 
are therefore collectively designated a 'peptide fingerprint'. Molecular mass 
searching using this fingerprint is a powerful and accurate tool in protein 
identification. 
2.6.1 Chemicals and materials 
Sequencing grade modified trypsin was obtained from Promega. 
AmBic, formic acid and TFA were supplied by Sigma Chemical Co. Ltd., 
Poole, UK. 
Acetonitrile was supplied by BDH Laboratory Supplies, Poole, UK. 
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A Speed Vac® Plus vaccum centrifuge (model SCIlOA) was obtained from 
Savant. 
Remaining chemicals and materials have been described m preVIOUS 
methods sections. 
2.6.2. Solutions 
All solutions were made Up in diH20 unless otherwise stated. 
Wash buffer A (10 ml) 
25 mMAmBic 
50% (v/v) acetonitrile 
Digest stock solution (100 ml) 
25 mMAmBic 
ImMCaCh 
Tryptic digest buffer (in digest stock solution) 
0.0125% (w/v) trypsin 
Wash buffer B (10 ml) 
5% (v/v) formic acid 
Analysis buffer (10 ml) 
0.1% (v/v) TFA 
50% (v/v) acetonitrile 
2.6.3. Digest protocol 
19.77 mg 
5.0ml 
197.7 mg 
14.7 mg 
12.5 J.1g1ml 
0.5 ml 
10 J.11 
5.0ml 
Protein digestion followed staining of the 2-DE gels with brilliant blue 
G-colloidal stain. All protein spots that were visualised in the 2-DE gel containing 
the photoaffinity labelled membrane protein at the approximate molecular weight 
were excised, crushed and added to 3 mlOptiphase scintillation fluid in 6 ml capacity 
PonyTM vials. The samples were vortexed and subjected to scintillation counting 
using a Tri-Carb® liquid scintillation analyser, model 1900CA. This enabled the 
120 
Chapter 2 Materials and methods 
precise spot containing the radiolabelled protein to be determined. Once this had 
been elucidated, the corresponding spot in a second 2-D gel was excised and 
subjected to tryptic digestion. Excision of the spot was performed carefully so as not 
to include any of the surrounding gel. 
The excised spot was chopped into small. pieces (approx. 1 mm2) and 
contained in a 1.5 ml capacity Eppendorf tube. The gel pieces were washed in 500 J.11 
wash buffer A three times for 10 min at room temperature with gentle agitation. The 
pieces were then dried down completely in the Speed Vac® Plus; this process usually 
took approx. 30 min but required constant monitoring of progress. The dried gel 
pieces were then re-swelled in tryptic digest buffer; just enough solution was added 
to cover the gel. This rehydration step took about 3-5 min and functioned to draw 
trypsin into the gel. Tryptic digest buffer was added to the re-swelled gel in an 
appropriate volume to keep the gel submerged during the digestion. The volume of 
buffer was determined by the size of the gel spot and the amount of protein it 
contained, plus the ratio of trypsin to protein required; trypsin was used in at least a 
1 : 1 00 ratio with protein. The gel pieces were incubated in digest buffer overnight at 
37°C in an incubation room, not a heating block. Following digestion, excess 
solution was removed and stored on ice. The gel was washed three times in very 
small volumes of wash buffer B for 30 min with gentle agitation. Extraction of 
peptides was carried out in small volumes to avoid the adsorption of peptides to the 
sides of the tube. After each wash period, the solution was removed, combined with 
the initial digest solution from the overnight incubation and stored on ice. The final 
collated sample was spun to dryness in the vaccum centrifuge. The precipitate was 
washed by resuspension in 100 J.11 diH20, before being spun to dryness again. This 
last wash step was repeated and the final dried sample was stored at 4°C until 
analysis. 
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2.7 MALDI-TOF MASS SPECTROMETRIC ANALYSIS OF 
PEPTIDE FRAGMENTS PRODUCED FROM TRYPTIC DIGEST 
OF A PROTEIN 
When analysing an unknown protein the simplest and most rapid method for 
its unequivocal identification with high sensitivity and accuracy is to analyse the 
masses of the tryptic peptides using MALOI-TOF (matrix assisted laser 
desorption/ionisation time of flight) mass spectrometry. The peptide mass fingerprint 
can then be used to search databases to find a positive match for the protein, 
providing that the unknown protein is contained within the databases. 
2.7.1 Chemicals and materials 
CI8 ZipTips were obtained from Millipore. 
Acetone was supplied by BOH Laboratory Supplies, Poole, UK. 
a-cyano-4-hydroxycinnamic acid (4-HCCA) and trifluoroacetic acid (TFA) 
were supplied by Sigma Chemical Co. Ltd., Poole, UK. 
The stainless steel sample plate, the MALOI-TOF (Voyager OE-STR) and 
the calibration standards (Ca12) were obtained from PerSeptive Biosystems, PE 
Applied Biosystems, Cheshire. 
Remaining chemicals and materials have been described 10 previous 
methods sections. 
2.7.2 Concentration and desalting procedure using Ct8 ZipTips 
The final dried peptide sample was washed to removed salts and buffers that 
may be present; this clean-up procedure results in better spectra from mass 
spectrometric analysis. 
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2.7.2.1 Solutions 
All solutions were made up in diH20 
100% Acetonitrile 
Wash solution B (lOa ml) 
0.1% TFA 
MALDI-TOF elution buffer (100 ml) 
50% acetonitrile 
Q-TOF elution buffer (100 ml) 
0.1% TFA 
50% methanol 
2.7.2.2 Procedure 
100 III 
50ml 
100 III 
50ml 
Materials and methods 
The sample was cleaned up using the ZipTip immediately prior to analysis, 
to prevent polymers from the Eppendorf tubes anlor tips contaminating the pure 
sample. 
The dried peptide sample was resuspended in 10 III 50% acetonitrile prior to 
the ZipTip clean-up. The tip was washed with 10 III 100% acetonitrile by drawing up 
and down several times: this was then repeated twice. The tip was then washed once 
with 10 I.d 50% acetonitrile, followed by three times with 10 III 0.1 % TF A (the acidic 
pH of TF A promoted maximum binding of the peptides to the mini column). The 
resuspended sample was then drawn up and down through the tip several times to 
ensure complete binding of the peptides. The bound peptides were washed with 
0.1 % TF A, by drawing 10 fll through the tip three times; at this point all washes were 
retained. The peptides were eluted in either 50% acetonitrile (MALDI-TOF analysis) 
or 0.1% TFA in 50% methanol (Q-TOF analysis), in a volume of2 J,tl. If the sample 
was found to be too concentrated in this small volume, appropriate dilutions could be 
made during analysis. 
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2.7.3 MALDI-TOF analysis of peptide fragments 
2.7.3.1 Solutions 
All solutions were made up in diH20 unless otherwise stated. 
Resuspension buffer (lO ml) 
0.1% (v/v) TFA 
50% (v/v) acetonitrile 
10 J.11 
5.0ml 
Saturated matrix solution (in resuspension buffer) 
100% (w/v) 4-HCCA 10 mg.mr1 
2.7.3.2 Sample plate preparation 
A stainless steel 100-position sample plate was used for peptide fragment 
analysis. Prior to sample loading the plate was cleaned to ensure it was 
contaminant-free. This was achieved by washing the surface with methanol and a 
lint-free lab tissue. The plate was rinsed with diH20, followed by acetone and 
allowed to air dry. 
2.7.3.3 Matrix and sample preparation 
A variety of matrix compounds are available for sample analysis, however, 
the matrix used for peptide analysis was a-cyano-4-hydroxycinnamic acid 
(4-HCCA). A saturated matrix solution was made by dissolving 10 mg 4-HCCA in 
1 ml 50% (v/v) acetonitrile, 0.1 % (v/v) TFA. The solution was mixed well by 
vortexing and any undissolved matrix was pelleted out of solution by centrifugation 
at 1800 g for 5 min. The supernatant was used for sample analysis. A 100% solution 
was required so that the matrix was present in molar excess of the peptides. The 
matrix solution was made in the same solvent as that used to re-dissolve the dried 
peptides; the organic solvent was present to prevent aggregation of the peptides and 
TF A functioned to maintain the pH below 4 to preserve the matrix crystallisation 
properties. 
The sample was prepared for analysis on the plate using the dried droplet 
recipe; 0.5 J.11 of sample (following ZipTip clean-up) was spotted onto the plate, and 
0.5 J.11 of saturated matrix solution was added to this. The drops were mixed well by 
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pipetting the combined sample/matrix solution up and down the tip several times. 
The mixed sample was allowed to crystallise by drying in a constant stream of room 
temperature air. During this time the peptides were incorporated into the crystallising 
matrix to produce peptide-doped crystals. 
2.7.3.4 Sample analysis 
In conjunction with every sample analysed, a multi-point calibration was 
performed. This was conducted using one of a number of commercially available 
calibration mixtures; Cal2 (PerSeptive). The mixture contains a number of proteins 
with known molecular masses, all of which only occur in one isoform. The mixture 
was chosen based on the molecular weight range under study. The components of 
Cal2 are shown in table 2.4. 
PROTEIN CALIBRATION PEAKS (Da) CHARGE 
Monoisotopic Average 
Angiotensin 1 1,296.6853 1,297.51 +1 
ACTH (clip 1-17) 2,093.0867 2,094.46 +1 
ACTH (clip 18-39) 2,465.1989 2,466.72 +1 
Insulin (bovine) 2,865.8083 2,867.80 +2 
ACTH (clip 7-38) 3,657.9294 3,660.19 +1 
Insulin (bovine 5,730.6087 5,734.59 +1 
Table 2.4 Peptide constituents of the Cal2 calibration mixture 
and their associated molecular masses. 
The calibration mixture was applied to the sample plate with matrix in the same way 
as the peptide mixture. Analysis of the standards provided an external calibration of 
the MALDI-TOF. The aim of the calibration step 'was to get mass peak data 
identical, or as close to as possible, to the masses shown in table 2.4. Only when this 
was achieved could reliable interpretation of the sample peak masses be performed. 
The calibration was performed prior to sample analysis because, although 
not essential, peaks masses could be assigned immediately once the calibration file 
had been specified. An absolute requirement of the calibration was that every time 
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the vacuum seal on the MALDI was broken, i.e. to load additional samples, a new 
calibration step had to be performed due to small changes in internal pressure that 
had probably occurred. 
Standards and samples were analysed in linear or reflector mode; linear 
analysis was performed initially because it had a higher degree of sensitivity, i.e. it 
was able to detect peptides of low abundance. However, it only measured the 
average masses of the peptides. If a good spectrum were gained with this method, 
then the sample was analysed in reflector mode to obtain an improved mass 
resolution and accuracy of the peptide data by measuring the monoisotopic masses of 
the peaks. If reflector data was obtained, this was used in database searches, due to a 
higher degree of accuracy. 
The sample plate was loaded into the ion source region, which is at a high 
internal pressure, and allowed to equilibrate. In this region, under vacuum, the 
solvent was removed, leaving co-crystallised peptide molecules homogeneously 
dispersed within matrix molecules. A pulsed nitrogen laser (337 nm) was used to 
ionise the molecules; an intermediate intensity (approx. 2000) was initially used, 
which was altered accordingly due to the strength of the signals detected. The 
relationship between the peptide ion current and laser intensity has been shown to be 
highly non-linear; a threshold level is required initially to produce the' ions, the 
abundance of which increases rapidly to a maximum level with increasing laser 
power. However, the system as a whole is thought to function more efficiently when 
laser intensity is close to the threshold. The laser was pulsed to avoid thermal 
decomposition of the peptide molecules. Samples were analysed in delayed 
extraction (DE) mode with a low mass gate of 400 Da, to eliminate peaks produced 
from the matrix, and the system was set to analyse positive ions exclusively. 
The basic principle by which the MALDI-TOF analyses peptide molecules 
is as follows. When the laser hits the surface of the crystals the energy is transferred 
to the matrix which, in turn, sublimes and carries the intact peptides into the vapour 
phase, while simultaneously ionising them, i.e. peptides are desorbed from the probe 
surface. The peptide fragment ions, all possessing equal kinetic energies, are 
accelerated down the field-free drift region by the electric field towards the anode 
and to reach the detector. Therefore, the time it takes for the ions to travel from the 
ion source to the detector is entirely dependent on the mass of the ion, i.e small ions 
reach the detector before larger ions. Once the ions hit the detector, the impact signal 
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is converted into digitized data. Data accumulated from successive laser shots are 
summed to yield a time of flight (TOF) mass spectrum, which is more accurate and 
has a better signal-to-noise ratio than data from single shots alone. The TOF 
spectrum represents the detector signal versus time. The mass of an ion is calculated 
by the following equation: 
T ~ (m I z) 1/2 
whereby the time of flight for a molecule (t) is proportional to its 
mass (m) and charge (z) to travel the distance. 
This relationship, in conjunction with the Cal2 peak data of known m and z, 
is used to calibrate the spectra, calculate the ion masses and convert the data into a 
conventional mass spectrum of a mass-to-charge ratio. Fortunately, the laser 
ionisation technique employed in MALDI-TOF predominantly produces singly 
protonated ions; therefore the mass-to-charge ratio is the true mass plus lOa. The 
data system not only collates all the accumulated data, but also controls all 
instrument parameters and data processing and manipulation to produce an output of 
peptides masses (m I z) on the x axis against signal intensity i.e. abundance of the 
peptide, on the y axis. 
2.8 Q-TOF MASS SPECTROMETRIC ANALYSIS OF 
PEPTIDE FRAGMENTS PRODUCED FROM TRYPTIC DIGEST 
OF A PROTEIN 
In addition to the peptide map that can be obtained from MALDI-TOF 
analysis of the tryptic digested protein, other sequence information can also be 
retrieved and used to increase the power of searching when identifying a protein from 
databases. This type of analysis was performed in order to gain a partial sequence 
from one or more of the peptide fragments generated from the digest. The Q-TOF 
(quadrupole time-of-flight) mass spectrometer (Micromass UK. Ltd) used for this 
analysis is located in the Biochemistry department of the University of Leeds; 
analysis of my samples were performed by Dr. Alison Ashcroft. 
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Briefly, the Q-TOF is an electrospray tandem mass spectrometer. As 
opposed to the MALDI-TOF, where sample is analysed by desorption from a sample 
plate, in the Q-TOF minute volumes of sample (2-3 ~l) are sprayed into the 
instrument through a fine needle over a period of 20-30 min. As its name indicates, 
tandem mass spectrometers consist of two consecutive analysers; in the case of the 
Q-TOF, a quadrupole followed by a TOF analyser. Once sprayed into the instrument, 
at high vaccum, the solvent rapidly evaporates providing a constant stream of peptide 
Ions. 
The sample is initially analysed using only the TOF system, to identify 
multiply-charged ions, which is indicative of a peptide fragment. These charged ions 
differ by half of a mass unit, and it is these ions which are of interest to me; they are 
selected using the quadrupole mass analyser for further analysis. 
The principle purpose of Q-TOF analysis of my samples was to obtain a 
partial sequence of at least one of the peptide fragments to use in protein 
identification. By selecting a particular peptide ion, the ion beam enters the 
quadrupole, which in turn is tuned to pennit only the transit of those ions with the 
selected mass-to-charge ratio. These specified ions enter a cell, in which 
fragmentation occurs due to collision of the ion with an inert gas, usually argon. 
Fragmentation can cause cleavage at any of the bonds within the peptide structure 
but, under conventional conditions, is predominantly restricted to the backbone of the 
peptide (see section 5.8.5) The generated fragments are accelerated orthogonally by 
applying a pulsed electric field and their masses detennined by the TOF analyser, in 
the same way as the latter stages in MALDI-TOF analysis. 
In order to visualise the partial amino acid sequence from the peptide 
fragment, it is usual to select the series of y-ions, which sequentially differ by the 
exact mass of one of the possible twenty naturally occurring amino acid residues. As 
such, the sequence is read from the intervals between the peaks of the y-ion series to 
reveal the partial sequence (sequence tag). 
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2.9 PROTEIN IDENTIFICATION USING ON-LINE 
DATABASE SEARCHES 
Tryptic digest data, in the form of peptide masses analysed and calculated by 
MALDI-TOF or the sequence tag produced from Q-TOF analysis, were used in 
on-line database searches in an attempt to identify the protein. Proteins can be 
unequivocally identified from databases (if its sequence is present) with a relatively 
limited set of peptide masses (as little as 5-6) when screened against more than 
100,000 proteins (Pappin, 1997). In addition, a single sequence tag is adequate for 
unequivocal protein identification, unless it is present within a conserved domain of 
several distinct proteins of a family. However, this also means that the tag can be 
matched to homologous proteins in other species, if required. 
A number of database search engines are available on the World Wide Web, 
the sites relevant to protein identification using tryptic digest fragment data and 
sequences tags are shown in Appendix II. 
2.9.1 Data input and search parameters 
Each program functions in essentially the same way, however, detailed 
instructions for use are provided on individual web sites. The programs scan their 
respective databases and generate theoretical peptide fragments, based on the specific 
protease used, for each of the sequences they possess. The molecular masses of these 
peptides are computed from their primary amino acid sequence. Depending on the 
type of search specified, these are either average or monoisotopic masses. The 
program scans all of this theoretical information, in conjunction with actual masses 
input by the operator, simultaneously comparing both sets of data. If a theoretical 
fragment lies within a user specified tolerance level of an actual fragment mass, the 
match is recorded. If the number of matching peptide fragments for a protein 
exceeds the minimum number of matches required, that protein is added to the list of 
possible matching proteins. 
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The following criteria of the unidentified protein are utilised in the search: 
• cleavage reagent 
• peptide masses (Da) 
• mass accuracy 
• number of missed cleavages 
• modifications during electrophoretic separation and 
isolation, for example, oxidation of methionine or 
tryptophan, alkylation of cysteine, etc. 
Additional parameters may be included to selectively identify the protein, while 
excluding false positives: 
• species of origin 
• estimated molecular mass 
• estimated pI 
• type of protein anticipated. 
All peptides that had a good signal-to-noise ratio were utilised in the search, 
in conjunction with other fragments that formed distinctive peaks in the spectrum. 
When a complex spectra, which included the less abundant peaks, was analysed, the 
mass tolerance was increased due to the possibility that mass accuracy may have been 
compromised as a result of a low signal intensity (Parker, 1998). However, as with 
all modifications to search parameters, care needed to be taken to avoid 
misidentification of the protein if an aspect was altered too aggressively. For 
example, if a larger mass tolerance was specified it would increase the possibility of 
matching unrelated proteins, whereas decreasing the tolerance would increase the 
incidence. of missing the crucial match. The main point taken into account during 
searching was that the smaller the permitted ranges of any of the parameters used 
produced a higher level of confidence so that if a match was found, it was highly 
likely to be genuine. 
Searching using sequence tags is even simpler; generally only the original 
protein mass is required, plus the parent peptide which was fragmented (optional) 
and the defined amino acid sequence. 
Different search tools can be used to ensure complete coverage of all the 
databases available. 
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2.9.2 Elimination of false peptides 
Modified trypsin from Promega, which has been demonstrated not undergo 
autolysis, was used to digest the isolated protein. However, in order to eliminate any 
peptides produced from autolytic digestion of trypsin, a theoretical digest of the 
protein was performed using the MS-Digest program from Prospector (see 
Appendix II). This generated the masses of peptides that would have been produced 
if in fact autolysis had occurred. These masses were analysed in conjunction with the 
isolated protein's masses and any coinciding peptides were not used in the database 
searches. 
This site was also used to perform theoretical digests of other proteins 
thought to be similar to the isolated protein, in order to establish that they were not 
the same entity. 
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CHAPTER 3: INTERACTION OF A POTENTIAL 
PHOTO AFFINITY LABEL WITH PEPTIDE TRANSPORTERS 
IN RAT JEJUNUM 
3.1 Development and synthesis of the photoaffinity label 
Previous investigations of peptide transport by rat jejunum (Lister et al., 
1995) have shown that although naturally occurring dipeptides are significantly 
hydrolysed following apical absorption into the enterocyte, some chemically 
synthesised peptides have an inherent resistance to hydrolytic breakdown while still 
being efficiently transported. Results from this study demonstrated that the presence 
of a D-amino acid at the N-terminus of a dipeptide reduces peptidase activity 
sufficiently to permit its intact transmural transport; D-phenylalanine (D-Phe) at the 
amino terminal confers stronger resistance to hydrolysis in comparison to other 
amino acids, e.g. D-alanine. In particular, one dipeptide was shown to possess an 
extremely efficient resistance to hydrolysis coupled with a substantial rate of 
transport at both the brush-border membrane (BBM) and the basolateral membrane 
(BLM), in comparison to the other peptides studied; this was 
D-phenylalanyl-L-alanine (D-Phe-L-Ala). This dipeptide was therefore used as a 
substrate backbone with which to synthesise a potential photoaffinity label for the 
identification of peptide transporters at both the apical and basolateral membranes of 
rat small intestine. 
The dipeptides and the photoaffinity label used in the work contained in this 
thesis were custom-synthesised using standard techniques (P. D. Bailey, 1990) by 
Professor P. D. Bailey and Dr. I. Collier in the Chemistry Department of Heriot Watt 
University, Edinburgh, UK. Briefly, each peptide was created by condensation of the 
N-tertiary-butyl-oxy-carbonyl-derivative of the N-terminal amino acid with the 
carboxy-benzyl-L-derivative of the C-terminal amino acid. The products were 
subjected to a series of acid and alkali washes to eliminate starting materials and 
by-products, prior to removal of the protecting groups. Finally, the samples were 
freeze-dried and the purity was demonstrated to be >95% by mass spectrometry, 
NMR and HPLC. For the photoaffinity label, an azide group (N3) was attached to 
position 4 on the phenylalanine ring of D-Phe-L-Ala to confer its extreme 
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photo-reactivity. This, in turn, would permit highly specific labelling of an active 
site of a protein to which the dipeptide moiety will selectively bind. The chemical 
structure of the potential photoaffinity label ([4-azido-D-Phe]-L-Ala) is shown in 
figure 3.1. 
3.2 Aims of the experiments 
This study utilised the technique of the isolated, in situ, luminally and 
vascularly perfused rat jejunum (abbreviated to 'vascular perfusion' in subsequent 
text) to demonstrate a highly specific interaction of the photoaffinity label with the 
peptide transporters in the BBM and BLM. This particular perfusion approach 
permitted the application of [4-azido-D-Phe ]-L-Ala to both sides of the enterocyte, 
i.e adjacent to either the apical or the basolateral membrane, whilst maintaining the 
intact jejunum in situ. The blood supply to the jejunum was isolated and replaced 
with a perfusate of a physiological solution containing substrate(s) if required, in 
parallel with a separate perfusate (± substrates) in the lumen. Transmural transport of 
[4-azido-D-Phe]-L-Ala itself was measured, in addition to the effect that it had on the 
transport rate of another dipeptide (D-Phe-L-Gln). Inhibition of the transport of the 
second peptide would indicate that the potential label can directly interact with the 
peptide transporter(s). Substrate inhibition would demonstrate that 
[4-azido-D-Phe]-L-Ala is an effective substrate and therefore likely to be an efficient 
label with which to identify the membrane proteins responsible for peptide transport 
in the jejunum. 
The primary aim of these experiments was to demonstrate an unequivocal 
direct interaction of [4-azido-D-Phe]-L-Ala with the peptide transporters so that it 
could be used to specifically label the membrane protein(s) to aid in their 
identification and isolation. 
3.3 Viability of the vascular perfusions 
Previous investigations using the vascular perfusion method (Hanson & 
Parsons, 1976; Boyd et al., 1975; Nicholls et al., 1983) have demonstrated that it is 
an extremely reliable technique for the study of substrate transport by the small 
intestine (see section 1.2.4). In addition, it is the only preparation that pennits direct 
access of substrates to the basolateral membrane of the mucosa from the vasculature, 
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Figure 3.1 
Chemical structure of the potential photoaffinity label [4-azido-D-Phe]-L-Ala. For 
details of synthesis see section 3.1. 
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in situ. Viability of the intestine subjected to this technique has previously been 
indicated by an essentially normal histology and absence of oedema in the tissue 
following the perfusions, in addition to an active transport of substrates and constant 
oxygen consumption from the vascular perfusate by the intestine during the 
perfusions. 
Rats were starved overnight prior to perfusion and glucose-fed in order to 
obtain consistent data. Initially, glucose feeding was introduced to lessen the rates of 
glucose utilisation by the small intestine when rats were maintained on the Bantin & 
Kingman diet (Kellett & Barker, 1989); however other beneficial effects were soon 
evident. These advantages included an enhanced sensitivity of the intestine to 
regulation by endocrine/paracrine mediators and, more importantly, the highly 
reliable reproducible results that could be obtained. 
Viability of the vascular perfusion data included in this thesis was assessed 
using two factors. Firstly a high portal vein recovery (>90%) of vascular perfusate 
was achieved. In association with this, a constant vascular flow rate, measured from 
the portal vein effluent, indicated that the isolated segment of intestine was not under 
any undue stress. Although a complete (100%) venous recovery was not always 
attained from a flow rate of 1.5 ml'min-1 (pump determined rate), previous 
investigations (A. Pennington, D Phil thesis, 1992) have demonstrated that flow rates 
of 1.5 ± 0.2 ml'min-1 are acceptable, because the rate of active glucose transfer across 
the intestine was not affected. Reasons for minor variations in flow rate were not 
always apparent, but if a continual decline in the portal vein recovery rate was 
observed, the perfusion was abandoned. A second indication of a viable perfusion 
was a constant rate of glucose utilisation by the isolated segment of jejunum. This 
was measured by assaying the glucose concentration remaining in the vascular 
effluent, after its passage through the mesenteries adjacent to the jejunum, using the 
GOD-Perid® method performed on the Cobas-MlRA automated analyser. The 
concentration of glucose remaining in the effluent samples was used to calculate the 
rate of uptake of glucose by the jejunum, expressed as J.1Il101·min-1'[g dry Wt.]-l 
(equation 1, section 2.1.9.1). A typical example of glucose uptake during the course 
of a vascular perfusion with a dipeptide is shown in figure 3.2. 
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Figure 3.2 
A representative time coW'Se showing the uptake of glucose from the vasculature 
during a typical series of vascular perfusions with a dipeptide. Data points represent 
the mean ± s.e.m. (n = 5). A steady state of uptake was achieved at 15-20 minutes, 
and so the time period analysed was between 20 and 50 minutes. The rate of glucose 
uptake for this period is 2.24 ± 0.33 J.1IIlol.min"l.[g dry Wt.]"l. 
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3.4 Transmural transport of [4-azido-D-PheJ-L-Ala across the 
jejunum 
In order to establish whether it would be worthwhile to develop 
[4-azido-D-Phe]-L-Ala as a photo affinity label, initial experiments were performed to 
investigate if it was accepted as a substrate by the intestinal peptide transporters. 
This was investigated by determining whether it was transported intact across the 
intestine, from the lumen to the serosa, at a reasonably efficient rate. Vascular 
perfusions in which the jejunal lumen was perfused with either D-Phe-L-Gln or 
[4-azido-D-Phe]-L-Ala, both at a concentration of 1 mM, were conducted. The 
cumulative rate of dipeptide appearance in the vasculature was measured (which 
demonstrated transmural transport), together with the accumulation in mucosal and 
muscle tissues during the perfusion for both substrates. In addition, exit ratios of 
substrate accumulation/transport were calculated. A summary relating the 
physiological significance of exit ratios to the activity of peptide transporters and 
their interaction with substrates is shown in table 3.1. 
D-Phe-L-Gln is transported efficiently through the intestine, demonstrated 
by its rate of intact cumulative appearance in the vascular effluent (0.244 ± 0.022 
!Jl11ol.min,l.[g dry wt.],l s.e.m.) (figure 3.3(1». Previous perfusion studies with 
D-Phe-L-Gln (Bronk et al., 1995) formed the basis of its utilisation as a 
representative dipeptide to demonstrate peptide transport through the jejunum in situ. 
Other studies (Lister et al., 1995) had shown that the presence of a D-amino acid at 
the N-terminal of a mixed dipeptide confers hydolysis resistance, but, does not 
substantially reduce transepithelial transport across rat small intestine in vitro. The 
usefulness of D-Phe-L-Gln was due to its rapid transport rate, relative to other 
D-amino acid-containing dipeptides, and inherent resistance to hydrolysis both at the 
apical membrane and within the cytosol. 
Transport of the photoaffinity label was compared to D-Phe-L-Gln in order 
to assess its suitability as a substrate for the peptide transporters. Figure 3.3(1) shows 
that [4-azido-D-Phe]-L-Ala is transported through the intestine at a rate that is 
lO-fold faster than that of D-Phe-L-Gln (2.66 ± 0.62 J,1mol.min,I.[g dry Wt.],I, 
P < 0.001). In addition, it accumulates to a lesser extent in the mucosa 
(4.88 ± 0.93 mM compared to 7.95 ± 0.92 mM, P < 0.05), although its muscle 
concentration is over 2-fold higher (5.68 ± 0.35 mM compared to 2.18 ± 0.35 mM, 
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Table 3.1 
A brief explanation of the tissue exit ratios calculated in the vascular perfusion studies and their physiological relevance in the study of transmural 
peptide transport of a single substrate and in transport inhibition studies. It should be noted that this is a simplified account of mucosal tissue analysis 
used to reflect the activities of the peptide transporters at the BBM and BLM. Inclusion of transport rates and actual tissue concentrations gives a 
more detailed view, but is too complex to be contained in this summary table. BL T; basolateral transporter. 
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14.> 
-+- 1 mM D-Phe-L-Gln 
• 1 mM [4-azido-D-Phe]-L-Ala *** 
Perfusion time (min) 
Figure 3.3 (I) 
A comparison of the transmural transport rates of D-Phe-L-Gln and 
[4-azido-D-Phe]-L-Ala, at 1 mM concentration, from the lumen to the serosa of the 
jejunum. Data points represent the mean ± s.e.m. (n = 5) *** P < 0.001 depicts a 
significant difference in transport rates. 
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Figure 3.3 (II) 
Interaction oU4-azido-D-Phel-L-Ala with peptide transporters 
ImM 
D-Phe-L-G In 
ImM 
D-Phe-L-Gln 
* 
o Mucosa 
• Muscle 
**** 
ImM 
[4-azido-D-Phe]-L-Ala 
IJ Mucosal exit ratio 
• Muscle exit ratio 
* * 
ImM 
[4-azido-D-Phe ]-L-Ala 
Tissue accumulations (a) and exit ratios (b) of D-Phe-L-Gln and 
[4-azido-D-Phe]-L-Ala following perfusion, at a concentration of 1 mM, from the 
lumen to the serosa of the jejunum (see figure 3.3 (I)). Bars represent the 
mean ± s.e.m. (n = 5). * P < 0.05, **** P < 0.0001 depict significant differences. 
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P < 0.0001), than that observed with D-Phe-L-Gln (figure 3.3(IIa». The exit ratios 
(figure 3.3(IIb» of [4-azido-D-Phe]-L-Ala, for both the mucosa and muscle tissue, 
are very low in comparison to D-Phe-L-Gln. The mucosal exit ratio is more than 
IS-fold less (5.15 ± 1.33 versus 80.7 ± 17.2 P < 0.05), and in the muscle tissue it is 
only 26% (5.93 ± 0.82 compared to 22.8 ± 5.9, P < 0.05) of that of D-Phe-L-Gln. 
The exit ratios are defined as the ratio of substrate concentration in the tissue to the 
concentration of substrate in the final vascular sample. It gives an indication as to the 
site of efficient interaction of a substrate with the transporter( s) or the location of 
transport inhibition within the intestinal tissue (see table 3.1). The smaller exit ratios 
observed with [4-azido-D-Phe]-L-Ala indicate that it accumulates to a very low 
extent in the tissues with respect to its rapid transport rate, i.e. exit across the 
basolateral membrane occurs faster than entry across the apical membrane. This 
suggests that the label may be a more efficient substrate for the basolateral peptide 
transporter than it is for PepTI. This higher efficiency of interaction with the 
basolateral transporter results in exit from th~ cell to occur at such a rapid rate that 
mucosal levels are considerably reduced and the label is transferred into the vascular 
effluent at an extremely fast rate. 
In summary, the rapid rate of transmural transfer reveals that the label 
interacts with the two transporter proteins extremely efficiently, although a faster 
cellular efflux than entry suggests that it is a better substrate for the basolateral 
transporter than for PepTI. As such, further studies to elucidate its potential as a 
photoaffinity label were performed. 
3.5 Direct interaction of [4-azido-D-PheJ-L-Ala with peptide 
transporters 
Initial perfusions have demonstrated that the label is transported across the 
enterocyte intact and at a considerable rate to suggest it is an effective substrate for 
both intestinal peptide transporters. This work was progressed to show a direct 
interaction of the label with the membrane proteins responsible for peptide transport. 
This was achieved by performing transport inhibition studies in which the jejunal 
lumen was perfused with a substrate (1 mM D-Phe-L-Gln, the control) in conjunction 
with the label, which was included in either the luminal or the vascular perfusate at a 
concentration of 2.5 mM. Inhibition of D-Phe-L-Gln transport in the presence of 
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[4-azido-D-Phe]-L-Ala would indicate a direct interaction of the label with the 
peptide transporters, due to substrate-specific competition for the binding site. The 
results from these perfusions are shown in figure 3.4 (I & II). 
Addition of the label to the vasculature has no effect on the basic rate of 
D-Phe-L-Gln transport (0.234 ± 0.025 compared to 0.244 ± 0.022 
Jlmol·min-I.[g dry Wt.]-I) (figure 3.4 (I)), nor is there any change evident in substrate 
accumulation in mucosal or muscle tissue (figure 3.4 (II). However, if the label is 
perfused through the lumen of the jejunum, in conjunction with the substrate, a 
significant reduction in the rate of D-Phe-L-Gln transport is observed (0.146 ± 0.016 
~ol·min-I.[g dry wt.rl versus control, P < 0.001). This is associated with an 
enhanced accumulation of substrate in the mucosal layer (12.8 ± 1.44 mM versus 
control, P < 0.05). A relatively larger mucosal exit ratio, although not statistically 
significant, supports the detected increased mucosal concentration of substrate, with 
respect to the substantially lower transport rate. Collectively, these results indicate 
that the label does not inhibit basolateral exit of the substrate from the cell by 
interaction with an extracellular site of the membrane protein. Inhibition of transport 
following inclusion of the label in the lumen might implicate PepT!, but an increased 
level of substrate in the mucosa indicates that inhibition is occurring at the endofacial 
site of the basolateral transporter more predominantly than at the apical membrane. 
Competition of the label with the substrate for the same intracellular active site of the 
basolateral transporter therefore prevents exit of the substrate from the cell. Thus, 
there seems to be an asymmetry in binding of the label to the basolateral transporter. 
These findings were further investigated by performing washout 
experiments using the 'perturbation' method in which the intestine is loaded with 
substrate from the lumen and its washout into the vascular bed is monitored (Boyd & 
Parsons, 1978). During the initial 30 min of these perfusions, the lumen of the 
intestine was perfused with 1 mM D-Phe-L-Gln and then the substrate was removed 
from the solution and the perfusion continued with a substrate-free medium for an 
additional 30 min (figure 3.5). In the inhibition experiment, [4-azido-D-Phe]-L-Ala 
was perfused through the vasculature at a concentration of 2.5 mM from the 30 min 
time point, when the substrate was removed, for the remaining 30 min to determine 
whether its presence would inhibit washout of the substrate into the vascular effluent. 
The vascular appearance of substrate per min was measured throughout the 60 min 
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Figure 3.4 (I) 
Direct interaction of [4-azido-D-Phe]-L-Ala with intestinal peptide transporters as 
demonstrated by its effect (at 2.5 mM) on the transmural transport rate of 1 mM 
D-Phe-L-Gln (control) from the lumen to the serosa. Data points represent the 
mean ± s.e.m. (n = 5). *** P < 0.001 depicts a significant difference in transport rate 
against the control. 
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Figure 3.4 (II) 
Interaction oU4-azido-D-Phel-L-Ala with peptide transporters 
* 
2.5mM 
[ 4-azido-D-Phe]-L-Ala 
(L) 
2.5mM 
[4-azido-D-Phe]-L-Ala 
(L) 
Mucosa 
• Muscle 
2.5mM 
[4-azido-D-Phe]-L-Ala 
(V) 
Mucosal exit ratio 
• Muscle exit ratio 
2.5mM 
[4-azido-D-Phe]-L-Ala 
(V) 
Effect of [4-azido-D-Phe]-L-Ala, present at 2.5 mM in either the lumen or the 
vasculature of the jejunum, on tissue accumulation (a) and exit ratio (b) of 
D-Phe-L-Gln following vascular perfusion at 1 mM from the lumen to the serosa of the 
jejunum. Bars represent the mean ± s.e.m. (n = 5). * P < 0.05 depicts a significant 
difference against the control. 
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Interaction oU4-azido- D-Phel-L-Ala with peptide transporters 
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Perturbation experiments demonstrating that [4-azido-D-PheJ-L-Ala does not inhibit 
substrate mucosal efflux when presented to the serosal face of the basolateral 
membrane. ImM D-Phe-L-Gln was perfused through the lumen from 0-30 min and 
then removed from the perfusate (control; diamonds) for the remaining 30 min. 
Inhibition of substrate efflux into the serosa was investigated by perfusing 
[4-azido-D-PheJ-L-Ala at a concentration of 2.5 mM through the vasculature from 
30-60 min (triangles). 
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perfusion of the two conditions and the results are shown in figure 3.5. It is evident 
from these perfusions that the presence of the label on the vascular side of the 
intestine has no effect on the washout of a second dipeptide from the mucosa. 
This evidence (see figure 3.5) strengthens the conclusions from the results of 
the previous vascular perfusions and reinforces the implication of an apparent 
binding asymmetry of the label with the basolateral peptide transporter. 
3.6 Comparison of the transport properties of D-Phe-L-Ala and 
[4-azido-D-Phe]-L-Ala 
In order to assess whether the structural modifications of the original 
dipeptide, necessary to synthesise the label, would influence its interaction with and 
transport by the peptide transporters, transport and tissue accumulation of both 
dipeptide substrates were measured and compared to D-Phe-L-Gln. The results of 
this study are shown in figure 3.6 (I & II). Figure 3.6(I) (inset) demonstrates that 
D-Phe-L-Ala has a lower transmural transport rate than D-Phe-L-Gln, at the same 
luminal concentration (0.177 ± 0.01 v. 0.244 ± 0.022 Jlmol'min-1'[g dry wt.r1, 
P < 0.001). Accumulation of D-Phe-L-Ala in the mucosal and muscle tissue 
(figure 3.6(II» is also significantly lower than D-Phe-L-Gln (in the mucosa it is only 
3.16 ± 0.59 mM v. 7.95 ± 0.92 mM, P < 0.01 and in the muscle it is only 
0.56 ± 0.07 mM v. 2.18 ± 0.35 mM, P < 0.01). The corresponding mucosal exit ratio 
for D-Phe-L-Ala is approximately 50% of that for D-Phe-L-Gln, corroborating the 
previous suggestion that that with respect to their different transport rates 
D-Phe-L-Ala accumulates to a lesser extent within the tissue. Collectively the results 
indicate that D-Phe-L-Ala is a less efficient substrate for both peptide transporters 
than D-Phe-L-Gln, but this may be more pronounced at the apical membrane, 
resulting in the overall lower rate of transport. 
A comparison of the original dipeptide (D-Phe-L-Ala) and the 
peptide-derivative label shows that D-Phe-L-Ala is transported at a much lower rate 
than [4-azido-D-P]-L-Ala (0.177 ± 0.01 v. 2.657 ± 0.279 Jlffiol.min-1.[g dry Wt.]-l, 
P < 0.001). In conjunction with this is a similar mucosal concentration of substrate 
(3.16 ± 0.59 mM v. 4.88 ± 0.93 mM) coupled with a significantly higher mucosal 
exit ratio (38.9 ± 5.8 v. 5.15 ± 1.33, P < 0.01). This suggests that D-Phe-L-Ala is 
accumulating to a larger extent in the mucosa than the label, with respect to its 
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A comparison of the transmural transport rates of D-Phe-L-Gln, D-Phe-L-Ala and 
[4-azido-D-PheJ-L-Ala, at 1 mM concentration, from the lumen to the serosa of the 
Jejunum. Data points represent the mean ± s.e.m. (n = 5). *** P < 0.001 and 
$$$ P < 0.001 depict a significant difference in transport rate against 1 mM 
D-Phe-L-Gln and D-Phe-L-Ala, respectively. 
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interaction o[f4-azido-D-Phel-L-Ala with peptide transporters 
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* 
ImM 
[4-azido-D-Phe]-L-Ala 
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ImM 
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Tissue accumulations (a) and exit ratios (b) of D-Phe-L-Gln, D-Phe-L-Ala and 
[4-azido-D-Phe]-L-Ala following perfusion, at a concentration of 1 mM, from the 
lumen to the serosa of the jejunum (see figure 3.6 (I)). Bars represent the 
mean ± s.e.m. (n = 5). * P < 0.05, ** P < 0.01, **** P < 0.0001, and $$ P < 0.01, 
$$$$ P < 0.0001, depict significant differences against 1 mM D-Phe-L-Gln and 1 mM 
D-Phe-L-Ala, respectively. 
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considerably lower rate of transport, implying it has a lower level of interaction with 
the basolateral transporter. Also apparent is a reduced muscle concentration of 
substrate (0.56 ± 0.07 mM v. 5.68 ± 0.35 mM, P < 0.0001). However, there is no 
associated change in muscle exit ratio indicating that with respect to their entirely 
different transport rates there doesn't appear to be any difference in substrate 
accumulation in the muscle tissue. 
Overall these perfusions indicate specific differences in transport of 
D-Phe-L-Ala and the modified label, most notably that the addition of the azide 
group to the D-Phe ring seems to confer an increased affinity of the substrate to both 
peptide transporters. This enhanced efficiency of interaction is more pronounced at 
the basolateral membrane. 
To conclude this investigation, another series of perfusions were perfonned 
m which the transmural transport of the substrate (l mM D-Phe-L-Gln) was 
measured under the possible influence of D-Phe-L-Ala. In these experiments 
D-Phe-L-Ala was used at a concentration of2.5 mM in the lumen or the vasculature. 
The results of these perfusions are shown in figure 3.7 (I & II). The basic rate of 
D-Phe-L-Gln transport was stimulated by the presence of 2.5 mM D-Phe-L-Ala in 
both the lumen and the vasculature to similar extents. In the lumen a 40% increase in 
rate was observed, from 0.244 ± 0.022 to 0.345 ± 0.038 J.lmol.min-I.[g dry Wt.]-I 
(P < 0.001) and in the vasculature an increase of 35% to 0.33 ± 0.036 
J.lmol·min-I'[g dry Wt.]-I (P < 0.001) was measured (Fig 3.7(1)). There were no 
associated changes in the tissue concentrations of the dipeptides (Fig 3.7(lIa)). 
However, the mucosal exit ratios of D-Phe-L-Gln when D-Phe-L-Ala was present in 
either the lumen or the vasculature were approx. 50% of that when D-Phe-L-Gln was 
perfused alone (Fig 3.7(IIb)), although not significant. This indicates that the effect 
of D-Phe-L-Ala, present either in the lumen or the vasculature, was to stimulate 
peptide exit from the mucosa across the basolateral membrane. 
It was initially assumed that D-Phe-L-Ala may have an inhibitory effect on 
D-Phe-L-Gln transport because, although it has been shown to be a relatively less 
effici~nt substrate for both transporters, they share the same system and would 
therefore be competing for the same active site(s). But this is not the case. The 
increase in transmural transport rate without a corresponding increase in tissue levels 
suggests that D-Phe-L-Ala may be stimulating D-Phe-L-Gln transport at both the 
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Figure 3.7 (I) 
Effect of D-Phe-L-Ala, present at 2.5 mM in either the lumen or the vasculature of 
the jejunum, on the transmural transport rate of 1 mM D-Phe-L-Gln from the lumen 
to the serosa. Data points represent the mean ± s.e.m. (n = 5). *** P < 0.001 depicts 
significant differences against the control (1 mM D-Phe-L-Gln). 
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Figure 3.7 (II) 
Interaction oU4-azido-D-Phel-L-Ala with peptide transporters 
2.5mM 
D-Phe-L-Ala (L) 
2.5 mM 
D-Phe-L-Ala (L) 
Mucosa 
• Muscle 
2.5mM 
D-Phe-L-Ala (V) 
Mucosal exit ratio 
• Muscle exit ratio 
2.5mM 
D-Phe-L-Ala (V) 
Effect of D-Phe-L-Ala, present at 2.5 mM in either the lumen or vasculature of the 
jejunum, on tissue accumulation (a) and exit ratio (b) of D-Phe-L-Gln following 
vascular perfusion at 1 mM from the lumen to the serosa of the jejunum. Bars 
represent the mean ± s.e.m. (n = 5). 
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apical and basolateral membrane to the same degree. This stimulation in rate may 
potentially be due to substrate co-operativity exhibited by D-Phe-L-Ala on the apical 
and basolateral transporters in the transport of other peptides (see section 3.7.5). 
3.7 Discussion 
3.7.1 Peptide transport was studied with an inwardly-directed proton 
gradient 
Previous studies, in which the mechanism of peptide transport by the basolateral 
transporter was investigated, examined whether transport was stimulated by an 
inwardly directed proton gradient in the same way that PepTl functions. The results 
were conflicting. The first experiments, performed by Dyer and co-workers (1990) 
on basolateral membrane vesicles from rabbit intestine, suggested that transport is 
stimulated by a H+ gradient because proton ionophores (CCCP and TTFB) inhibit 
uptake of Gly-Pro by the vesicles. They proposed a mechanism similar to PepTl. 
Some subsequent investigations agreed with their findings, for example Thwaites et 
al. (1993a,b) also proposed an equivalent transport process to PepT!. However, 
other groups using Caco-2 cells (Matsumoto et al., 1994) and membrane vesicles 
prepared from fish (Thamotharan et al., 1996) obtained results that disputed the 
previous conclusions, and implied that transport was not H+ coupled at all. The pH 
dependence of transport was examined and all investigating groups agreed that, 
although there did not appear to be an optimum pH for transport, uptake across the 
basolateral membrane was slightly stimulated by a more acidic medium (Saito et ai., 
1993; Thwaites et ai., 1993a; Matsumoto et al., 1994; Terada et al., 1999). In 
reference to these previous investigations, peptide transport at both the brush-border 
and basolateral membrane was studied, using the vascular perfusion technique, in the 
presence of an inwardly directed H+ gradient. The solutions used to perfuse the 
lumen of the intestine and its adjacent vasculature were of a slightly acidic pH of 6.8, 
which created the proton gradient, whilst keeping the perfusate medium 
physiologically viable. 
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3.7.2 Interaction of the photoaffinity label with PepT! and the 
basolateral transporter 
Vascular perfusions demonstrated that the photo affinity label is transported 
at an extremely rapid rate through the intestine as a whole, with respect to the other 
D-amino acid-containing peptides used in this study. As such, it appears to be a very 
effective substrate for the peptide transporter proteins located in both the apical and 
basolateral membranes. In addition, the label does not accumulate in mucosal tissue 
to a significant level, although a high concentration was observed in muscle, which 
suggests that it interacts with the basolateral transporter protein with an even greater 
efficiency than it does with PepTI. 
Additional perfusions examining substrate inhibition between D-Phe-L-Gln 
and [4-azido-D-Phe]-L-Ala have demonstrated that the label does not inhibit peptide 
transport from the serosal side of the basolateral membrane. However, an increased 
mucosal accumulation of D-Phe-L-Gln implies that it does inhibit transport at the 
endofacial surface of the basolateral transporter to a relatively higher degree than a 
potentially lower level of inhibition that may be occurring at the apical membrane. 
Transport inhibition at the apical membrane cannot be seen directly with this 
technique due the overwhelming inhibition observed at the basolateral membrane. 
However, its occurrence should not be completely discounted. 
Investigations with Caco-2 cells have demonstrated that inhibition on 
cellular uptake of substrates by various peptide-like compounds is more pronounced 
at the apical membrane in comparison to the basolateral membrane (Saito et al., 
1993; Terada et al., 1999). In other words, the substrates seem to have a lower 
affinity for the serosal face of the basolateral transporter than they do for the luminal 
surface of PepT1. In addition, kinetic analysis of the basolateral transporter and 
PepT1 has shown that all the substrates studied had a lower Km and higher V max for 
PepT1 (Saito et al., 1993; Matsumoto et al., 1994; Terada et al., 1999). Therefore, it 
appears that the basolateral transporter has a lower affinity and lower capacity for 
peptide uptake into the cell from the extracellular medium, in contrast to a higher 
affinity and capacity when performing the role of peptide transfer out of the cell (Inui 
et al., 1992), although this area is not absolutely clear and is disputed by other groups 
(Thwaites et al., 1993b), who state that the opposite is true. A conceivable 
explanation as to why transport inhibition by [4-azido-D-Phe]-L-Ala was not seen 
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when included in the vascular perfusate (asymmetric interaction) is described in 
section 3.7.3. 
In contrast to basolateral uptake, PepTI has a higher capacity for solute 
transport into the cell. This may form the basis for a possible explanation as to why 
the label isn't seen to inhibit D-Phe-L-Gln transport at the brush-border membrane, 
i.e. both substrates may be transported simultaneously without any deleterious effects 
on their rates. Or, as mentioned previously, inhibition may be occurring but cannot 
be detected due to the scale of inhibition located at the basolateral membrane. 
Despite the fact that transport inhibition at the brush-border could not be directly 
observed, it should not be concluded that the label does not interact with PepTI (its 
efficient binding is proven by its rapid transmural transfer rate). In addition, previous 
experiments with PepTI-expressing Xenopus oocytes (Boyd et al., personal 
communication) demonstrated significant inhibition of D-Phe-L-Gln transport by 
[4-azido-D-Phe]-L-Ala. As such, [4-azido-D-Phe]-L-Ala is an extremely effective 
substrate but its presence may be required in a higher concentration in order to 
observe any inhibitory effects at the apical membrane that can be detected over-and-
above the inhibition that is occurring at the basolateral membrane. 
If the 'transport capacity' theory is extrapolated to the basolateral 
membrane, wherein the transporter has a lower affinity and capacity for transport in 
comparison to PepTI, D-Phe-L-Gln transport would be impaired by the excess 
presence of the label. The label has been shown to be a more efficient substrate for 
the basolateral transporter than D-Phe-L-Gln and will therefore predominantly bind 
and its own transport will override that ofD-Phe-L-Gln. 
3.7.3 Asymmetrical binding of [4-azido-D-Phel-L-Ala to the 
basolateral peptide transporter 
There is an asymmetry in binding of [4-azido-D-Phe]-L-Ala to the 
basolateral peptide transporter, i.e. it inhibits D-Phe-L-Gln transport when present at 
the endofacial side of the protein but not when at its exofacial surface. This is 
demonstrated by studies whereby the presence of [4-azido-D-Phe]-L-Ala in the 
luminal perfusate caused a 40% reduction in rate of D-Phe-L-Gln transport coupled 
with a considerable increase in mucosal tissue concentration, indicating that peptide. 
transport was predominantly inhibited at an intracellular site of the basolateral 
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transporter. In contrast, [4-azido-D-Phe]-L-Ala had no effect on the rate of 
D-Phe-L-Gln transport or on its accumulation in the tissues when included in the 
vascular perfusate. This lack of effect was reinforced by the perturbation 
experiments, in which the presence of [4-azido-D-Phe]-L-Ala on the serosal side of 
the intestine did not affect the washout ofD-Phe-L-Gln from the intestine. 
Previous investigations using Caco-2 cells have shown that efflux across the 
basolateral membrane occurs at a much faster rate than uptake into the cell across this 
membrane (Inui et al., 1992), although other groups state that uptake exceeds exit 
(Thwaites et al., 1993b). Other studies have demonstrated that uptake across the 
basolateral membrane is lower than uptake across the BBM, (Saito et al., 1993; 
Thwaites et al., 1993a, b; Terada et al., 1999) and that efflux across the BLM 
exceeds exit by the BBM (Inui et al., 1992; Matsumoto et al., 1994). In addition, 
these groups have also shown that the direction of transmural transport is important. 
Transport from the BBM to the BLM (corresponding to the absorptive process in 
vivo) occurs preferentially in the enterocyte as opposed to the reverse (Inui et al., 
1992; Saito et al., 1993; Thwaites et al., 1993b). Nevertheless, net secretion of 
peptides by the intestine can occur under optimal conditions. Collectively, this 
information can be used to explain the asymmetry in binding of the label to the 
basolateral transporter. For example, the perfusion data imply that the label has a 
very low affinity for the basolateral transporters extracellular surface, but this may 
not actually be the case. Uptake by the basolateral membrane has been previously 
demonstrated to be lower than efflux (Inui et al., 1992). This suggests that the label 
isn't unable to interact with the active site on the exofacial surface; a higher 
concentration of the label may be required to observe an inhibition of substrate 
transport that is predominantly occurring more rapidly in the opposite (absorptive) 
direction. In other words, the asymmetrical interaction of the label with the 
basolateral transporter, indicated by this data, correlates with the unidirectionality of 
the absorptive process; it binds with higher affinity to the transporters endofacial 
active site, to which peptides bind during their exit from the enterocyte into the 
bloodstream. 
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3.7.4 Modifications to the D-Phe-L-Ala structure confers an increased 
affinity for the peptide transporters 
Pursuing the observed differences in transport rate of D-Phe-L-Gln and the 
potential photoaffinity label, it was decided to determine whether the modification to 
the D-Phe-L-Ala structure performed for label synthesis alters its interaction with the 
transporters. D-Phe-L-Ala was perfused through the lumen at 1 mM concentration 
and its transport rate and accumulation was compared with that of D-Phe-L-Gln and 
the label (Fig. 3.6 (I & II)). D-Phe-L-Ala is transported at a lower rate than 
D-Phe-L-Gln and accumulates to a lesser extent in the jejunal tissue layers. Reduced 
exit ratios, coupled with a lower rate of transport, implies that D-Phe-L-Ala is 
probably a less effective substrate for both transporters, although this is more 
pronounced at the apical membrane due to entry at a lower rate. However, this may 
be coupled with, to a certain extent, that D-Phe-L-Ala is a better substrate than 
D-Phe-L-Gln for the b~solateral transporter and exits the cell more rapidly once 
inside. The rate of D-Phe-L-Ala transport is also considerably less than that of the 
azide label (more so than compared to D-Phe-L-Gln). However, exit ratios 
demonstrate that its mucosal accumulation is much higher when taking into account 
their respective transport rates. Therefore, the addition of the positively charged 
azide group to D-Phe-L-Ala appears to increase its affinity for t~e peptide 
transporters, most notably at the basolateral membrane. This must be due to their 
charge differences because the azide group is very small and would not have any 
effect on transport on the spacial arrangement of the substrate, as the transporters 
have been shown to accept an extremely diverse range of substrates of various shapes 
and sizes. 
A few studies have been published which have scrutinised the effects of 
charge on the transport of dipeptides. A general conclusion is that anionic and 
zwitterionic peptides are transported more efficiently at a pH of approx. 5.5, whereas 
transport of cationic peptides is maximised at a slightly higher pH -6.5 (Temple et 
al., 1995; Wenzel et al., 1996; Steel et al., 1997; Amasheh et al., 1997). Therefore, 
differently charged substrates have different pH dependences/optima. These 
variations in transport rate at different pHs are thought to be due to a difference in 
affinity of the substrate for the transporter rather than the transporter's intrinsic 
activity (Steel et al., 1997). The same studies have demonstrated that differently 
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charged peptides have distinct flux-coupling ratios for H+ -mediated transport. 
Anionic peptides are transported in conjunction with two protons, whereas neutral 
peptides are coupled with one proton and cationic peptides also with one proton, if 
any at all. In this way H+ dependence is not fixed but rather depends on the charge 
carried by the transported peptide. As such, the total charge translocated into the cell 
remains constant despite the varying anionic, neutral or cationic nature of the 
substrate itself. PepTl has two histidine residues (Hiss7 and His12l) located on 
transmembrane domains 2 and 4, respectively; protonation of both residues is 
essential for the transporter to bind anionic peptides and this does not occur unless 
pHo < 6.5 (Temple et al., 1995). Transport of a neutral peptide requires a single 
residue to be protonated but a cationic peptide can bind in the absence of an 
associated H+. Temple et al. (1996) proposed a model for the binding of substrate 
and H+ for PepTI that stated that the empty carrier is negatively charged (C"). The 
charged state of the carrier is entirely dependent on the external pH, i.e. when pHo is 
7.4 the empty carrier is returned to the external surface of the membrane with a 
negative charge (C") but if pHo is 5.5 the carrier is returned in a neutral state (CH+). 
It is therefore evident that cationic peptides would bind more efficiently at a higher 
pH than neutral peptides. The study also states that H+ binding is rate limiting for 
transport, not the return of the empty carrier to the external surface. Collectively 
these studies suggest that at pH 6.8 (the pH of the perfusate medium used in vascular 
perfusions) the positively charged [4-azido-D-Phe]-L-Ala would be transported more 
efficiently than the zwitterionic D-Phe-L-Gln or D-Phe-L-Ala because it doesn't 
necessarily require co-binding of a proton. This possible higher affinity for the 
transporter(s) may form the basis for the more rapid transfer rate. It isn't known 
what causes a faster transport rate at the basolateral membrane due to a lack of 
knowledge in that area. However, the studies previously mentioned (Dyer et al., 
1990; Thwaites et al., 1993a, b; Saito et al., 1993; Terada et al., 1999) imply that 
basolateral transport could be W -coupled and so the same process may also occur in 
this membrane. 
3.7.5 Stimulation of substrate transport by D-Phe-L-Ala 
The results obtained when investigating the effects of D-Phe-L-Gln 
transport in the presence ofD-Phe-L-Ala (Fig. 3.7 (I & II» were suprising. It appears 
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that absence of the azido group on the D-Phe ring confers an innate ability to 
stimulate D-Phe-L-Gln transport through the intestine, or rather the addition of the 
azido group to D-Phe-L-Ala diminishes this stimulatory ability and converts the 
peptide structure into an inhibitor. Stimulation of transmural D-Phe-L-Gln transport 
by D-Phe-L-Ala is similarly observed when D-Phe-L-Ala is present in either the 
lumen or the vasculature of the jejunum. But, there are no corresponding changes in 
tissue concentrations of substrate. The first observation made from the perfusion 
data is that, although the label, at a concentration of 2.5 mM, doesn't appear to 
interact with the exofacial surface of the basolateral transporter, it seems as though 
D-Phe-L-Ala can. 
It was expected that D-Phe-L-Ala would inhibit D-Phe-L-Gln transport in 
the same way that the label does, because both dipeptides would be competing for the 
same active site on the membrane protein(s). However, D-Phe-L-Ala appears to be 
enhancing transport of D-Phe-L-Gln at both the apical and the basolateral membrane 
(the stimulation being more predominant at the basolateral membrane, implied by 
smaller exit ratios). The process by which one molecule stimulates binding of 
another distinct molecule to an enzyme can be classified as allosteric control. An 
allosteric enzyme, which can be stimulated in this way, is described as exhibiting 
'positive substrate cooperativity'. In this process, at low substrate concentrations 
only a few substrate molecules bind to the enzyme's active site (with relatively poor 
affinity), but as more substrate binds, the positive cooperativity effect increases the 
ability of the enzyme to bind additional substrate by increasing its affinity. An 
allosteric activator decreases the level of cooperativity required, by reducing the Km, 
and therefore acts to increase substrate binding. An indication that an. enzyme is 
under allosteric control is that a sigmoidal curve is formed when plotting a graph of 
substrate concentration against its activity. To determine whether this was true with 
peptide transporters, the rate of D-Phe-L-Gln transfer to the vasculature was 
measured at different luminal concentrations. The results of this are shown in 
figure 3.8. It is evident that there is a sigmoidal (or S-shaped) curve depicting 
transport rate when the substrate is D-Phe-L-Gln. 
The process by which D-Phe-L-Ala stimulates D-Phe-L-Gln transport at 
both the apical and basolateral membrane may be a factor of allosteric control of the 
peptide transporters. This control appears to be more predominant at the basolateral 
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Figure 3.8 
Relationship between D-Phe-L-Gln concentration and its rate of transfer to the 
serosa. D-Phe-L-Gln was perfused through the lumen at a specified concentration for 
40 minutes. The sigmoidal curve is indicative of allosteric control. Data points 
represent the mean ± s.e.m (n values are depicted on the specific points on the graph). 
Data was obtained from the Bronk laboratory (personal communication). 
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membrane implied by reduced mucosal exit ratios of D-Phe-L-Gln in the presence of 
D-Phe-L-Ala. This suggests that D-Phe-L-Ala appears to interact with the 
basolateral transporter more efficiently than it does with PepTl, or that it exerts more 
control at this membrane, or that the basolateral transporter is more sensitive to 
regulation. Previous studies with Caco-2 cells have shown that preincubation with 
one dipeptide causes stimulation in the transport of a distinct dipeptide (Thamotharan 
et al.,1998; Walker et al., 1998; Shiraga et al., 1999). This stimulation is a result of 
an increase in V max of transport with no change in Km, and is associated with an 
increase in PepTI mRNA levels and mRNA stability in the cell, in addition to an 
enhancement ofPepTl protein abundance at the apical membrane. As such, it seems 
to be a result of transcriptional control to provide a larger popula~ion of transporters 
at the membrane to increase absorption. However, this stimulation only follows at 
least 24-72 hours preincubation with the dipeptide. In addition, it is only caused by 
particular dipeptides, i.e. Gly-Sar (Thamotharan et al., 1998) and Gly-Phe (Shiraga et 
al., 1999) have been shown to cause a stimulation in transport, whereas Gly-Gln did 
not have the same effect (Shiraga et al., 1999). This implies that the effect may be 
peptide-specific. The mechanism of stimulation in transport described in these 
studies cannot really be used to explain the stimulation in D-Phe-L-Gln transport 
observed with D-Phe-L-Ala in the perfusions presented here, due to the shorter time 
periods of exposure to peptide. However, Sharp et al. (1996) demonstrated that there 
was an additional rapid regulatory response of SGL Tl to jejunal glucose, that 
preceded the onset of increased protein expression at the brush-border membrane in 
rat, which occurred within 30 min of exposure. This same response may be 
equivalent as to what is being observed with peptide transport in these present 
perfusions. However, these perfusions alone cannot unequivocally discriminate 
which process of activation is occurring (if any). 
Further work is required to elucidate the stimulation/inhibition of 
D-Phe-L-Gln transport by the modified dipeptide and the original structure. 
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3.8 Conclusions 
(1) [4-azido-D-Phe]-L-Ala is transported at a significantly more rapid rate than 
D-Phe-L-Gln, but accumulates to a lesser extent in mucosal tissue and a 
higher extent in muscle. Therefore, [4-azido-D-Phe]-L-Ala appears to be a 
more effective substrate for the peptide transporters at both the BBM and 
BLM than D-Phe-L-Gln, but has a relatively more efficient interaction with 
the basolateral transporter than with PepTl. 
(2) Inhibition of substrate transport by [4-azido-D-Phe]-L-Ala at the 
brush-border membrane (PepTl) is not apparent from these perfusion 
experiments. However, previous data (Boyd et at., personal 
communication) have demonstrated transport inhibition in PepTl-
expressing Xenopus oocytes, indicating a direct interaction of the label with 
the transporter protein. 
(3) [4-azido-D-Phe]-L-Ala inhibits transport at the endofacial active site of the 
basolateral transporter, but not by interaction with its exofacial surface. 
Therefore, it has an asymmetrical interaction for the transporter that agrees 
with previous studies concerning the unidirectionality of transport, which 
corresponds to the absorptive process in vivo. 
(4) Addition of the azide group to D-Phe-L-Ala increases its rate of transmural 
transport. This enhanced affinity is probably due to the presence of a 
positive charge, i.e. cationic peptides are more efficiently transported at 
slightly higher pH's (PH 6.8). 
(5) D-Phe-L-Ala stimulates substrate transport at both membranes, but more 
predominantly at the BLM. The peptide transporters may be under allosteric 
control. Further work is required to confirm this theory. 
In summary, although certain discrepencies concerning the nature of 
inhibition/stimulation in substrate transport by peptide transporters are observed with 
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the vascular perfusions, the main aim of the investigation has been fulfilled. It has 
been demonstrated unequivocally thet [4-azido-D-Phe]-L-Ala is able to interact 
specifically with the peptide transporters at both the apical and basolateral 
membranes in rat jejunum in a substrate-specific way. [4-azido-D-Phe ]-L-Ala is 
therefore a potentially good reagent to be used for photo affinity labelling in the 
identification of the membrane proteins responsible for peptide transport in rat 
jejunal mucosa. 
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CHAPTER 4: PHOTOAFFINITY LABELLING OF PEPTI IN 
RAT JEJUNAL BRUSH-BORDER MEMBRANE VESICLES 
USING [4-AZIDO-3,5-3H-D-PHE1-L-ALA 
4.1 Tritiation of [4-azido-D-Phe]-L-Ala to allow its detection 
The radioactive form of the photo affinity label is shown' in figure 4.1. 
[4-azido-D-Phe]-L-Ala was custom-synthesised using standard techniques 
(P. D. Bailey, 1990) by Professor P. D. Bailey and Dr. I. Collier in the Chemistry 
Department of Heriot Watt University, Edinburgh, UK (see section 3.1 for details). 
The D-Phe ring was tritiated at positions 3 and 5 to permit detection of the label and, 
therefore, to allow the detection of a protein to which it may bind to. Attachment of 
the tritium groups CH) to form [4-azido-3,S)H-D-Phe]-L-Ala was performed by 
Zeneca. 
4.2 Purity of BBMV prepared from rat jejunum 
Brush-border membrane vesicles prepared from rat jejunal mucosa were 
routinely analysed by enzyme assays to assess their purity and enrichment in 
comparison to the initial crude homogenate sample. Assays were performed for 
enzymes that are highly specific for the apical membrane; sucrase and alkaline 
phosphatase. In addition, an enzyme specific for the basolateral membrane was also 
assayed (ouabain-sensitive Na+/K+-ATPase) to eliminate the possibility of 
cross-contamination. The results of the assays are shown in figure 4.2. The data 
demonstrate that the BBMV used were consistently of a high purity with negligible 
contamination by other membranes. 
4.3 Feasibility of using [4-a~ido-3,S-~-D-Phe]-L-Ala to identify 
PepTI in membrane vesicles 
As mentioned previously, the potential label has been shown to have a high 
affinity for PepTI in the apical membrane of intact jejunum, i.e. it is transported at a 
very rapid rate from the lumen to the serosa during vascular perfusions. This 
unidirectionality of transport corresponds to the absorptive process in vivo. The label 
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0 CH3 . 
3H N~COO-
N3+ 
NH3+ 
Figure 4.1 
Chemical structure of the radioactive photoaffinity label 
[4-azido-3,5}H-D-Phe]-L-Ala. The hydrolysis resistant dipeptide, D-Phe-L-Ala, was 
synthesised by standard techniques (P. D. Bailey, 1990) prior to the addition of the 
azido group (N3) to position 4 of the D-Phe ring. The label was tritiated at positions 
3 and 5 of the D-Phe ring by Zeneca to permit its detection by scintillation counting. 
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Figure 4.2 
Purity of BBMVs were assessed by assaying enzymes specific for a given membrane 
in the intestinal enterocyte. Assays were performed for sucrase and ALP (BBM 
markers) and ouabain-sensitive Na+/K+-ATPase (BLM marker). The specific activity 
of the enzymes in the homogenate and BBMV are shown (a) and are expressed as 
follows: sucrase, )lmol·min-I.[mg proteinr l .; ALP, U·[mg proteinr l ; ATPase, 
)lmol .hr-I.[mg proteinr l .. Also shown is the enrichment of each enzyme in BBMV as 
compared to the original crude homogenate (b). Bars represent the mean ± s.e.m. 
(n = 6). 
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binds extremely efficiently to an extracellular (luminal) active site of PepTl although 
it probably does not interact with such a high affinity with an intracellular site. This 
lower cytosolic affinity has been implied by previous studies (lnui et al. 1990; Saito 
etal., 1993; Thwaites et al., 1993b; Matsumoto et al., 1994). These have shown that 
exit across the BBM into the lumen occurs at a much lower rate than uptake into the 
cell via PepTl, and also that the reverse transport from the BLM to the BBM is less 
rapid than the forward (absorptive) process. However, the BBMV prepared by the 
method described in this thesis have been previously demonstrated to be correctly 
orientated (C. P. Corpe, 1993) that is, right side out. This means that the membrane 
forming the vesicles has the same orientation as in the intact epithelium. As such, 
the extracellular active site of PepTl will be located on the outer surface of the 
vesicle and so, labelling of the peptide transporter should be highly efficient. 
It is also important to note that the label was transported intact from the 
lumen to the serosa in the perfusions; this resistance to hydrolysis is essential for a 
photoaffinity label in order to avoid labelling of other unrelated membrane proteins. 
4.4 Labelling procedure and expression of results 
Photoaffinity labelling (PAL) of membrane vesicles was performed in a 
medium of pH 5.5. The low pH of this solution reflects the luminal acidic 
microclimate located adjacent to the brush-border membrane in vivo and, therefore, 
acts to maximise interaction of the label with the active site of the membrane protein. 
Vesicles were initially labelled in one of two possible conditions; in an 
'unprotected' or 'protected' environment. Unprotected vesicles were labelled 
directly in the absence of substrate, whereas protected vesicles were pre-incubated in 
a high concentration of a substrate for 15 min prior to labelling. The substrates used 
were either a dipeptide (D-Phe-L-Gln) or its equivalent free amino acids (D-Phe and 
L-Gln), all at a concentration of 16.7 mM. This protection was used to provide 
information regarding the type of substrate with which a labelled protein would 
interact, i.e. it would demonstrate substrate-specific labelling by inhibition of label 
incorporation. 
[4-azido-3,S}H-D-Phe]-L-Ala was added to the vesicles at a final 
concentration of 4.2 J.1M and a total radioactivity content of 740 kBq (20 J.11 volume). 
When exposed to light, the azido group becomes extremely reactive and will form a 
covalent attachment to a number of different bonds within close vicinity. The low 
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concentration ensures that the level of non-specific labelling is kept to an absolute 
minimum and that label incorporation is due to a substrate/active site interaction. 
Results from PAL experiments are presented as graphs of gel slice number 
on the x-axis (which corresponds to a decrease in molecular weight from left to right) 
against radioactivity detected by scintillation counting (dpm) on the y-axis. A peak 
in the data indicates that the label has covalently attached to a membrane protein. 
Results from unprotected vesicles are shown in conjunction with substrate-protected 
studies. These collated data are normalised to the same initial radioactivity content 
of the sample to allow results of the different labelling conditions to be directly 
compared. 
Label incorporation by a membrane protein is expressed as the percentage of 
radioactivity bound, with respect to the initial radioactivity content, and also shown is 
the percentage inhibition caused by substrate preincubation/enzymatic treatment of 
vesicles. Finally the amount of [4-azido-3,5}H-D-Phe ]-L-Ala actually bound to the 
protein is calculated. 
4.5 Photoaffinity labelling of BBMV to identify PepTl 
BBMV we~e photo affinity labelled with the peptide derivative 
[4-azido-3,5)H-D-Phe]-L-Ala in the presence or absence of either D-Phe-L-Gln or 
its constituent amino acids, on the basis that compounds which compete with the 
label for binding should decrease the extent of specific labelling. The results are 
shown in figure 4.3. There appears to be a high level of incorporation of the label by 
a membrane protein shown to have an apparent molecular weight of approx. 130 kDa 
when analysed by slab gel SOS-PAGE (data not shown). Binding of the radioactive 
label to this protein is strongly inhibited by pre-incubation with the dipeptide but not 
by the amino acids. The dipeptide inhibits 56% of label binding (table 4.1 and 
figure 4.4) whereas the amino acids provide very little protection (6%). It is also 
interesting to note that incubation with the dipeptide and the amino acids collectively 
confers slightly more inhibition than the dipeptide alone (62%). 
The pattern of label incorporation seen in figure 4.3 was highly reproducible 
and the data collectively suggests that the predominantly labelled 130 kDa protein 
specifically interacts with dipeptides but not with amino acids. 
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Figure 4.3 
Representative result of photoaffinity labelling of BBMV at pH 5.S with 
[4-azido-3 ,S)H-D-Phe]-L-Ala. Labelling was performed under four different 
conditions; unprotected (diamonds) and protected by 16.7 mM D-Phe-L-Gln 
(squares), D-Phe and L-Gln at 16.7 mM (triangles) or both peptide and amino acids 
(circles). The x-axis of gel slice number represents a decrease in molecular weight 
from left to right, down the rod gel, and the y-axis shows label incorporation by a 
membrane protein. A peak demonstrates that a protein has bound the radioactive 
label. 
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Protein-bound % label Total label 0/0 
3H-dpm Bq bound bound inhibition 
Unprotected 1775 29.82 0.0032 27 fmoles 
D-Phe-L-Gln 780 13.1 0.0014 12 fmoles 56% 
D-Phe & L-Gln 1677 28.17 0.003 25 fmoles 6% 
D-Phe-L-Gln, 668 11.22 0.0012 10 fmoles 62% 
D-Phe & L-Gln 
Table 4.1 
Incorporation of [4-azido-3,S)H-D-Phe]-L-Ala by the 130 kDa protein III 
unprotected and substrate-protected BBMV. The data shown correspond to 
figure 4.3 and show the amount of radioactivity bound to the protein (also expressed 
as a percentage of the total radioactivity added to the vesicles), in addition to the 
amount of label bound to the protein. The inhibition caused by preincubation with a 
substrate is expressed as a percentage. The mean initial amount of radioactive label 
added to the four vesicle suspensions was 56 x 106 dpm (940.8 kBq). 
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D-Phe & L-Gln 
Inhibition of [4-azido-3 ,S)H-D-Phe]-L-Ala binding to the 130 kDa protein as a 
result of pre-incubation with substrates (at 16.7 mM). Unprotected labelling (in the 
absence of substrates) is taken to be 100% incorporation. The degree by which the 
substrates inhibit labelling indicates the preferred nature of substrate with which the 
membrane protein interacts. 
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The amount of [4-azido-3,5.3H-D-Phe]-L-Ala covalently bound to the 
130 kDa protein is very low; in the unprotected vesicles only 27 fmoles from an 
initial 840 pmoles specifically binds, i.e just 0.0032% (table 4.1). However, the low 
level of incorporation suggests that the covalent attachment of the label to the 
membrane protein should be very specific and that the highly reactive azido group is 
not forming a bond with random proteins with which the dipeptide backbone does 
not interact. 
It is evident that not only is there predominant labelling of the 130 kDa 
protein, but also there is a considerable amount of label incorporation by other BBM 
proteins. Labelling of all proteins appears to be inhibited by the dipeptide but not the 
amino acids, albeit to varying extents. The high molecular weight proteins (approx. 
slice numbers 4-11 in figure 4.3) are thought to be peptide hydrolases associated with 
the apical membrane, but the nature of the lower molecular weight proteins are not 
known. 
Due to the extent of label incorporation by many proteins in the BBMV it is 
impossible from these data to identify PepTl individually. 
4.6 Effect of bestatin on singular identification of PepTl 
Initial photoaffinity labelling experiments failed to identify PepTl 
specifically from the other proteins located in the brush-border membrane of the 
jejunum. In addition to PepTl ,peptide hydrolases present in this membrane were 
also specifically labelled by [4-azido-3,5.3H-D-Phe]-L-Ala in a substrate-inhibitable 
way. Therefore, an approach was required to prevent label incorporation by these 
peptidases while still permitting binding to PepTI. The first step in this approach 
was to use bestatin. Bestatin is an immunostimulant given orally with anti-cancer 
therapy (Takano et al., 1994). In addition to this important therapeutic use, it is a 
potent inhibitor of exopeptidases, dipeptidases and several aminopeptidases, except 
aminopeptidase A (Wilkes & Prescott, 1985), in the apical membrane. It has also 
been shown to be a transportable substrate of the intestinal peptide transporter 
(Kramer et al., 1990b). However, a considerably higher concentration is required for 
interaction with PepTl than with the peptidases; the concentration being three orders 
of magnitude higher (10 mM compared to ..... 10 IlM) (Kramer et al., 1990b; Takano et 
al., 1994). Due to the differences in affinity of the distinct membrane proteins, it 
was thought that preincubation of BBMV with a low concentration of bestatin 
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(20 J.1M) would inhibit label incorporation by the peptidases and aid in the distinct 
labelling of PepTl. 
Figure 4.S shows the results of these experiments. It is evident that the 
presence of bestatin has no effect on blocking label incorporation by the BBM 
peptidases, in particular it only inhibits 6% of label binding (table 4.2, figure 4.6) to 
the 130 kDa protein principally detected in figure 4.3. A similar low extent (or lack) 
of inhibition was observed as an overall effect throughout the membrane as a whole. 
However, D-Phe-L-Gln again has a dramatic effect and completely abolishes label 
incorporation by all proteins, especially by the 130 kDa protein (87.S% inhibition). 
The amount of label attachment to the unprotected 130 kDa protein is 
comparable with the initial experiments; only 31 finoles is covalently bound to the 
protein (0.0037% of the initial 840 pmoles). Again this low level of incorporation 
indicates a highly specific interaction of [4-azido-3,S)H-D-Phe]-L-Ala with all 
proteins. 
The overall result of these experiments is that PepTI cannot be individually 
identified due to a lack of inhibition of peptidase labelling by bestatin. 
4.7 Papain treatment ofBBMV to digest peptide hydrolases 
Because of the failure in identifying PepTI by using bestatin to block 
hydrolase labelling, another approach to inhibit label incorporation by these proteins 
was required. The study was progressed by treating the vesicles with papain prior to 
labelling. Papain has been demonstrated to cleave, and solubilise, the extracellular 
domain of hydro lases from the bilayer structure of the membrane whilst preserving 
the integrity of the vesicles (Berteloot et al., 1980; Ganapathy et al., 1981; Kenny & 
Maroux, 1982). Other studies have shown that papain treatment of BBMV (at a 
concentration of O.S mg.mr!) causes a stimulation of peptide transport by PepTI 
(Ganapathy et al., 1981; Inui et al., 1984). This stimulation in peptide transport was 
associated with peptidase digestion from the apical membrane and, as such, was due 
to an increase in enrichment ofPepTI transport activity. 
Vesicles were initially digested with 0.5 mg.mr! papain (0.21 U mr! 
enzyme activity) using a method previously described (Louvard et 01., 1975; 
Ganapathy et 01., 1981) in which the reaction was quenched by chilling the digestion 
mixture to 4°C. The results from papain digestion ofBBMV are shown in figure 4.7 
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Figure 4.5 
Representative result of photoaffinity labelling of BBMV at pH 5.5 with 
[4-azido-3 ,S)H-D-Phe]-L-Ala. Vesicles were preincubated with 20 /-lM bestatin 
(triangles) in an attempt to block labelling of brush-border peptide hydrolases to 
allow specific labelling of PepTl . Also shown are labelling of unprotected vesicles 
(diamonds) and vesicles protected by 16.7 mM D-Phe-L-Gln (squares). The x-axis of 
gel slice number represents a decrease in molecular weight from left to right, down 
the rod gel, and the y-axis shows label incorporation by a membrane protein. A peak 
demonstrates that a protein has bound the radioactive label. 
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Protein-bound % Total label % 
3H-dpm Bq bound bound inhibition 
Unprotected 2083 34.99 0.0037 3] fmoles 
D-Phe-L-Gln 2S1 4.22 O.OOOS 4 fmoles 87.S% 
Bestatin 1980 33 .26 0.003S 29 fmoles 6% 
Table 4.2 
Incorporation of [4-azido-3 ,S)H-D-Phe]-L-Ala by the 130 kDa protein In 
unprotected and substrate-protected BBMV. The data shown correspond to 
figure. 4.S and show the amount of radioactivity bound to the protein (also expressed 
as a percentage of total radioactivity added to the vesicles), in addition to the amount 
of label bound to the protein. The inhibition caused by preincubation with a substrate 
is expressed as a percentage. The mean initial amount of radioactive label added to 
the three vesicle suspensions was 56 x 106 dpm (940.8 kBq). 
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Unprotected D-Phe-L-Gln Bestatin 
Extent of [4-azido-3 ,5)H-D-Phe]-L-Ala binding to the 130 kDa protein as a result of 
pre-incubation with D-Phe-L-Gln (at 16.7 mM) or bestatin (at 20 /lM). Unprotected 
labelling (in the absence of additional compounds) is taken to be 100% incorporation. 
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and figure 4.8. It is immediately apparent that digestion of the vesicles in this way 
completely abolishes label incorporation by all brush-border membrane proteins, not 
just the hydro lases. 
It was thought that simply chilling the digestion mixture to 4°C did not 
quench the reaction fully. So, another digestion was performed with the same papain 
concentration but the reaction was stopped by a 5-fold dilution in a mannitollHEPES 
buffer, pH 7.5 (as described by Berte100t et al., 1980). Figures 4.7 and 4.8 show the 
results of this experiment. Again it is evident that the digestion was too aggressive 
and did not leave PepTl in the membrane able to bind the label. A third experiment 
utilised half of the original papain concentration (0.25 mg·mr1) in an attempt to 
reduce the extent of digestion. This, again, resulted in complete inhibition of 
labelling throughout the whole of the membrane. 
Louvard and co-workers (1975) suggested that freezing the vesicles 
accelerated solubilisation by papain so, experiments using previously frozen and 
freshly prepared vesicles were performed. Traces of radioactive label incorporation 
were again practically identical to the data already presented (data not shown). 
Overall, papain digestion of BBMV performed to specifically identify 
PepTl by photo affinity labelling did not work as anticipated. 
4.8 Discussion 
4.8.1 PAL ofBBMV: labelling of peptide hydrolases 
Initial experiments to specifically label PepTl in rat BBMV were 
unsatisfactory. Due to a large number of membrane proteins covalently binding the 
label, PepTl could not be positively identified. 
The pattern of labelling observed under all four conditions was highly 
reproducible. Label incorporation in an unprotected environment was also very 
similar to that seen in a series of studies performed by Kramer and co-workers in 
which BBMV from rat (1987), rabbit (1988, 1990c) and pig (1990b) were labelled 
with photolabile derivatives of known PepT! substrates. The 130 kDa molecular 
weight protein predominantly labelled by [4-azido-3,5-3H-D-Phe]-L-Ala in this study 
corresponds to the protein of 127 kDa that was identified by Kramer's group. In 
Kramer's investigations, pre-incubation of vesicles with other (non-radioactive) 
PepT! substrates caused a clear concentration-dependent decrease in the extent of 
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Representative result of photoaffinity labelling of BBMV at pH 5.5 with 
[4-azido-3 ,S) H-D-Phe]-L-Ala. Prior to labelling vesicles were incubated with 
papain in an attempt to digest the brush-border peptidases out of the bilayer to allow 
specific labelling of PepTl. Vesicles were digested with 0.5 mg·mr 1 papain 
(triangles) and 0.25 mg·mr 1 papain (circles) and the reaction quenched by chilling to 
4°C, or they were digested with 0.5 mg·mr 1 and the reaction quenched by a 5-fold 
dilution in a mannitol/HEPES buffer (squares). Also shown is unprotected labelling 
of BBMV (diamonds). The x-axis of gel slice number represents a decrease in 
molecular weight from left to right, down the rod gel , and the y-axis shows label 
incorporation by a membrane protein. A peak demonstrates that a protein has bound 
the radioactive label. 
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Protein-bound % Total label 0/0 
3H-dpm Bq bound bound inhibition 
Unprotected 2196 36.89 0.0038 32 fmoles 
0.5 mg.mr1 papain 98 1.65 0.00017 1.4 fmoles 96% 
0.25 mg·mr1 papain 62 1.04 0.00011 0.9 fmoles 97% 
0.5 mg·mr l papain 85 1.43 0.00015 1.3 finoles 96% 
( mannitol/HE PES) 
Table 4.3 
Incorporation of [4-azido-3 ,5)H-D-Phe]-L-Ala by the 130 kDa protein m 
unprotected BBMV and vesicles pre-digested with papam. The data shown 
correspond to figure 4.7 and show the amount of radioactivity bound to the protein 
(also expressed as a percentage of total radioactivity added to the vesicles), in 
addition to the amount of label bound to the protein. The inhibition of labelling 
caused by papain treatment is expressed as a percentage. The mean initial amount of 
radioactive label added to the four vesicle suspensions was 58 x 106 dpm 
(974.4 kBq). 
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Unprotected 0.5 mg.mr l 0.25 mg·mr l 0.5 mg·mr l 
(mannitol) 
1 
Effect of papain digestion on [4-azido-3 ,5)H-D-Phe]-L-Ala binding to the 130 kDa 
protein. Unprotected labelling (in the absence of papain treatment) is taken to be 
100% incorporation. 
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labelling of this protein, whereas bile acids, sugars and amino acids had no effect. 
They therefore suggested that it could be a component of the peptide transport 
system. Even so, they examined whether certain hydro lases of this molecular weight 
were contributing to label binding, e.g. aminopeptidase N, dipeptidyl peptidase IV. 
Immunoprecipitation studies indicated that these hydro lases were not a part of the 
transport system and so they postulated that the 127 kDa protein was directly 
involved in the transfer of oligopeptides and peptide-like drugs across the enterocyte 
BBM. Further studies by this group were to reconstitute the 127 kDa protein into 
proteoliposomes (Kramer et al., 1992). This resulted in specific binding of p-lactam 
antibiotics and dipeptides to the protein, in addition to observing a stereospecific 
transport activity. A longitudinal examination of the small intestine revealed that the 
127 kDa protein was present throughout its entire length (Kramer et al., 1998). This 
protein was demonstrated to be highly glycosylated; treatment with various 
de-glycosylating enzymes produced a lower molecular weight of the protein 
(95-100 kDa). This apparent heavy glycosylation, coupled with the fact that when 
subjected to 2-D electrophoresis the protein did not focus into a sharp spot (Kramer 
et al., 1990d), but was evenly distributed over a pH range of approx. 1 unit (PH 5-6), 
implies that it is a microheterogenous glycoprotein. 
In reference to the previous papers by Kramer and co-workers, Daniel & 
Adibi (1993) conducted investigations into the substrate-specific requirements of 
PepTI. They stated that because the photoreactive azide analogues, i.e. 
benzylpenicillin, cephalexin, Gly-Pro, that Kramer et al. used to label the 127 kDa 
protein did not contain a free a-amino group, it is unlikely that the labelled protein 
represents the H+ /peptide cotransporter. 
The high molecular weight proteins that have incorporated the label in this 
study are probably peptide hydrolases associated with the apical membrane. These. 
hydro lases form a large proportion of BBM proteins; for example aminopeptidase 
has been shown to represent approx. 8% of the total protein present in the membrane 
(Desnuelle, 1979). Their molecular weights range from 170 kDa of aminopeptidase 
A, through 130 kDa (aminopeptidase N, dipeptidyl peptidase IV), to 93 kDa of 
endopeptidase (Kenny & Maroux, 1982). Because they are peptide hydro lases they 
specifically interact with peptides, and therefore, in conjunction with PepTl, will 
also bind the photo labile dipeptide. 
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4.8.2 Distinct molecular weight ofPepTl 
The molecular weight of the protein predominantly labelled by the modified 
dipeptide (130 kDa) does not correlate with molecular weights of PepTI that have 
previously been published. Fei et al. (1994) and Daniel et al. (1996) both identified 
PepTl in rabbit small intestine with an apparent molecular weight of 71 kDa. 
Investigations with rat brush-border membranes identified a protein of 75 kDa (Saito 
et al., 1995; Ogihara et at., 1996), thought to be only 63 kDa without glycosylation 
(Saito et al., 1995). Studies in human tissue by Liang and co-workers (1995) 
identified a protein of 78.81 kDa molecular weight, deduced from its primary amino 
acid sequence, whereas Dantzig et al. (1994) postulated that a protein of 92 kDa 
(designated HPT-l) is associated with hPepTl. A later study by Fei's group in 1997, 
on Caco-2 cells, identified a 120 kDa protein that they hypothesised as being PepTI. 
It is evident that there are variations in the apparent molecular weight of 
PepTI and these are due to the diversity of animal species under study, but in 
addition it may also be due to discrepancies in technique by the different groups. It 
may be that a functional transport protein isolated from an intact tissue, which is the 
case in this present study, has a different subunit composition, or molecular weight, 
from a transporter that has been functionally expressed by injection of its cDNA into 
oocytes. This may explain the apparent differences in the molecular weight of the 
protein that has been labelled by [4-azido-3,S}H-D-Phe]-L-Ala in this study to 
previously published results. Although moderately higher molecular weights have 
been described (120 kDa by Fei et 01., 1997), these were found in human tissue. The 
molecular weight consistently recorded for smaller animals, in particular rat, is 
approx. 70-75 kDa. The detected protein in this study may be a dimer of these 
proteins previously documented. However, this is unlikely because the BBMV were 
subjected to SDS-PAGE in the presence of a reducing agent (~-mercaptoethanol) and 
therefore all bonds between potential subunits of proteins would have been destroyed 
by the denaturing conditions employed. Therefore, although the 130 kDa protein has 
been predominantly labelled by [4-azido-3,5-3H-D-Phe]-L-Ala it may in fact be a 
protease, or possibly a regulator of peptide transport. PepTI was not resolved 
because of extensive labelling of other proteins. Its presence, individually, at 75 kDa, 
could not be individually identified by this method. 
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4.8.3 Inhibition of label interaction with peptidases by bestatin 
Although peptidases located in the BBM are not directly involved in peptide 
transport, they bind peptide structures and have been shown in the initial studies to 
interact with the photoaffinity label. A step was taken in an attempt to eliminate 
specific label incorporation by these peptidases by incubating vesicles with bestatin 
(at 20 JlM concentration) prior to labelling. The results, however, were 
disappointing. Bestatin did not inhibit labelling of the peptidases to any appreciable 
extent and so PepTI could not be specifically identified. 
The concentration of bestatin added to the vesicles was comparable to that 
described in previous papers, for example, Wilkes & Prescott (1985) performed a 
series of hydrolase-inhibition experiments using bestatin at increasing concentrations. 
Their results showed that the extent and rapidity of inhibition increased as a result of 
bestatin concentration. Complete inhibition was achieved with 19.1 J.LM after only 
5 min incubation. Other values published for bestatin are that rabbit aminopeptidases 
are inhibited with an ICso value of 5 /lM (Takano et al., 1994) and half-maximal 
inhibition of aminopeptidase N is seen with approx. 10 /lM bestatin (Kramer et al., 
1990b). Therefore, at a bestatin concentration of 20 JlM a certain degree of label 
inhibition should have occurred. 
In addition to being an inhibitor of peptide hydro lases, bestatin is also a 
substrate for PepTI. However, a higher concentration is required for interaction with 
the peptide transporter than with the peptidases. A half-maximal inhibition of 
cephalexin uptake into BBMV was observed with an ICso of approx. 10 mM bestatin 
(Kramer et al., 1990b); this concentration is three orders of magnitude higher than 
that described for peptidases. A separate study has measured transport of bestatin 
into membrane vesicles and demonstrated that uptake consisted of two saturable 
components (Takano et al., 1994). A high affinity component was understood to be 
due to binding of bestatin to aminopeptidases on the surface of the vesicles, whereas 
a low affinity component was a result of specific uptake by PepTl into the 
intravesicular space. At the low concentrations used in this study, bestatin should 
have bound preferentially to the hydrolases leaving PepTI free to be photoaffinity 
labelled. 
The lack of effect by bestatin might be due to its incubation time with the 
membrane vesicles. Studies by Wilkes & Prescott (1985) imply that bestatin is an 
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inhibitor that gams equilibrium with peptidases to form a tightly bound 
enzyme-inhibitor (E-I) complex in a time dependant manner. Mechanisms have been 
proposed suggesting an initial collision complex followed by a slow conformational 
change that takes approx. two hours to achieve. These induced changes may involve 
the formation of ligands between zinc (in the peptidase active site) and bestatin, 
possibly via a-hydroxy and carboxyl groups. These findings indicate that it may be 
feasible to increase the incubation time of vesicles with bestatin to 2 h for PepTI 
identification. 
4.8.4 Papain digestion ofpeptidases 
Papain digestion of the vesicles was no more successful than the use of 
bestatin. Membrane surface constituents that are known to be detached from, or 
loosely attached to, the lipid core can be solubilised either by proteolytic digestion or 
by treatment with detergents. Hydrolases are asymmetrically orientated within the 
brush-border membrane, i.e. the bulk of the molecule (including the catalytic site) is 
exposed at the luminal surface (Kenny & Maroux, 1982) and are therefore on the 
extravesicular side of BBMV. They are composed of 3 domains; a large hydrophilic 
region protruding out of the cell, a hydrophobic region plunged into the lipid core of 
the bilayer and a small cytoplasmic tail located inside the cell (which constitutes only 
2.5-5% of its total mass) (Desnuelle. 1979). The mechanism of hydrolase 
solubilisation is not known but proteases such as papain are thought to split a limited 
number of bonds at the hydrophilic/hydrophobic junction at the membrane surface, 
therefore shaving off the extracellular part and leaving the hydrophobic part in the 
bilayer. Untreated BBMV have a regular array of knobs on their external surface, 
shown by negative staining preparations (Kenny & Maroux, 1982). After papain 
treatment the surface of the vesicles are smooth; this has been interpreted as 
correlating with the release of the susceptible hydrolases. Not all hydro lases are 
released from the membrane at the same rate, for example aminopeptidase N and 
dipeptidyl peptidase IV are readily solubilised whereas aminopeptidase A and 
y-glutamyltransferase are released more slowly (Kenny & Maroux, 1982). These 
differences in rate of release from the membrane has been attributed to bond 
accessibility, i.e. how deep the enzyme is buried within the membrane lipids, in 
addition to several structural parameters. These include the geometry of fit of papain 
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at the surface of the membrane and the primary structure of the accessible region of 
the susceptible polypeptide chain. 
Previous studies using papain digestion of BBMV have demonstrated that it 
causes a stimulation of peptide transport by PepTI (Ganapathy et al., 1981; Inui et 
al., 1984). This increase in transport correlates with protein removal during 
digestion; a 42% stimulation in Gly-L-Pro transport corresponded to the 
solubilisation of 45% of protein in the apical membrane, resulting in a 2.5-fold 
enrichment in specific transport activity (Ganapathy et al., 1981). A similar 
occurrence was seen in the study by Inui (1984); a 2-fold enhancement in specific 
activity of cephalexin transport closely matched the extent of protein removal using 
papain (40-50% digestion). It was suggested (Ganapathy et al., 1981) that the 
stimulation in peptide transport might be the result of a reduction in the thickness of 
the unstirred water layer adjacent to the apical membrane, implied by a substantial 
decrease in extravesicular space. 
Although peptide transport was demonstrated to have remained intact 
following papain digestion of BBMV in previous studies using an identical method, 
it is apparent that papain digestion in this study completely abolished label 
incorporation, not only by the hydrolases but also by PepTI. This could possibly be 
due to an incubation time that was too prolonged. The previous studies (Ganapathy 
et al., 1981; Inui et al., 1984) used BBMV prepared from rabbit small intestine, 
whereas this study used rat jejunal BBMV. This species difference may contribute to 
the discrepancies resulting from papain digestion observed, although it isn't likely. 
4.8.5 pH-dependence of label interaction with PepTI 
A possible reason why PepTI does not appear to be incorporating the 
photoaffinity label to a great extent may be due to the pH at which labelling is 
performed (PH 5.5), although pH 5.5-6.5 was generally thought to be the optimum 
for transport of all peptides. Previous photoaffinity labelling studies by Kramer and 
co-workers (1987, 1988, 1990b,c) were performed at a pH of 7.4, and they also failed 
to specifically identify PepT1 at the correct molecular weight. Separate studies 
(Temple et al., 1995; Wenzel et al., 1996; Steel et al., 1997; Amasheh et al., 1997) 
suggest that cationic peptides (such as the label) have a higher affinity for PepT! at a 
pH of approx. 6.5. Therefore, photoaffinity labelling at the same pH at which the 
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vascular perfusions were performed (PH 6.8) may reveal stronger labelling of PepTl. 
Labelling was originally conducted in a buffer of pH 5.5 because of the simplicity of 
its contents, i.e MES only, titrated with Hel. A physiological buffer at pH 6.8 is an 
option for future work. 
In conclusion, PepTI could not be specifically identified by the approaches 
to photoaffinity labelling described in this chapter. 
4.9 Conclusions 
(1) The pattern of [4-azido-3,5}H-D-Phe]-L-Ala incorporation by brush-border 
membrane proteins was highly reproducible. 
(2) A large number of proteins in the apical membrane were specifically 
labelled by [4-azido-3,5}H-D-Phe]-L-Ala. Labelling is inhibited by a 
dipeptide but not by free amino acids. 
(3) Incorporation of [4-azido-3,5}H-D-Phe]-L-Ala by membrane proteins is 
highly specific; only approx. 0.003% of the initial amount actually forms a 
covalent attachment. 
(4) One protein is predominantly labelled (130 kDa), but it is probably not 
PepTI. 
(5) The high molecular weight proteins that have been labelled are probably 
hydrolases associated with the apical membrane. 
(6) PepTl cannot be distinguished from other labelled proteins by 
pre-incubation with bestatin (to block peptidase labelling) or by papain 
digestion {to solubilise peptidases from the membrane}. 
Overall, photoaffinity labelling ofBBMV could not individually identify PepTl. 
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CHAPTER 5: IDENTIFICATION OF A CANDIDATE PEPTIDE 
TRANSPORTER IN THE BASOLATERAL MEMBRANE 
5.1 Purity of BLMV prepared from rat jejunum 
Basolateral membrane vesicles prepared from rat jejunal mucosa were 
routinely analysed by enzyme assays to assess their purity and enrichment in 
comparison to the initial crude homogenate sample. An assay was performed for an 
enzyme that is highly specific for the basolateral membrane (ouabain-sensitive 
Na+/K+-ATPase) in addition to assays for two marker enzymes of the apical 
membrane (sucrase and alkaline phosphatase), to assess the possibility of 
cross-contamination. The results of the assays are shown in figure S .1. The data 
demonstrate that the BLMV used for photoaffinity labelling experiments were 
consistently of a high purity with negligible contamination by brush-border 
membranes. 
5.2 Viability of using [4-azido-3,5-3H-D-Phe]-L-Ala to identify 
the basolateral peptide transporter in membrane vesicles 
[4-azido-3,S}H-D-Phe]-L-Ala has been shown to interact directly with the 
basolateral peptide transporter by experiments using the technique of isolated, in situ, 
luminally and vascularly perfused jejunum (see chapter 3). The label was transported 
intact through the intestinal wall at a very rapid rate, suggesting a high affinity for 
peptide transporters in both the apical and basolateral membranes of the cell. In 
addition, it accumulates to a very low extent in the mucosal tissue, with respect to its 
rapid transport rate (implied by small exit ratios), indicating that it might be a more 
efficient substrate for the basolateral transporter than it is for PepTl. 
These initial studies demonstrated that the label was a substrate for the 
basolateral peptide transporter. Subsequent perfusions unequivocally showed that the 
label interacts directly with the active site of the transporter protein (see chapter 3). 
In these transport inhibition experiments, the presence of 
[4-azido-3,S}H-D-Phe]-L-Ala in the luminal perfusate, and subsequent transport into 
the enterocyte, resulted in inhibition of dipeptide exit from the cell, although its 
presence on the serosal side did not have the sam'e effect. Therefore, there appears to 
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Purity of BLMV s were assessed by assaying for enzymes specific for a given 
membrane in the intestinal enterocyte. Assays were performed for Na+/K+-ATPase 
(BLM marker), sucrase and ALP (BBM markers). The specific activity of the 
enzymes in the homogenate and BLMV are shown (a) and are expressed as follows : 
sucrase, ~mol·lmin- l . [mg proteinr1; ALP, U·[mg proteinr1; ATPase, 
/-lmol· hr-I. [mg protein r I.. Also shown is the enrichment of each enzyme in BLMV as 
compared to the original crude homogenate (b). Bars represent the mean ± s.e.m. 
(n = 8). 
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be an asymmetry in binding of the label to the basolateral peptide transporter. 
Previous studies by other groups have also demonstrated an asymmetry in interaction 
of substrates with both the basolateral transporter and PepTI that corresponds to the 
absorptive process in vivo. Investigations using Caco-2 cells have shown that efflux 
of substrates, across the basolateral membrane, is more rapid than uptake (Inui et al., 
1992). In addition, uptake across the BLM is considerably lower than uptake across 
the BBM (Saito et al., 1993; Thwaites et al., 1993a,b; Terada et al., 1999), whereas 
efflux across the BLM exceeds exit by the BBM (Inui et al., 1992; Matsumoto et al., 
1994). The direction of transport is also important, i.e. the route of transfer which 
corresponds to the absorptive process in vivo occurs preferentially in the enterocyte, 
as opposed to the reverse (Inui et al., 1992; Saito et al., 1993; Thwaites et al., 
1993b). 
Although there appears to be an element of binding asymmetry of the label 
with the basolateral transporter, [4-azido-3,5)H-D-Phe]-L-Ala is a potentially good 
photolabile reagent for the specific labelling of the peptide transport protein in 
basolateral membrane vesicles. Although the orientation of the vesicles was not 
directly determined in this study, it is well known that they are orientated in a random 
manner (Murer & Kinne, 1980). In addition, the vesicles are 'leaky' and so, small 
molecules are able to diffuse into the intravesicular space. Therefore, the label will 
be able to gain an effective interaction with the endofacial active site of the 
basolateral transporter irrespective of the vesicles' orientation. 
5.3 Labelling procedure and expression of results 
Photoaffinity labelling of BLMV was performed in a medium of pH 5.5. 
The mechanism of peptide transport at the basolateral membrane has not been 
elucidated, although previous studies have suggested that transport may be enhanced 
in a slightly acidic medium (PH 5.5-6.0). However, unlike PepTl, there doesn't 
appear to be an optimum pH (Saito et al., 1993; Thwaites et al., 1993a; Matsumoto et 
al., 1994; Terada et al., 1999). 
Vesicles were labelled in an unprotected or protected environment, 
following the same procedure whereby BBMV were previously labelled (section 4.5), 
to elucidate the preferred nature of substrate with which a labelled protein interacts. 
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The basolateral membrane peptide transporter has been shown to be 
temperature sensitive (Inui et al., 1992), i.e. transport is abolished at a low 
temperature (4°C). Vesicles were incubated at 4°C during equilibration to pH 5.5, to 
prevent proteolytic breakdown of the membrane constituents. However, due to the 
temperature sensitivity of transport, vesicles were incubated at room temperature for 
15 min (with or without substrates), to allow interaction of the label and/or substrates 
with the active site of the transporter, prior to photolysis. 
Photoaffinity labelled membrane proteins were initially resolved either by 
SDS-PAGE or IEF in rod gels. Proteins separated by SDS-PAGE are presented as 
graphs of gel slice number (3 mm sections) on the x-axis, against radioactivity 
detected by scintillation counting (dpm) on the y-axis. IEF-resolved proteins are also 
presented as graphs of gel slice on the x-axis (2 mm sections), although here they 
represent the pH gradient throughout the length of the gel, versus radioactivity on the 
y-axis. A peak in either data indicates that the label has covalently attached to a 
membrane protein. Results from unprotected vesicles are shown in conjunction with 
substrate-protected studies. These sets of data from the different conditions are 
nonnalised to the same initial radioactivity content in the sample to allow results to 
be directly compared. 
Label incorporation by a membrane protein is expressed as the percentage of 
radioactivity bound, with respect to the initial radioactivity content, and also reported 
is the percentage inhibition of labelling caused by substrate preincubation. Finally 
the amount of [4-azido-3,5)H-D-Phe]-L-Ala covalently bound to the protein is 
calculated. 
5.4 Photoaffinity labelling of BLMV 
BLMV were photoaffinity labelled with [4-azido-3,S}H-D-Phe]-L-Ala in 
the presence or absence of either D-Phe-L-Gln or its constituent amino acids, on the 
basis that compounds which compete with the label for binding to the active site of 
proteins should decrease the extent of labelling. A representative example of the 
results is shown in figure 5.2. The x-axis in this graph represents a decrease in 
molecular weight, proceeding from left to right, through the length of the rod gel. 
A definitive radioactive peak in the data indicates that a membrane protein 
has been specifically labelled by the dipeptide derivative. However, label binding 
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Figure 5.2 
Representative result of photoaffinity labelling of BLMV at pH 5.5 with 
[4-azido-3,5) H-D-Phe]-L-Ala followed by SDS-PAGE. Labelling was performed 
within four different environments; unprotected (diamonds) and protected by 
D-Phe-L-Gln (squares), D-Phe and L-Gln (tdangles) or both peptide and amino acids 
(circles), all at 16.7 mM. The x-axis of gel slice number represents a decrease in 
molecular weight from left to right, down the rod gel, and the y-axis shows label 
incorporation by a membrane protein. A peak demonstrates that a protein has bound 
the radioactive label. The labelling ratio represents the proportion of radioactivity 
bound to an unprotected protein compared to protein protected by the dipeptide:- a 
large ratio indicates a higher degree of substrate-inhibitable label interaction. 
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Protein-bound % label Total label 0/0 
3H-dpm Bq bound bound inhibition 
Unprotected 9830 165.15 0.018 151 finoles 
D-Phe-L-Gln 1937 32.55 0.003 25 fmoles 83% 
D-Phe & L-Gln 7663 128.75 0.014 118 fmoles 22% 
D-Phe-L-Gln, 3371 56.63 0.006 50 finoles 67% 
D-Phe & L-Gln 
Table 5.1 
Incorporation of [4-azido-3 ,5}H-D-Phe]-L-Ala by the 112 kDa protein In 
unprotected and substrate-protected BLMV. The data shown corresponds to 
figure 5.2 and shows the amount of radioactivity bound to the protein (also 
expressed as a percentage of the total radioactivity added to the vesicles), in addition 
to the amount of label bound to the protein. The inhibition caused by preincubation 
with a substrate is expressed as a percentage. The mean initial amount of radioactive 
label added to the four vesicle suspensions was 56 x 106 dpm (940.8 kBq). 
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Figure 5.3 
Inhibition of [4-azido-3 ,5)H-D-Phe]-L-Ala binding to the 112 kDa protein as a 
result of preincubation with substrates (each at 16.7 mM). Unprotected labelling (in 
the absence of substrates) is taken to be 100% incorporation. The degree by which 
the substrates inhibit labelling indicates the preferred nature of substrate with which 
the membrane protein interacts. 
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ratios for each of the peaks in figure 5.1 were calculated (shown in the subsequent 
table) to determine which protein in the membrane demonstrated maximal 
substrate-inhibitable labelling. Pre-incubation with the dipeptide strongly inhibited 
label incorporation by the protein contained within slice number 12, but free amino 
acids had very little effect. The dipeptide inhibits 83% oflabel binding (table 5.1 and 
figure 5.3) whereas the amino acids provide very little protection (22%). 
Interestingly, pre-incubation with both the dipeptide and amino acids provides 
slightly less protection of labelling than the dipeptide alone (67%). Repetitive 
analysis over a series of identical experiments of the migration distance of the 
labelled protein, in comparison to standard molecular weight markers, by silver 
stained SDS-PAGE slab gels indicates it has a molecular weight of 112 ± 2 kDa 
(n = 30). A representat~ve example of this data analysis is shown in figure S.4. It 
should be noted that a single band is present in the peak sample, suggesting an 
individual protein species has been photo affinity labelled. 
The pattern of [4-azido-3,S}H-D-Phe]-L-Ala incorporation by the 
basolateral membrane is highly reproducible. The 112 kDa protein is dominantly and 
consistently labelled, plus it specifically interacts with peptides but not with free 
amino acids. As such, it is proposed as a candidate to be the basolateral peptide 
transporter in rat small intestine. 
5.5 Effect of medium osmolarity on label incorporation 
In addition to the specific labelling of the 112 kDa protein, there also 
appears to be a low level of radioactivity incorporated throughout the range of 
membrane proteins. In addition to the high extent of protection provided by the 
dipeptide on labelling of the 112 kDa protein, limited protection of this low level of 
labelling is not only provided by the dipeptide, but also by the free amino acids, 
although the reason for this is not clear. It was initially thought that the high 
concentrations of the substrates used might be the causing factor in inhibition of 
labelling. This theory was investigated by performing a series of experiments with 
the vesicles in different medium osmolarity, using mannitol at different 
concentrations in an unprotected vesicle suspension. The concentrations of mannitol 
reflected the high substrate concentrations used in the protection studies; 16.7 mM 
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kDa 
SDS-PAGE analysis of samples forming the radioactive peak (slices 11 & 12), plus 
surrounding gel slices, to determine the molecular weight of the labelled protein. The 
gel slices coincide with the unprotected BLMV separated by SDS-PAGE in rod gels 
shown in figure 5.2. Samples were electrophoresed on a 10% gel 
(70*80*0.75 mm) and the bands visualised by silver staining. Repeated analysis of the 
labelled protein with reference to known standards indicates an apparent molecular 
weight of 112 ± 2 kDa (n = 30). 
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The effect of osmolarity on photoaffinity labelling is demonstrated by preincubation 
of BLMV in mannitol, in equivalent concentrations to that of the substrates shown in 
figure 5.2. Vesicles were labelled in an unprotected environment (diamonds) and in 
the presence of 16.7 mM mannitol (squares) or 33.4 mM mannitol (triangles) before 
SDS-PAGE electrophoresis. The x-axis of gel slice number represents a decrease in 
molecular weight from left to right, down the rod gel, and the y-axis shows label 
incorporation by a membrane protein. A peak demonstrates that a protein has bound 
the radioactive label. 
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Protein-bound % label Total label % 
3H-dpm Bq bound bound inhibition 
Unprotected 12,859 216.03 0.021 176 fmoles 
16.7 mM 11,517 193.49 0.019 160 fmoles 9% 
mannitol 
33.4 mM 11,685 196.31 0.019 160 fmoles 9% 
mannitol 
Table 5.2 
Effect of medium osmolarity on incorporation of [4-azido-3,5)H-D-Phe]-L-Ala by 
the 112 kDa protein. The data shown corresponds to figure 5.4 and shows the 
amount of radioactivity bound to the protein (also expressed as a percentage of the 
total radioactivity added to the vesicles). The amount of label bound to the protein is 
taken across the peak (slices 14-16). The inhibition caused by preincubation with 
mannitol is expressed as a percentage. The mean initial amount of radioactive label 
added to the three vesicle suspensions was 60 x 106 dpm (1 MBq). 
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Figure 5.6 
Effect of medium osmolarity on inhibition of [4-azido-3,5}H-D-Phe]-L-Ala binding 
to the 112 kDa protein. Unprotected labelling is taken to be 100% incorporation. 
The degree by which the presence of mannitol inhibits labelling is negligible. 
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representing the dipeptide, and 33.4 mM representing the amino aicds. The results of 
this study are shown in figure 5.5. 
It is evident that incubation of the vesicles in high concentrations of 
mannitol did not affect labelling of the 112 kDa membrane protein; only 9% 
inhibition at the 112 kDa protein was observed (figure 5.6, table 5.2). In addition, 
there was no difference in radioactivity in the remainder of the proteins. 
Therefore, medium osmolarity does not affect label incorporation by the 
112 kDa protein, and so the inhibition of labelling by the dipeptide must be entirely 
due to a substrate-active site interaction. These data demonstrate that the 
abolishment of label incorporation by the 112 kDa protein, due to the presence of the 
dipeptide, is substrate-specific. 
5.6 Two-dimensional electrophoresis of the photoaffinity labelled 
basolateral membrane protein 
Two-dimensional electrophoresis (2-DE) is an extremely powerful 
technique for the isolation and purification of a single protein from a complex 
mixture. A single protein band in the silver-stained slab gel (figure 5.4) suggests that 
the radioactive peak sample contains a single protein species. However, it cannot be 
assumed that another protein of the same molecular weight isn't present, although not 
necessarily photoaffinity labelled. In order to achieve complete isolation of the 
protein of interest, an additional separation technique was employed, in conjunction 
with SDS-PAGE. Isoelectric focusing (IEF) resolves proteins based on their 
isoelec~c point (PI), i.e. the protein focuses at the pH, within a gradient in a gel, at 
which it has no net charge. This step was used, in conjunction with the initial 
SDS-PAGE separation, to specifically isolate the 112 kDa protein from other 
basolateral membrane proteins in rod gels. Collectively, the two distinct, but 
step-wise procedures, form a 2-DE gel. 
The first dimension in the 2-DE procedure was to identify and separate the 
radioactively labelled 112 kDa protein from other proteins by the principal method of 
SDS-PAGE, as before. However, a relatively large quantity of protein was required 
to take through each of the different steps of the 2-DE process, and so multiple 
(identical) vesicle suspensions were labelled simultaneously, either in an unprotected 
state or protected by D-Phe-L-Gln. The membranes were subjected to SDS-PAGE in 
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rod gels as before, and labelled proteins were detected by scintillation counting. The 
results from the series of identical unprotected labelling experiments are shown in 
figure 5.7 (data is not shown for the equivalent dipeptide-protected vesicles). 
The samples from the gel slices that contained the 112 kDa protein (from the 
unprotected and dipeptide-protected vesicles) were pooled individually and 
concentrated in preparation for the next stage. 
The second dimension in the 2-DE gel was IEF. The concentrated aliquots 
of the unprotected and dipeptide-protected labelled proteins were electrophoresed 
through an internal pH gradient of 4 to 7, in separate rod gels. A representative 
example of the results from this step is shown in figure 5.8. 
The unprotected radioactively labelled 112 kDa protein focuses at an 
isoelectric point of 6.5; a sharp definitive peak indicates excellent resolution within 
the pH gradient. There is another smaller peak, again at pH 6.5, which corresponds 
to the same 112 kDa protein, which was protected by the dipeptide during labelling. 
Pre-incubation with D-Phe-L-Gln appears to provide 41% protection oflabelling. 
Samples were taken from these two discrete peaks and subjected to 
SDS-PAGE in a 10% slab gel for molecular weight analysis. The silver stained gel is 
shown in figure 5.9. Protein bands at the correct molecular weight indicate that the 
112 kDa protein is present in both peaks. 
The two radioactive peak samples contain a single band, suggesting that an 
individual protein is present after the 2-DE separation. It is very unlikely that two or 
more proteins in a mixture would possess identical molecular weights and isoelectric 
points, and therefore it appears that the 112 kDa protein has been successfully 
isolated as an individual species. 
The two steps in the 2-DE procedure were also performed in reverse order, 
I.e. IEF prior to SDS-PAGE, using combined concentrated samples as before. 
Similar radioactive peaks at 112 kDa and pI 6.5 were obtained irrespective of the 
order of the dimensions of separation. 
Isoelectric focusing of [4-azido-3,5-3H-D-Phe]-L-Ala was also performed in 
order to eliminate the possibility of the free label forming the radioactive peak seen 
in the IEF stage of2-DE of the labelled protein, although any unbound/loosely bound 
label would have been washed from the sample during the labelling procedure, or 
eluted from the preliminary SDS-PAGE gels. The label focuses at a pI of 6.0 
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Figure 5.7 
SDS-PAGE of a number of identical photoaffinity labelled (unprotected) BLMV. 
The samples from the peak containing the 112 kDa protein were pooled and 
concentrated to 50 ~l in preparation for the next step in the 2-DE procedure within 
rod gels. 
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Unprotected D-Phe-L-Gln 
Isoelectric focusing (a) of the photo affinity labelled 112 kDa protein isolated from 
SDS-PAGE of unprotected BLMV (triangles) and from vesicles protected by 
16.7 mM D-Phe-L-Gln (squares). The x-axis depicts the gel slice number of the rod 
gels and the y-axis show label incorporation by a membrane protein and the pH 
gradient throughout the gels (also depicted by the smooth line)_ A peak represents 
label binding by a protein. Also shown is the extent of inhibition caused by 
pre-incubation with the dipeptide (b); unprotected labelling is taken to be 100%. 
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SDS-PAGE analysis of the samples forming the final radioactive peak following 
2-DE of the labelled 112 kDa protein in rod gels. Lane 1 is an aliquot of the 
concentrated protein isolated from the first dimension (SDS-PAGE) (see figure 5.7) 
which was then run in the second (lEF) dimension. Lanes 2-4 are samples forming 
the peaks obtained from the final IEF stage (see figure 5.8); lanes 2 and 3 are from the 
peak in the unprotected vesicles, and lane 4 is the peak sample from the vesicles 
protected by D-Phe-L-Gln. Samples were electrophoresed on a 10% gel 
(70*80*0.75 mm) and the bands visualised by silver staining. Repeated analysis of the 
labelled protein with reference to known standards indicates an apparent molecular 
weight of 112 ± 2 kDa (n = 30). 
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(figure 5.10), which is considerably different from the pI of the labelled protein. 
Therefore, the radioactive peak detected in the 2-DE separation of the membrane 
proteins is entirely due to the labelled 112 kDa protein. 
5.7 Identification of the candidate basolateral peptide 
transporter 
Once it had been determined that the 112 kDa protein could be individually 
isolated from the basolateral membrane, a sufficient quantity was obtained to begin 
principal analysis of its sequence, to be used for its identification using on-line 
databases. Although specific information about the protein had already been 
determined by previous methods, i.e. an approximate molecular weight and 
isoelectric point, these themselves are not very useful for identification purposes. In 
addition, although a pI of 6.5 was measured for the protein, the value is probably not 
absolutely accurate. The pI was measured with an electrode directly from a slice of 
gel containing a high concentration of urea (9 M), and urea, at this concentration, can 
interfere with accurate pH measurement. 
The most rapid and reliable way to obtain initial sequence information to 
use m database searches, which requires the minimum quantity of protein and 
extracts the maximum data possible, is to convert the protein into a peptide mixture 
for analysis. This was initially attempted on the protein sample isolated by the 2-DE 
method described in section 5.6, but the presence of contaminants interfered with 
subsequent analysis. Therefore, another technique of 2-DE was used, which utilised 
an immobilised pH gradient. This produces a single spot in a second dimension slab 
gel, containing a pure sample of protein. However, sequence analysis requires a 
substantial amount of protein, therefore 2-DE was performed using a combined and 
concentrated sample of relatively pure protein, rather than a crude BLMV sample, to 
ensure the protein was present in the necessary quantity. 
5.7.1 Isolation and purification of the 112 kDa protein from membrane 
vesicles 
The primary step towards sequence analysis was to isolate and purify a 
labelled sample of the 112 kDa protein, by simultaneous electrophoresis of a number 
of SDS-PAGE rod gels. Several unprotected photoaffinity-Iabelled BLMV samples 
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Figure 5.10 
Isoelectric focusing of the photoaffinity label ([4-azido-3,S}H-D-Phe]-L-Ala) in a 
rod gel. 1 III of label was electrophoresed through the gel; this is equivalent to 
2.2 x 106 dpm (37 kBq) of radioactivity. The x-axis depicts the gel slice number and 
the y-axis show radioactivity detected and the pH gradient throughout the gel (also 
depicted by the smooth line). The peak shows the exact pH in the gradient where the 
label foc~ses (PI 6.0). 
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were run simultaneously, as before (section 5.6), to obtain a concentrated protein 
sample. 
The final concentrated aliquot was analysed to determine the amount of 
protein contained. For this, a calibration curve (50-400 ng) was constructed within a 
10% SOS-PAGE slab gel using BSA as the standard, in conjunction with an aliquot 
(3 I.ll) of the final protein sample (figure 5.11a). The gel was electrophoresed and 
then silver stained. The relative density of the BSA protein bands to the 112 kDa 
protein band was used to calculate the amount present in that small aliquot 
(figure 5.11 b). This value was then extrapolated to the total volume of the protein 
sample. 
The silver stained BSA standard curve was linear in the protein range used 
(r2 = 0.998). The amount of protein estimated to be in a 3 J.lI aliquot of the 112 kDa 
sample was 205 ng. The total volume of the sample was approximately 120 J.lI, 
therefore the total amount of protein was 8.2 J.lg. This is equivalent to 
7.32 x 10-11 moles (73 pmoles) of protein. This concentration of protein was 
extracted from 20 initial rod gels, therefore the amount that was obtained from 
200 J.lg BLMV (starting material for one gel) was approx. 410 ng (3.65 pmoles) of 
112 kDa protein. This is equivalent to approx. 0.002% of the total amount of protein 
located in the basolateral membrane. It is clear that the 112 kDa protein is only a 
minor constituent of the total basolateral membrane proteins. As such, the highly 
consistent, and individual, labelling of this small quantity indicates that the 
interaction of the dipeptide label with the protein is extremely specific. 
5.7.2 2-DE of the 112 kDa protein using an immobilised pH gradient 
The concentrated, labelled 112 kOa protein sample was subjected to 2-0E in 
a non-linear pH gradient from 3 to 10 (a non-linear gradient means that the scale 
between approx. pH 4 to 8 is 'stretched', or more resolved, to allow better separation 
within this range). This non-linear gradient was used for a more accurate resolution 
surrounding the measured pI of the labelled protein. The second dimension involved 
a standard SDS-PAGE separation within a vertical slab gel, followed by staining with 
. 
Colloidal coomassie blue. The Colloidal stain was used in replacement of silver stain 
for two main reasons. Firstly, and most importantly, silver staining can interfere with 
sequence analysis and secondly, it is generally accepted that if the protein spot can be 
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The amount of 112 kDa protein in the final concentrated sample was calculated using 
a calibration curve ofBSA in a silver stained SDS slab gel (a). The relative intensity 
of the BSA bands (b) was used to estimate the amount of 112 kDa protein in the gel 
by measuring the integrated density value (lDV) using a spot densitometry program in 
a gel documentation system (AlphaEase™ version 3.3). The standard curve ofBSA is 
shown by the continuous line and the dashed line shows the trendline of the curve. 
The IDV of the 112 kDa protein aliquot (3 Ill), and therefore the amount present in 
the gel, is indicated by the arrow. 
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visualised with the Colloidal stain, it is present in a sufficient quantity for mass 
spectrometric sequence analysis to be performed. 
The stained 2.:.DE gel is shown in figure 5.12. It is apparent that a minor 
spot at 112 kDa molecular weight (PI approx. 6.5) can be seen, in addition to two 
very dense spots at a molecular weight of 40 kDa (spots A & B), with very few other 
spots present in the gel. A second 2-DE gel was run simultaneously; the spots in this 
gel were excised, crushed and subjected to scintillation counting to determine which 
contained the radioactive protein. However, negligible radioactivity (no higher than 
background levels) was found in all of the spots (data not shown). 
Due to the procedures used to isolate the labelled 112 kDa protein, it is 
thought that the two predominant 40 kDa protein spots must be components· of the 
original 112 kDa protein, despite the fact that the radioactive label cannot be detected 
in any of the spots. This assumption is based upon their relative density within the 
gel, with respect to other (minor) spots present, in conjunction with their apparent 
molecular weight, i.e. both spots are approximately half of the initial 112 kDa and as 
such, are speculated to be components. Thus, mass spectrometric sequence analysis 
was initially performed on the protein in these two spots. 
In addition, as a protective measure, a protease-inhibitor cocktail was 
included in the solutions throughout the subsequent isolation procedures and during 
2-DE of the resultant sample (performed by Mrs. Julie Affleck). As predicted the 
two spots could not be detected in the final 2-D gel (figure 5.13), and the 112 kDa 
protein predominated. 
However, radioactivity in the 112 kDa spot remained undetectable. The 
next approach was to utilise a different staining technique to avoid the fixing step 
that was required for the Colloidal blue stain, which was thought to prevent elution 
of the protein from the gel prior to scintillation counting. A negative stain (zinc) was 
performed, but again radioactivity could not be detected, possibly due to quenching 
by the stain. A final approach to demonstrate that the protein isolated was the intial 
protein that was specifically labelled from vesicles, was to perform IEF on the IPG 
strip, section the strip and subject the slices to scintillation counting. A peak of 
radioactivity was detected at the precise point in the IPG strip that corresponded to 
the pI at which the 112 kDa protein focused following the second dimension (data 
not shown). 
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Figure 5.12 
~112kDa 
AB 
Two-dimensional electrophoresis of a concentrated sample of 112 kDa protein from 
the basolateral membrane. First dimension (x-axis); IEF in an irnrnobilised dry strip 
(IPG, Pharmacia) pH 3-10, non-linear (range from pH 4-8 shown), second dimension 
(y-axis); 12% SDS-PAGE gel, stained with Colloidal Coomassie blue (Sigma). A 
spot at 112 kDa cannot be detected, but the two 40 kDa spots (A & B) are thought to 
be proteolytic breakdown products originating from the 112 kDa protein. 
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Figure 5.13 
Two-dimensional electrophoresis of a concentrated sample of the photo affinity 
labelled protein isolated from the basolateral membrane; a protease-inhibitor cocktail 
was present throughout the isolation and electrophoresis stages to prevent proteolytic 
breakdown. In reference to figure 5.12, the two proteolytic products (spots A & B at 
40 kDa) are not apparent, whilst the major spot at 112 kDa is preserved intact. For 
details of2-DE see figure 5.12. 
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Sequence analysis of the labelled protein could now be performed on a 
protein at the correct molecular weight. 
5.8 Mass spectrometric sequence analysis 
As mentioned in section 5.7, the most efficient method of obtaining initial 
sequence information of a protein is to digest it with trypsin to produce a series of 
peptide fragments. Trypsin cleaves the polypeptide backbone of proteins at the 
carboxylic side of lysine and arginine residues. The masses of the resulting peptides 
depend entirely on the primary amino acid sequence and therefore, are diagnostic of a 
given protein, and as such are designated a 'peptide fingerprint'. 
The two 40 kDa protein spots (A & B) were digested as described in section 
2.6 and the final samples desalted and concentrated using the ZipTip procedure 
(section 2.7.2), prior to analysis by MALDI-TOF and Q-TOF mass spectrometry. 
5.8.1 MALDI-TOF MS analysis 
The peptide mixtures were analysed on a MALDI-TOF mass spectrometer 
(PE Biosystems Voyager DE-STR) located at Central Science Laboratory, Sand 
Hutton, York, with the invaluable help and tuition from Dr. David Ashford (Biology 
department, University of York). 
The peptide mixture was analysed in reflector mode usmg delayed 
extraction, which together provided a greater resolution and, therefore, higher degree 
of accuracy in the data; usually better than ± 0.5 Da in the mass range studied. The 
excellent resolution of the data allows the detection of the isotopic peaks of the 
peptides rather than an average mass, i.e. the l3C content of the peptide can be 
observed. An example of an isotopic peak pattern from one of the peptide fragments 
(2066.28 Da in spot A) is shown in figure 5.14. A close examination of the 
individual peptide peaks provides confidence that the component isotopic peaks are 
well resolved, the monoisotopic peak is correctly defined and the data is therefore 
accurate. Use of the monoisotopic peak masses in database searches is considerably 
more reliable than using the average masses of the peptides. 
The main spectrum resulting from MALDI-TOF analysis of spot A is shown 
in figure 5.15, and the spectrum for spot B in figure 5.16, although additional spectra 
were also obtained (data not shown). Analyses of different dilutions were performed 
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Chapter 5 Identification ora candidate basolateral peptide transporter 
to maximise detection of all peptide fragments present in the samples. Only the most 
intense peptide peaks are labelled on the spectra due to spatial limitations, i.e. a close 
association of adjacent peaks, but a summary of all the peptide masses generated 
from digestion of spots A and B are shown in table 5.3. A total of 83 peptides were 
detected in spot A, and 53 peptides in spot B. Interestingly, 24 of the peptides had 
identical masses in both spots. In addition to these matches, another 5 peptides were 
very similar, i.e. ± 1 Da, between the two spots. This difference could have been due 
to a misalignment and/or labelling of the monoisotopic peak of the peptides, which 
would cause the discrepancy of a difference of 1 Da in the mass values. As such, it is 
highly probable that these 5 peptides of the two spots are also equivalent. Therefore, 
between 29 and 35% of spot A matched spot B, and 45-55% of spot B corresponded 
to spot A. 
5.8.2 Database searches with the peptide fingerprint 
The monoisotopic masses of the peptide fragments were used to search 
databases such as SwissProt, GenPept, Owl and NeBlnr. This was performed using 
a range ofbioinformatics search tools, for example, PeptIdent, ProFound, MS-Fit and 
Mascot (see Appendix II for details). I performed four distinct searches within each 
of the on-line tools, using a different group of the peptide masses in each. The first 
search was performed solely using peptides generated from spot A, the second using 
peptides solely from spot B, then third using the 29 peptides common to both spot A 
and spot B, and, finally, using all peptide masses from both spots (a total of 
136 peptides). The searches were initially performed by specifying the approximate 
molecular weight of the protein and the isoelectric point, although large variances 
were used to allow for potential inaccuracies due to measurement from gels, and this 
was then progressed to leaving these parameters unspecified in order to search all 
possibilities. 
Prior to analysis of the basolateral protein and subsequent database searches, 
the same procedure was performed on a known protein to determine the reliability 
and precision of the combined techniques in its identification; the protein used was 
BSA. The monoisotopic peptide masses generated from an in-gel digest of BSA 
(data not shown) were used in searches to define the optimum parameters required to 
obtain an accurate positive match, which could then be extrapolated to searches for 
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Peptides found in Peptides found in Peptides found in 
spots A & B sj!otA S]!otB 
832.4 908.4851 2706.584 834.5177 
842.6 922.5296 2721.606 844.6521 
1020.7 924.4205 2777.684 855.3453 
1058.7 949.5595 2791.004 870.3359 
1201.8 970.4833 2826.665 876.4318 
1325.8 1003.535 3334.151 892.414 
1358.8 1008.403 3340.328 992.82 
1776.1 1011.627 3352.034 1427.941 
1975.3 1046.702 3364.307 1624.156 
1994.3 1062.865 3541.405 1717.921 
2066.3 1091.483 3555.375 1732.056 
2211.4 1093.502 3622.213 1752.245 
2239.5 1261.54 3797.279 1784.338 
2241.5 1359.69 3809.218 1824.251 
2298.5 1390.883 3811.422 1830.806 
2664.7 1565.118 3813.444 2068.651 
2792.5 1644.933 3887.454 2225.532 
2807.7 1995.339 3892.575 2230.591 
2824.7 2023.276 3895.775 2242.461 
2836.7 2071.312 3912.823 2285.442 
2922.8 2094.357 3928.884 2300.589 
3333.1 2203.413 3947.711 2319.53 
3339.3 2214.471 3955.775 2790.709 
3350.2 2214.471 3959.746 2793.022 
2226.428 3962.136 2808.068 
2231.618 3979.499 2914.97 
2233.573 3999.232 2925.857 
2241.515 5561.339 3097.109 
2409.443 5562.716 3810.479 
2565.624 
Table 5.3 
Monoisotopic masses of peptide fragments (in Da) of the protein contained within 
spots A & B (see figure 5.12), generated by in-gel tryptic digestion, followed by 
MALDI-TOF MS analysis in reflector mode. The first column shows the peptides 
common to both spots, and the bold type depicts additional closely matching peptides 
between spots A & B (± 1 Da). 
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the unknown basolateral membrane protein. From the 32 peptide masses detected by 
MALDI-TOF, approx. 50% of these were positively matched to BSA in the 
databases. In addition, although some peptides corresponded to other (unrelated) 
proteins, these matched with a considerably lower probability, typically less than half 
of that specified for BSA. The two main parameters which can be changed to alter 
the precision of the search are: (1) the number of missed cleavages, and (2) the mass 
tolerance level. Increasing either of these parameters resulted in a greater degree of 
error and increased the probability of matching false positives. By utilising BSA as a 
standard protein it was found that the values which resulted in the predominant 
identification of BSA, with the lowest matches to other proteins, was to use one 
missed cleavage and a mass tolerance of ± 0.5 Da. 
Initially these values were specified in searches for spots A & B and this did 
not achieve a positive match to any rat protein. The parameters of all searches were 
then widened to a considerable extent, but, again, no proteins from rat tissue were 
positively identified. In progression, the animal species searched was also expanded 
to include all taxa, in an attempt to identify potential homologues, but again no 
probable matches were obtained. 
A small number of the peptide fragments matched to various proteins in the 
databases, which is approximately 12-24% of the total number of peptides, 
depending on the degree of accuracy in the search. However, no individual protein 
showed a substantial probability for positively matching, or a probability that 
exceeded the rest (as was found with BSA). In addition, the proteins identified from 
the database were mostly from a tissue distinct to the small intestine. As such, I 
could not identify the protein from the database searches using the peptide fingerprint 
data, even incorporating the widest possible search parameters. 
5.8.3 Elimination of pep tides generated by autolysis of trypsin 
The commercially available trypsin (Promega) used for the digests had been 
modified to prevent autolysis (section 2.7), therefore, no trypsin peptides should have 
been generated during the in-gel digestion procedure. In addition, the database 
searches did not match porcine trypsin to the peptide fingerprint. However, to ensure 
that no tryptic peptides were associated with the real peptides, I performed a 
theoretical digest of porcine trypsin using the MS-Digest program (Appendix II). 
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This bioinformatics tool can perform a digest of any known protein sequence 
contained within the databases by analysing the primary sequence, identifying 
potential cleavage sites for trypsin and generating theoretical peptides of a defined 
mass. The user can specify the number of missed cleavages permitted during the 
digestion; I performed the digest with 0, 1 and 2 missed cleavages, to cover the entire 
spectrum. Potential modifications to amino acid residues under the preparative 
conditions employed, for example, oxidation of methionine or reduction of cysteine 
during gel electrophoresis, was also specified. 
However, only two trypsin peaks corresponded to the actual peptides; these 
peptides were common to both spots. Therefore, 'false' peptides originating from 
trypsin would not interfere with the searches, to any appreciable extent, in preventing 
a positive match to be found to spot A or B, if present in the database. 
5.8.4 Is the photoaffinity labelled 112 kDa protein PepTl? 
The peptide fingerprint profiling did not identify PepTI as a match for the 
protein from either of the spots, or a combination of both. Despite this, I performed a 
theoretical digest of rat PepTI using the MS-Digest program and compared the 
generated peptides with those of spots A and B. 
A comparison of the two fingerprints revealed that only five fragments 
matched, i.e. only 4% of the peptides from spots A and B corresponded to PepTI 
(figure 5.17). The molecular mass of the peptides and their membrane location 
within the rat PepTI sequence are shown in table 5.4. 
5.8.5 Q-TOF MS analysis 
The peptide fingerprint data from spots A and B did not correspond to any 
other protein contained within the databases. The next step was to obtain additional 
information about the protein's sequence. In particular, a partial amino acid 
sequence of one of the peptide fragments is very useful, and can be used solely to 
unequivocally identify the parent protein from databases, or in conjunction with the 
peptide fingerprint to provide confidence to potential matches. 
Q-TOF MS analysis was kindly performed by Dr. Alison Ashcroft at the 
Department of Biochemistry, University of Leeds. However, due to a lower tolerance 
of the Q-TOF for contaminants, in comparison to the MALDI-TOF, we were only 
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1 MGMS~SBGCF GYPLSIFFIV VNEFCEBFSY YGMRALLVLY F~NFLGWDDD 50 
51 LSTAIYHTFV ALCYLTPILG ALIADSWLG~ F~TIVSLSIV YTIGQAVISV 100 
101 SSINDLTDHD HDGSPNNLPL HVALSMIGLA LIALGTGGIK PCVSAFGGDQ 150 
151 FEEGQEKQRN ~FFSIFYLAI NAGSLLSTII TPIL~VQQCG IHSQQACYPL 200 
201 AFGVPAALMA VALIVFVLGS GMY.KIS;FQPQG NIMGKVA~CI ~FAI~N~F~H 250 
251 BS!£AFPKRNH WLDWA~E~YD E~LISQI~IM TKVMFLYIPL PMFWALFDQQ 300 
301 GS~WTLQATT MTG~IGTIEI QPDQMQTVNA ILIVIMVPIV DAVVYPLIAK 350 
351 CGFNFTSLKK MTVGMFLASM AFVVAAIVQV EIDKTLPVFP SGNQVQIl$,VL 400 
401 NIGNNDMAVY FPG~NVTVAQ MSQTDTFMTF DVDQLTSINV SSPGSPGVTT 450 
451 VAHEFEPGH~ HTLLVWGPNL Y~VV~DGLNQ KPE~GENGI~ FVSTLNEMIT 500 
501 ItMSG~VYEN VTSHSASNYQ FFPSGQ~DYT INTTEIAPNC SSDFKSSNLD 550 
551 FGSAYTYVI~ S~SDGCLEV ~EFEDIPPNT VNMALQIPQY FLLTCGEVVF 600 
601 SVTGLEFSYS QAPSNM~SVL QAGWLLTVAI GNIIVLIVAE AGHFD~QWAE 650 
651 YVLFASLLLV VCIIFAlMA~ FYTYINPAEI EAQFDEDEKK l$,GVG~ENPYS 700 
701 SLEPVSQTN~ 
Figure 5.17 
Primary amino acid sequence of rat PepTI (SwissProt accession number P51574). 
Potential cleavage sites for trypsin, i.e. at the carboxylic sides of lysine and arginine 
residues (except ifadjacent to a proline), are underlined. The five sequence fragments 
which match the masses of peptides from spots A and B (figure 5.12) are shown in 
red type; bold type indicates an overlap between two adjacent peptide fragments. 
(Original in colour). 
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Mass Amino acid Membrane Matching Number of missed 
(Da) location location spot cleavages 
970.5587 250-257 Loop; TM 6& 7 A 2 
992.4723 563-571 Loop; TM 9 & 10 B 0 
1830.9345 491-506 Loop; TM 9 & 10 B 2 
2793.2943 503-527 Loop; TM 9 & 10 B 1 
3809.8898 283-314 TM 7 to loop A&B 2 
Table 5.4 
Peptide masses generated from an in silico digestion of rat PepTl, using the 
MS-Digest program, which correspond to peptides produced from in gel tryptic 
digestion of spots A & B, thought to be components of the candidate basolateral 
peptide transporter. Only one matching peptide is produced from zero missed 
cleavages, the majority result from 2 missed cleavages; the probability of the peptides 
being exact matches is reduced with an increasing number of missed cleavages. 
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able to gain sequence information from spot A. The TOF spectrum produced from 
analysis of spot A, performed initially to detect the peptide fragments, is shown in 
figure 5.18. The peptide fragments are identified from the spectrum as 
multiply-charged peaks, in particular one doubly-charged fragment of spot A had a 
mass of 876.44 Da (a total mass of 1750.9 Da); this· was used for partial sequence 
analysis. 
In order to reveal a section of its sequence, the peptide had to be fragmented; 
this was achieved by collision with argon (an inert gas). Fragmentation can cause 
cleavage at any of the bonds within the peptide structure but, under conventional 
conditions, is predominantly restricted to the backbone of the peptide; y- and b-ions 
are the most predominant products of this fragmentation (figure 5.19). The spectrum 
produced from fragmentation of the doubly-charged 876.44 Da peptide is shown in 
figure 5.20. The fragmentation spectrum is difficult to interpret completely, but the 
upper rnIz region displays a simple fragmentation pattern which is typical of 
doubly-charged tryptic peptides (Shevchenko et a1., 1996b). The partial amino acid 
sequence, using the y-series ions, is read in a reverse direction from the spectrum, 
which corresponds to the direction from the amino to carboxyl ends of the peptide 
(see figure 5.19 & 5.20). Amino acid residues are easily assigned based on the mass 
difference between adjacent peaks (Appendix TIl). A partial sequence of 9 amino 
acids was obtained using the stretch of sequence ions; six of the residues are definite 
and the remaining three are thought to be highly probable (> 99% certain) (shown in 
brackets): 
NH2- / -Thr-Ser-Asn-Phe-Val-Thr-(Ala-Thr-Ser)- / -COOH 
A peptide sequence tag consists of this amino acid sequence combined with 
the distance, in mass units, to the N and C termini of the peptide. Full details of the 
sequence tag are shown in table 5.5. The sequence tag was used to search databases 
in an attempt to identify the protein contained within spot A on the 2-DE gel. The 
searches were performed with either the six definite residues, or using the complete 
nine residue sequence, on tools such as TagIdent, ProteinInfo, Peptide Search, 
MOWSE and Mascot (Appendix TI); both full length sequence databases and 
expressed-sequence tag (EST) databases were searched. A number of potential 
matches for the sequence was identified with the 9 amino acid residues (see 
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C1 C2 
hl h2 
al a2 
H H R2 0 H H R4 
I I I II I I I 
NH-C C N C-C-N-C C N C-COOH 2 II I I II I I I 
R1 0 H H R3 0 H 
Z2 Zl 
Y2 Y1 
X2 Xl 
Figure 5.19 
Potential bond cleavages within the peptide structure are indicated in red type. Q-TOF 
fragmentation of the peptide leads to the formation of distinct ion series; if the charge 
is retained on the N-terminus, the ions formed are of type an, bn and cn, whereas if the 
charge is retained on the C-terminus, the Xn, Yn and Zn ions are formed. Ions of the 
same type, and incremented n, differ by the mass of an amino acid residue, minus H20, 
(the 'residue mass') at that point in the sequence. A consecutive ion series is used to 
define amino acid sequence of a peptide. 
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Fragment ion mass Mass difference between Corresponding amino 
(Da) adjacent ions (Da) acid residue 
yl 588.36 87.05 Ser (S) 
y2 675.41 101.03 Thr (T) 
y3 776.44 71.04 Ala (A) 
y4 847.48 101.04 Thr (T) 
y5 948.52 99.07 Val (V) 
y6 1047.59 147.07 Phe (F) 
y7 1194.66 114.12 Asn (N) 
y8 1308.78 86.96 Ser (S) 
y9 1395.74 100.99 Thr (T) 
ylO 1496.73 
Table 5.5 
Peptide ion fragmentation data from Q-TOF analysis of the doubly-charged 
876.47 Da peptide from spot A. The series of ions corresponds to the designated 
y-ions in the mass spectrum (figure 5.19). Fragmentation of the peptide is shown by 
a change in mass; the mass difference of adjacent ions represents an individual amino 
acid residue in the sequence. The sequence is read from the data from high to low 
mass, i.e. y 10 to Y 1, which correlates with a direction from the amino to carboxyl 
terminus. Thus the sequence tag of the peptide (1750.9 Da) is as follows; 
(1496.73) TSNFVTATS (588.36) 
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table 5.6). However, these were disregarded because it was highly unlikely that these 
were the labelled 112 kDa protein because the peptide fingerprint did not match the 
proteins in the databases, in addition, the complete (9 amino acid) sequence was not 
found. 
Overall, the protein in spots A and B could not be identified by either 
MALDI-TOF or Q-TOF analysis alone, combined with database searches, or a 
combination of both mass spectrometric analysis methods. If the basolateral 
membrane protein was contained within the databases, a positive match would have 
been found using the data presented here. 
5.9 Discussion 
5.9.1 Photoaffinity labelling of BLMV to identify the peptide 
transporter 
The pattern of labelling in BLMV is highly reproducible. A single protein 
of 112 kDa molecular weight is consistently, and predominantly, labelled with 
[4-azido-3,5)H-D-Phe]-L-Ala under the conditions employed; indicated by the 
magnitude of the radioactivepeak and the peptide-protection ratio. Due to the 
evidence that label incorporation is completely abolished by the presence of a 
dipeptide, whereas amino acids have very little effect, this extremely specific 
substrate-protection implies that it is a dipeptide binding protein that does not interact 
with free amino acids. 
The consistency of label incorporation by unprotected basolateral membrane 
proteins is demonstrated by the data in figure 5.7, where the 112 kDa protein is 
predominantly labelled in all samples. A minor peak of radioactivity can also be 
detected at the very end of the rod gel. This minor peak is always present, 
irrespective of the duration of electrophoresis, therefore it doesn't correspond to any 
particular molecular weight of protein. As such, the radioactivity is probably not due 
to a labelled protein but to unbound/loosely bound label adhering to the sides of the 
glass tube during elution from the bottom of the gel. 
The pattern of label incorporation by the basolateral membrane is distinct to 
that observed with the brush-border membrane (see chapter 4). This corroborates the 
enzyme assay data in that the two vesicle preparations are extremely pure with 
negligible cross-contamination. 
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Protein Sequence 0/0 identity 
(organism) 
Cell wall protein XSNFVNATS 87% 
(A. thaliana) 
Hypothetical protein TATFVTATX 75% 
(H pylori) 
GAP-like protein XSNSVTATS 87% 
(H sapiens) 
Bap gene product XSSFVTASS 75% 
(D. melanogaster) 
CG5891 gene product TSNSVSATS 77% 
(D. melanogaster) 
Breast cancer susceptibility protein TNSFVTAAS 66% 
(R. norvegicus) 
KIAA0495 protein TSKFVSATX 75% 
(H sapiens) 
Lectin TSTLVTATS 77% 
(R. pseudoacacia) 
Spike protein XSNFVTXTS 87% 
(murine hepatitis virus) 
Table 5.6 
Example of results obtained from database searches (using the BLAST program) with 
the nine amino acid sequence tag generated from Q-TOF fragmentation of a tryptic 
peptide from the 112 kDa basolateral membrane protein (refer to table 5.5). 
Matching residues in the partial sequence are represented in bold type. However, 
although proteins were matched from the sequence tag alone, these were disregarded 
as a result of peptide fingerprint mismatches. As such, the above proteins are not a 
positive match for the 112 kDa protein, when taking all sequence data into account. 
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It is apparent that label binding to proteins in both membranes is very low, 
suggesting a highly specific interaction. However, a slightly higher label 
incorporation is seen with the 112 kDa basolateral membrane protein compared to 
BBM proteins (0.018% v. 0.003%). This difference of label interaction between the 
two predominantly labelled proteins in the BLM and BBM could be due to the label 
being a more efficient substrate for the basolateral protein, as indicated by the 
vascular perfusion experiments (section 3.7.2). However, a relatively higher 
proportion of the protein in the membrane, compared to PepTI in the brush-border, 
may also be a factor. The exact proportion of the peptide transporters in their 
respective membranes, relative to the total protein content, is not known, however, 
this potential difference must be acknowledged. However, because interaction with 
the label by the proteins is extremely specific, and the extent of labelling is very low, 
the difference between the two is probably not significant. 
Another distinction between labelling of the basolateral membrane 
compared to the brush-border membrane is that D-Phe-L-Gln provides a higher 
degree of protection to the 112 kDa protein in comparison to all of the proteins 
labelled in BBMV. This is most likely due to the relatively different affinities and/or 
transport capacities of the two peptide transporters (Saito et al., 1993; Matsumoto et 
at., 1994; Terada et al., 1999). The basolateral transporter has been shown to have a 
lower capacity for transport than PepTI and therefore the presence of the dipeptide in 
the suspension, prior to the label, may incur preferential binding. The high 
concentration of D-Phe-L-Gln would saturate the system and prevent the label (at a 
considerably lower concentration; 4.2 ~M) from interacting with the active site. The 
higher capacity ofPepTI for transport may mean that both the dipeptide and the label 
can bind to a limited extent simultaneously. The lower level of transport inhibition at 
the apical membrane by the label in the perfusion experiments (section 3.7.2) 
corroborates this theory. 
Whereas there are a great number of peptide hydro lases located in the apical 
membrane, none are found in the basolateral membrane. As such, the preferentially 
labelled 112 kDa protein is definitely not a peptidase. 
The highly specific blocking of labelling by the dipeptide is not due to the 
high concentrations of substrate employed in this procedure. Examinations into the 
effect of medium osmolarity on label incorporation demonstrated that inhibition was 
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entirely due to the structure of the dipeptide substrate, not its presence in such high 
concentrations. 
Collectively, the results from labelling experiments, with reference to the 
corresponding perfusion data, indicates that the 112 kDa protein is a potential 
candidate to be the, as yet unidentified, basolateral peptide transporter in rat small 
intestine. 
5.9.2 Isolation of the candidate peptide transporter by 2-DE in rod gels 
It appears that a single labelled protein could be isolated from the basolateral 
membrane simply by SDS-PAGE separation, but it is probable that more than one 
protein in the basolateral membrane at that molecular weight exists. So, an 
additional protein separation technique was performed to ensure individual isolation 
of the 112 kDa protein. Isoelectric focusing separates proteins based on a 
characteristic which is distinct from their molecular weight. Proteins were 
electrophoresed through an internal pH gradient, formed by carrier ampholytes within 
a rod gel, to resolve solely on the basis of their isoelectric point, i.e. the pH at which 
their net charge is zero. The resolving power of IEF in the rod gels is such that the 
difference in pH that can be routinely measured between two adjacent slices (of 
2 mm) is as accurate as 0.05 of a pH unit. 
A step-wise combination of SDS-PAGE and IEF in rod gels demonstrated 
that only one protein is labelled by [4-azido-3,5)H-D-Phe]-L-Ala in the basolateral 
membrane. This labelled protein focused at an isoelectric point of 6.5 and analysis of 
the final peak samples following the 2-DE separation shows a single band at 112 kDa 
molecular weight. This implies that an individual protein has been successfully 
labelled and isolated by a combination of a photoaffinity labelling technique and 
2-DE. 
There is a discrepancy in the amount of labelled protein loaded onto the IEF 
gels, and the amount that is present in the radioactive peak following resolution. On 
average, the 112 kDa protein detected following SDS-PAGE, covalently binds 
approx. 7800 dpm (131 Bq) of radioactivity (see figure 5.7). A pooled concentrate of 
eight of these labelled protein samples, subjected to IEF, is therefore approx. 
63,000 dpm (1.06 kBq) of radioactivity. However, the peak of radioactivity observed 
following the second dimension in unprotected vesicles was only 20,000 dpm 
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(336 Bq), i.e. only 32% of the radioactivity loaded onto the IEF gel was detected 
following electrophoresis. This loss of labelled 112 kDa protein is potentially due to 
three factors. Firstly, during the sample concentration step, after SDS-PAGE, a 
certain amount of protein is lost; this has been discovered by routine analysis to be as 
high as 50% (data not shown), probably due to adsorption of the protein to the 
concentrator membrane. Secondly, not all of the protein applied to the surface 
actually enters the IEF gel, due to the sample overlay procedure employed. Finally, it 
is possible that not all of the protein in the peak would have been extracted from the 
gel slice. A combination of all three can be used to explain this substantial loss of 
protein throughout the procedure. Celis & Bravo (1984) have reported a comparable 
level of protein loss during a 2-DE procedure, incorporating capillary IEF. It was 
stated that, during each of the different steps of a 2-DE procedure, a certain amount 
of the initial protein would be lost. After completion of these 2-DE gel studies, 
approx. 50% of the initial protein applied to the gel could not be recovered. The 
higher extent of protein loss observed during the 2-DE separation in rod gels 
presented here can be attributed to the additional steps of protein extraction and 
concentration prior to the second dimension. 
5.9.3 Preparation of the candidate basolateral peptide transporter for 
sequence analysis 
Although the 2-DE in rod gels provided crucial infonnation about the 
photo affinity labelled BLM protein, the techniques did not result in isolation of the 
protein in a suitable fonn to pennit further analysis. Thus, other methods of 
preparation were used to achieve isolation of the protein in the fonn required, i.e. 
2-DE to obtain a single spot on a slab gel. However, sequence analysis needed a 
substantial amount of protein, and so a concentration step- preceded 2-D 
electrophoresis. 
The 112 kDa protein was isolated from the basolateral membrane using the 
SDS-PAGE rod gel procedure and the amount of protein in the final concentrated 
sample was calculated using a BSA calibration curve in a slab gel. The slab gel was 
silver stained using the Bio-Rad method; a procedure based on a photographic 
chemical process, first introduced by Merril et al. (1981). 
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Silver staining was used throughout the photoaffinity labelling and gel 
electrophoresis studies primarily due to its enhanced sensitivity over many other 
stains, e.g. Coomassie brilliant blue R-250. This increased sensitivity has many 
advantages for its use in the isolation and purification of the 112 kDa protein. 
Firstly, protein loss was kept to an absolute minimum; less of the sample is required 
for its detection. Secondly, the dilute samples resulting from the protein extraction 
procedure could be analysed efficiently. And lastly, the purity of the final 
concentrated protein sample could be visually assessed. The use of silver staining in 
the BSA calibration gel also has the benefit of linearity between the density of the 
stain and amount of protein, although care has to be taken because as the density of 
the protein bands reach saturation, the stain becomes non-linear. However, 
saturation wasn't reached in the BSA calibration curve in figure 5.11; this curve was 
linear throughout the range of BSA used, demonstrated by the correlation factor 
(r2 = 0.998). Despite this, the relationship between the density of the stain and the 
concentration of the protein is characteristic for each protein, therefore BSA would 
probably not stain in the same manner as the 112 kDa protein. BSA is widely used as 
a standard, and studies that have investigated the relationship between staining of 
different proteins have shown that BSA has an intermediate density curve, i.e. the 
density does not increase too fast or too slow with concentration (Celis & Bravo, 
1984). In addition, BSA was relatively inexpensive for the quantities required and 
readily available in the laboratory. It was therefore used as a calculated estimate of 
the approximate amount of protein in the pure sample. Determination of the exact 
amount of 112 kDa protein in the sample wasn't crucial, as this step was performed 
solely to determine whether there was enough of the protein present in the sample to 
continue with further analysis. 
In order to obtain a single spot, consisting solely of the photoaffinity 
labelled 112 kDa basolateral membrane protein necessary to perform initial sequence 
analysis, a concentrated sample (obtained from SDS-PAGE in rod gels) was 
subjected to 2-DE using an immobilised pH gradient. The gradient (pH 3 to 10), cast 
on an 18 cm dry strip, allows excellent resolution to be achieved. A single spot, 
which contains the protein of interest, can be visualised by simple staining. 
However, the pattern of protein spots in the initial slab gel following 2-DE 
was not as anticipated. As opposed to the expected single spot at approx. 112 kDa 
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(pI 6.S), two very abundant spots at approx. 40 kOa were also detected. In spite of 
this, as anticipated, very few other spots were detected in the gel, and those that were 
present were significantly less dense in comparison to the two 40 kDa spots. The 
lack of additional spots is due to the protein isolation/concentration procedure; a 
relatively pure sample of the 112 kDa protein was obtained for 2-0 electrophoresis 
by combining samples from SOS-PAGE, at a specific molecular weight, therefore 
eliminating the majority of contaminating proteins from the basolateral membrane. 
Visualisation of the two dominant 40 kDa spots in the gel, and the presence 
of a minor spot at 112 kDa, led to the belief that they may be components of the 
original protein generated by cleavage. However, neither the two dominant 40 kDa 
spots, nor the remaining minor spots, were found to be radioactive. A lack of 
radioactivity in both spots suggested that [4-azido-3,S)H-0-Phe]-L-Ala has become 
completely detached from the protein. 
It was not entirely clear why the 112 kDa protein should be cleaved and the 
photoaffinity label lost during the 2-DE procedure using the immobilised gradient, 
whereas the radioactively labelled protein could still be found at 112 kDa following 
2-DE in rod gels. The conditions and solutions used for both protocols are very 
similar, i.e. the same reducing power was used, which might have affected bonding 
between distinct polypeptides. However, this is very unlikely because if the protein 
were composed of two separate domains it would have been apparent due to the 
reduCing conditions of SOS-PAGE. The only major distinction between the two 
different 2-DE procedures is a factor of time. Prior to 2-DE on the immobilised 
gradient, a period for re-swelling of the dehydrated gel is required; this is performed 
at 20°C for 22 h. This gel rehydration step is then followed by the isoelectric 
focusing step, which requires a minimum of 24-36 h for completion, also performed 
at 20°C. In contrast, although the IEF step in the 2-DE in rod gels is also performed 
at room temperature, the focusing time is just 8.S h. During both procedures, at this 
ambient temperature, breakdown of the protein structure can occur. The prolonged 
period (7-fold longer) for the immobilised strip rehydration and focusing, allows a 
greater degree of proteolysis to occur; this is thought to be the predominant reason 
behind the detection of the two 40 kDa proteins, and loss of the original 112 kDa 
protein. It also probably caused the loss of radioactivity, due to cleavage of the 
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portion of protein binding the label and subsequent elution from the bottom of the 
SDS-PAGE gel. 
Despite the proteolytic breakdown of the labelled 112 kDa protein, work on 
the candidate basolateral peptide transporter was progressed. Due to their 
predominance in the gel, it is assumed that these two 40 kDa polypeptides were 
constituents of the 112 kDa protein, and so analysis continued with these two spots. 
Subsequent to this work, additional 112 kDa protein was isolated by Mrs. 
Julie Affleck. As a precautionary measure, a protease-inhibitor cocktail was included 
in the solutions at all stages of the isolation and 2-DE steps to attempt to prevent 
proteolysis of the original protein. It can be seen in figure 5.13 that breakdown of the 
protein was avoided, demonstrated by the presence of a major spot at 112 kDa and a 
lack of additional spots at 40 kDa. As such, work could then be progressed using the 
complete protein sequence. 
5.9.4 Identification of the candidate basolateral peptide transporter 
Conventional means of protein identification have involved sequencing of 
the primary amino acid structure, for example, by Edman sequencing (Edman & 
Begg, 1967), providing that the amino terminus is not blocked. Another route is to 
use the antigenic properties of the protein, i.e. specific antibodies, if available. 
However, more efficient methods are now available for protein analysis, which are 
based on mass spectrometry. The use of MS has several advantages, from a greater 
sensitivity to a high throughput, eliminating the expensive running costs of earlier 
methods. An enhanced sensitivity, in turn, means that less sample is required for 
analysis, which creates its own benefits to the worker. 
The two MS techniques used for analysis of the candidate basolateral 
peptide transporter protein are MALDI-TOF (matrix-assisted laser 
desorption/ionisation time of flight) and Q-TOF (quadrupole time of flight). 
5.9.4.1 MALDI-TOF mass spectrometric analysis 
MALDI-TOF MS was the principal method used in analysis of the protein, 
due to certain advantages over Q-TOF, for example, its ease of use and speed of 
analysis. In addition, it has an inherent high sensitivity and is relatively tolerant 
towards low levels of contaminants. It was originally developed by Karas and 
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Hillenkamp (Karas et al., 1988; Hillenkamp et al., 1991), and has been subsequently 
refined to become an effective and versatile method for the analysis of peptides and 
proteins. The advantages of this method of analysis are:- (1) samples can be analysed 
without extensive purification, (2) common biochemical reagents, such as salts, 
buffers, detergents, etc. at low levels, do not affect analysis, (3) most proteins can be 
analysed providing they can be dissolved in the appropriate solvents, (4) only a small 
sample is required, usually between 1-10 pmol and, (5) analysis is complete within a 
matter of minutes. 
MALDI-TOF can be used to measure the molecular mass of a protein with 
extreme precision, i.e. to 0.01-0.1%, compared to an accuracy of between 5 and 10% 
by conventional SDS-PAGE methods (James et al., 1993). However, whilst an 
accurate molecular weight of the protein would have been an achievement, large 
quantities of protein are required in extremely high concentrations, which would have 
proven difficult to prepare, and superfluous when the molecular weight was only 
used in database searches, in which a calculated estimate sufficed. 
The MALDI-TOF technique was utilised for the analysis of peptide 
fragments generated from digestion of the 112 kDa protein using trypsin. Trypsin 
cleaves peptide bonds at the carboxylic sides of lysine and arginine residues, and so 
the masses of the peptides produced depend on the primary sequence of the protein. 
As such, they are individual for a particular protein, and therefore designated a 
'peptide fingerprint'. The process of searching databases with these highly specific 
masses to identify proteins is termed 'peptide fingerprint profiling'. 
The ionisation technique of MALDI-TOF predominantly produces singly 
protonated ions and so the mass-to-charge ratio is the true mass of the peptide plus 
1 Da. In the spectra, the mass-to-charge ratio is represented on the x-axis and the 
relative intensity of the peaks on the y-axis. An external calibration is used to 
calculate the masses of the peptide fragments, i.e. peptides of known molecular mass 
are analysed prior to the sample and utilised by the data software to assign each 
tryptic peptide a mass value. 
The heights of the peptide mass peaks are arbitrary values of the most 
intense (100%) peptide relative to the rest. The peak intensity is generated by a 
succession of laser shots, which are summed to yield a time of flight (TOF) mass 
spectrum that is more accurate, and has a better signal-to-noise ratio, than data from 
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single shots alone. Therefore, although some peptides appear to be more abundant 
than others, this may not be so; it may be due to the ability of that particular peptide 
to 'fly' down the field-free region, relative to the others. 
5.9.4.2 Peptide fingerprint of the candidate basolateral peptide transporter 
Analysis of the tryptic digestion mixture of spot A from the 2-DE gel detects 
a total of 83 peptides, with 53 peptides detected from spot B. MALDI-TOF can not 
detect all of the tryptic peptides present, for a number of reasons, i.e. a few dominant 
peptides may suppress detection of other less abundant peptides. In addition, some 
hydrophobic peptides might not be observed due to their low solubility or because of 
their ability to adsorb to the Eppendorftubes and/or pipette tips used. 
A small number of the peaks in the MALDI-TOF spectrum might represent 
contaminants from the gel or from the Coomassie stain used to visualise the spots. 
Other peptides that might be present may also not be from the protein of interest, 
i.e. human keratins originating from either chemicals and/or sample handling. 
However, the actual pattern of keratin peptides can not be predicted in the spectrum, 
and cannot, therefore, be eliminated using a control (Shevchenko et al., 1996a). 
Additional unidentifiable peaks might result from the unexpected cleavage between 
Lys/Arg and Pro; this has been attributed to the high enzyme-to-substrate ratios used 
in in situ digestions (Mertz et al., 1994). However, a positive match from a database 
only requires a small number of corresponding masses, and so not all peptides are 
critical. In addition, incomplete maps, although may not unequivocally identify the 
specific protein, would identify variants or homologues from other species. 
Steps can be taken to eliminate contaminating peptides, such as gel 
components, for example, by electroblotting of the protein onto a hydrophobic 
membran~ (PVDF) or performing the digestion in solution. However, analysis of 
tryptic peptides from a membrane also has associated problems. These include the 
loss of some of the protein during transfer, limited or altered protease accessibility to 
cleavage sites resulting in peptide maps differing from that anticipated, and a 
preferential release of hydrophilic peptides (Ml2lrtx et al., 1994). Plus, the steps of 
washing and combining samples from the elution of peptides from the membrane can 
introduce its own additional background contaminants. In reference to the alternative 
to digest the protein in solution, previous to the in-gel digestion data presented in this 
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chapter, work was performed whereby the 112 kDa protein was digested in solution. 
However, the peptide mixture was not easily analysed and interpreted due to high 
levels of contamination. In-gel digestion permits washing of the sample to remove 
the vast majority of the buffers and salts in the high concentrations that can interfere 
with analysis. Thus, this was the method of choice. 
The masses of the peptides shown in figure 5.15, figure 5.16 and table 5.3 
were assigned by comparison to known standards in an external calibration; used to 
improve mass accuracy (Jungblut et al., 1997). Commercial calibration mixtures are 
generally used (e.g. Cal2 from PerSeptive) because they contain peptides that only 
occur in one isoform and they do not oxidise easily. Accurate mass assignment 
depends on a good calibration. It also depends on a good signal-to-noise ratio of the 
peak; if a signal is weak and noisy, the mass assignment will not be as accurate as for 
more intense peaks. The signal-to-noise ratio is improved by accumulating data from 
individual laser shots. Obtaining data using a delayed extraction method 
(i.e. implementing a time delay between the laser pulse and acceleration of the ion), 
as performed with spots A and B, also increases accuracy; usually better than 0.5 Da 
in a mass range up to 5000 Da (Jungblut et al., 1997). Collectively, these steps are 
taken to maximise precision in data acquisition; a resolution of more than 10,000 is 
good, how~ver, in these analyses a resolution of> 13,000 was achieved. It is now 
generally accepted that if the protein, or homologue, is known and its sequence 
present, the mass fingerprint profile is sufficient for its identification from databases 
(James et al., 1993). 
5.9.4.3 Proteolysis of the candidate basolateral peptide transporter 
It was very interesting to discover that 24-29 of the peptides detected in 
spots A and B had identical masses. This indicates that the two spots probably did 
originate from one protein. Prior to MALDI-TOF analysis, it was speculated that 
proteolytic breakdown of the 112 kDa protein during the prolonged IEF procedure 
resulted in loss of the radioactive label and a lack of detection of a spot at the correct 
molecular weight. These peptide fragment data corroborate this theory, and suggest 
that the two 40 kDa spots form the originally labelled protein. It appears as though 
proteolysis occurred in stages during incubation of the sample at room temperature 
while performing IEF, i.e. breakdown of the 112 kDa protein to a 40 kDa polypeptide 
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principally occurred, and then further breakdown of this fragment to a distinct 
polypeptide would cause the two spots to be formed. The two protein spots possess 
exactly the same molecular weight, but differ slightly in isoelectric point. The loss of 
as few as one or two amino acids from the polypeptide sequence can result in a shift 
of pI to produce a second spot. A considerably greater number of peptides were 
detected from spot A than spot B. In addition, the more basic spot (spot B) is slightly 
less abundant than spot A. This collectively suggests that the process of proteolytic 
breakdown is due to the 40 kDa polypeptide (spot A) being degraded slightly further 
to form spot B. At some point during proteolysis of the protein, the portion of the 
polypeptide that formed the active site and therefore bound 
[4-azido-3,5)H-D-Phe]-L-Ala was cleaved and eluted from the gel. This must have 
occurred during the initial breakdown of the 112 kDa protein to the 40 kDa fragment, 
not during further degradation of spot A to spot B, otherwise radioactivity would still 
be detected in spot A. 
Although the 112 kDa protein spot was not detected from the 2-DE gel, it 
was assumed that the two 40 kDa spots formed at least part of the original protein, 
for reasons described above. As such, the peptide fingerprints from both spots were 
used in database searches for identification of the candidate basolateral peptide 
transporter. 
5.9.4.4 Database searches 
Despite the various searches described in section 5.8.2, the peptide 
fingerprint of the protein isolated from the basolateral membrane did not positively 
match to any known protein in the databases with any real significance. In addition, 
only five of the possible 136 peptides produced from the two spots coincided with 
similar masses of peptides produced from a theoretical digest of rat Pep T 1. 
It is generally accepted that approx. 50% of peptide masses should match in 
order for a protein to be accepted (Mertz et al., 1994), which is precisely what was 
obtained with prior experimentation with BSA. The searches with the peptide 
masses from spots A and B matched a maximum of 24%, and this only occurred 
when the search parameters were expanded to include all possible variations and 
therefore induced a low degree of accuracy within the search. Searches with slightly 
more precision failed to even reach a match of 20%. Even if the peptide map from 
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this protein were incomplete, it would be expected to match, or that variants or 
species homologues would be identified. However, a lack of positive identification 
suggests it is a novel protein. 
Occasionally proteins cannot be identified by MALOI peptide maps, due to 
detection of only a few peptides (Shevchenko et al., 1996c), and so additional 
sequence information is required. This was obtained in the form of a partial amino 
acid sequence of one of the peptide fragments by Q-TOF analysis. The sequence tag 
(nine amino acids) was also used in database searches to identify the basolateral 
protein. Identification of proteins using MS fragmentation data has a very high 
degree of reliability, therefore suggesting that the protein isolated from the 
basolateral membrane is not contained within either the full length sequence 
databases, or the EST databases, searched. ESTs are partial sequences (-300 bp) of 
cDNAs derived from differentiated tissues or cells, whose orientation (5' --+ 3') and 
reading frame are usually unknown. As such, they represent portions of expressed 
genes. The peptide sequence tags are ideally suited for searching these databases in 
the hope of identifying a gene whose partial sequence, if not the full sequence, has 
been determined. Only a small amount of correlative sequence is required to achieve 
identification (Courchesne et al., 1997). Although a number of proteins were found 
to match the majority of the sequence tag (up to 87%), the complete sequence could 
not be matched (table 5.6). In addition, the peptide fingerprints of the proteins that 
did contain a corresponding sequence did not match to the fingerprint(s) of the 
112 kDa protein. 
It is generally accept~d that if a protein has been previously isolated, and its 
sequence is contained within the databases, a peptide fingerprint or a partial sequence 
will unequivocally find the match (James et al., 1993). Some proteins can be 
identified with as little as 5-6 peptide masses, but these are highly specific for that 
particular protein; in general a considerably higher probability when compared to 
other proteins is the defining factor for a good match. The fact that the protein was 
not positively correlated with any other known protein is not due to the reliability of 
the combined techniques, because prior analysis of BSA by the same methods 
resulted in its unequivocal identification from all databases. MALDI-TOF and 
Q-TOF (electro spray ionisation) form a layered approach to protein identification 
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which, if the protein was contained within the databases, it would be unequivocally 
identified, if not by one method alone, then undoubtably by a combination of the two. 
It is therefore clear that the 112 kDa protein, which has been specifically 
photoaffinity labelled with a dipeptide analogue, and which is postulated to be a 
candidate to be the basolateral peptide transporter, has not been previously identified, 
and as such appears to be a novel protein. 
5.9.5 Is PepTI responsible for the basolateral transport of pep tides? 
Over the years, studies of peptide transport in the basolateral membrane 
have been consistently neglected in favour of PepTI. This was probably (initially) 
due to the fact that physiologically occurring peptides are hydrolysed within the 
enterocyte before transport of the constituent amino acids out of the cell. However, 
the demonstration that intact peptides, and peptidomimetic drugs, are transported out 
of the cell across the basolateral membrane, suggested that there must be a carrier 
present. 
It was then postulated that PepTI was also responsible for the exit of 
peptides from the cell, i.e. it was thought that there wasn't a distinct transport protein 
in the basolateral membrane. During the cloning and expression of rabbit PepTI by 
Hediger's group (Fei et al., 1994), hybrid depletion studies performed to block 
PepTI expression resulted in a loss of induced Gly-Sar transport activity in Xenopus 
laevis oocytes. As such, they suggested that peptide transport activity in the 
basolateral membrane is also due to PepTI expression. 
However, at present there is overwhelming evidence proving the existence 
of a distinct transporter protein at the basolateral membrane. In particular, PepTl 
expression has been immunolocalised exclusively to the apical membrane (Ogihara et 
al., 1996; Walker et al., 1998), in addition to distinct transport characteristics 
demonstrated by a number of kinetic studies (section 1.5). 
The sequence data presented here reinforces the distinction between the two 
transporters. Only a few (maximum of 5) of the peptide fragments generated from 
the candidate basolateral peptide transporter correspond to tryptic peptides of rat 
PepT1. Interestingly, these five peptides are located in just two loops, which connect 
adjacent transmembrane domains. Sequence comparisons of peptide transporters in 
both the small intestine and kidney, in a number of animals (in particular rat, rabbit, 
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human), have shown that the majority of sequence homology is located in the 
transmembrane domains and cytosolic domains, with only a low level conserved in 
the extracellular loops. In particular. Paulsen & Skurray (1994) demonstrated that 
two sequences were not only conserved between peptide transporters, but also found 
in various other transporters, the only similarity being that they showed a 
H+-dependence in the transport of their substrates (section 1.4.3). 
The majority of the (limited) matching rat PepTI peptides to the present data 
are located in the notably large extracellular loop connecting TM 9 and 10. and the 
remainder in the intracellular loop adjoining TM 6 and 7. Due to the high degree of 
homology observed between the peptide transporters cloned thus far, it could be 
anticipated that the basolateral peptide transporter might show similar sequence 
similarity. especially in the TM domains. However. not only is there very little 
corresponding data between the two transporters in the small intestine, but the 
similarity that is observed is found in the least expected place within the structure. 
Despite the location of similarity. the fact that only five of the possible 134 peptides 
that could be generated from rat PepTI with two missed cleavages. correlate shows 
that there doesn't appear to be a significant amount of similarity between the two 
proteins at all. 
In addition, the partial sequence of 9 amino acids does not match to any part 
of the primary sequence of rat PepTI. Therefore, it can be concluded that the 
112 kDa protein identified by photoaffinity labelling from the basolateral membrane 
is definitely not PepTI, and, as such, is a novel protein and a candidate to be the 
basolateral peptide transporter in rat small intestine. 
5.10 Conclusions 
(1) Photo affinity labelling of BLMV produces a highly consistent pattern of 
[4-~ido-3,5-3H-D-Phe]-L-Ala incorporation by membrane proteins, which 
is distinct to that seen with BBMV. 
(2) A single protein is specifically labelled by [4-azido-3,S)H-D-Phe]-L-Ala, 
which has a molecular weight of approx. 112 kDa and an isoelectric point of 
6.5. 
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(3) Label incorporation by the 112 kDa protein is completely abolished by 
preincubation with a dipeptide, but not by free amino acids. Therefore, it is 
proposed as a candidate to be the basolateral peptide transporter. 
(4) The labelled 112 kDa protein can be individually isolated from the 
basolateral membrane by 2-DE, either in rod gels or using an immobilised 
gradient, although the latter method results in proteolysis of the protein to 
form two spots (at 40 kDa) in the final stained gel. 
(5) Tryptic digestion of the two 40 kDa spots followed by MALDI-TOF 
analysis reveals a high degree of similarity between the sequence of the 
polypeptides (> 50%), suggesting they originated from the same (112 kDa) 
protein. 
(6) The peptide fingerprint of the candidate basolateral peptide transporter did 
not positively match to any previously sequenced contained within the 
databases. 
(7) A sequence tag of nine amino acids, obtained by Q-TOF analysis of one of 
the tryptic peptides, also did not fully match to any sequence in either the 
full length sequence databases or EST databases, although a number of 
proteins were identified with corresponding sequences (up to 87 % match). 
(8) Neither the peptide fingerprint, nor the sequence tag, corresponded to the 
primary sequence of rat PepTl to an appreciable extent. This demonstrates 
that the basolateral peptide transporter is not PepTI, but a distinct protein. 
In summary, using the methods described, I have identified, isolated and performed 
initial sequence analysis on a protein from the basolateral membrane of rat small 
intestine, which I propose is a candidate to be the, as yet, unidentified peptide 
transporter. The sequence information obtained thus far collectively indicates that 
the 112 kDa protein is novel. 
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CHAPTER 6: SHORT-TERM REGULATION OF PEPTIDE 
TRANSPORT IN RAT JEJUNAL MUCOSA 
6.1 Aims of the experiments 
Initial studies in our laboratory (Boyd et al., 1996) demonstrated a 
stimulatory effect of leucine on peptide (D-Phe-L-Gln) transport in rat small 
intestine. It has been reported that specific amino acids in the diet have an ability to 
up-regulate peptide transport, over a period of days (Ferraris et al., 1988; Shiraga et 
aI., 1999), due to an increase in the abundance of PepTI protein at the apical 
membrane, i.e. long-term regulation (see section 1.6.1). The report by Boyd and co-
workers indicated an element of short-term regulation. 
Interest in short-term regulation of peptide transport has been limited, 
despite the fact that this information is crucial if we are to understand the 
fundamental physiological processes that control the absorption of nutrients after a 
meal. As such, I decided to investigate the short-term regulatory processes 
controlling intestinal peptide transport, in particular, to elucidate whether there are 
different mechanisms of control at the apical and basolateral membranes. The 
technique used in this study, the luminally and vascularly perfused isolated rat 
jejunum in situ technique, permits some preliminary deductions into the membrane 
location of regulatory control in intact tissue, because the accumulation of peptide in 
the mucosal tissue and the corresponding exit ratios can be measured. The exit ratios 
are defined as the ratio of substrate concentration in the tissue to the 'concentration of 
substrate in the vascular effluent sample. It gives an indication as to the relative rate 
of transport at the two opposing membranes (see table 3.1), therefore allowing the 
site of inhibition/stimulation to be determined. 
6.2 Viability of the vascular perfusions 
Assessment of the viability of the vascular perfusions was as described 
previously in section 3.3. Briefly, the reliability of the data obtained using this 
technique was appraised using two factors; (1) a consistent, high portal vein recovery 
(> 90%), and (2) a constant rate of glucose utilisation by the isolated jejunal segment. 
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6.3 Regulation of peptide transport by leucine 
The first step in this study was to reproduce the preliminary experiments of 
Boyd et al. (1996), although the time constraints were altered slightly to permit the 
infusion of specific drugs, and to observe their effects, in subsequent experiments. 
L-Ieucine was added, at a concentration of 10 mM, at the 20 min time point 
of the perfusion. It was included in either the luminal or vascular perfusate to 
determine its effect on the transmural transport of 1 mM D-Phe-L-Gln from the 
lumen to the serosa of rat jejunum. The results of these perfusions are shown in 
figure 6.1 (I & II). 
It is evident that leucine stimulates the rate of D-Phe-L-Gln transport, 
irrespective of whether it is present in either the lumen or vasculature of the intestine 
(figure 6.1(1». The control transport rate is stimulated by 37% in both cases; from 
0.259 ± 0.036 J.lmol.min:1.[g dry wt.]-l in the control perfusions to 0.356 ± 0.016 
J.lmol.min:I'[g dry Wt.]-I (P < 0.001) with leucine in the vasculature, and to 
0.354 ± 0.041 J.lmol·min:1'[g dry Wt.]-I (P < 0.001) with leucine in the lumen. 
To ensure that the stimulation in rate is directly due to leucine, the 
percentage increase in peptide appearance at 20 min (before addition of leucine) was 
compared to the percentage increase in peptide appearance following leucine 
stimulation (50 min). When leucine was perfused through the vasculature the 
increase in cumulative peptide appearance at 20 min was 16% and at 50 min was 
25%, therefore an increase in transport is apparent following the addition of leucine. 
With leucine in the lumen the values were a 20% increase at 20 min and a 27% 
increase at 50 min, again suggesting that the stimulation is entirely due to leucine. 
To corroborate this evidence, statistical analysi~ was performed on the raw data, 
which indicated no significant difference between the control perfusions and either of 
the leucine perfusions at the 20 min time point, before a steady state was reached. 
However, the precise location of this stimulation can not be deduced from 
this data alone; the concentration of D-Phe-L-Gln in the mucosa, and the 
corresponding exit ratios (shown in figure 6.1 (II» provide this additional 
information. It is apparent that leucine in both the lumen and vasculature causes a 
significant reduction in the exit ratio of D-Phe-L-Gln from the mucosal tissue; from 
91.9 ± 15.07 (control) to 46.66 ± 4.41 (P = 0.014) with leucine in the lumen, and to 
33.59 ± 7.1 (P = 0.011) with leucine in the vasculature. This is associated with a 
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Figure 6.1(1) 
Regulation of peptide transport by leucine, demonstrated by its effect on the 
transmural transport rate of 1 mM D-Phe-L-Gln (control). Leucine, at 10 mM 
concentration, is present in either the lumen (L) or the vasculature (V). Data points 
represent the mean ± s.e.m. (control, n = 4; leucine in L & V, n = 6). *** P < 0.001 
depicts a significant difference in transport rate against the control. 
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Figure 6.1(11) 
Localisation of peptide transport regulation by leucine, demonstrated by its effect on 
the mucosal accumulation (a) and exit ratios (b) of 1 mM D-Phe-L-Gln. Leucine, at 
10 mM concentration, is present in either the lumen or the vasculature of the 
jejunum. Bars represent the mean ± s.e.m. (control, n = 4; leucine in L & V, n = 6). 
* P < 0.05 depicts a significant difference against the control. 
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significant decrease in mucosal accumulation of peptide when leucine is in the lumen 
(from 8.59 ± 0.75 mM (control) to 4.78 ± 0.83 mM (P = 0.014). There is also a trend 
in the reduction of the mucosal concentration of peptide when leucine is in the 
vasculature; to 7.56 ± 0.41 mM, that is just outside the limits of significance 
(P = 0.18). The accumulation of D-Phe-L-Gln by muscle tissue was very low, 
approx. 20% of that concentrating in the mucosal tissue; the effects of leucine on 
muscle concentrations of peptide and corresponding exit ratios are negligible (data 
not shown) 
The reduced mucosal concentrations of peptide and significantly smaller 
exit ratios, associated with increased rates of transport, suggest that transport at the 
basolateral membrane is stimulated to a greater extent than at the apical membrane. 
In other words, peptide is exiting the cells at a more rapid rate than it is entering via 
PepT1. 
6.4 Effect of rapamycin in the vasculature 
In view of the similarity of the previous results using either luminal or 
vascular leucine, subsequent work was continued with leucine present on the vascular 
side of the intestine, because of the locality of its effects on basolateral membrane 
transport. 
The stimulatory effect of leucine is thought to be due to a possible activation 
of p70 86 kinase (see section 6.8.1 in the discussion). Therefore, in order to 
demonstrate a p70s6k-dependent pathway, an inhibitor of this enzyme was used in the 
vascular perfusions. Rapamycin inhibits the phosphorylation and activation of p70S6k 
(ICso = 0.05 nM), via its action on mTOR (the mammalian !arget Qf rapamycin); an 
upstream regulator ofp70s6k. It was included in the vascular perfusate (at 25 nM), in 
conjunction with leucine, to determine its effect on the leucine-stimulation of peptide 
transport. It was also used in the absence of vascular leucine to assess any potential 
effects it may have on normal (control) rates of peptide transport. The results of 
these studies are shown in figure 6.2 (I & IT). 
It can be seen (figure 6.2(1» that the presence of rapamycin in the 
vasculature completely abolishes the leucine-stimulation of peptide transport, from 
0.356 ± 0.016 J.Ullol·min:1.[g dry Wt.]-l to 0.245 ± 0.023 J.1mol·min.-1.[g dry wt.r1 
(P < 0.00 1), i.e. back to the control rate of transport (P > 0.1). This is also 
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Figure 6.2(1) 
Effect of vascular rapamycin (at 25 nM concentration) on the leucine stimulation of 
1 mM D-Phe-L-Gln transport, and on control rates of transport, at the basolateral 
membrane. Data points represent the mean ± s.e.m. (control, n = 4; leucine (V), 
n = 6; leucine & rapamycin (V), n = 6; rapamycin (V), n = 5). *** P < 0.001 depicts 
a signifiant difference against the control, $$$ P < 0.001 depicts a significant 
difference against leucine (V). 
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Localisation of peptide transport regulation by leucine, demonstrated by the effect of 
vascular raparnycin on the mucosal accumulation (a) and exit ratios (b) of 1 mM 
D-Phe-L-Gln. Leucine is present in the vasculature of the jejunum at 10 mM, 
raparnycin is also in the vasculature at 25 nM, with or without leucine. Bars 
represent the mean ± s.e.m. (control, n = 4; leucine (V), n = 6; leucine & 
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demonstrated by the relative percentages at 20 min versus 50 min; although at 20 min 
there is a 38% reduction in vascular peptide appearance when rapamycin is in the 
vasculature, at 50 min a comparable decrease of approx. 28% following addition of 
leucine is observed, compared to only a decrease of 4% compared to the controls. 
This indicates the reduction in rate of leucine-stimulated transport is due to 
rapamycin. Associated with this reduction in rate is an increase in mucosal 
concentration of peptide (from 7.56 ± 0.41 mM to 10.33 ± 0.84 mM, P = 0.01) and 
an increase in the exit ratio (from 46.66 ± 4.41 to 103.86 ± 21.9, P = 0.03), i.e. both 
values again back to control levels (P > 0.1). In contrast, there is no effect of 
vascular rapamycin on normal peptide transport, either on rates or tissue 
accumulations. In addition, the effects on muscle concentrations and corresponding 
exit ratios are negligible (data not shown) in all perfusions. 
These data show that rapamycin blocks the leucine-stimulation of 
basolateral membrane peptide transport, corroborating the initial conclusions 
regarding the location of regulation of peptide transport by leucine, i.e. the 
basolateral membrane. The data also suggest that leucine operates via a p70S6k_ 
dependent pathway to stimulate basolateral peptide transport. 
6.5 Effect of rapamycin in the lumen 
, It has been established that rapamycin has an inhibitory effect on the 
leucine-stimulated proportion of basolateral peptide transport, but no effect on 
control levels, when present in the vasculature. In order to obtain a more complete 
view of regulation by leucine, the role of rapamycin from the lumen on peptide 
transport was investigated. The previous perfusions were repeated, but rapamycin 
was included in the luminal perfusate, as opposed to the vascular perfusate with 
leucine. The results from this series of perfusions are shown in figure 6.3 (I & II). 
It is evident that rapamycin, when present in the lumen, appears to have no 
effect on the rate of leucine-stimulated transport, nor on the mucosal concentration or 
exit ratios, of D-Phe-L-Gln. A slightly higher (albeit not significant) rate at 20 min 
(before addition of leucine) (17%) ultimates in a slight reduction (4%) in transport 
rate at 50 min, demonstrating no effect of luminal rapamycin on the leucine 
stimulation in rate. 
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Figure 6.3(1) 
Effect of luminal rapamycin (at 25 nM concentration) on the leucine stimulation, and 
on control rates, of 1 mM D-Phe-L-Gln transport. Data points represent the mean ± 
s.e.m. (control, n = 4; leucine (V), n = 6; leucine (V) & rapamycin (L), n = 6; 
rapamycin (L), n = 6). *** P < 0.001 depicts a significant difference against the 
control. 
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However, it is apparent that, in the absence of leucine in the vasculature, 
rapamycin causes a stimulation in the rate of peptide transport (42%), which is 
equivalent to the stimulation induced by vascular leucine. The rate increases from 
0.259 ± 0.036 J.lmol.min:1'[g dry Wt.]'l (control) to 0.367 ± 0.049 J.lmol.min:1'[g dry 
Wt.]'l (P < 0.001). A stimulation by rapamycin is initially observed at 20 min; an 
increase of 60% compared to the control, which suggests that the drug might be 
exerting an effect earlier than was initially assumed, resulting in the final stimulation 
once a steady state is reached. Although the mucosal concentrations of D-Phe-L-Gln 
are reduced to comparable levels seen with the leucine effect, they are not significant 
against the control. In contrast, the mucosal exit ratios are reduced by approx. 50% 
(albeit not significant). 
Therefore, in the lumen, rapamycin has essentially the opposite effect on 
peptide transport, than when perfused in the vasculature, demonstrating that 
rapamycin, at a low concentration, acts locally. The data also suggest that the 
element of regulatory control observed at the basolateral membrane is not present in 
the apical membrane (PepTI), but that an entirely different process is involved. 
6.6 Effect of wortmannin in the vasculature 
It has been indicated by initial perfusions that there is a potential role of 
p70S6k in the regulation of basolateral peptide transport. p70S6k has a number of 
upstream regulators; the protein involved in the rapamycin-sensitive pathway is 
mTOR. Another protein which may exert control over p70S6k is phosphatidylinositol 
3-kinase (PI 3-kinase), for which a specifi~ inhibitor is wortmannin (IC so = 5 nM). 
Thus, perfusions were performed with wortmannin infused through the vasculature 
(200 nM), with and without leucine, to determine the role of PI 3-kinase in peptide 
transport regulation. Again the transmural transport, and tissue concentration, of 
1 mM D-Phe-L-Gln was measured. The results of these studies are shown in 
figure 6.4 (I & II). 
Wortmannin appeared to have no effect on the leucine-stimulation of 
transport rate (0.333 ± 0.038 v. 0.356 ± 0.016 J.1mol·min:1'[g dry Wt.]'l, P > 0.1). 
Transport percentages at 20 min were decreased slightly (but not significantly) by 
13% by wortmannin, however, the final (50 min) percentage was reduced by only 
7%, indicating no effect on leucine-stimulated transport by wortmannin. The 
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Figure 6.4(1) 
Effect of vascular wortmannin (at 200 nM concentration) on the leucine stimulation 
of 1 mM D-Phe-L-Gln transport at the basolateral membrane, and on control rates of 
transport. Data points represent the mean ± s.e.m. (control, n = 4; leucine (V), n = 6; 
leucine & wortmannin (V), n = 6; wortmannin (V), n = 6). *** P < 0.001 depicts a 
significant difference against the control. 
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presence of vascular wortmannin caused a significant increase in mucosal 
accumulation of D-Phe-L-Gln (from 7.56 ± 0.41 mM to 10.92 ± 1.13 mM, 
P = 0.019), and also increased the corresponding exit ratios (from 46.66 ± 4.41 to 
78.08 ± 13.61, P = 0.05). Wortmannin alone (without leucine in the vasculature) 
stimulated peptide transport by 50% in comparison to control rates; from 0.259 ± 
0.036 to 0.386 ± 0.047 I-lmol'min:I'[g dry wt.]-I (P < 0.001), from an initial 91% 
stimulation at 20 min before a steady state was reached. Associated with this 
increase in rate was a reduction in exit ratio, similar to the level seen with leucine; 
from 91.9 ± 15.07 to 44.72 ± 4.86 (P = 0.012). However, mucosal accumulation of 
D-Phe-L-Gln did not change from the concentration observed in the controls. Again 
the muscle accumulations of peptide and corresponding exit ratios did not change to 
any appreciable extent in any of the perfusions. 
Overall, if perfused through' the vasculature simultaneously with leucine, 
wortmannin appears to have no effect on the leucine-stimulated transport rate. 
However, the increases in mucosal concentration of peptide and exit ratio, in 
conjunction with no change in transmural transport rate, suggest that transport at the 
apical membrane is stimulated by wortmannin, whereas transport at the basolateral 
membrane does not change, and is essentially rate-limiting in these conditions. 
Alone, wortmannin also stimulates the transport rate of peptide, and a corresponding 
reduction in exit ratio suggests that the increase in the rate is due to a more rapid rate 
of transport at the basolateral membrane. Therefore, the results from this series of 
perfusions appear contradictory, i.e. wortmannin also stimulates apical membrane 
transport when perfused vascularly at the same time as leucine, but only basolateral 
membrane transport is stimulated when wortmannin is perfused alone. 
6.7 Effect of wortmannin in the lumen 
The previous experiments do not reveal conclusive information regarding 
the role of PI 3-kinase in the regulation of peptide transport at either the apical or 
basolateral membranes. However, in order to obtain a complete overview of 
regulation involving PI 3-kinase, as with rapamycin and mTOR, experiments were 
performed with wortmannin in the lumen (with and without vascular leucine). The 
results are shown in figure 6.5 (I & II). 
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Perfusion time (min) 
Figure 6.5(1) 
Effect of luminal wortmannin (at 200 nM concentration) on the leucine stimulation, 
and on control rates, of 1 mM D-Phe-L-Gln transport. Data points represent the 
mean ± s.e.m. (control, n = 4; leucine (V), n = 6; leucine (V) & wortmannin (L), 
n = 3; wortmannin (L), n = 3). *** P < 0.001 depicts a significant difference against 
the control. 
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Leucine (V) 
* 
Leucine (V) 
Leucine (V) & 
Wortmannin (L) 
Leucine (V) & 
Wortmannin (L) 
Wortmannin (L) 
Wortmannin (L) 
Regulation of peptide transport by vascular leucine (10 mM) and luminal 
wortmannin (200 nM), demonstrated by the effects on the mucosal accumulation (a) 
and exit ratios (b) of 1 mM D-Phe-L-Gln. Bars represent the mean ± s.e.m. (control, 
n = 4; leucine (V), n = 6; leucine (V) & wortmannin (L), n = 3; wortmannin (L), 
n = 3). * P < 0.05 depicts a significant difference against the control. 
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The presence of wortmann in in the lumen causes a modest increase (13%) in 
the leucine-stimulated transport rate, from 0.356 ± 0.016 J.lmol·min:I'[g dry wt.r! to 
0.403 ± 0.048 J.lmol.min:I.[g dry wt.]"l, P < 0.05). However, there are no associated 
changes in mucosal concentration of D-Phe-L-Gln although the exit ratios are 
reduced by approx. 30% (not significant). A lack of change in transport rate 
accompanied by a reduction in exit ratio suggests that apical membrane transport 
might be inhibited to a certain extent. Wortmannin alone has no effect of the control 
rate of peptide transport, nor on mucosal accumulations although again a reduction in 
exit ratio is apparent (not significant), indicating a possible inhibition at the apical 
membrane. 
Overall, it appears as though wortmannin does not affect peptide transport 
from the luminal perfusate, however the apparent decreases in exit ratios indicate a 
potential role of PI 3-kinase in apical membrane peptide transport. Further work is 
required to substantiate this conclusion. 
6.8 Discussion 
6.8.1 Regulation ofbasolateral peptide transport by leucine 
As mentioned previously, Boyd et al. (1996) reported that leucine has a 
stimulatory effect on transmural peptide transport in the small intestine of rat. Other 
amino acids, e.g. L-Ala, L-Phe and L-Val, were also shown to induce a certain level 
of stimulation on peptide transport when perfused through the vasculature 
(1. R. Bronk, personal communication). In recent years it has been shown by 
different groups that certain amino acids, most predominantly leucine, have the 
ability to specifically activate a cytosolic enzyme; p70S6k (Hara et al., 1998; Patti et 
al., 1998; Wang et al., 1998; Shigemitsu et al., 1999). This led to using leucine to 
investigate short-term regulation of transport and the role of a p70s6k-dependent 
pathway in its control mechanism. 
The rate of D-Phe-L-Gln transport was increased significantly when leucine 
was present in the lumen or the vasculature of the small intestine. It is apparent from 
tissue data that transport at the basolateral membrane was stimulated to a greater 
degree than apical membrane transport. Transport by PepTl might also have been 
stimulated, albeit to a lesser extent than the basolateral transporter, and as such, 
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cannot be detected due to the predominance of basolateral membrane transport 
stimulation. 
It is evident that the same regulatory control by leucine is found irrespective 
of its location of infusion to the small intestine. Therefore, it doesn't matter from 
which side of the cell that leucine enters, the overwhelming effect is predominant 
stimulation of the basolateral peptide transporter. 
p70S6k is a cytosolic enzyme involved in many varied cellular responses, in 
particular it is directly involved in translation; its major known substrate being the 
40S ribosomal subunit protein S6, which is essential for the translation of mRNAs 
whose 5'-untranslated region contains a short oligopyrimidine sequence (Hara et al., 
1998). Phosphorylation of p70S6k has also been shown to be controlled by the level 
of nutrients to which the cell is exposed, reflected by the responses to fasting and 
re-feeding in vivo; starvation causes a reduction in p70S6k phosphorylation and, 
therefore, activation, whereas re-feeding restores the phosphorylation and activity 
(Hara et al., 1998). This process probably functions to provide additional substrate 
for the increased level of protein synthesis that is induced. However, these are 
long-term control aspects which require a time period of days to occur, the effects of 
leucine on peptide transport seen in these perfusion experiments occur in a time scale 
of minutes and, as such, are short-term responses. 
The activity of p70S6k depends on multi-site phosphorylation of the p70 
polypeptide. There are at least three different regions of phosphorylation that have 
been identified, each of which is independently regulated (Hara et al., 1998); 
(1) a series of SerlThr-Pro motifs clustered in a pseudo substrate 
autoinhibitory domain in the non-catalytic C-terminal tail 
(Ser434, Ser441, Ser447, Thr444 in p70al) 
(2) Thr412 situated in a unique hydrophobic region 
(3) Thr2s2 situated in the catalytic loop 
However, only phosphorylation of Thr412 and Thr2S2 are absolutely essential for 
activity, although insulin causes phosphorylation at all three sites. Depletion of 
amino acids results in a decrease of phosphorylation of all residues in region (1), 
while activation of p70S6k by amino acids is associated with increased 
phosphorylation at these residues in region (1). As such, the stimulation of p70S6k 
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activity, due to increased extracellular amino acid concentrations, is probably due to 
increased p70 phosphorylation (Hara et al., 1998). 
The data from these investigations with leucine implicate p70S6k as a 
regulator of peptide transport at the basolateral membrane of rat small intestine. The 
fact that this effect is localised at the basolateral membrane, and is not observed at 
the apical membrane, suggests that PepTI is not under the control of p70S6k• These 
data emphasise the distinction between the peptide transporters at the apical and 
basolateral membranes of the small intestine, i.e. they appear to be different proteins. 
It corroborates previous work presented in this thesis (chapter 5), and work published 
by other people (section 1.5), in that the unidentified basolateral peptide transporter is 
not PepTI. 
The work by Shigemitsu and co-workers (1999) investigated the structural 
requirements of leucine to induce the stimulation in p70S6k activity. It was found that 
stereoselectivity is crucial, i.e. D-Ieucine did not activate p70S6k• In addition, the 
primary amine group is also essential for activation, but a free carboxyl group or 
a-hydrogen is not required. 
It isn't known whether the stimulatory effect of leucine on p70S6k is due to a 
specific receptor situated on the cell surface, or whether it occurs following transport 
of leucine into the cell (Patti et al., 1998). If an acceptor molecule for leucine does 
exist (at this time it has only been postulated), it appears that recognition of leucine 
by the acceptor must be quite specific, due to the predominance of its effects on 
enzyme activity. Shigemitsu et al. (1999) proposed that the amino acid transporter 
for leucine, i.e. the system L transporter, would probably not be a candidate for the 
acceptor molecule, because it doesn't possess very strict structural requirements; it 
also transports lIe, Val, Met, Phe and His residues. Patti and co-workers 
demonstrated that a mixture of these amino acids, i.e. substrates for the L-transporter, 
did not induce p70S6k activity to an appreciable extent; leucine alone was shown to be 
dominant. In addition to the lack of knowledge about the acceptor molecule, the 
nature of the intracellular signal generated in response to leucine stimulation, that 
initiates the changes in regulatory protein phosphorylation(s), is also unknown. 
Despite this, the effect of leucine has been demonstrated to result in phosphorylation 
of certain sites on p70S6k, which is likely to be mediated by SerlThr kinases that lie 
upstream of p70S6k (Patti et al., 1998). 
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The effect of leucine on p70S6k activation appears to be specific; other 
kinases, e.g. insulin receptor kinase, protein kinase B (PKB), mitogen-activated 
protein kinases (MAPK), are not stimulated (Hara et al., 1998; Patti et al., 1998; 
Wang et al., 1998). Therefore, leucine does not elicit a stress response. 
p70S6k activity can be controlled by a number of proteins lying upstream, in 
various pathways, all of which have not been identified. Two major proteins shown 
to regulate p70S6k activity are mTOR and PI 3-kinase. To examine whether these two 
proteins are involved in the leucine-stimulation of basolateral peptide transport, 
perfusions were performed in the presence of specific inhibitors of the enzymes; 
rapamycin, which inhibits mTOR, and wortmannin, which inhibits PI 3-kinase. 
6.8.2 Role of mTOR in leucine/p70S6k-stimulated basolateral peptide 
transport 
mTOR is known to lie upstream of p70S6k, and exerts control over its 
phosphorylation state, and therefore its activation. The cascade pathway is 
designated 'the FRAP/mTOR pathway (FRAP; FK506-binding protein rapamycin-
associated protein) (Shigemitsu et al., 1999). However, the physiologic regulators of 
the mTOR (FRAPIRAFT-lIRAPT-I) kinase are not known (Hara et al., 1998). Full 
understanding of the biochemical mechanisms that underlie regulation of p70S6k are 
also not known, but rapamycin (the substrate for mTOR) is known to cause the 
dephosphorylation of p70S6k in vivo (Shigemitsu et al., 1999). Rapamycin binds to 
FKBPI2, and the rapamycin-FKBP12 complex binds to mTOR, resulting in 
inhibition of mTOR protein kinase activity. This results in a decrease in p70S6k 
phosphorylation and activity (Shigemitsu et al., 1999). 
The previously mentioned reports (Hara et al., 1998; Patti et al., 1998; 
Wang et al., 1'998; Shigemitsu et al., 1999), which demonstrated that leucine 
stimulated p70S6k activity, also showed that rapamycin blocked the effects of the 
amino acid. Therefore, to elucidate whether this mTORlp70S6k pathway was 
involved in regulation of basolateral peptide transport, perfusions were performed 
with rapamycin. 
The presence of rapamycin in the vasculature of the small intestine resulted 
in inhibition of the leucine-stimulated proportion of basolateral peptide transport. 
However, rapamycin did not affect the normal (control) rates of transport. These data 
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implicate p70S6k in leucine stimulated basolateral peptide transport, and a role for 
mTOR in the regulation pathway. 
With reference to the p70s6k/mTOR pathway proposed to regulate 
basolateral peptide transport, it is thought that rapamycin does not induce 
dephosphorylation of p70S6k primarily by inhibiting p70S6k kinases, but by 
stimulating p70S6k phosphatase activity (Hara et al., 1998). The pathway they 
suggested is as follows (showing modifications to include effects on basolateral 
peptide transport); 
Rapamycin Leucine 
1 ? 
• 
mTOR • - - -
- • - X 
~ L 
Phosphatase 
1 ---1 Inhibitory input 
P7r ? Lack of data 
---+ Stimulatory input 
Basolateral peptide transporter 
Figure 6.6 
Proposed pathway for short-term regulation of peptide transport at 
the basolateral membrane by p70S6k (Hara et al., 1998). 
Hara et al. (1998) proposed that leucine could control p70S6k vIa a common 
phosphatase, i.e. independent pathways that converge through regulation of this 
phosphatase. However, the existence of this phosphatase is just speculative; an 
enzyme, which fulfils the criteria of expected regulatory behaviour, has not been 
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identified. Control of p70S6k by leucine might otherwise be to regulate mTOR kinase 
(shown by question mark in diagram), and therefore mTOR would function as a 
checkpoint control. These two situations are equivalent to the postulated mechanisms 
thought to be involved in basolateral peptide transport, however, the exact 
mechanism cannot be deduced from this data alone, further studies are required. 
6.8.3 Role of mTOR In the regulation of apical membrane peptide 
transport 
In contrast to the basolateral membrane, peptide transport at the apical 
membrane was not stimulated by leucine. In addition, the presence of rapamycin at 
the apical membrane (in the lumen, in situ) has a completely different effect than 
when in the vasculature. It appears not to have any effect on the leucine stimulation 
at the basolateral membrane, which initially suggests that the drug acts locally, i.e. it 
doesn't traverse the cell. However, without vascular leucine, rapamycin appears to 
stimulate peptide transport, to a rate comparable to the leucine-stimulation at the 
basolateral membrane. A stimulation by rapamycin is initially observed at 20 min, 
which suggests that the drug might be exerting an effect earlier than was initially 
assumed, resulting in the final stimulation once a steady state is reached. However, 
although the exit ratios do not significantly differ from the control perfusions, there 
appears to be a 50% reduction. The leucine-stimulatory effect at the basolateral 
membrane and the rapamycin-stimulatory effect are not additive, because the rate 
remains the same when both are present at their respective membranes, as when 
either is present alone. Therefore, they might act through a common effector, leading 
to the same response, or that one pathway might inhibit the second pathway. The 
precise mechanism cannot be concluded from these data alone. 
The data presented here does not reveal the regulatory pathway which 
controls peptide transport by PepTl, but there is obviously a mechanism of control 
present, demonstrated by the action of rapamycin. PKC has been implicated in the 
regulation of apical peptide transport (Brandsch et al., 1994), i.e. PKC inhibits PepTI 
activity due to a decrease in V max, but no change in Km; PKC inhibitors restored 
peptide transport by blocking the inhibitory effect of PKC. It was postulated that 
regulation of this kind may involve post-translational modifications due to 
phosphorylation/dephosphorylation of the transporter protein. This could be either a 
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direct effect by PKC itself, or indirect via the action of additional protein kinases or 
phosphatases. Muller et al. (1996) also reported a potential role of PKA in regulating 
PepTI transport in a cAMP-dependent manner. The effect of rapamycin on apical 
peptide transport might involve one of these processes. 
A potential role of PKC is suggested from the results of these experiments. 
PKC activation depends upon phosphorylation at three distinct sites: (1) at an 
activation loop site, (2) a hydrophobic C-terminal site, and (3) a site subject to 
autophosphorylation (Parekh et ai., 2000). The unphosphorylated translation product 
has little or no intrinsic activity. The process of ligand binding at the membrane 
results in PKC becoming a substrate for kinases acting on the activation loop site and 
C-terminal sites. Phosphorylation of these two sites occurs due to two distinct 
pathways; phosphorylation at both is required for optimum activity (Parekh et ai., 
1999). This is followed by autophosphorylation of the third site. Phosphorylation of 
the activation loop is essential for activity of PKC, whereas the two remaining sites 
play a more subtle role by maintaining a closed conformer that is resistant to 
phosphatase activity, thereby retaining activation of PKC for a considerable length of 
time (minutes to hours) (Parekh et ai., 2000). Dissociation of the ligand from the 
membrane surface allows the kinase to diffuse away, although phosphorylation of all 
three sites maintains the latent activity. The phosphorylated PKC enzyme can then 
be recruited back to the membrane and re-activated by DAG (diacylglycerol) alone. 
PDK1, or a close relative, is responsible for PKC activation loop 
phosphorylation; constituting one of the distinguishable pathways. mTOR 
phosphorylates the C-terminal site of PKC in the V 5 domain; this is the second 
pathway. Activation of this latter site is inhibited by rapamycin (Parekh et ai., 1999), 
resulting in a 10-fold decrease in PKC activity. The elements operating between 
mTOR and PKC are not yet known, but the simplest model would be that mTOR 
controls a phosphatase that acts upon this PKC site (Parekh et ai., 2000). 
As mentioned previously, rapamycin in the lumen of the small intestine 
causes a stimulation in peptide transport, potentially by inhibiting the 
mTOR-dependent phosphorylation of the C-terminal site of PKC, thereby relieving 
the inhibition on PepTI by active PKC. However, further work is required to 
elucidate fully the nature of the kinase pathway involved in regulation of peptide 
transport by Pep T 1. 
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Overall, the data obtained with vascular leucine and rapamycin (luminal or 
vascular) indicates that the basolateral transporter is likely to be distinct from PepTl, 
indicated by the differential regulatory pathways at the two membranes. The results 
presented in this section corroborate data presented previously in this chapter and in 
chapter 5. The distinct mechanisms of peptide transport regulation also demonstrate 
that rapamycin has a localised effect, probably due to the relatively low concentration 
employed (25 nM). 
6.8.4 Role of PI 3-kinase In leucine/p70s6k -stimulated basolateral 
peptide transport 
PI 3-kinase is also known to lie upstream of p70S6k, and its activation results 
in the production of phosphatidylinositol-3,4,5-triphosphate (PtdIns-3,4,5-P3) and 
other inositol lipids phosphorylated in the D-3 position of the inositol moiety 
(Petritsch et al., 1995). These lipids are thought to act as second messengers that 
propagate the extracellular signal inside the cell, possibly by activating an 
intermediate kinase, which is part of a cascade, eventually resulting in p70S6k 
activation. Some studies have demonstrated a complete inhibitory effect of 
wortmannin (a PI 3-kinase inhibitor) on the amino acid-stimulation of p70S6k activity 
(Wang et al., 1998; Patti et al., 1998), whereas others have reported a moderate 
reduction in activity (Shigemitsu et al., 1999), or no effect at all (Hara et al., 1998). 
Therefore, because of a possible role of PI 3-kinase in the regulation of basolateral 
peptide transport through p70S6k, perfusions were performed in the presence of 
wortmannin. 
However, the data anSIng from these perfusions were confusing. In 
conjunction with vascular leucine, vascular wortmannin appeared to moderately 
enhance the leucine-stimulation of transport at the basolateral membranes and also 
stimulated a little at the apical membrane, whereas alone wortmannin appeared to 
solely stimulate basolateral membrane transport. Although these data are not clear, it 
implies that there is a PI 3-kinase-dependent element of control at the basolateral 
membrane. If PI 3-kinase inhibits peptide transport under control conditions, the 
inhibition of PI 3-kinase by wortmannin will relieve its inhibitory effect on transport, 
thereby producing a stimulation of rate. This is a very similar situation as found with 
rapamycin at the apical membrane, i.e. a stimulatory effect is observed with the drugs 
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alone, but the anticipated inhibition of the leucine effect due to the action of the 
drugs on their respective targets was not observed. Therefore it seems as though 
there might be a wortmannin-sensitive pathway, in addition to a leucine-sensitive 
pathway, possibly leading to a common effector. 
PI 3-kinase acts through PKB to exert its downstream effects on p70S6k• 
However, amino acids do not stimulate PKB activity (Patti et ai., 1998; Wang et ai., 
1998). Therefore, if PI 3-kinase was implicated in the regulation of peptide transport 
via p70S6k, it must be independent of PKB activation, and so another alternative 
upstream pathway may be involved. 
Despite this speculative assumption, the data from these experiments are not 
clear, and the effects observed with wortmannin in conjunction with leucine are 
contradictory to the effects seen with wortmannin alone. These data do not, 
therefore, point to an obvious mechanism and require further work for clarification. 
6.8.5 Role of PI 3-kinase in the regulation of apical membrane peptide 
transport 
In contrast to vascular wortmannin, luminal wortmannin has no effect on 
leucine-stimulated transport, or on control rates. Therefore, this indicates that 
PI 3-kinase is not involved in regulation of PepTl transport at the apical membrane. 
However, because mucosal exit ratios were reduced by the presence of wortmannin 
in the lumen, PI 3-kinase may be involved in apical peptide transport; further work is 
required for elucidation of its exact involvement in transport. 
As stated previously, PDKI is involved in phosphorylation and activation of 
PKC (Parekh et ai., 2000). (Parekh et ai., 2000). PI 3-kinase is located upstream of 
PDKl, therefore it might be expected that wortmannin would have a stimulatory 
effect on apical membrane peptide transport, in the same way that rapamycin does at 
this membrane. However, this response is not evident, suggesting that if PKC did 
have a role in the regulation of PepTl transport, it must be via a pathway which is 
independent of PI 3-kinase. 
Again the data demonstrate that wortmannin acts locally at the membrane to 
which it was infused. Also apparent is the distinction between PepTl and the 
basolateral peptide transporter; rapamycin and wortmannin appear to have reciprocal 
effects at each membrane:-
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Apical membrane 
• PI 3-kinase is not involved in regulation of peptide transport 
• mTOR regulates transport in an undefined stimulatory capacity, 
possibly via PKC 
Basolateral membrane 
• a p70s6k/mTOR pathway regulates transport 
• an independent PI 3-kinase pathway might also be involved 
6.9 Future work 
It is clear that although some initial aspects of regulation can be determined 
using the vascular perfusion technique described (for example, rapamycin-sensitive 
pathways), other pathways are extremely complicated (for example, 
wortmannin-sensitive pathways). Other (in vitro) methods can be used in 
conjunction with the perfusion technique to clarify the results obtained, for example, 
purified membrane vesicles, which completely separate the distinct regulatory 
situations at the different membranes. However, studies using intact tissue are 
invaluable for the elucidation of the physiological situation which occurs in vivo, 
which sometimes cannot be deduced from isolated membranes. 
6.10 Conclusions 
(1) The peptide transporters at the apical (PepT1) and basolateral membranes 
appear to be distinct proteins, demonstrated by different regulatory processes. 
(2) The drugs used in this study (rapamycin & wortmannin) have a localised 
action, i.e. at the membrane to which they were infused, at the low 
concentrations employed. 
(3) Peptide transport at the apical membrane is regulated by an mTOR-sensitive 
pathway, which is independent of PI 3-kinase, and might involve PKC 
(Brandsch et al., 1994; Parekh et al., 1999, 2000). 
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(4) Peptide transport at the basolateral membrane is regulated by a p70s6k/mTOR 
pathway, which is stimulated by leucine. In addition, a possible role of 
PI 3-kinase is postulated, which is independent of the p70s6k/mTOR pathway. 
Overall, certain aspects of short-term regulation of peptide transport in the small 
intestine have been demonstrated, but further work is required to clarify other 
ambiguous data. Short-term regulation of intestinal peptide transport has been 
overlooked thus far, but such knowledge is essential if we are to fully understand the 
physiological processes behind peptide transport as a whole. These investigations 
provide an insight into the complexity of the control of transport, and indicate that 
considerably more studies are needed. 
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CHAPTER 7: DISCUSSION 
All results have been previously discussed in detail at the end of each 
individual chapter, as such this discussion section will collectively review the 
important points of this thesis. For a more detailed explanation of the specific results 
and conclusions, please refer to the relevant chapter. 
7.1 Interaction of a potential photoaffinity label with intestinal 
peptide transporters 
The overall aim of this thesis was to investigate the peptide transporters at 
both the brush-border and basolateral membrane of rat intestinal mucosa, with 
particular attention to the, as yet unidentified, basolateral transport protein. An 
approach was taken to specifically label the transporters by using a radioactive 
photoaffinity labile compound which, when applied to (brush-border or basolateral) 
membrane vesicles, would covalently attach to the substrate binding site of the 
transporter in the presence of light and permit detection of the specific protein(s). 
The potential label is a derivative of a dipeptide known to be accepted as a substrate 
by the intestinal transporters (Lister et al. , 1995). [ 4-azido-D-Phe]-L-Ala was 
synthesised by Prof. P. D. Bailey and Dr. I. Collier in the Chemistry department, 
Heriot Watt University, Edinburgh. Prior to the undertaking of this labelling study, a 
direct interaction of the potential label with the peptide transporters had to be 
unequivocally proven. A series of perfusions (luminally and vascularly perfused rat 
jejunum, in situ) demonstrated an efficient dipeptide label-active site interaction 
(Chapter 3). 
[4-azido-D-Phe]-L-Ala was shown to be a substrate for the intestinal peptide 
transporters (PepTl and the basolateral transporter) by its extremely rapid, intact 
transmural transfer from the lumen to the serosa of the jejunum. A significantly 
lower mucosal concentration of the label, in comparison to D-Phe-L-Gln under the 
same conditions, suggested that the label is more efficient substrate for the 
basolateral transporter than PepTl, i.e. exit from the cell occurs at a faster rate than 
entry. 
263 
Chapter 7 Discussion 
A direct interaction with the active site of the transporter(s) was 
demonstrated by the ability of [4-azido-D-Phe]-L-Ala to inhibit the transport of a 
second dipeptide (D-Phe-L-Gln). This inhibition occurred only when 
[4-azido-D-Phe]-L-Ala was presented to the cytosolic face of the basolateral 
transporter (i.e. included in the luminal perfusate), where it prevented exit of 
D-Phe-L-Gln from the mucosal cells. The presence of [4-azido-D-Phe]-L-Ala on the 
extracellular side of the basolateral transporter (i.e. included in the vascular 
perfusate) did not affect D-Phe-L-Gln efflux from the enterocytes. The results from 
these perfusions collectively indicate an asymmetry of interaction of 
[4-azido-D-Phe]-L-Ala with the basolateral transporter. The substrate affinity and 
transport capacity for uptake across the membrane into the cell by the basolateral 
transporter is considerably lower than when functioning in an efflux direction (Inui et 
al., 1992; Saito et al., 1993) although some groups dispute this (Thwaites et al., 
1993b) stating the reverse is true. Its physiological role is predominantly in the 
efflux direction, performing an absorptive role within the intestine, i.e. the transfer of 
peptides from the cell into the bloodstream. Therefore, the label may he able to bind 
to the exofacial site of the basolateral transporter, but, due to a lower extracellular 
affinity for substrates, a higher concentration may be required to observe inhibition at 
the serosal face of the membrane. In summary, the data concerning the basolateral 
transporter corresponds to the unidirectionality of the absorptive process in vivo, 
which has been indicated for the transporter by a large number of research groups. 
Inhibition of substrate transport at the apical membrane (i.e. via PepTl) by 
[4-azido-D-Phe]-L-Ala is not apparent, however, it may be occurring, albeit to a 
lower extent than that seen at the endofacial side of the basolateral transporter, and as 
such cannot be ruled out completely. Previous experiments, by our collaborators in 
the Department of Human Anatomy, University of Oxford, with PepTl-expressing 
Xenopus oocytes (Boyd et al., personal communication) demonstrated a significant 
inhibition of D-Phe-L-Gln transport by [4-azido-D-Phe]-L-Ala, therefore proving a 
direct interaction of the label with PepTI active site. PepTI is thought to have a 
greater capacity for transport than the basolateral transporter (Inui et al., 1992; Saito 
et al., 1993; Matsumoto et al., 1994; Terada et al., 1999), which may, at least 
partially, explain the lack of inhibition at the apical membrane. Again, a higher 
concentration of [4-azido-D-Phe]-L-Ala may be required for inhibition to be detected 
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at PepTl. Although transport inhibition is not clearly observed at the apical 
membrane, the rapid transfer rate of the potential label from the lumen to the 
vasculature demonstrates that it is accepted as a substrate and transported by PepTl 
(corroborating the Oxford data). [4-azido-D-Phe]-L-Ala is not traversing the 
intestinal wall via a paracellular flow mechanism, because this has been previously 
demonstrated to be negligible (Lister et ai., 1995). 
Overall, the data demonstrate that [4-azido-D-Phe]-L-Ala can interact with 
both of the intestinal peptide transporters, and so the structure was further developed 
to be used as a photoaffinity label to identify the membrane proteins. 
7.2 Modifications to the D-Phe-L-Ala structure confers an 
enhanced affinity for the peptide transporters 
An additional, and very interesting, fact emerged from these perfusion 
studies; the addition of the azide (N3 +) group to D-Phe-L-Ala, performed for label 
production, conferred an enhanced interactive ability of the dipeptide substrate with 
the transporters. The presence of a net positive charge on the structure results in a 
more rapid rate of transmural transfer, in particular exit across the basolateral 
membrane is considerably enhanced. This is probably not due to a change in intrinsic 
activity of the transporters, but to the pH of the perfusate medium. Cationic peptides 
have been shown previously to be more efficient substrates for PepTI at a pH of 
approx. 6.5, whereas anionic and neutral substrates are most efficient at a more acidic 
pH (5.5) (Temple et aI., 1995; Wenzel et al., 1996; Steel et al., 1997; Amasheh et al., 
1997). The luminal and vascular perfusate solutions were both at pH 6.8, therefore 
transport of the cationic label would be maximised, whereas the neutral dipeptides 
(D-Phe-L-Gln & D-Phe-L-Ala) would be relatively less efficient substrates. These 
distinct pH dependencies for transport emerge from different H+ flux coupling ratios 
of differently charged substrates (section 3.7.4), i.e. anionic substrates are 
co-transported with 2H+, zwitterionic substrates with 1 H+, and cationic substrates 
with IH+, but can be transported in the absence of H+. It is not clear whether the 
same mechanism is present at the basolateral membrane, due to a lack of knowledge 
in that area. However, some studies have indicated a proton-dependence in 
basolateral transport (Dyer et al., 1990; Thwaites et al., 1993a, b; Saito et al., 1993; 
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Terada et aI., 1999), and so equivalent flux coupling ratios for this transporter cannot 
be disregarded. 
7.3 Identification ofPepTl in the apical membrane 
A tritiated form of the photo affinity label ([4-azido-3,S}H-D-Phe]-L-Ala) 
was used in an attempt to identify PepTl from brush-border membrane vesicles 
(Chapter 4). However, the results were disappointing; a large number of membrane 
proteins incorporated the dipeptide label. Despite this, the amount of label 
incorporation, even by the protein that was predominantly labelled, was only 0.003% 
at maximum and is therefore highly specific with very little random, non-specific 
covalent binding. However, substrate protection by a dipeptide was not isolated to a 
single protein species, therefore PepT! could not be individually detected. It is 
thought that the high molecular weight proteins, which bound the dipeptide label in a 
substrate-specific manner, are peptide hydrolases known to be present in great 
abundance in the apical membrane. These proteins are also specific for peptide 
substrates, which is the reason why they incorporated the photo affinity label. 
Previous studies by Kramer and co-workers (1987, 1988, 1990a,b), using 
photo labile derivatives of known PepTl substrates, identified a 127 kDa 
micro heterogenous protein which they implied could be a component of the peptide 
transport system. A protein of 130 kDa molecular weight was predominantly 
labelled in the study presented in this thesis, which is thought to correspond to the 
127 kDa protein of Kramer's. Their studies suggested that the protein was not a 
peptide hydrolase and was present throughout the length of the small intestine 
(Kramer et al., 1998). Reconstitution of the protein into proteoliposomes resulted in 
a specific transport activity similar to PepTl, which retained its stereo selectivity for 
substrates (Kramer et al., 1992). However, investigations by Daniel & Adibi (1993) 
into the substrate-specific requirements of PepTl revealed that because the 
photoreactive azide analogues, i.e. benzylpenicillin, cephalexin, Gly-Pro, that Kramer 
et al. used to label the 127 kDa protein did not contain a free a-amino group, it is 
unlikely that the labelled protein represents the H+/peptide cotransporter. 
There is a major difference in the molecular weight of the protein that was 
chiefly labelled in this study compared with previously published molecular 
weight(s) of PepTl. The reported molecular weights of the PepTl from small 
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intestine in small mammals are; 71 kDa in rabbit (Fei et al., 1994; Daniel et al., 
1996), and 75 kDa in rat (Saito et al., 1995; Ogihara et al., 1996). These values are 
considerably lower than 130 kDa observed. in this study and so this predominantly 
labelled protein is thought not to be PepTl; the protein may be a protease, or possibly 
a regulator of peptide transport as previously described by Kramer et al. (1987, 1988, 
1 990a,b). Labelling ofPepTl alone cannot be observed due to the overall high level 
of incorporation by other proteins, therefore although it is probably present at a 
molecular weight of approx. 75 kDa, it cannot be individually detected. 
Efforts were made to block incorporation of the label by the peptide 
hydrolases, using bestatin and papain digestion, to leave PepTl free to be singly 
identified. Although bestatin is also a substrate for PepTl, a notably higher 
concentration is needed for interaction with the peptide transporter; three orders of 
magnitude greater than the concentration which inhibits peptidase activity. For 
example, peptidase inhibition is observed with a concentration in the range of 
5-10 JlM (Takano et al., 1994; Kramer et al., 1990b), whereas an ICso of 10 mM was 
reported for cephalexin uptake into BBMV (Kramer et al., 1990b). However, the 
results were not as anticipated; 20 JlM bestatin failed to prevent hydrolase labelling 
which, in hindsight, is possibly due to the incubation time employed. It has been 
proposed that binding of be stat in to peptidases involves a mechanism, which includes 
a slow conformational change, that takes up to 2 h to achieve (Wilkes & Prescott, 
1985). This observation indicates that increasing the incubation time of bestatin with 
BBMV to 2 h will block labelling of peptidases and allow PepTl identification. 
Although treatment of vesicles with papain has been previously 
demonstrated to cause an enrichment in peptide transport activity (Ganapathy et al., 
1981; Inui et ai., 1984) due to cleavage of the peptidases from the surface of the lipid 
bilayer, in this study photoaffinity label binding by all membrane proteins was 
abolished. The reason for this is not clear, but may involve an incubation time that 
was too prolonged. 
In summary, PepTl could not be individually identified from BBMV by the 
photoaffinity labelling technique due to a high extent of label incorporation by 
additional membrane proteins other than the peptide transporter. It is a possibility 
that the relatively low level of label binding by PepTl may be due to the pH of the 
equilibration buffer (pH 5.5). Experiments in Chapter 3, corroborated by results 
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from previous studies (Temple et ai., 1995; Wenzel et ai., 1996; Steel et ai., 1997; 
Amasheh et ai., 1997), indicate that label incorporation might be enhanced at a 
slightly higher pH (6.5-6.8), due to its net positive charge. Future work of this type 
should take the distinct pH dependencies of differently charged substrates into 
account. 
7.4 Identification of a candidate basolateral peptide transporter 
In contrast to the lack of achievement in identifying PepT1 from BBMV, a 
112 kDa protein thought to be a candidate to be the basolateral transporter was 
successfully identified and isolated from BLMV (Chapter 5). Whereas many proteins 
in the brush-border membrane incorporated the label, a single discrete peak of 
radioactivity, representing label-binding by a protein, was detected in basolateral 
membranes. Ratios of unprotected labelling v. dipeptide-protected labelling was 
considerably higher with this protein than the others with a lower extent of label 
incorporation, indicating the predominance of labelling. This pattern of labelling was 
highly reproducible. Labelling of the 112 kDa protein was abolished by 
preincubation with a dipeptide, whereas free amino acids had very little effect.:i 
D-Phe-L-Gln actually provided a higher degree of protection to the putative 
basolateral transporter from labelling, when compared to PepTI. This may be due to 
a combination of the high concentration ofD-Phe-L-Gln (16.7 mM), a lower affinity 
of the basolateral transporter for substrates and a relatively lower capacity for 
transport, in comparison to PepTI. Therefore, whilst the basolateral transporter 
would probably be saturated by D-Phe-L-Gln and would therefore not interact with 
the substantially lower concentration of label (4.2 ~M), the higher transport capacity 
of PepTI might mean that binding of the label and D-Phe-L-Gln could occur 
simultaneously. 
Also in contrast to brush-border membrane labelling experiments, a 
considerably higher proportion of the initial label formed a covalent attachment to the 
112 kDa protein (6-fold higher than to the predominantly labelled 130 kDa protein in 
BBMV). This increased level of binding may reflect the situation that was 
determined in the perfusion experiments (Chapter 3), whereby the label appeared to 
be a more efficient substrate for the basolateral transporter than for PepTI. However, 
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potential differences in the abundance of the peptide transporters in their respective 
membranes, relative to other proteins, must also be acknowledged. 
In summary, a candidate for the basolateral peptide transporter was 
identified by a photoaffinity labelling method. However, the method of detection of 
a labelled protein did not clarify whether the radioactive peak contained a single 
protein species. As such, the labelled protein sample was SUbjected to a second 
method of separation; IEF. In addition to ensuring that the labelled sample contains 
an individual protein, this technique allows further information about the protein to 
be determined, i.e. its isoelectric point. The pI of the protein was shown to be 
approx. 6.5, whereas the pI of free [4-azido-3,S.3H-D-Phe]-L-Ala was 6.0, therefore 
the radioactive peak detected in the gels was not due to unbound label. 
7.5 Sequence analysis of the candidate basolateral peptide 
transporter 
The technique of photoaffinity labelling, combined with rod gel separation, 
permitted the isolation of the 112 kDa protein in sufficient quantities to progress 
towards performing initial sequence analysis. A concentrated radioactively labelled 
sample of the 112 kDa protein, isolated from rod gels, was subjected to 2-DE using 
an immobilised pH gradient in the first dimension and standard SDS-PAGE slab gels 
in the second dimension. 
However, the results were not as expected; although a single spot of 
112 kDa was present, it was not predominant. In addition, two very dense spots at 
approx. 40 kDa each could be detected. There were very few other spots that could 
be detected in the 2-DE gel, which could be attributed to the initial isolation 
procedure of the 11'2 kDa protein from other membrane proteins. The abundance of 
the two 40 kDa spots, coupled with a low density 112 kDa spot, and very little else 
within the gel, implied that the 112 kDa protein might have been proteolysed, thus 
reSUlting in the two spots. However, scintillation counting of the protein spots 
revealed that none were radioactively labelled. Therefore, during proteolytic 
degradation of the 112 kDa protein, cleavage of the portion that bound 
[4-azido-3,S-3H-D-Phe]-L-Ala was thought to have occurred, and the resulting 
polypeptide eluted from the bottom of the SDS-P AGE gel. Despite the proteolytic 
breakdown of the labelled 112 kDa protein, work on the candidate basolateral peptide 
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transporter was progressed. Due to their predominance in the gel, it is assumed that 
these polypeptides were constituents of the 112 kDa protein, and so analysis 
continued with these two spots. 
To investigate whether proteolysis was responsible for the relatively minor 
112 kDa spot, an anti-protease inhibitor cocktail was included in all solutions during 
isolation and 2-DE of the labelled protein (work performed by Mrs. Julie Affleck). 
As anticipated, a very dense spot at 112 kDa (pI 6.5) could be detected, associated 
with the removal of the two 40 kDa spots thought to be proteolytic products. These 
results corroborated the initial conclusions, and therefore the sequence data that was 
eventually obtained from the two 40 kDa spots could be attributed to the 112 kDa 
protein. 
A lack of radioactivity following 2-DE of the labelled protein was 
investigated further. It was thought that the fixing stage of the staining procedure 
resulted in the prevention of protein elution from the gel prior to scintillation 
counting. As such, a stain was utilised which did not require fixing; a negative (zinc) 
stain. However, although radioactivity could be detected to a certain level, it was not 
abundant enough and so this stain also seemed to be quenching radioactivity to some 
extent. Therefore, a radioactive spot could not be unequivocally detected following 
2-DE. An alternative approach was taken; an IPG strip was focused with the labelled 
112 kDa protein, which was then sliced into sections, and these sections were 
subjected to scintillation counting. Using this method, a peak of radioactivity could 
be detected, which corresponded to the precise position in the pH gradient in the 
second dimension gel where the 112 kDa protein focused and was detected by the 
presence of a spot. Therefore, the protein could then be identified with certainty in 
the fmal 2-DE gel. 
The two 40 kDa spots, representing the candidate basolateral protein, was 
analysed by two mass spectrometry techniques; MALDI-TOF (matrix-assisted laser 
desorption/ionisation time of flight) and Q-TOF (quadrupole time of flight). 
MALDI-TOF was principally used to obtain a peptide fingerprint, following 
digestion of the protein with trypsin. The peptide fingerprint of a protein depends 
entirely on its primary amino acid sequence because trypsin cleaves the polypeptide 
backbone at the carboxylic sides of lysine and arginine residues, except when 
adjacent to a proline residue. As such the fingerprint is specific for that individual 
protein. Proteins can be unequivocally identified from databases from their peptide 
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fingerprint; the process of searching databases to identify proteins in this way is 
termed 'peptide fingerprint profiling'. 
MALDI-TOF analysis of the peptides produced from the two 40 kDa protein 
spots revealed 83 peptides in spot A and 53 peptides in spot B. It was very 
interesting to discover that 24-29 of the peptides detected in spots A and B had 
identical masses, indicating that they did indeed originate from one single protein 
(the candidate basolateral transporter). Due to the fact that more peptides were 
detected from spot A than spot B, it is thought that the original 112 kDa protein was 
broken down to initially form spot A, and then further proteolysis resulted in another 
distinct spot (B). 
Peptide fingerprint profiling of data from spots A & B, utilised in a 
combination of different ways, did not match to any protein from any of the 
databases searched. 
Additional sequence information of the candidate basolateral transporter was 
obtained from Q-TOF analysis. This produced a partial sequence of one of the 
peptide fragments resulting from the tryptic digest; the sequence was from a peptide 
detected in spot A. A sequence tag was constructed as follows; 
NH2- / -Thr-Ser-Asn-Phe-V al-Thr-(Ala-Thr-Ser)- / -COOH 
The sequence consists of nine amino acid residues; six of which are definite and the 
remaining three are highly probable (> 99%) (shown in brackets). The sequence tag 
was used to search databases in an attempt to identify the protein contained within 
spot A on the 2-DE gel. The six definite residues, or the complete nine residue 
sequence, were used to search both full length sequence databases and 
expressed-sequence tag (EST) databases. Although some protein matches were 
found for the majority of the nine amino acid sequence, a total match to all residues 
was not evident. In addition, despite the fact that the proteins matched to most of the 
sequence, their peptide fingerprints did not correlate with the fingerprint of the 
112 kDa protein, and therefore could not be identified as a positive match. 
Overall, the protein in spots A and B could not be identified by either 
MALDI-TOF or Q-TOF analysis alone, combined with database searches, nor from a 
combination of both mass spectrometric analysis methods. If the basolateral 
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membrane protein were contained within the databases, a positive match would have 
been found using the data presented here. It is generally accepted that if a protein has 
been previously isolated, and its sequence is contained within the databases, a peptide 
fingerprint or a partial sequence will unequivocally find the match (James et al., 
1993). It is therefore clear that the 112 kDa protein, which has been specifically 
photo affinity labelled with a dipeptide analogue, and which is postulated to be a 
candidate to be the basolateral peptide transporter, has not been previously identified, 
and as such appears to be a novel protein. 
In the past it has been postulated that PepTI is responsible for the exit of 
peptides from the cell across the basolateral membrane, i.e. it was thought that there 
wasn't a distinct transport protein. During the cloning and expression of rabbit 
PepTI by Hediger's group (Fei et al., 1994), hybrid depletion studies performed to 
block PepTI expression resulted in a loss of induced Gly-Sar transport activity in 
Xenopus laevis oocytes. As such, they suggested that peptide transport activity in the 
basolateral membrane is entirely due to PepTI expression. However, at present there 
is overwhelming evidence proving the existence of a distinct transporter protein in 
the basolateral membrane. In particular, PepTI expression has been 
immunolocalised exclusively to the apical membrane (Ogihara et al., J 996; Walker et 
al., 1998), in addition to distinct transport characteristics demonstrated by a number 
of kinetic studies (section 1.5). 
As mentioned, the sequence data presented here does not positively match to 
any known protein sequence and, as such, reinforces the distinction between PepTl 
and the basolateral transporter. Only a few (maximum of 5) of the peptide fragments 
generated from the candidate basolateral peptide transporter correspond to tryptic 
peptides of rat PepTl. Interestingly, these five peptides are located in just two loops 
connecting adjacent transmembrane domains; the majority are located in the notably 
large extracellular loop connecting TM 9 and 10, and the remainder in the 
intracellular loop adjoining TM 6 and 7. Sequence analysis comparisons of the 
peptide transporters cloned thus far have revealed that the conserved sequences are 
predominantly located in the TM domains, with a lower degree of homology in the 
interconnecting loops. The fact that only a very small percentage of the tryptic 
peptides of the candidate basolateral protein match to peptides of PepTl,. and tha~ 
these are found in these loops, implies that they are not the same protein. In addition, 
the partial sequence of nine (or six) amino acids is not contained within the primary 
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sequence of rat PepTl, nor any other peptide transporter which has presently been 
cloned and sequenced. 
Subsequent experiments, which studied the short-term regulation of 
intestinal peptide transport, also provide evidence that the two transporters are not 
one protein, demonstrated by distinct regulatory processes at the apical and 
basolateral membranes. 
7.6 Short-term regulation of intestinal peptide transport 
Although investigations were devised to understand the nature of short-term 
regulation of peptide transport in the small intestine (Chapter 6), an additional aspect 
of possible regulation was also observed indirectly, as a result of a separate study 
(Chapter 3). Therefore, both areas of regulation will be discussed in this section. 
7.6.1 Substrate regulation of its own transport 
Suprising and unexpected results were obtained when investigating the 
effects of D-Phe-L-Oln transport under the influence of D-Phe-L-Ala (Chapter 3). It 
was anticipated that the presence of D-Phe-L-Ala would inhibit transport of the 
substrate (D-Phe-L-Oln) ~ue to competition for the same active site(s), in the same 
manner as the photoaffinity label. However, it was observed that D-Phe-L-Ala 
actually acted to stimulate substrate transport, both from the vascular side and the 
luminal side of the jejunum, although the stimulation appears to be greater on the 
basolateral transporter (implied by smaller exit ratios). 
Previous investigations (Thamotharan et al., 1998; Walker et al., 1998; 
Shiraga et al., 1999) have demonstrated that pre-treatment of Caco-2 cells with one 
dipeptide causes a stimulation in the transport of a second dipeptide; this stimulation 
occurs at a transcriptional level to provide a more abundant population of 
transporters at the cell membrane. However, this follows 24-72 h preincubation and 
so the differences in exposure time to peptide mean that this cannot be the 
mechanism by which D-Phe-L-Ala is acting in this study. 
The results with peptide transport presented here correlate with the 
conclusions by Sharp et al. (1996) on the regulation of sugar transport, whereby an 
additional rapid response of SOL Tl to jejunal glucose, that preceded the onset of 
increased protein expression, occurred within 30 min exposure. 
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The exact mechanism by which the transport stimulation occurs could not be 
elucidated from these experiments alone. However, due to the rapid time course of 
stimulation by D-Phe-L-Ala, it seems likely that there may be an aspect of allosteric 
control involved, indicated by the presence of a sigmoidal curve when D-Phe-L-Gln 
concentration is plotted against transporter activity. 
Whichever the process (Sharp's mechanism / allosteric control), it seems 
that either D-Phe-L-Ala interacts with the basolateral transporter with greater 
efficiency than with PepTl, or that it exerts more control at this membrane, or that 
the basolateral transporter is more sensitive to regulation in this way than PepTI. 
These results have just touched the surface of peptide transport regulation in this 
manner and more extensive studies are required to further the understanding the 
precise mechanism. 
7.6.2 Protein kinase cascades involved in regulation of intestinal 
peptide transport 
Previous studies in our laboratory (Boyd et al., 1996) demonstrated that 
leucine stimulates transmural peptide (D-Phe-L-Gln) transport in rat small intestine. 
Other amino acids, e.g. L-Ala, L-Phe and L-Val, have also been shown to have a 
similar effect, albeit to differing extents (J. R. Bronk, personal communication). The 
time course of the perfusion technique used in these experiments (50 min) indicated 
an element of short-term regulation of peptide transport. 
Subsequent to these results other groups have shown that certain amino 
acids, most predominantly leucine, have the ability to specifically activate an enzyme 
located in the cytosol of various cell types; p70S6k (Hara et al., 1998; Patti et ai., 
1998; Wang et al., 1998; Shigemitsu et al., 1999). The time course of this activation 
was also in the order of minutes, therefore indicating that this process was also a 
short-term event. As such, it was postulated that the leucine stimulation of peptide 
transport demonstrated by Boyd et al. (1996) might involve a p 70S6k -dependent 
mechanism, therefore leucine was used to investigate short-term regulation of 
transport and the role of a p70s6k-dependent pathway was studied using specific 
inhibitors of the enzyme. 
In order to determine whether leucine had similar or distinct effects on 
peptide transport at the apical and basolateral membranes, it was perfused through 
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either the lumen or the vasculature of the small intestine. However, the overall effect 
was a stimulation in transport rate of D-Phe-L-Gln, predominantly at the basolateral 
membrane, irrespective of the location of infusion of leucine, indicated by tissue 
concentration and exit ratio data. 
The data from these investigations implicate p70S6k as a regulator of peptide 
transport at the basolateral membrane of rat small intestine and also emphasise that 
distinct transporters exist at the apical and basolateral membranes. It corroborates 
other work presented in this thesis (Chapter 5), and work published by other people 
(section 1.5), in that the unidentified basolateral peptide transporter is not PepTl. 
The activity of p70S6k is controlled by a number of upstream proteins in 
different pathways, some of which have not yet been identified, although two known 
proteins are mTOR and PI 3-kinase. The previously mentioned reports (Hara et al., 
1998; Patti et al., 1998; Wang et al., 1998; Shigemitsu et al., 1999), which 
demonstrated that leucine stimulated p70S6k activity, also showed that rapamycin 
blocked the effects of the amino acid. Perfusions were performed in the presence of 
specific inhibitors of these enzymes; rapamycin, which inhibits mTOR, and 
wortmannin, which inhibits PI 3-kinase, to examine whether either of these two 
proteins are involved in the leucine-stimulation ofbasolateral peptide transport. 
Rapamycin, perfused through the vasculature of the small intestine, resulted 
in inhibition of the leucine-stimulated proportion of basolateral peptide transport, but 
did not affect the normal (control) rates. These data implicate p70S6k in leucine 
stimulated basolateral peptide transport, and a role for mTOR in the regulation 
pathway. It is thought that rapamycin does not induce dephosphorylation of p70S6k 
primarily by inhibiting p70S6k kinases, but by stimulating p70S6k phosphatase activity 
(Hara et al., 1998). The pathway they suggested is shown in figure 6.6 (section 
6.8.2). 
As reported, leucine did not predominantly stimulate peptide transport at the 
apical membrane. The presence of rapamycin at the apical membrane (in the lumen) 
had an opposing effect than when infused to the basolateral membrane in the vascular 
perfusate. Firstly, it did not function to inhibit the leucine stimulation at the 
basolateral membrane, suggesting that the low concentration of the drug used 
induced a local response. Secondly, without vascular leucine, rapamycin stimulated 
peptide transport from the lumen. This stimulation appeared to initiate before the 
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20 min time point when leucine was added, therefore rapamycin might be inducing 
an effect earlier than was initially assumed, resulting in the final stimulation once a 
steady state has been reached. The stimulation by leucine at the basolateral 
membrane and the stimulation by rapamycin at the apical membrane are not additive, 
because the rate remained constant when either or both were present in their 
respective perfusates. Therefore, they might either exert their effects through a 
common mediator or one pathway might inhibit a second pathway, resulting in the 
same response. The precise mechanism cannot be concluded from these data. 
The data presented here do not permit elucidation of the regulatory pathway 
which controls peptide transport by PepTl, but there is obviously a mechanism of 
control present, as demonstrated by the action of rapamycin. PKC has been 
implicated in the regulation of apical peptide transport (Brandsch et al., 1994) and 
mTOR has been shown to phosphorylate the C-terminal site of PKC in the V5 
domain; activation of which is inhibited by rapamycin (Parekh et al., 1999). The 
precise mediators functioning in the pathway between mTOR and PKC are not yet 
known, but the simplest model would be that mTOR controls a phosphatase that acts 
upon this PKC site (Parekh et al., 2000). In these perfusions, rapamycin in the lumen 
stimulated peptide transport, potentially by inhibiting the mTOR-dependent 
phosphorylation of the C-terminal site of PKC, thereby relieving the inhibition on 
PepTl by active PKC. 
PI 3-kinase is also known to lie upstream of p70S6k; some studies have 
demonstrated an inhibitory effect of wortmannin (a PI 3-kinase inhibitor) on the 
amino acid-stimulation of p70S6k activity (Wang et al., 1998; Patti et al., 1998), a 
moderate reduction in activity (Shigemitsu et al., 1999), or no effect at all (Hara et 
al., 1998). As such, perfusions were performed in the presence of wortmannin due 
to a possible role of PI 3-kinase in the regulation of basolateral peptide transport 
through p70S6k• The data arising from these perfusions were confusing, although a 
PI 3-kinase-dependent element of control at the basolateral membrane was indicated. 
If PI 3-kinase inhibits peptide transport under control conditions, the inhibition of 
PI 3-kinase by wortmannin will relieve this inhibitory effect on transport, thereby 
producing the stimulation in rate which was observed when wortmannin was infused 
to the intestine in the vascular perfusate. PI 3-kinase can act via PKB, but amino 
acids have been shown not to stimulate PKB activity, therefore the effect of 
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wortmannin must be independent of this enzyme, via another pathway. In summary, 
at the basolateral membrane, there appears to be a wortmannin-sensitive pathway, in 
addition to a leucine-sensitive pathway, possibly leading to a common effector. 
Despite this speculative assumption, the data from experiments with vascular 
wortmannin do not provide a complete picture and do not, therefore, point to an 
obvious mechanism and, as such, require further work for clarification. 
In contrast to vascular wortmannin, luminal wortmannin has no effect on 
leucine-stimulated transport, or on control rates. Therefore, this indicates that 
PI 3-kinase is not involved in regulation of PepTl transport at the apical membrane. 
However, because mucosal exit ratios were reduced by the presence of wortmannin 
in the lumen, PI 3-kinase may be involved in apical peptide transport; further work is 
required for elucidation of its exact involvement in transport. PDKI is located 
upstream of, and is involved in phosphorylation and activation of, PKC (Parekh et 
al., 2000). (Parekh et al., 2000). PI 3-kinase is located upstream ofPDKl, therefore 
it might be expected that wortmannin would have a stimulatory effect on apical 
membrane peptide transport, in the same way that rapamycin does at this membrane. 
However, inconclusive effects by luminal wortmannin suggests that if PKC did have 
a role in the regulation of PepTl transport, it might be via a pathway which is 
independent of PI 3-kinase. 
In conclusion, the main points gained from these investigations are: (1) the 
peptide transporters at the apical and basolateral membranes are distinct proteins, 
(2) at the apical membrane PI 3-kinase may not involved in regulation of PepTI, and 
mTOR has an undefined stimulatory capacity, possibly via PKC, and (3) at the 
basolateral membrane a p70S6k/mTOR pathway regulates transport and an 
independent PI 3-kinase pathway might also be involved. The precise mechanisms of 
regulation require investigation in detail, however, these studies provide initial 
information and reveal the complexity of short-term regulation of peptide transport in 
the small intestine, in addition as to how very little we actually know at present. 
Overall, the data presented in this thesis provide important information 
about peptide transport in the small intestine, in particular concerning the basolateral 
transporter protein which has not, to date, been identified. Only when intestinal 
peptide transport as a whole has been elucidated, and the mechanisms controlling 
regulation at both the apical and basolateral membranes been deduced, can efficient 
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delivery of peptidomimetic drugs be achieved. The crucial element of the future will 
be the cloning and sequencing of the basolateral peptide transport protein, providing 
us with a complete picture of intestinal absorption. 
278 
(b) 
8.8 
2 
4 
6 
8 
18 
12 
14 
16 
17.5 
-251-299 
9 
-
-
-
-
-
-
-
-
9 
Appendix I 
-188 
-. 
HPLC elution profiles of dipeptide substrates 
~OHTROH D~t~ s~ste. 459 !IV 
t::=============--- 7.55 
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198 298 i 389 i 458 
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-r 
f 
HPLC elution profiles ofD-Phe, D-Phe-L-Gln and [4-azido-D-Phe]-L-Ala. Standard 
samples are run at a concentration of 0.01 mM; the area of the peak is used to 
calculate the concentration of D-Phe-L-Gln or [4-azido-D-Phe]-L-Ala in vascular 
samples, following perfusion, by comparison to sample peak areas. (a) The mobile 
phase is 10% methanol / 90% 21 mM KH2P04; D-Phe elutes at 7.55 min, whereas 
D-Phe-L-Gln elutes at 9.73 min. (b) The mobile phase is 15% methanol / 85% 
21 mM KH2P04; D-Phe elutes at 5.76 min, D-Phe-L-Gln elutes at 6.17 min and 
[4-azido-D-Phe]-L-Ala elutes at 14.7 min. 
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Appendix II Proteomics search tools 
Web sites for peptide fingerprint profiling 
Peptldent: http://www.expasy.ch/tools/peptident 
ProFound: 
MS-Fit: 
MASCOT: 
MS-Digest: 
http://www.prowl.rockefeller.edulcgi-binlprofound 
http://www.prospector.ucsf.edulucsfhtm13.2/msfit.htm 
http://www.matrixscience.coml 
http://www.prospector.ucsf.edulucsfhtm13.2/msdigest.htm 
Web sites for peptide sequence tag database searching 
T agIdent: http://www.expasy.ch/tools/tagident 
ProteinInfo: 
MOWSE: 
BLAST: 
Appendix II 
http://www .prowll.rockefeller.edulprowl-cgi/proteininfo 
http://srs.hgmp.mrc.ac. uklcgi -binlmowse 
http://www.ncbi.nlm.nih.gov.blast! 
Web sites for the proteomics search tools utilised in the identification of proteins 
from peptide fingerprints or peptide sequence tags. 
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Appendix III Molecular masses ofthe twenty common amino acid residues 
Amino acid Three (one) letter code Monoisotopic mass Average mass 
Glycine Gly (G) 57.021 57.052 
Alanine Ala (A) 71.037 71.079 
Serine Ser (S) 87.032 87.078 
Proline Pro (P) 97.053 97.117 
Valine Val (V) 99.068 99.133 
Threonine Thr (T) 101.48 101.105 
Cysteine Cys (C) 103.009 103.145 
Isoleucine He (I) 113.084 113.160 
Leucine Leu (L) 113.084 113.160 
Asparagine Asn (N) 114.043 114.104 
Aspartate Asp (D) 115.027 115.089 
Glutamine GIn (Q) 128.059 128.131 
Lysine Lys (K) 128.095 128.174 
(147) 
Glutamate Glu (E) 129.043 129.116 
Methionine Met(M) 131.040 131.199 
Histidine His (H) 137.059 137.142 
Phenylalanine Phe (F) 147.068 147.177 
Arginine Arg (R) 156.101 156.188 
(175) 
Tyrosine Tyr(Y) 163.063 163.176 
Tryptophan Trp (W) 186.079 186.213 
Appendix III 
The monoisotopic and average masses (Da) of the twenty common amino acid 
residues, which are used for mass spectrometric determination of a peptide sequence. 
Note that leucine and isoleucine. and lysine and glutamine, cannot be differentiated 
in the sequence due to identical, or very similar, masses. Arginine and lysine 
residues have a greater mass (+ 19 Da) when cleaved into a y-type ion (from a tryptic 
peptide) due to their location at the carboxylic end, i.e. plus OH. 
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